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vABSTRACT
This dissertation draws out various facets of the conditions preparing and
situating Valium as a marketable substance and cultural entity.  It offers one
explanation for the widespread prescription and use of Valium in the 1960s.
The post-World War II conceptualization of mental health and illness as a
spectrum, with the majority of Americans falling between the poles and therefore either
neurotic or at risk, heightened interest in mental health.  Increased availability of health
insurance brought more Americans to their physicians.  National programs –
establishment of the National Institutes of Mental Health, the Hill-Burton Act, and
formation of a Joint Commission on Mental Illness and Health through the 1955 Mental
Health Study Act – recognized widespread support for programs to increase the number
of mental health practitioners and facilities focused on neuroses, personality disorders,
and outpatients in general.  Popular theories, including Walter Cannon’s homeostasis
and Hans Selye’s General-Adaptation-Syndrome, promoted the idea that stress, and
response to it, were among the most important aspects of health.  The American public
increased its demands for mental health services.  Interplay between these conditions
promoted use of psychopharmaceuticals.  They were quick to prescribe and therefore
allowed doctors to see more patients each day.  They somaticized mental illness,
bringing it within the boundaries of traditional medical insurance coverage.  They did
not cure an illness; they reduced symptoms and therefore either allowed the body to
vi
recover, or in an ongoing fashion prevented immature personalities from reaction to
stresses in a manner leading to more serious medical problems.
In the 1950s, it became possible to screen chemicals for a tranquilizer.  The
expense of creating and treating experimental neuroses in animals to screen chemical
compounds was prohibitive.  Yet these experiments informed pharmacologists; they
could identify antineurotic or tranquilizing drugs through physical manifestations.  With
availability of antibiotics, pharmaceutical industries could keep fairly healthy
populations of mice, rats, cats, and monkeys for testing.  Chlorpromazine’s discovery
and introduction into institutional psychiatry, around 1953, set out the basic features
defining a tranquilizer.  By 1958, pharmacologists had the ability and expectations
required to inject a mouse with diazepam, check if it rolled off an inclined screen and,
observing the tumbling rodent, recognize the ingested molecule was a potentially
marketable tranquilizer. 
Valium’s development and discovery took place when tranquilizers were new
and held out promise as mental health prophylactics, mild sedatives, and safe hypnotics. 
Mild mental illness needed rapid, effective, and fairly inexpensive treatment.  Faced
with patients undergoing severe or ongoing stress, doctors turned to anxiety-reducing
drugs in order to prevent psychosomatic mechanisms resulting leading to any of a
dozen physical illnesses.  Compared with earlier alternatives – barbiturates, alcohol,
major tranquilizers – Valium was safe, nonaddicting, and had few if any dangerous side
effects. 
11  Valium is the brand name for diazepam, a benzodiazepine tranquilizer the
Swiss  pharmaceutical company Hoffman-LaRoche began marketing in the United
States in 1963.  Diazepam is no longer produced or sold by the company.  Throughout
this dissertation I use the terms Roche and Hoffmann-La Roche interchangeably. 
Company literature similarly uses the terms.
2  The character June Cleaver is the mother in the 1950s television show ‘Leave
it to Beaver.’
3  For examples of books from 1970s and early 1980s see: Barbara Gordon, I’m
Dancing as Fast as I Can (New York: Harper & Row, 1979); Eve Barbmann and
Sidney M Wolfe, Stopping Valium, and Ativan, Centrax, Dalmane, Librium, Paxipam,
Restoril, Serax, Tranxene, Xanax (New York: Warner Books, 1983); for a differently
gendered book see Anton Holden, Prince Valium (New York: Chelsea House, 1992);
the theme is less prevalent in books intended to keep youth off drugs, such as Gail
CHAPTER 1.  INTRODUCTION.
THE VALIUM STORY
Introduction
Valium is a cultural icon, ripe with meanings, rife with contradictions.1  Viewed
in hindsight, its place is remarkably like that of June Cleaver – mother in the iconic
1950s and 1960s television show ‘Leave it to Beaver’ – stuck forever in a perfect home,
raising a perfect family, always perfectly calm.  She is permanently associated with
motherhood and subjugation of female independence to her own need and desire to
nurture a family.2  And like June Cleaver, Valium is a creation of history; widely
associated with memories of a world that never existed.
In the United States, retrospect taints images of Valium.  After the Women’s
Movement, publicization of the gendered nature of psychiatry stuck to diazepam,3 the
2Winger, Valium: The Tranquil Trap (New York: Chelsea House, 1986); the traditional
themes appear in the more recent book Joan E. Gadsby, Addiction by Prescription: One
Woman’s Triumph and Fight for Change (Toronto: Key Porter Books, 2000).
4  The song “Mother’s Little Helper” appears on the 1966 record Aftermath, by
the Rolling Stones.  
Kids are different today, 
I hear every mother say.
Mother needs something to calm her down,
and though she’s not really ill, there’s a little yellow pill.
She goes running for the shelter of a mother’s little helper,
and gets helps her on her way, gets her through her busy day.
5  Decrying sexism in psychiatry played an important part in the women’s
movement of the 1960s and 1970s.  Although critiques focused mainly on
psychoanalytic theory, somatic psychiatry was tarred with the same brush. 
Thematically the works focus on use of male behavior and socialization to define
normal and healthy behavior, thereby define women and female socialization as
unhealthy.  An excellent example of feminist critiques of psychoanalysis is Juliet
Mitchell’s Psychoanalysis and Feminism: Freud, Reich, Laing, and Women (New
York: Vintage Books, 1974).  One of the best known critiques is Phyllis Chesler’s
Women & Madness: When is a Woman Mad and Who is it Who Decides? (Garden City,
NY: Doubleday, 1972).  Carol Gilligan’s landmark In a Different Voice: Psychological
Theory and Women’s Development (Cambridge: Harvard University Press, 1982)
challenges the concept that masculine socialization should be the norm for humanity in
general, thereby pre-defining female difference as pathological.  She argues for
redefining models of human development based on interaction rather than dominance
and power, encorporating female models of maturity.  For an overview of the
relationship between mental health and feminism see Stéphanie Austin, The Influence of
the Feminist Movement in/on the History of Psychology (unpublished thesis, Wilfred
Laurier University, 1999); for a more general critique of sexism in medicine see Gena
Corea, The Hidden Malpractice: How American Medicine Treats Women as Patients
and Professionals (New York: William Morrow and Company, Inc., 1977).
For a selection of recent books with focus on addiction to tranquilizers see:
drug marketed as Valium.  It became the Rolling Stones ‘Mother’s Little Helper,’ a
crutch used by women to cope with minor stresses.4  Beginning in the mid-1970s,
authors write about Valium as an addictive mental sedative or taming agent, given
mainly to women (particularly mothers) for long-term use, often for social reasons.5 
3Stephen Fried, Bitter Pills: Inside the Hazardous World of Legal Drugs (New York:
Bantam Books, 1998); Joan E. Gadsby, Addiction by Prescription: One Woman’s
Triumph and Fight for Change (Toronto: Key Porter Books Limited, 2000); recent
books on the history of psychiatry or psychopharmacology, containing substantial
sections on Valium include: David Healy,  The Creation of Psychopharmacology
(Cambridge, Harvard University Press, 2002); Davd Herzberg, Happy Pills in America:
From Miltown to Prozac (Baltimore: The Johns Hopkins Press, 2009); Seymour
Rosenblatt and Reynolds Dodson, Beyond Valium: The Brave New World of
Psychochemistry (New York: G. P. Putnam’s Sons, 1981); Edward Shorter, A History
of Psychiatry: From the Era of the Asylum to the Age of Prozac (Toronto: John Wiley
& Sons, Inc., 1997); Mickey C. Smith, A Social History of the Minor Tranquilizers: The
Quest For Small Comfort in the Age of Anxiety (New York: Pharmaceutical Products
Press, 1991).
6  In 1975, doctors wrote fifty-three million prescriptions for Valium, in 1978
the number was down to 44.9 million.  B. D. Colen, “America’s Psychic Aspirin:
Valium: Problems with America’s ‘Perfect Drug,’ The Washington Post January 21,
1980.
7  The concept of the conservative backlash is generally accepted.  A liberal
backlash, in this context, refers to increasing belief that the Women’s Movement
represented goals which denied the rights of the individual, as well as belief by some
liberal groups that the women’s movement’s goals were far less important than that of
the broader civil rights movements.
8  For a vivid example of the changes compare diagnostic categories in the first,
second, and third editions of the Diagnostic and Statistical Manual of the American
Psychiatric Association.  Overall, the first edition attempts to merge interests of
Concerns rose and fell alongside the Women’s Movement that prescribing Valium
mainly to women indicated society’s sexism; the Women’s Movement raised awareness
of Valium’s dangers, the implication being that it thereafter declined in use.  Yet sales
of Valium, and benzodiazepines in general, did not decline until the late 1970s,6 by
which point there was both a conservative and liberal backlash against the Women’s
Movement.7  By 1980, Americans conceptualized mental illness and health in new
ways,8 emphasizing the individual’s capacity to cope as boundary between mental
4institutional psychiatrists with the newer focus on neuroses seen after World War II.  As
a result neuroses are differentiated more than in any previous diagnostic manual. 
Valium prescribing fit well with the broad categories of ‘psychoneurotic,’ ‘personality,’
and ‘psychophysiologic autonomic and visceral disorders.’  The second edition contains
only ten types of neuroses, renamed as types of  reactions; suggesting short term
treatment associated with specific events rather than long-term treatment for personality
disorders.  It maintains the same categories for psychosomatic disorders aside from re-
naming ‘neurasthenic neurosis’ as ‘psychophysiologic nervous system reaction.’  Drug
dependence on tranquilizers becomes a recognized condition. The third edition
introduces a ‘menu’ approach; disorders are defined through identification of core and
secondary symptoms.  This promotes treatment of symptoms as an appropriate path to
treatment of mental disorders.  American Psychiatric Association.  Committee on
Nomenclature and Statistics, Diagnostic and Statistical Manual for Mental Disorders,
first edition (Washington, DC: American Psychiatric Association, Mental Hospital
Service, 1952); American Psychiatric Association.  Committee on Nomenclature and
Statistics, Diagnostic and Statistical Manual of Mental Disorders, second edition
(Washington, DC: American Psychiatric Association, 1968); American Psychiatric
Association.  Task Force on Nomenclature and Statistics,  Diagnostic and Statistical
Manual of Mental Disorders, third edition (Washington, DC: American Psychiatric
Association, 1980); for an excellent description of the logic underlying creation of the
third edition see Robert L. Spitzer, B. W. Janet, M. S. W. Williams and Andrew Skodol,
“DSM-III: The Major Achievements and an Overview,” American Journal of
Psychiatry 137, no 2 (1980): 151-64.
9  In the 1960s, Valium was marketed for treatment of psychosomatic
conditions.  Today a psychosomatic condition, despite official medical definitions, is
one which is not easily diagnosed or treated within a single doctor’s specialty, which
does not fit the disease path of any recognized condition, or appears a temporary
condition associated with patient distress; it is a diagnosis associated with non-
treatment; Authors such as Dr. James Le Fanu suggest another reason for minimal
prescribing of Valium by 1990.  He argued a widespread belief that Valium was highly
addictive made patients wary of doctors prescribing the drug.  James Le Fanu, “Health:
Second Opinion,” The Independent (London) January 28, 1990. 
health and illness.  This reshaped Valium’s appropriate uses.9 
  Valium as a social entity is a stand-in for discussing the general issue of
medicalizing female problems, and the continuing tendency among psychiatrists to use
statistically gendered diagnoses.  For example, women are more often than men
510  See chapter 6.
11  Aside from Edwin M. Schur’s Labeling Women Deviant: Gender, Stigma,
and Social Control (New York: Random House, 1984), two of the best sources for these
arguments are articles by Ruth Cooperstock, and articles published in Social Science
and Medicine.  Ruth Cooperstock, “Sex Differences in the Use of Mood-Modifying
Drugs: An Explanatory Model,” Journal of Health and Social Behavior 12, no. 3
(1971): 238-244; Ruth Cooperstock, Social Aspects of the Medical Use of Psychotropic
Drugs (Toronto: Alcoholism and Drug Addiction Research Foundation of Ontario,
1974); Edward W. McCrane, “Alleged Sex-Role Stereotyping in the Assessment of
Women’s Physical Complaints: A Study of General Practitioners,” Social Science and
Medicine 12 (1978): 111-116; Constance A Nathanson, “Illness and the Feminine Role:
A Theoretical Review,” Social Science and Medicine 9 (1975): 57-62; Eva Lynn
Thomson, “Sexual Bias in Drug Advertisements,” Social Science and Medicine 13A
(1979): 187-191; Mary T. Westerbrook and Reginald A. Mitchell, “Changes in Sex-
Role Stereotypes from Health to Illness,” Social Science and Medicine 13A (1979):
297-302.
diagnosed as depressed or anxious.  Understanding gendered diagnoses is a major issue
to which a history of Valium can contribute, but it is not a widely recognized issue
before 1967.
In this dissertation I attempt to understand how Americans, particularly mental
health professionals, understood mental health and illness, the nature and purpose of
tranquilizers, and how they conceptualized Valium before the period when it became a
widely used drug.  Although most clinical trials of Valium that used outpatient
populations had at least a 60:40 ratio of female to male participants,10 few authors
publishing in medical journals before 1966 discussed why this occurred or whether it
was a problem.  By the 1970s, sociologists and medical professionals recognized
substantial discrepancies in medical diagnoses and treatments for men compared to
women.11  They questioned categories used and the factors shaping physicians’
612  Examples of the assumption can be seen in literature focusing on
feminization, the creation of female gender through socializing girls differently than
boys. Laurie Davidson and Laura Kramer Gordon, The Sociology of Gender (Chicago:
Rand McNally College Publishing Company,1979); 
13  For an excellent history of attempts to control illicit drugs in the United
States see David F. Musto, The American Disease: Origins of Narcotics Control,
expanded edition (New York: Oxford University Press, 1987).
14  From the 1940s to the early 1960s, the overwhelming proportion of
physicians were men.
treatment choices.  That men and women were substantially the same was sometimes a
tacit assumption.12  Increased focus on addiction and dangerous controlled substances
after 1970 promoted Americans looking back at Valium and seeing something
obviously addictive;13 experts who failed to recognize the danger must have been
negligent.  Perhaps physicians knew the drug was addictive and prescribed it
nevertheless, or the insidious drug companies bamboozled physicians, hiding
knowledge of the drug’s dangers as they squeezed all profit possible from unnecessary
prescriptions.14  Looking back beyond the 1971 declaration of President Nixon’s War
on Drugs, it is easy to see danger in substances which prewar people, even medical
exerts, rarely noted.  
Framing Roche’s development and marketing of Valium without reference to
the period after 1963, the widespread use of Valium within the context of contemporary
‘knowledge’ appears rational.  After World War II, Americans were more aware of
mental health; they knew stressful conditions wrought havoc on the body, caused
neuroses and psychosomatic disorders in otherwise seemingly healthy individuals, and
7they were personally at risk.  Openly taking tranquilizers during the day, not being in
perfect mental health, no longer put them outside the boundaries of ‘normal’ members
of society or into a dependent role.  In the early 1960s, normal medical science
explained anxiety as some dangerous or complicating factor underlying multifarious
medical ailments.  Physicians, and more so the popular press, highlighted interaction
between psyche and soma, mind and body, in all illnesses.  With better tranquilizers,
physicians finally had the ability to treat not only neuroses, neurotic reactions to stress
or personality disorders, but also psychosomatic disorders, and anxiety and tension with
mainly somatic disorders.  The nation’s strength required creation of strong independent
citizens, of men freed from the fetters of their own upbringing and history. 
Tranquilizers reduced anxiety and apprehension, calmed emotional fear based on
previous experience, and freed people to interact with the present in an informed and
rational, not emotional, manner.  There was a national push to prevent severe mental
illness through preventive or early treatment of neuroses, addiction, social and
personality disorders.  Why wouldn’t a doctor prescribe Valium as freely as Aspirin? 
Didn’t he care for America?  Preventive action wiped out polio, why not severe mental
illness?  Didn’t he trust science?
It is easy to point flippantly to the time being ripe for Valium to sweep into use,
painting a false picture of historic inevitability.  This approach abdicates the historian’s
responsibility, using some black box causal agent entitled ‘culture.’  The idea of Valium
as inevitable can foster a search for someone to blame for later-seen problems: a
8gullible and frightened public wanting a medical cure for social problems, doctors
beguiled by advertising, or a medical community refusing to accept evidence of
Valium’s addictiveness.  Valium’s rise and fall as inevitable can act as background for
illustration of change in women’s social position, to argue the dangers of unregulated
marketing to doctors, or point out changes in how people related to physicians.  Each of
these interpretations is incomplete.
This dissertation proposes another possibility; widespread prescription and use
of Valium made sense in the mid-1960s for a wide variety of reasons: how men and
women interpreted physical and psychological problems, what physicians and
psychiatrists thought they could and should do to help, and how Hoffmann-La Roche
marketed a drug they had reason to believe beneficial as well as profitable.  Examining
broad patterns of contemporary medical knowledge, beyond specific changes in detail,
suggests how Americans understood mental health, the roles of anxiety, stress, and
tension, and the framework within which Valium was discovered and developed, and
conditions around physicians’ common decisions to prescribe Valium and similar minor
tranquilizers.
Terminology and Assumptions
My choice of wording in this dissertation, overall, is intentional even where
seemingly sloppy.  Use of the terms ‘pharmaceuticals,’ ‘prescription drugs,’ ‘ethical
drugs,’ and similar subgroupings constrain discussions of Valium. ‘Pharmaceutical’
9implies a substance has medicinal value, intentionally composed through chemical
synthesis.  This terminology omits some opiates and naturally occurring substances
with psychotropic effects.  ‘Prescription drug’ overtly classifies drugs based on method
of acquisition, and implies the government, physicians, and pharmacists support its use. 
The alternative term ‘ethical drug,’ will not be used, because it is too historically
specific, based on the way large-scale and self-regulating or industry-self-regulating
manufacturers defined their separateness from new, small-scale, firms with little
reputation to lose from unethical behavior. 
I have chosen to use the term drug in many contexts.  Referring to Valium
(diazepam) as a drug removes preconceptions regarding the rationality of its use,
whether it was addictive, and whether it should have become a controlled substance. 
What is more important, the term drug allows comparison of Valium with barbiturates
and alcohol, drugs commonly used for similar purposes.  As with Valium, most people
obtained barbiturates by prescription, even though barbiturates faced restrictions on use
earlier and more thoroughly than did Valium.  Both were sleep aids, relieved stress and
tension, used to treat alcoholism, and reduced tremors.  Alcohol was a popular
nonprescription alternative to Valium; a widely used drug, it served as an imperfect
tranquilizer, reducing tension and stress, but with problematic side effects.  Leo
Sternbach, the chemist who first synthesized Valium, recognized the link; when talking
to a reporter about Valium he said “My wife doesn’t let me take it,” and continued with
10
15  Anon.  “Chemist Gave World Valium,” National Post (Canada) October 3,
2005.
16  See chapter 5.
the quip “I like Scotch.”15
Construing Valium as a drug, rather than a pharmaceutical, implies a broader
context.  Widespread tranquilizer use was not new in the 1960s.  Mother had little
helpers before; dishwater was not the only thing sloshed in the suburban kitchen. 
Looking at Valium as part of a second wave of tranquilizers, within the story of
developing minor rather than major tranquilizers, is also over-confining.  Roche
developed Valium as part of a research program attempting to create an improved
version of mephenesin, a muscle relaxant which predates the beginning of the
psychopharmaceutical revolution (typically the starting bell is the 1953 introduction of
chlorpromazine to psychiatry).16  Hoffman-La Roche’s benzodiazepines had roots in the
1940s, an age when physicians treated women complaining of insomnia, anxiety,
worry, or nervousness with barbiturates, while they prescribed themselves an after work
martini for similar complaints.
I toss the terms ‘anxiety,’ ‘stress,’ and ‘tension’ around in the following chapters
with apparent abandon.  In part this is intentional, reflecting similar conceptual
slipperiness within writings of the time.  To the extent I can tease out separate meanings
from sources of the late 1940s through early 1960s, ‘anxiety’ refers to distressing
heightened apprehension within the mind and body, and without currently reinforcing
11
17  Cannon’s more important writings can be found in books summarizing his
research.  Walter B. Cannon, Bodily Changes in Pain, Hunger, Fear and Rage; An
Account of Recent Researches into the Function of Emotional Excitement (New York:
D. Appleton and Company, 1920); Water B. Cannon, The Wisdom of the Body (New
York: W. W. Norton & Company, 1939); Walter B. Cannon, The Way of An
Investigator, A Scientist’s Experiences in Medical Research (New York: W. W. Norton
& Company, 1945); Russell Charles Maulitz, Walter B. Cannon: Scientific Explanation
in Regulatory Physiology (Boston: Unpublished Thesis, Harvard University, 1966);
Elin L. Wolfe, A. Clifford Barger, and Saul Benison, Walter B. Cannon, Science and
Society (Boston: Harvard University Press, 2000).
external causes.  Physically, anxiety existed as an adrenal-feedback loop, wherein
anxiety led to the heightened alertness which was anxiety; it could be cause or effect. 
‘Tension’ more commonly refers to whole-body behavior; it was a state including
psychological as well as physical (mainly muscle) effects.  Tension was an effect of
anxiety or stress.  ‘Stress’ was the most general of the three terms, used to refer to a
cause and effect, internal and external event, a thing and a state.  Although all three
terms tie into the theoretical framework of homeostasis and General-Adaptation-
Syndrome, the nature of stress is most tightly bound to these concepts.
‘Homeostasis’ and ‘General-Adaptation-Syndrome’ refer to ideas pervading
medical thought in the 1950s.  I deal with these concepts more fully in chapter three. 
Walter Cannon, in the 1910s, argued the body responded to stresses in many ways, but
with a goal of returning to the original, dynamically balanced state, homeostasis.17 
Stressors were anything causing deviation from homeostasis.  Stress in general harmed
the body.  Usual stressors caused minimal damage, but excessive stress could manifest
in a wide variety of somatic conditions.  Hans Selye’s General-Adaptation-Syndrome
12
18  Over the course of his career, Selye moved from physiological/medical
research, to administration, theory, and proselytizing his theories.  Hans Selye, The
General Adaptation Syndrome of the Diseases of Adaptation (n.p.: Association for the
Study of Internal Secretions, 1946); Hans Selye, The Physiology and Pathology of
Exposure to Stress; a Treatise Based on the Concepts of the General-Adaptation-
Syndrome and the Diseases of Adaptation (Montreal: Acta, 1950); Hans Selye, The
Story of the Adaptation Syndrome: Told in the Form of Informal, Illustrated Lectures
(Montreal, Acta, 1952); David Le Vay, “Hans Selye and a Unitary Conception of
Disease,” The British Journal for the Philosophy of Science 3, no. 10 (1952); Nancy E.
Gross, Living With Stress. Forward by Hans Selye (New York: McGraw-Hill, 1958);
Russell Viner, “Putting Stress in Life: Hans Selye and the Making of Stress Theory,”
Social Studies of Science 29, no. 3 (1999).
was a slightly more dynamic version of homeostasis.18  Facing stressors, Selye argued,
an individual tried to adapt.  When adaptation failed or was impossible, physical
problems developed.  Selye argued these failures of adaptation took common forms;
they were a syndrome.  In both Cannon’s homeostasis and Selye’s General-Adaptation-
Syndrome, focus is on the manifest physical ailments resulting from environmental
stress.
Physicians prescribed Valium for a diverse group of psychiatric and somatic
conditions.  In general, the psychological ailments were neuroses rather than psychoses;
functional problems of personality, manifestation of psychological problems
physiologically, and behavior associated with stereotyped responses to internal or
external stressful stimuli.  Variously termed psychophysiologic or psychosomatic
disorders, neurotic reactions, neurotic personality, anxious personality, or anxiety
reaction, one symptom underlay all…anxiety.  Although boundaries between these
groups were nebulous, and practitioners applied them in particular ways, the core ideas
13
differ.  Neurotic reactions were considered responses of a fairly normal or mature
personality to ongoing or extreme external stressors.  Worry and hand-wringing after
death of a parent might fit this prognosis, and warrant prescription of Valium to ensure
the bereavement period was short and failed to cause more lasting physical or mental
problems.  Neurotic personalities required long-term treatment to prevent physical or
behavioral problems.  Neurotic people had immature personalities, often overreacted to
minor stresses, and commonly developed self-sustaining, and fairly unfixable, neuroses. 
Valium prevented these over-reactions developing into neuroses.  An anxious
personality was similar to a neurotic personality, possibly manifesting fewer
stereotyped responses.  Compared with anxiety reactions, an anxious personality
involved self-perpetuating anxiety, while anxiety reaction identified a person prone to
overreact to external stresses.  All these conditions included a component of anxiety,
and therefore treatable with Valium.  Each could lead to psychosomatic disorders,
somatic illnesses caused and perpetuated by anxiety.  When used to treat psychiatric
illness, Valium treated symptoms, but in treating psychosomatic disorders it neutralized
the underlying cause.
Synthesis of 7-chloro-1,3-dihydro-1-methyl-5-phenyl 2H-1,4-
benzodiazepin-2-one, also known as Valium
Leo Henryk Sternbach, whose discovery of the benzodiazepines led to Roche’s
marketing of Librium and Valium, was part of the larger group of “organic medicinal
14
19  Milan Uskovic, preface comments to Good Chemistry: The Life and Legacy
of Valium Inventor Leo Sternbach, by Alex Baenniger, Jorge Alberto Costa e Silva, Ian
Hindmarch, Hans-Juergen Moeller, and Karl Rickels (New York: McGraw-Hill, 2004),
iii.
20  Milan Uskovic, in Baenniger et al, Good Chemistry, iii; Sternbach received
patents for these processes and assigned rights to Hoffmann-La Roche.  For example,
see Leo H. Sternbach, assignor to Hoffmann-La Roche Inc.  1946.  Process of
Epimerizing Calcium δ-Arabonate.  U.S. Patent 2,438,881, filed February 12, 1946, and
issued March 30, 1948; Moses Wolf Goldberg and Leo Henryk Sternbach, assignors to
Hoffmann-La Roche, Inc. 1949. Debenzylation of Benzylated Imidazolido-Thiophane
Compounds. U.S. Patent 2,489,238, filed June 8, 1948, and issued November 22, 1949.
21  The related patents included Leo Henryk Sternbach, assignor to Hoffmann-La
Roche, inc.  1959.  1,4-Benzodiazepines 4-Oxides.  U.S. Patent 2,893,992, filed May
15, 1958, and issued July 7, 1959; Earl Reeder and Leo Henryk Sternbach, assignors to
Hoffmann-La Roche, inc.  1962.  Benzodiazepine Compounds.  U. S. Patent 3,051,701,
filed December 10, 1959, and issued August 28, 1962; Rodney Ian Fryer, Robert
August Schmidt and Leo Henryk Sternbach, assignors to Hoffmann-La Roche, inc. 
1963. 5-Prydiyl-1,4-Benzodiazepine Compounds.  U.S. Patent 3,100,770, filed August
11, 1961, and issued August 13, 1963; Leo Henryk Sternbach and Gabriel Saucy,
assignors to Hoffmann-La Roche.  1964.  2-Methyl-7-Trifluoromethyl-4H-3,1
Benzoxazine-4-one.  U.S. Patent 3,120,521, filed March 23, 1962, and issued February
4, 1964; Oscar Keller, Norbert Steiger, and Leo Henryk Sternbach, assignors to
Hoffmann-La Roche, inc.  1964.  Aminobenzodiazepines.  U.S. Patent 3,121,075, filed
May 28, 1962, and issued February 11, 1964; Oscar Keller, Norbert Steiger and Leo
chemists”19 who moved to the United States from the increasingly desperate situation in
1930s and 1940s Europe.  Hoffmann-La Roche, a Swiss company, hired Sternbach and
set him to work in Nutley, New Jersey, on synthesis of vitamins.  Within a few years he
established his reputation with a commercially viable method of synthesizing biotin,
vitamin B7.20  This success led to promotion and recognition.  In the 1950s, when Roche
began putting significant resources into the search for tranquilizers, Sternbach joined
this effort.  Within a few years he would gain fame for his discovery, synthesis, of a
new group of tranquilizers, the benzodiazepines.21  As one of his associates explained,
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Henryk Sternbach, assignors to Hoffmann-La Roche, inc.  1964.  Substituted-1,4-
Benzodiazepine-5-one Compounds.  U.S. Patent 3,121,077, filed May 28, 1962, and
issued February 11, 1964; Earl Reeder and Leo Henryk Sternbach, assignors to
Hoffmann-La Roche, inc.  1964.  Amino Substituted Banzophenone Oximes and
Derivatives Thereof.  U.S. Patent 3,136,815, filed November 2, 1961, and issued June
9, 1964.  
22  Milan Uskovic, in Baenniger et al, Good Chemistry, iii.
23  For an example of the story as told by Sternbach see: Leo H. Sternbach, The
Benzodiazepine Story (Basle, Switzerland: Editiones Roche, 1983), 8-12; to compare
‘stories’ for Ehrlich and Fleming see Paul de Kruif, Microbe Hunters (New York:
Harcourt, Brace and Company, 1926); Gwyn MacFarlane, Alexander Fleming: The
Man and the Myth (Cambridge: Oxford University Press, 1985).
24  Lloyd Shearer, “The Man Who Invented Valium,” Oakland Tribune
(Oakland, CA), June 27, 1976.
“He decided to reexamine the chemistry of his student period in Poland and resurrected
the benzodiazepines into the most significant series of drugs to combat anxiety[.]”22
Sternbach couched his account of the discovery in terms highlighting
similarities to Paul Ehrlich’s discovery of Salvarsan (for syphilis), and Alexander
Fleming’s discovery of Penicillin.23  Based on solid scientific principles and insight, he
decided on an approach; Sternbach turned to modification of certain azo dye
intermediaries, known as 4,5-benzo[hept-1,2,6-oxidiazines] because of his previous
experience modifying them.24  Expecting a process with high yields, similar structures
to existing tranquilizers, and ability to create a wide variety of side chain variants
(assumed important in conferring bioactive characteristics), he found lack of useful
resulting compounds a disappointment.  It appeared his hard empirical work was all in
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25  Sternbach recalls his efforts as an empirical and planned approach. 
Sternbach, The Benzodiazepine Story, 7.
26  Baenniger, et al., Good Chemistry
27  Sternbach, The Benzodiazepine Story, 11.
28  Baenniger et al, Good Chemistry, 51-52.
29  Leo Sternbach from The Benzodiazepine Story as quoted in Baenniger, et al,
Good Chemistry, 51-52.
vain.25  One of his superiors “demanded that he abandon his work”26 and turn to other
matters.  But, as with Ehrlich and Fleming, hard work ended with near failure and
serendipitous success.  Needing to free up laboratory space, Sternbach focused his
attention on compounds already synthesized, but hitherto untested.27  He recalled how
“Earl Reeder, my coworker, drew my attention to a few hundred milligrams of two
products, a nicely crystallized base and its hydrochloride.”28  Although synthesized in
1955, the compounds remained untested.  According to Sternbach, other tasks in the lab
pushed aside research on these compounds.  Yet, when faced with cleaning up the lab,
“instead of throwing them away, we submitted the water soluble salt for testing.”29
My personal cynicism regarding myths of heroic inventors – because they fit
tidily with both the expectations of American society and contingencies of the patent
system – resulted in this dissertation looking at the ‘discovery’ of Valium more broadly. 
Roche set up a laboratory to search for certain types of substances; they risked capital
for a long-term pay-off.  For five years Roche allowed Leo Sternbach to experiment, to
develop new compounds.  It is improbable they gave him rein simply to substitute side
17
30  See the end of chapter five and beginning of chapter six for discussion of the
types of compounds and tests used at Roche.
31  This trend was general for chemistry, not specific to pharmaceutical
development.
chains on a new molecule chosen simply because he had experience with them as a dye-
stuff,30 even if prevailing theories in drug development argued substitution of side
chains modified properties.31  Creating new pharmaceuticals wholesale, without choice
of a central compound based on known activity, is what Sternbach recollects.  Leaders
at Roche invested in a financially promising field, presumably tranquilizers.  But
looking more closely at how physicians and scientists understood tranquilizers helps
explain why the Roche pharmacology laboratory identified the usefulness of
Sternbach’s synthesized compounds.  Understanding the relationship between
Sternbach’s discovery and Roche’s development and marketing of Valium requires
greater focus on the role of pharmacological testing.  Sternbach submitted a substance;
Lowell Randall recognized it had properties the company desired.
Overview
This dissertation draws out different facets of the conditions preparing and
situating Valium as a marketable substance and cultural entity.  It offers explanation for
the widespread prescription and use of Valium in the 1960s.  Due to constraints of time
and space, it only sets up future discussions of why Valium became associated with
women, questions of addictiveness, and why it declined in use. 
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Chapter two discusses the shift from mental health and mental illness as discrete
entities to a continuum, with most Americans either neurotic or potentially neurotic; a
view rising rapidly to prominence during and shortly after World War II.  This change
made it possible to see tranquilizers’ usefulness for improving or protecting the mental
health of a substantial portion of Americans.
Chapter three focuses on increasing interest in mental health as an integral part
of treating psychological, psychosomatic, and somatic based illness.  After World War
II, Congress set up national programs and studies to protect Americans’ mental health. 
In part, justification came from efforts to prevent debilitating long-term mental illness,
something newly considered possible, and necessary for financial reasons.  The new
psychopharmaceuticals tumbling out of pharmaceutical companies, after 1953, offered
the possibility of turning back the rising tide of the long-term institutionalized mentally
ill, affordably.  
Chapter four examines another side of the equation, how physicians,
psychologists, and scientists understood the nature of stress, anxiety, and neuroses. 
Although traditionally discussed as relatively distinct, psyche and somatic based
theories became increasingly intertwined by the 1950s.  Combination of these theories
is evident in the work of Jules Masserman and Horsley Gantt, two of the most
influential figures establishing externally measurable characteristics associated with
neuroses in laboratory animals.  These theoretical underpinnings informed Roche’s
search for a marketable compound; events leading to the synthesis by Leo Sternbach of
19
a compound eventually marketed as Valium.
Chapter five focuses on how physicians, scientists, and allied health
professionals conceptualized existing psychopharmaceuticals.  They associated
tranquilizers, sedatives, and hypnotics with specific actions within the body and with
observable signs.  The chapter includes discussion of how drugs affecting the psyche
related to one another, their categorization and presumed modes of action.  A
substantial portion of the chapter examines the chain of events at Hoffmann-La Roche
leading to Leo Sternbach’s discovery of the chemical compounds later introduced into
the American market as Valium.
Chapter six examines Valium’s transition from chemical compound, to a drug
worthy of further study and marketing.  I focus first on the battery of pharmacological
tests performed by Lowell Randall in company laboratories.  Randall tested Sternbach’s
compound, and identified it as a tranquilizer worthy for Hoffmann-La Roche to put
substantial resources towards clinical testing and marketing.  The specific battery of
tests Randall chose, reflects properties associated with potential market competitors; it
suggests how medical and pharmaceutical scientists conceptualized tranquilizers, as
well as the specific substances Roche saw as competition.  Clinical trials further shaped
and informed potential marketing approaches; shaping Valium as a treatment for
psychiatric and psychosomatic conditions.
Chapter seven outlines Roche’s early marketing efforts, tying together
contemporary understandings of mental health and illness, in an effort to understand
20
why Valium became so widely used.  Roche’s compound entered a marketplace filled
with popular, preexisting tranquilizers, sedatives, and hypnotics.  Contrary to
expectations of hindsight, which suggests marketing Valium as Mother’s Little Helper,
Roche’s marketing program focused mainly on psychosomatic conditions and the
anxiety component of somatic illnesses.
The chapter concludes with brief discussion of Valium’s rapid rise in popularity,
and reflections on how understandings of mental health and its relationship to minor
tranquilizers might shed light on continuing debates about Valium’s place in history. 
After its introduction in 1963, Valium rose in use, becoming the most prescribed brand-
name drug by 1969.  The chapter draws together earlier portions and suggests how
Valium fit into contemporary ways of conceptualizing medicine, the mind, and the
body.
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32  Military psychiatry in World War One is largely remembered for the concept
of shell shock transforming from a physiological to psychological condition.  It well
represents that the focus during the Great War was on inner mental factors.  One of the
most clear contemporary statements of the theoretical approach can be found in a 1919
volume of Science.  W. H. R. Rivers wrote “One, and perhaps the most important out-
come of this combined activity has been the general recognition of the essential part
taken in the production and maintenance of the psycho-neuroses by purely mental
factors.  In the early stages of the war especial stress was laid in the physical effects of
shell explosion, an attitude which found expression in the term shell-shock.  As the war
has progressed the physical conception of war-neurosis has been gradually replaced by
one according to which the vast majority of cases depend on a process of causation in
which the factors are essentially mental.” W. H. R. Rivers, “Psychiatry and the War,”
Science 49, no. 1268 (1919): 367.
CHAPTER 2. ADAPTATION UNDER PRESSURE: 
EFFECTS OF WORLD WAR II 
ON DEVELOPING CONCEPTS OF NEUROSES
World War II was a crucial turning point in the behavioral sciences.32 
Commonalities of experience among American medical and mental health professionals
in World War II, specifically the interaction between the war experience and changes in
conceptualization of mental health and illness, created new truisms.  World War II
established the concept of mental health and illness as a continuum, that prevention or
early treatment was essential to ensure neurotic reactions did not develop into full-
blown and strongly fixed neuroses, and that mental health – especially prevention of
neuroses – was a broadly important social issue.  The prewar concept of mind and self
as inner- and inter-acting phenomena shifted towards greater focus on interaction of a
fixed personality and a changing world.  People adjusted to reality, to social role.  Too
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harsh or sudden a change exceeded a threshold of stress, leading to stereotyped and less
adaptive responses.  To an extent people could modify environment or social role, but
between 1945 and 1965 focus was on returning to the norm, to stability, to accepted
role within mainstream, middle-class, American definitions of social place.  The newly
established need to promote mental health and treat mental illness increased focus on
mental issues throughout American culture.  When the war ended, the newly trained
mental health professionals returned to the U.S. with more status and a far, far, larger
potential clientele.
Changes solidifying during World War II provided fertile ground for
development and marketing of tranquilizers, including Valium.  The new understanding
of mental illness as a continuum, with mental health as a goal rather than a state,
increased the experts’ tendency to focus on neuroses rather than psychoses or organic
illness.  Psychiatrists continued identifying severely mentally ill individuals, but after
the war there was a newly identified massive population of neurotic, or seemingly
normal preneurotic, Americans who needed protection lest stressors lead into relatively
untreatable full-blown neuroses.  Prevention of mental illness, and treatment at the
earliest stages, became essential.  Roche highlighted Valium’s usefulness as a
preventative in its advertising campaigns.  The shift from conceptualizing neuroses
mainly in terms of inner conflict, towards focus on interaction between an individual
and its environment, placed focus on reactions to stress rather than resolution of
conflicts.  Roche marketed Valium, at least in part, as a substance mitigating
23
33  At this time the majority of psychoanalysts, and other varieties of
psychotherapists, held medical degrees.
overreaction to stressful situations or conditions.  Dissemination of knowledge within
the military created a cadre of general physicians taught to consider mental health. 
Among soldiers, direct training or experience with mental health ideas, as well as
routinization of concepts such as group morale, importance of leadership, and
regularization of rest and relaxation, inadvertently taught them principles of the new
mental health.
Preparing for War
In the early 1940s, practitioners dealing with mental illness fell into two main
groups based on where they practiced, clinic or institution.  Clinical psychiatrists and
psychotherapists usually saw a small handful of financially well-off patients with
neuroses.33  To them, neuroses resulted from maladaptation, blocked development of
internal drives, or conditioned responses.  The problems resulted in inappropriate,
inefficient, stereotyped, or primitive responses.  Treatment focused on developing a
patient’s insight, the ability to understand underlying motivations and therefore respond
to the environment effectively, unhindered by the past.  Institutional psychiatrists
worked mainly with physical treatment of institution-based patients, often those
suffering from psychoses.  They considered many of their patients chronic cases and
untreatable.  Most of the population in mental care institutions suffered from conditions
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34  Howard McC. Snyder, “Observations of Psychiatry in World War II,”
American Journal of Psychiatry 104 (March 1947): 222; Francis J. Braceland,
“Psychiatric Lessons from World War II,” American Journal of Psychiatry 103 (March
1947): 587; David J. Flicker, “Army Psychiatric Literature, Factors in Interpretation,”
American Journal of Psychiatry 98 (May 1942): 796; Uno H. Helgesson, “Some
Current Features of Psychiatry in the United States Navy,” American Journal of
Psychiatry 99 (March 1943): 633;   William C. Menninger, “Psychiatric Experience in
the War, 1941-1946,” American Journal of Psychiatry 103 (March 1947): 580.
35  Braceland, Psychiatric Lessons, 587; military planing before the war was
extensive, allowing relatively quick recruitment, training, arming, and deployment of
troops.
36  The Navy situation differed substantially in terms of planning and
expectations.  The Navy and Marines developed a plan for identification and
dispensation of potential neuropsychiatric cases toward the end of 1938.
such as extreme vitamin deficiencies, dementias resulting from syphilis, manic-
depression, and schizophrenia.  Most military psychiatrists at the beginning of World
War II were institutional psychiatrists, accustomed to large caseloads, managing
chronic cases, and focusing on care of the body with little hope of curing the mind.34
The United States entered World War II relatively late.  Internal debates over
the utility, morality, and need to play an active role delayed national action.  But, once
engaged, the United States turned to a military footing quickly and dramatically.  The
Marine Corps and Navy expanded from 403 thousand in early December 1941 to
number almost 3.9 million when Japan surrendered in 1945.35  Because of rapid
mobilization, flaws in existing systems rapidly became obvious.
Military leaders proved ill-prepared for neuropsychiatric problems among the
troops.36  Medical leaders held relatively little clout within the military, especially the
Army.  Assistant Surgeon General of the Navy, Captain Dallas G. Sutton, explained
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37  Anon, “Medical Officer Announces Plans for Psychiatry in War,” The
Science News-Letter 35, no.11 (1939): 165.
38  Lawrence S. Kubie claimed only one article was published in a U.S. military
medical journal on the problems related to screening recruits between Armistice and
Pearl Harbor days.  “Technical and Organizational Problems in the Selection of
Troops,” Military Affairs 9, no.1 (1945): 16; psychiatrists published articles relating to
the issue in their own journals.
39  Paul Wanke, “American Military Psychiatry and Its Role Among Ground
Forces in World War II,” The Journal of Military History 63, no. 1 (1999): 137.
40  Menninger, Psychiatric Experience, 579.
41  The term neuropsychiatry defined a field encompassing all disorders of the
nervous system, including epilepsy, what were believed to be organic based
dysfunctions–such as schizophrenia, dementias, and idiocy–as well as functional
disorders–over or under stimulation, fatigue, poor transmission–of the nervous system
and its integrating portions of the brain.  Neuropsychiatry was therefore focused on
physical aspects of the mind and behavior, but this was not deemed incompatible with a
psychoanalytic outlook.
recruitment screening plans to “weed out psychopaths and potential victims of mental
disease[,]”37 to the public in early 1939; Army medical leaders were in a poor position
to bring similar plans to fruition.38  The Army Surgeon General was not a member of
the General Staff, so although charged with organizing medical services for the entire
Army, he lacked access to the corridors of power.  He reported to the Commanding
General of Service Forces, who oversaw fields such as the Quartermasters and Military
Police.39  The Surgeon General did not directly command medical personnel, and the
Army Air Force was outside his direct jurisdiction.40  Marginalization of psychiatry,
usually termed neuropsychiatry,41 was even greater than medicine in general.  Between
World Wars, Army physicians numbered around twelve-hundred, only thirty-seven of
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42  Wanke, American Military Psychiatry, 132
43  Wanke, American Military Psychiatry, 130.
44  Anon, “Men up for Army Training Will Have Psychiatric Examination,” The
Science News-Letter 38, no. 21 (1940): 334-35.
45  Menninger, Psychiatric Experience, 583.
46  Snyder, Observations of Psychiatry, 221.
whom the military classified as psychiatrists.42  The 1939 Military Medical Manual
exemplifies marginalization of mental illness.  Only one of its 685 pages covered
mental health.43 
The American Psychiatric Association created its own Military Mobilization
Committee, to advise and promote the role of psychiatrists during the conflict.  Citing
the same problem of a staffing crisis they, and individual members, promoted ‘home
service’ among older psychiatrists who, although too old for active service, could work
at induction centers within the United States.44  Recognition of need for screening
recruits was more widespread than reflected in actual, well-formed, and practical plans
ready for Army use.
Therefore, when the United States entered the war, military provisions for
mental health were sparse where they even existed.  There were no psychiatrists
assigned to existing combat divisions.  There were virtually no plans for treating mental
casualties, by fiat or expectation.45  Offices of the Surgeons General of the Army and
Air Forces had few mechanisms to coordinate efforts.46  Military headquarters lacked a
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47  Menninger, Psychiatric Experience, 581, 583.
48  Anon, “Men Who Break in Army Life Problem to Army Physicians,” The
Science News 40, no. 10 (1941): 148.
49  William C. Porter, “The Military Psychiatrist at Work,” American Journal of
Psychiatry 98 (November 1941): 319; Robert Knight estimated the cost per patient for
Veterans suffering from war neuroses at $30,000, largely due to need for lifelong
treatment.  Robert P. Knight, “The Treatment of the Psychoneuroses of War,” Bulletin
of the Menninger Clinic 7 (1943): 148.
50  Hugh E. Kiene and Major Arthur S. Hasell and Himon Miller, "Neuro-
psychiatrist to plan improvements.47  A 1939 American Psychiatric Association survey
concluded the Army needed a minimum of one psychiatrist per five-thousand soldiers;
rates existing in the Navy predicted need for one hundred fifty trained psychiatrists,
minimum.  Current staffing levels sat well below estimated need.48
Screening Recruits
Military leaders involved in neuropsychiatry recognized mental illness as an
economic and military manpower problem, but one they believed controllable by
preventing the medically ill from becoming soldiers.  Lieutenant Colonel William C.
Porter, Chief of the Neuropsychiatric Section at Walter Reed General Hospital, reported
that the Veterans Administration spent over 640 million dollars between 1923 and 1940
on veterans with neuropsychiatric disabilities.  Veterans’ facilities devoted almost one-
third of their resources to neuropsychiatric casualties.49  The interwar Army lost almost
two percent of its total man hours due directly to these hospitalizations, and indirect
“damage done to Army morale” was undoubtedly far greater.50  Clearly military
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Psychiatric Examination at the R. I. Army Induction Station," American Journal of
Psychiatry 98 (January 1942): 509.
51  Porter, Military Psychiatrist at Work, 319; Kiene noted this view when he
wrote, “members of the army medical staff stated that mental misfits had no place in the
Army as the personnel was too fully occupied...to allow time for proper diagnosis,
placement and treatment of those showing neuro-psychiatric problems.”   Kiene, Hasell
and Miller, Neuro-Psychiatric Examination, 509. 
52  Anon, Men Who Break in Army Life, 148; Flicker,  Army Psychiatric
Literature, 797; Kiene argued identifying and eliminating more ‘mental cases’ could
have reduced the massive financial burden of caring for WWI veterans with war
neuroses.  Kiene, Hasell and Miller, Neuro-Psychiatric Examination, 509.
efficiency required preventing these hospitalizations.  Editors of the neuropsychiatry
volume for The History of the Medical Department of the United States in the World
War argued it would have been better practice to reject all draftees thought mentally
unfit rather than burden the Army with the threat to morale and manpower required to
deal with them.  These editors’ proposed measure reflected the dominant military
solution.51  Rules set out by the Surgeon General’s office dictated that after ninety days
wartime service, the military assumed a soldier had been healthy when he first enlisted;
after ninety days of service, Uncle Sam’s dollar paid for treating medical problems. 
Early identification allowed the military to release soldiers while in training, or when
potential recruits, before the military obligation to treat them for the full course of an
illness kicked in.52
Therefore, psychiatric preparation for World War II focused on identifying
potential recruits who were mentally ill before they joined the Army, and quickly
weeding out new soldiers unsuitable for service.  Initial recruitment methods were slow
29
53  Kiene, Hasell and Miller, Neuro-Psychiatric Examination, 511.
54  H. H. Goldstein, “Neuropsychiatric Evaluation of the Potential Soldier,”
American Journal of Psychiatry 98 (July 1942): 29.
55  Kiene, Hasell and Miller, Neuro-Psychiatric Examination, 512-13.
and rejected a large proportion of candidates.  In November 1940, the Selective Service
began circulating Medical Circular No. 1, describing a double screening process
intended to identify neurologic or psychologic problems.  Two doctors, not necessarily
trained in the subject area, screened candidates for both organic and functional
problems, including mental deficiency, alcoholism, and other psychopathologies. 
Classification of mental disorders into organic and functional was common at the time. 
Psychiatric typologies used the classification ‘organic disorder,’ for conditions they
believed caused by physical ailments.  These were problems of the brain.  Functional
disorders included all categories believed to have their root in dysfunction of the mind
or integration of the nervous system.  Candidates wrote 'intelligence' tests and filled in
forms 149 and 200, which provided a brief school and work record.53  Physical
examinations of eyesight, ear-nose-throat, bone structure, and teeth preceded the
neuropsychiatric examination; only once a recruit passed inspection for flatfeet was his
mental structure considered.54  Work and police records provided insight into behavioral
problems.  Perhaps history of hospitalization suggested mental illness or alcoholism. 
Gastrointestinal, circulatory, or cardiac problems might represent either organic
diseases, or a psychoneurotic personality.55  Written records allowed more easy
identification of neuropsychiatric problems.  Examiners referred suspected mental cases
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56  Wanke, American Military Psychiatry, 131-32.
57  Anon, Men up for Army Training, 334-35.
58  John W. Appel, “Incidence of Neuropsychiatric Disorders in the United
States Army in World War II (Preliminary Report),” American Journal of Psychiatry
(January 1946): 433.
59  Kiene, Hasell and Miller, Neuro-Psychiatric Examination, 509.
60 Flicker, Army Psychiatric Literature, 796.
61  see Goldstein, Neuropsychiatric Evaluation, 29-32, for one description of the
procedures used to identify neuropsychiatric problems, and what behaviors and/or
histories were considered indicators of various diagnoses.
to Medical Advisory Boards, which included at least one psychiatrist, for final
dispensation.56  Yet lack of trained manpower continued hindering the military’s
institutional capacity to screen recruits for neuropsychiatric problems.57  
While two percent of American recruits had been denied service in World War
One due to neuropsychiatric problems, examiners in World War II turned away twelve
percent of candidates for this reason.58  Early optimists such as Colonel Stanley, First
Corps Area Surgeon, believed this higher rejection rate to be a good sign.  The “initial
induction neuro-psychiatric examination should be able to keep out of service at least
75 percent of the potential neuro-psychiatric casualties[,]”59 he enthused.  Barring large
numbers of recruits from service, optimists such as Stanley argued, proved that the
military had arranged effective identification of most potential mental problems.
Initial screening procedures focused on diagnosis,60 identifying organic and
functional disorders.61  A history of organic disorders – severe problems such as chronic
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62  Abram Kardiner, The Traumatic Neuroses of War (New York: Paul B.
Hoeber, 1941), 502.
63  Bromberg conceptualized the interaction of personality and neuroses
similarly.  He wrote “the neurotic reactions [depend]...on the psychological aspects of
the personality.”  Norbert Bromberg, “The Role of Conditioned Responses in
Emotional Disturbances of War,” American Journal of Psychiatry 103 (July 1946): 26.
64  Harry A. Steckel, review of Abram Kardiner The Traumatic Neuroses of
War. New York: Paul B. Hoeber, 1941 in American Journal of Psychiatry (January
1942): 624.
alcoholism, schizophrenia, mania, dementia, or severe mental retardation – excluded a
man from service.  After ruling out these major problems, the main concern of
neuropsychiatric screening was assessment of personality as “determined not only by...
constitutional endowment but also by... lifelong habits of attack or retreat, or motivation
and of persistence[.]”62  Personality was a window on the future, how potential soldiers
might respond to taking orders or recover from the trauma of combat.63
When assessing the effect of military psychiatry on civilian psychiatry in the
1950s, it is important to recognize how American medical society understood
personality as a pattern of interaction between individual and society.  As the physician
Abram Kardiner explained, “[t]he emphasis is placed upon the study of the “personality
as a whole[,]” through observation focused on “functional and functioning units and
drives.”64 These were components of personality which were observable as behaviors.  
Personality was an issue of functionality, patterns of behavior in interaction with the
social body and overall environment.  It was a relationship between inherited and
developed character, and the external world.  The potential soldier of World War II was
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65  William C. Porter, “What Has Psychiatry Learned During the Present War?”
American Journal of Psychiatry 99 (May 1943): 851.
66  Porter, What Has Psychiatry Learned, 851.
67  B. H. McNeel, “War Psychiatry in Retrospect,” American Journal of
Psychiatry 102 (January 1946): 502; Bromberg, The Role of Conditioned Responses,
26.
68  Appel, Incidence of Neuropsychiatric Disorders, 433.
69  Porter, The Military Psychiatrist at Work, 317; Porter assumed this deviation
from the social norm was caused by a biological problem, but it was not observable;
Psychopathic personality was classified among disorders of psychogenic origin with no
defined somatic cause – a category also including schizophrenia, manic-depressive
psychosis, and paranoia – in one of the more widely used diagnostic manuals.  Edwin P.
a social being with predispositions “favorable for military service”65 such as
aggressiveness, respect for authority, love of competitive sports with personal physical
risk, and “non-dependence on any one individual or group[.]”66  He was a man with a
personality allowing him to adjust to military life without succumbing to neuroses.67
Thirty-three percent of those who were rejected appeared to be cases of mental
insufficiency.  Of the remainder, most rejections attributed to problems related to
personality and neurosis.  Major Appel, writing shortly after the war ended, calculated
the proportion of neuropsychological rejections in certain categories.  Examiners
rejected only six percent due to neurological disease, but thirty-one percent of potential
recruits for apparent psychoneuroses, and twenty-one percent for psychopathic
personality.68  The diagnosis ‘psychopathic personality’ identified someone who had
“shown an inability to adapt himself in a adult, socially-acceptable manner to the
demands of ordinary life[.]”69 It was, like neurosis, a personality problem, an
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Jordan, ed., Standard Nomenclature of Disease and Standard Nomenclature of
Operations. Chicago: American Medical Association, 1942.  Neuroses were separately
classified.  “Psychopathic personalities are characterized largely by emotional
immaturity or childishness, with marked defects of judgement and without evidence of
learning by experience.” Description from Clarence O. Cheney, Statistical Manual for
the Use of Hospitals for Mental Diseases (Utica, NY: National Committee for Mental
Hygiene, 1942), in Dom Thomas Verner Moore, The Nature and Treatment of Mental
Disorders (New York: Grune & Stratton, 1944), 299.
70  Goldstein, Neuropsychiatric Evaluation, 30-31.
71  Anon, Men Who Break in Army Life, 148.
72  Kiene, Hasell and Miller, Neuro-Psychiatric Examination, 513.
inappropriate or socially maladaptive pattern of behavior.  The figures for diagnosis of
organic (disease and insufficiency) versus functional disorders reflects a combination of
how rare or common problems within these classifications were, as well as the ease of
diagnosing organic disorders compared with the murky identification of
psychoneuroses.70
Important assumptions underlay the early focus on screening to keep the
mentally ill out of the military.  First and foremost is an assumption that mental illness
is usually easily identifiable.  Examiners easily screened out the obviously mentally ill;
those making it past screening at recruitment stations were problematic because “many
of them, are not ‘crazy.’”71  Although the “prevention of all future maladjustments is
impossible,” screening could minimize mental casualties.72  Personal history and a short
interview will keep seventy-five percent of these cases out, Colonel Stanley argues. 
Examination of school, work, and hospitalization history, combined with a few simple
questions, would identify most recruits with a history or potential of mental illness. 
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75  Menninger, Psychiatric Experience, 578; Appel gives similar figures but for a
slightly shorter time period.  From 1 January 1942 to 30 June 1945 there were 1.75
million men rejected by the army, navy, or marines due to neuro-psychiatric concerns
(NP).  Appel, Incidence of Neuropsychiatric Disorders, 433.  Proportionately this is the
same as other estimates, 12% or 1 in 8 potential recruits turned away for NP disorders,
and this NP disorders being the justification for 37% of all draftee/recruit rejections.
Second is an assumption that mental illness affects only a subset of the population. 
Turning away twelve percent of potential recruits suggested examiners did not expect
the other eighty-eight percent to fall prey to mental illness.  People were either mentally
ill or they were not.  These early assumptions, that mental illness was an easily
identified ‘thing’ that some people had, and the majority did not have, were early
casualties of war.73
Military procedures gradually simplified inductee screening, but keeping the
mentally ill out remained a focus.  Even with streamlined medical examinations and
placement of psychiatrists at all Army induction centers,74 perceived neuropsychiatric
conditions remained one of the most common reasons for rejecting recruits.  Between 1
January 1942 and 30 December 1945, the military turned away approximately twelve
percent of potential recruits for neuropsychiatric problems.75  Despite changed
procedures, induction centers continued to deny approximately one in eight recruits
because of mental issues.
The optimistic belief that rigorous testing and screening at induction stations
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caught most potential problems and kept these men out of service was part and parcel of
a belief in fixed and predictable personality types.  The military promoted research to
identify characteristics of the average soldier, but investigators found it far more
problematic to figure out which characteristics predicted neuroses.76  Even once staff at
Walter Reed Hospital performed such studies, the results were impractical to
implement.  Porter and his colleagues looked at a group of men who had developed
neuropsychiatric problems, then tallied the number whose life histories showed some of
the fifteen characteristics contemporary psychology suggested would be good
predictors: 
(1) Bed wetting beyond four years age. (2) Thumbsucking or nail biting
beyond six years of age. (3) Failure to engage in competitive games
involving risk of injury. (4) Tantrums in childhood. (5) Abnormal
shyness or sensitiveness. (6) Preference of playing alone. (7) Repeated
grades, difficulty with teachers, chronic truancy in school record. (8)
Abnormal fears.  (9) Shunning of girls after puberty. (10) Faints.  (11)
Excessive autonomic system reactions to emotion (12) Sulkiness under
discipline. (13) Abnormal attachment to mother after puberty. (14)
Stammering. (15) Obsessional traits.77
The study found four or more traits were “not uncommon”78 in hospitalized soldiers, but
it required six or more before it was possible “to prognosticate a probable breakdown
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under stress.”79  The main problem was, although it was possible to find characteristics
common among soldiers who did break down, the same characteristics were also
common among soldiers who did not.  There appeared no clear divide between normal
men and future neurotics.80  Normal men might be latent neurotics.81
The military’s main concern was not mental health of prospective soldiers, it
was their usefulness for the war effort.82  As Captain Francis J. Braceland explained,
“[i]t was the functional capacity of a man which was to decide his future[.]”83 Overall,
testing for neuroses was less than intensive and focused on obvious signs of
dysfunctional or maladaptive personalities.  Apart from medical history reported by the
recruit, which examiners scanned for “previous treatment or hospitalization for nervous
and mental disorders,”84 they asked the young man questions including whether he “had
any worries”85 or would admit to previous mental illness.  Examiners forwarded
suspected cases, in theory at least, for further study and dispensation.  But in large part
the focus of induction centers was to find and send on any and all men with military
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uses the term “salvage.”
89  Wanke, American Military Psychiatry, 133, 139.
potential.86  They tried to exclude those men likely to “break down if they should be
inducted[,]” but as military psychiatrists were quick to recognize, there was no clear test
certain to predict who would adapt and who would break.  “It is obvious[,]” Major
McNeel wrote with benefit of hindsight in 1946 “that no single test or battery of tests
whether of I.Q. or personality can give the answer; as to whether a man will make a
satisfactory soldier.”87
Prevention and Salvage
Gradually, mental health efforts expanded from exclusion through induction
screening to include prevention and "salvage[.]"88  Induction centers played an
important role, but Army hospitals faced increasingly high admission rates for
neuropsychiatric disorders.  In 1942, slightly more than twenty-five of every thousand
men had been in hospital for mental health reasons during the year.  By August 1943
the number had risen to sixty-seven per thousand.89  The rates of hospitalization were
higher for those serving overseas, and even higher for those in active combat.  Rates as
high as two hundred and fifty per thousand, twenty-five percent, occurred among
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infantry involved in heavy combat.90   One 1943 assessment placed war neurosis as “the
most common mental casualty.”91  Robert Knight estimated neuropsychiatric casualties
made up thirty percent of all war casualties.  Faced with a massive problem, the military
began an equally massive effort to prevent workforce loss, and return those who 'broke'
to service or to the home front as quickly as possible.92
Medical officers within the military began interpreting the problem as one of
normal individuals or slightly damaged personalities facing overly rapid adaptation,
extended, or excessive stress.93  Psychoanalytic explanations before and during World
War II generally assumed illness resulted from internal conflicts; in war, the conflict
was usually between duty and danger.94  Unconscious processes created neurotic illness
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explanations were also used.  For an example of psychoanalytic and behavioral
explanations used in tandem see Hoch, Psychopathology of the Traumatic War
Neuroses, 125.
96  It also was used to argue WWI soldiers being treated for war neuroses (what
had been called shell shock) in the Veterans Administration hospitals, had
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because of “a desire to be removed from danger[,]” which when left untreated, became
fixed by “a progressive secondary goal of wishing to receive compensation or
pension.”95   
Medical officers continued using this interpretation of neuroses caused by
characteristics of the individual as an explanation for failures of psychiatric treatment.96 
For example, Major B. H. McNeel argued “[o]ne reason for the failure to return a large
proportion of men to the front line was that even in their pre-casualty state many were
vulnerable personalities.”97  In his assessment, the developmental environment of an
individual caused the original problem, a  “vulnerability... due to the habit patterns and
learned reactions”98 which were fairly fixed by the time the man entered the Army.
It followed logically that although most soldiers did not break, anyone could. 
“No one is immune from a war neurosis[,]” warned Lieutenant Colonel Roy Grinker
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reached a similar conclusion.  McNeel, War Psychiatry in Retrospect, 505.
100  Appel, Incidence of Neuropsychiatric Disorders, 434.  Note that Appel
considers these men as sick whether they require hospitalization or not; the men are sick
even if it is not apparent in a civilian setting; Flicker similarly argues “Many soldiers
were mildly psychoneurotic prior to induction, and having a restricted adaptability, fail
in military life.”  Flicker, Army Psychiatric Literature, 797.
and Major John Speigel.99  In the same vein, Major John Appel argued most people with
identified neurotic or psychopathic personalities leading to hospitalization during the
war were “no sicker than when they came into the Army[.]”100  The sickness had simply
manifested.  Although the stresses of war rendered them unfit for service, the
underlying flaws preexisted.
It is important to note the shift, from identification and exclusion to prevention
and rapid treatment, suggests changing interpretation of neuroses.  With the earlier
understanding, physicians could identify a person who was neurotic because, although
the problem was internal, it was also ongoing and likely to include noticeable external
manifestations; it was a disorder existing within the individual.  A neurotic personality
was prone to stereotyped, inefficient, and maladapted responses.  An individual either
had this disorder or did not, they were either neurotic or not.  Increasing interest in
prevention and rapid treatment indicates a shift toward focus on neurotic reactions,
rather than neurotic personalities, as the problem.  Although some people were neurotic
in most settings, others did not manifest these maladaptive reactions except under
stressful conditions.  Neuroses could exist within the individual without external signs
before they became fixed and self-sustaining, a full-blown neurosis.  Unfortunately,
41
101  Samuel Futterman and Eugene Pumpian-Mindlin, “Traumatic War Neuroses
Five Years Later,” American Journal of Psychiatry 108 (December 1951): 401.
102  See Hoch, Psychopathology of the Traumatic War Neuroses, 125; see also
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physicians could not rapidly fix an internal disorder if it was a disorder of personality.
Prevention and rapid treatment made sense if neuroses were formed because of
neurotic reactions to stress; lessening stressors could help an individual adapt.  Samuel
Futterman, working with the Veterans Administration, suggested in 1951 that the
symptoms seen in war neuroses – startle reactions, nightmares, anxiety, depression,
aggression – were active attempts by an individual to heal itself.  “The symptoms[,]” he
explained, “must be thought of in terms of abortive attempts at self-cure through a
reliving of the original danger in small doses in an effort to master the threat[.]”101  The
earlier idea of neuroses focused on an endogenous etiology, inner and interacting drives
caused poor reactions to the environment.  Neurotic reactions, the newer concept of
neuroses, involved interaction of a person with the external environment.  Neurotic
reactions had endogenous and exogenous origins.102  The new concept included the
earlier understanding of neurotic personalities, but acquired new breadth by including
everyone who showed neurotic reactions under stress.103  It placed greater emphasis on
anxiety and stress.
Neurotic reactions manifested in affective behavior, breakdown of emotional
control, as well as somatic symptoms.  By late 1941, Allies were reporting that up to
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one-quarter of medical cases involved peptic ulcers, and believed them “due, partly at
least, to nervous strain.”104  Neuropsychiatrists could explain certain physical
symptoms, such as peptic ulcer, as psychosomatic issues.  New York psychiatrist
Sandor Rado, a man with military experience in both World Wars, suggested “The
spread of psychoanalytic knowledge is cited as a biggest reason for the changing
symptoms of war neurosis, a change also reflected in civilian practice.  Certain
symptoms have lost their effectiveness since they are labeled ‘functional,’
‘psychogenic,’ or ‘escape mechanisms.’  Others supposed to be more physical, are still
useful because they have not been so labeled.”105
An example of the overlap between earlier and later explanations is evident in
Paul Hoch’s “Psychopathology of the Traumatic War Neuroses.”  Endogenous events
caused “emotional shock”106 and conflict between drives.  The primal (id) with a desire
to escape danger conflicted with “the sense of duty”107 (superego), leading to “total or
partial collapse of the self-government of the individual” who turned to illness as a way
to resolve the conflict.  Whether or not the individual became neurotic depended on the
ability of the ego/self to negotiate a socially acceptable solution.  How
neuropsychiatrists understood neuroses informed treatment choices.  Treatment of
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110  Appel’s assessment was that most NP patients would not require
hospitalization if not for the war experience.  They could have gone without treatment,
been outpatients, or stayed in privately run sanatoria.  In this category he placed
psychoneuroses, psychopathic personality, and mental deficiency.  Appel, Incidence of
internal conflict focused on reintegrating inner drives.  Instigation of problems by
external events led Paul Hoch to also emphasize exogenous factors specific to a
soldier’s environment, including fatigue, sudden threats or catastrophic events,
isolation, or changes in his group.  Whether the individual became neurotic or not
depended on his capacity to function or adapt and return to “the normal balance of
excitation and inhibition[.]”  Appropriate treatments included: reducing stressors
(making events more predictable), maintaining strong group affiliation, preventing
anxiety and somaticization from feeding back on each other (that is treating asthma or
gastro-intestinal concerns), and providing soldiers with the time and tools to adapt
through training and knowledge about mental health, or short-term medical treatment
focused on reducing stress sufficient to allow adaptation.108  Hoch’s understanding of
neuroses illustrates the shifting focus, increasing emphasis on the role of stress causing
“previously unstable or psychologically vulnerable individuals”109 to develop neurotic
reactions.
The military medical leadership recognized the shift from civilian to soldier was
stressful, and of course the hectic periods of battle interspersed with the monotonous
boredom of military life added further stressors not seen in civilian life.110  Brigadier
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Menninger declared that “[t]here are few, if any, life situations in civilian experience
which are comparable in their demands to the amount of adjustment that is required
regularly in the Army at War.”111  One of the most important problems, according to
contemporary assessments, was the requirement for soldiers to give up a cushy, self-
oriented, civilian life; “as a free and independent American he feels the necessary curb
of regimentation.  Things are done to him over which he has no influence[,]”112
explained Lieutenant Colonel Smith.  A civilian’s life focused on “comfort and
privilege,” and “to neglect personal responsibility.”113
Descriptions of the shift from a soft life of luxury to the virile masculine
teamwork of military life abounded.  Lieutenant Colonel Smith gives perhaps the most
amusing description: 
...simple observation points out certain problems and conflicts
encountered by GI Joe which are obvious and common in his experience
as he comes into the Army.  He has been taught that this is the greatest
nation in the world; that he is free, independent, and had the right to say
and do anything he pleases. ...self-expression and individual self-
determination have been encouraged. ...paternalism has...freed him of
any great degree of responsibility and with little effort he makes a
comfortable, near luxurious living. ....  His social and religious life have
emphasized good fellowship, passivism and absolute security.  His
political life tends to say, “Let George do it.”  At home he has affection,
the choice of what he wants to eat, a $39.95 inner-spring mattress, some
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kind of gadget to make the furnace go, and the bathroom has been
moved inside the house.  He gets to work by a five-cent ride or in a car
on time payments.  He has more entertainment than he knows what to do
with by movie, radio, baseball, games, and vacation with pay.  The girls
are pretty and the friends are plentiful.  He can take or leave them just
about as he chooses.  ....  Then comes war.114
A soldier faced a regimented lifestyle; “he is told when he will get up, eat, work,
go to bed; how he will talk, walk, and behave[.]”115  He could no longer focus on being
an individual. “He has little or no feminine companionship.  He is no longer an
individual person such as he was before but is held strictly accountable to the standard
of the group.”116  Strong and positive affiliation with the group was a sign of mental
health, while feeling isolated, having poor interaction with superiors, and general
“[u]nsatisfactory adjustment to the group in which he serves”117 suggested developing
neuroses.
Increasingly, military medical professionals believed that in stressful situations
even normal individuals sometimes returned to stereotyped responses as a defense. 
This was the essence of a neurotic reaction.  As Samuel Futterman explained, a neurotic
personality used “overidealization of the past” as a “defensive function” when the
“ego’s ability to master the environment has been violently shattered by the traumatic
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event. ....  Defensively, the ego overidealizes the pretraumatic period in an attempt to
find for itself some stability, some security[.]”118  
An initial neurotic reaction could be either passing, or develop into a continuing
problem characterized by rumination and reliving the traumatic event, or generalizing
anxiety and increased somatic symptoms.119  Adrenalin played an important role in
neuroses becoming chronic, suggesting to Lieutenant Commander Bromberg that
because “the patient cannot control his ruminations recapitulating traumatic
events,...these are on a physiological level.”120  The initial threat produced epinephrine
(also known as adrenalin), which increased “irritability to external stimuli[,]”121  which
in turn primed the system so “milder ordinary ineffective stimuli result in the liberation
of still more epinephrine.  Resultant physical symptoms further increase[d] fear so both
external and internal stimuli continue[d] and increase[d] the reaction.”122
In this new conceptualization of neuroses, stress was a major cause of mental
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illness, either because it tilted a precarious balance between drives or because it altered
learning behavior and response to stimuli.  If mental health was tenuous, if no
personality was infinitely adaptable, if normal men could break under stress, there was
a serious problem.  War was stressful.  Life was stressful.  This reinterpretation of
mental illness as a continuum, with vast numbers of Americans either neurotic or
potentially neurotic, combined with focus on the role of stress, broadened the scope and
importance of mental health professionals in the war effort.
Increased Roles for Neuropsychiatry
Psychiatrists recruited into the military could not meet the increased need for
mental health professionals.  Short and intensive programs trained physicians from
other fields.  Nurses, social workers, orderlies, and general officers became participants
in mental health boot camps.  In replacement training centers, psychiatrists worked in
teams with a psychologist, a psychiatric social worker (usually from the Red Cross),
and secretaries;123 soon, these mental health professionals operated in induction centers,
regional and station hospitals, evacuation centers, outpatient units, training camps, on
transports, and in disciplinary barracks.124  A Chief Consultant, then an entire Division
of Neuropsychiatry were appended to the Army Surgeon General’s staff.125  From
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beginning beyond the pale of military planning – in an Army whose regiments included
staff veterinarians, while psychiatrists disappeared from the order of battle above the
corps level – mental health became an important locus of the war effort.126
To meet assessed need, the military needed more trained professionals.  Most
Army and Navy physicians dealing with mental health matters gained training during
military service.  The number of naval officers with some degree of psychiatric training
climbed from 25 before the war to 693.  More than half received training while in
service.127  Of the 2400 physicians acting as neuropsychiatrists for the Army during the
conflict, only 993 were members of the American Psychiatric Association (APA).128 
Although membership was less ubiquitous among clinical psychiatrists, many of the
members joined the Association during the War.  The swell in numbers illustrates the
rising importance of psychiatry within the military, the status of the APA outside it, and
the dramatic increase in self-identified neuropsychiatrists among physicians.
Increased numbers of auxiliary mental health personnel supported and amplified
efforts at prevention and treatment.  Prevention included promoting "mental hygiene"
through education,129 planning the induction and training process, promoting fixed tours
of duty, and leadership training for officers.  "From the day he is inducted the process
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of incorporating him, as a person, into the fighting forces must begin[,]" explained
Major McNeel.  Recruits learned to understand emotion and bodily function as
linked.130  They learned emotional turmoil was normal for men in their situation, but the
military expected them to work through it quickly.  Soldiers’ indoctrination taught them
that anxieties were normal, but they needed to return to the group quickly.
New Ideas, New Treatments, New Results
When prevention failed, mental health efforts throughout the military focused
on triage, rapid treatment and return to duty, hospitalization, or discharge.  Part of the
reason mental health professionals returned from the war with a shiny new image was
their proven effectiveness in treating traumatic neuroses during World War II.  During
the war, medical officials treated large numbers of men suffering from similar
conditions.  The military leadership demanded firm diagnoses and short periods of
treatment leading to rapid return of soldiers to the war or home front.  These
requirements promoted use of shortcuts through traditional psychiatric practices.  They
promoted techniques such as group therapy, the use of drugs to lessen stress and allow
the mind time to adapt.  They justified short-term psychotherapy using narcotics to
promote reliving of events (abreaction), breaking through defenses to speed
psychoanalytic treatment, or force readjustment.  To an extent these were “old
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treatments” combined with “new technologies[.]”131
Group therapy developed in the 1920s and 30s as an offshoot of earlier efforts to
educate groups of patients with physical diseases such as tuberculosis.  In the 1910s, J.
H. Pratt extended his techniques of “instruction and encouragement”132 to patients
thought to suffer from illnesses experienced in the body, but caused by the mind.  A
series of papers by Trigant Burrow pounded out the theoretical basis, beginning in 1924
with “Social Images Versus Reality.”  A formal conference on ‘Group Method’ in 1932
led to William Allen White applying the technique at St. Elizabeth’s Hospital. By the
late 1930s the technique had firm roots in the United States.133
Noting the rapidly increasing need for psychiatric services after the United
States entered World War II, leaders of the new group psychotherapy schools
approached military leaders to offer their services.  The technique became widely used,
inside and outside formal hospitals and clinics, because it made more efficient use of a
scarce resource, trained neuropsychiatrists.  Group therapy offered the prospect of
treating large numbers of patients, while allowing the psychiatrist more distance than
psychoanalysis (this theoretically increased his objectivity).  It could assist identifying
the most easily cured cases who could then receive short-term psychotherapy, and
might even give the patients in group treatment insight into their own social
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Department promoted another type of group therapy during the war, dramatics. 
Amateur and impromptu dramatics were theoretically cathartic, as well as forcing
individuals to interact in a manner suggesting the group effort was more important, but
relied on, the effort of individuals.  Meiers, Origins and Development of Group
interactions.134   
That group psychotherapy focused on improved social adjustment, through
social interaction, was part of its charm; it fit contemporary beliefs about healthy
human behavior.  People, persons, had personalities which were patterns of interaction
within the group.  Roy Grinker and L. A. Spiegel influentially argued, in Men Under
Stress, that part of group therapy’s benefits came from its approximation of
humankind’s natural situation, “as a gregarious animal seeking a satisfactory niche in
his social setting.”135  Interacting within a group promoted becoming normal, fitting in
to the norms of groups.  “By working out his problems in a small way,” Grinker and
Spiegel wrote, “he should be theoretically able to face the larger group that is his world
in an easier manner.”136  The War Department formally recognized, in its Technical
Bulletin 103, superiority of group therapy over individual therapy when the soldiers
involved were having interpersonal problems, for example, “in dealing with suspicious,
hostile and guilty feelings” because it helped “minimize(s) personal feelings.”137
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Drugs such as bromides, amytals, and barbiturates provided a more medicalized
approach to treatment of war neuroses.  Whether used to enforce rest, promote reliving
repressed events, or short-circuit the feedback of anxiety’s psychosomatic effects,138 the
ultimate goal was the soldier curing himself sufficiently to return to work.  Apart from
alcohol, the most widely used drugs were sodium amytal and other barbiturates.139 
High doses rendered patients unconscious long enough to reduce fatigue, or work
through problems in a dream-like state.  But, while the soldier tidied his mind, nurses
needed to care for his body, so the procedure drained manpower too much for
widespread use.  Moderate doses of barbiturates promoted sleep and therefore reduced
the fatigue thought to play an important role in whittling down the soldier’s mental
defenses.  Harry MacKinnon promoted use of narcotics to promote relaxation and
sedation; most of the time patients became conscious before their mental defenses
returned to full force, so “the natural curing process can get a start before the defenses
return.”140  Dosages heavy enough to shut down conscious defenses provided the
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opportunity for neuropsychiatrists to distinguish, in theory at least, the difference
between malingerers and those with true psychological problems.141
Increasingly, military physicians relied on drugs for a shortcut through
psychotherapy, usually once rest alone failed to cure.142  Hypnotic and sedative effects
lowered mental defenses, effectively putting the superego to sleep while the doctor
talked to the ego and id.  Grinker and Spiegel gained fame, within the American
Psychiatric Association at least, by using sodium pentothal and suggestion to lead
soldier into reliving their traumas.143  The general techniques, called narcosynthesis and
narcoanalysis, lacked clear boundaries between them.144  In general, narcoanalysis used
narcotics to lessen defenses, release repressed material, and thereby shorten the normal
process of psychoanalysis from years to weeks.145  Narcosynthesis was a shock-therapy
version of narcoanalysis; using drugs not only to weaken defenses, but also to reduce
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reality testing.146  Neuropsychiatrists talked soldiers through their traumatic experiences
and taught how to place the distressing events at an emotional distance.  Some patients
obtained a cathartic experience, termed abreaction.147  Because soldiers experienced
trauma in an emotional manner, narcosynthesis attempted to force readjustment
between the individual and his experience of reality.148  It removed the excessive
emotional distance of repression so the soldier relived the traumatic experience and
learned a more socially acceptable way to recall or deal with it.  It was no longer
emotionally crippling.149  Use of barbiturates to hasten psychotherapy, through
hypnosis, recall of traumatic events, or abreaction, was the most publicized
technique.150
Recognition of drugs’ use beyond adjuncts to psychotherapy, although less
dramatic than narcosynthesis, were in practical terms the most novel treatment
shortcuts.  Use of pharmaceuticals as treatments entailed interpreting neuroses as
developing processes, continuation of emotional reactions through psychosomatic
feedback, resulting in somatic generalization of symptoms.151  Neuroses developed from
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neurotic reaction to external stimuli, to the full-blown neuroses blithely continuing even
with reduction or removal of the stressful stimuli.152  Robert Heath and Stephen
Sherman provide a clear statement of the effects of this reinterpretation on drug
treatment when they argued that the “subtle and intricate workings of the autonomic
nervous system”153 broadened logical uses of existing drugs.  Psychopharmaceuticals
acted on the nervous system.  
During the war, physicians used barbiturates and amytals to break the
psychosomatic cycle.  Heath and Sherman treated soldiers afflicted by long-standing
neuroses in a manner physically similar, but conceptually novel, compared to traditional
methods.  They assumed that traumatic events caused a physiologic reaction, release of
adrenalin, which made body and mind prone to overreact to further events, which in
turn resulted in production of more adrenalin.  Therefore, physicians tried to break this
cycle of adrenalin overreaction.  Heath and Sherman saw insomnia, sweaty palms,
“jitteriness, tremor, an empty feeling in the stomach, no appetite, pounding heart,
thumping in the head,” as signs of adrenal overreaction.154  Using ergotamine to
neutralize the epinephrine (adrenalin) short-circuited “the chain of activity[.]” 
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28; also Grinker and Spiegel, Brief Psychotherapy in War Neuroses, 125.
160  Menninger,  Psychiatric Experience, 579, 581; Postwar articles in medical
journals often suggest recognition that rapid treatment close to the front line was an
important discovery or outcome of the war experience.  While the World War II
experience heightened awareness that quick and close treatment sped cure for the
majority of neuropsychiatric casualties, one of the most important lessons psychiatrists
Ergotamine was a therapeutic drug, which appeared to decondition the over-response.155 
Heath still saw this somatic treatment as an “adjunct to psychotherapy[,]”156 but the key
effect was neutralizing the emotional response physically, which in turn allowed
objective analysis of traumatic memories.157  This idea of psychosomatic feedback,
from neurotic reaction to generalized and self-contained neuroses, played a key role in
justifying use of Valium to treat neuroses and their somatic signs including: anxiety,
fatigue, gastrointestinal, urinary, and sexual problems, muscle pains and headaches.158
With new protocols and treatments, most neuropsychiatric casualties quickly
returned to duty or their homes.159  Treatment centers close to combat sent sixty percent
of soldiers back to service within a week.  Within a month ninety percent returned to
service.160  Convalescent hospitals in the U.S. returned between fifteen and twenty-five
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drew from WWI was that treatment needed to be immediate.  While those treated
quickly, near the front lines, were likely to improve enough to return to the role of
cannon fodder, those evacuated to the United States and Britain for treatment tended to
prove chronic cases.  More than half of the soldiers injured in WWI suffered from acute
war neuroses.  In the United States approximately 68,000 of these men were still in
Veterans Hospitals during World War II.  Knight, The Treatment of the Psychoneuroses
of War, 148; see also Van de Water, Mental Combat Casualties, 391, 394-96.
161  Menninger, Psychiatric Experience, 579, 581; Neuropsychiatric discharges
made up 41% of all medical discharges given between 1 January 1942 and 30 June
1945.  70% of the NP discharges classified the reason for discharge as psychoneurosis. 
Appel, Incidence of Neuropsychiatric Disorders, 435.
162  Menninger, Psychiatric Experience, 581, 585.
163  McNeel, War Psychiatry in Retrospect, 503; Menninger, Psychiatric
percent of the remainder to duty, and even the remaining cases had a relatively high
discharge rate, suggesting the new methods provided sufficient cure to avoid expensive
long-term custodial care.161  Comparison with medical treatment of physical injury only
added to the luster of mental health professionals' prestige.  Neuropsychiatry 'cured' or
prevented problems to the extent that soldiers could continue as soldiers.  Every active
soldier was a psychiatric success story.
Conclusion
Before World War II, psychiatrists tacitly conceptualized most nonorganic,
functional, mental illnesses as problems of adaptation.  While this continued, the World
War II experience was a locus of change in mental health theory.  The new
conceptualization placed greater emphasis on stress, prevention, early treatment,162 the
individual as part of the group,163 and a continuum from mental health to mental
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593.
166  Porter, What Has Psychiatry Learned, 851.
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illness.164  Mental health professionals, overall, now considered neuroses far more
prevalent and socially important than organic disorders and psychoses.165  Some
individuals adapted more easily than others, but almost none could adapt continuously
under harsh and changing conditions.  In other words, most personalities were neurotic
to some extent, they lagged in extinguishing old stimulus response patterns and
developing new ones.166  Faced with uncertain conditions they fell back on old patterns. 
The problem was neurotic reactions to stress,167 something preventable by reducing
stress, giving people time to adjust, or training people to be more adaptable.  
Rather than focus on mental illness, experts increasingly decided that the focus
now needed to be on mental health, preventing vast numbers of fragile personalities
from developing neurotic reactions.  David Flicker describes true war-induced anxiety
as “only exceptionally a reaction to gross external danger.”168  Soldiers’ fears were real
and temporary, while in the civilian population “[m]an lives more frequently in a
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172  Heath and Sherman, Use of Drugs in the Treatment of Traumatic War
Neuroses, 356.
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borderline, often quite unrealized, anxiety state.”169
Change in prevalent treatments was part and parcel of the new conceptualization
of mental health and illness.  “The treatment obviously depends on one’s conception of
the disorder[,]” wrote Major McNeel.  Explanation of neurosis as “deep-seated
conflicts[,]” with endogenous drives playing a central role, fit with “special, rather
complex techniques” such as psychoanalysis.  The goal had been to teach the patient to
gain insight into his own mental processes so better to resolve conflicts between
internal forces and desires.  But focus on neurotic reactions to stress emphasized “a
simple reaction of the individual to the immediate situation,”170 which required rapid
treatment to prevent “fixation and persistent disability.”171  This rapid treatment could
now include more “[s]pecific therapy”172 with drugs to short-circuit the psychosomatic
feedback loop of developed neuroses.  Mental health practice needed to be preventative,
part of “the field of psychosomatic medicine”173 which, Captain Braceland prophetically
suggested, might lead to “much more attention...to emotional overlay upon actual
organic diseases.”174
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Although war neuroses, dealing with the World War II military, describe
neurotic reactions in men, a gendered understanding is used.  Neurotic, inappropriate,
responses were emotional behaviors and therefore associated with the feminine. 
Lieutenant Commander Norbert Bromerg, writing on “The Role of Conditioned
Responses in Emotional Disturbances of War,” declares it axiomatic that “a traumatic
stimulus causes a disturbance in the organism which we call emotion[.]”175  The
emotional overreaction linked mental and physical/somatic responses, and therefore
treatments dulling emotional responses to stress reduced psychosomatic
complications.176  While the primitive stereotyped response of neuroses isolated the
mind from emotion, cure or symptomatic relief required relinking emotional response
to events, then learning appropriate methods to tamp down emotional responses.177 
Implicitly, the ideas of mental health and illness developing in the mid-twentieth
century defined emotional response as unhealthy, and cerebral racinotation – objective,
logical, and freed from the constraints of personal history – as the preferred way to
interact with society.
The effects of World War II on the field of mental health were profound and
long lasting.  Large numbers of soldiers, nurses, and general physicians received crash
courses in prevention, identification, and treatment of mental health problems.  There
61
178  Menninger, Psychiatric Experience, 580.
179  Grinker and Spiegel, Brief Psychotherapy in War Neuroses, 131.
180  Braceland, Psychiatric Lessons, 592; Gregg, Lessons to Learn, 219; 
Menninger, Psychiatric Experience, 580; Smith, Treatment Activities, 303.
181  Elmer L. Caveny and Edward A. Strecker, “Subsequent Nation-Wide Effects
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109 (January 1953): 482.
182  Grinker and Spiegel, Brief Psychotherapy in War Neuroses, 131; Navy
were also simply more trained psychiatrists; the Army trained over sixteen hundred
physicians during World War II, thirteen hundred of these using a three-month
course.178  “Never before has there been so much interest among medical men in
psychiatry as we have seen expressed in the Army[,]”179 wrote Lieutenant Colonel
Lloyd Grinker and Major John Speigel.  Physicians, psychologists, and auxiliary
personnel returned to civilian life indoctrinated in the new ways of understanding
mental health and illness.180  When the 250 neuropsychiatry-trained physicians
produced by the Navy returned to the U.S. the majority worked in private practice,
usually focused on neuropsychiatry.  Fifty-five percent worked primarily in
neuropsychiatry, fifteen percent in general practice, thirteen percent in
psychoanalysis.181  In Grinker and Speigel’s assessment, military experience produced a
shift from traditional psychoanalysis to more modern dynamic psychiatry.  Military
trained neuropsychiatrists were "interested in dynamic psychiatry[,]” Grinker and his
colleague proclaimed, because “they have seen how little value there is in diagnostic
labeling, persuasion, suggestion and authoritative forcing."182  Innovative techniques,
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neuropsychiatrists no longer associated with the military were employed in ways typical
of broader changes in psychiatric practice.  Only 10% worked in custodial mental
hospitals, 13% practiced psychoanalysis, while 54% went into private practice which
they did not consider psychoanalysis-based.  Caveny and Strecker, Subsequent Nation-
Wide Effects, 482.
combined with belief in a widespread need for active prevention and treatment of
neuroses, made mental illness an important and potentially solvable national problem. 
The new techniques, especially group therapy and drug therapy, introduced treatment
options to those without the funds and time for long-term psychoanalysis.  
Therefore, after the war, Americans had a different understanding of mental
health.  Mental health was a goal, not a thing.  Mental health and mental illness were a
continuum.  Those institutionalized with chronic psychoses were still a problem, but it
was easy to think of the institutionalized mentally ill as ‘them.’  Neuroses were the real
danger, neuroses affected ‘us.’  Normal people, faced with stressful situations, could
become neurotic.  All of ‘us’ were at risk; the age of anxiety had begun.
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CHAPTER 3. THE AGE OF ANXIETY:
NATIONAL BATTLES AGAINST MENTAL ILLNESS
From the end of World War II, through to the early 1960s, average Americans
consciously sought mental health.  The mental health professions tried, and failed, to
meet the growing demand for services.  Americans increasingly looked at their
personal, family, and national problems as problems related to personal mental health. 
At least as important was developing focus on promoting and maintaining mental health
other than treatment of mental illness.  Physician Thomas A. Gonda,183 in an article for
the Annual Reviews of Medicine summarized the change; “the trend[,]” he wrote, “has
been to devote increasing attention and effort to the problems of life stress and to the
treatment and prevention of neurotic disorders.”184
How psychiatrists understood mental health shifted from focus on personality
developed “as a reaction to the real social world in which an individual grew up[,]”185 to
interest primarily in an individual’s current situation.  The latter emphasized
interactions with the external environment, especially an organism’s social
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ecosystem.186  Dr. Leon Saul, a Professor of Clinical Psychiatry at the University of
Pennsylvania,187 tied focus on neuroses to perceived growth in the field of psychiatry. 
“The emotional factors, which produce neurotic symptoms[,]” he wrote, were the same
“emotional forces by which we all live.  
As a result the scope of psychiatric ailments broadened.”188  The
conceptualization of mental health in terms of neuroses, personality defects, and
psychoses promoted identification of diverse situations as problems of adaptation and
inability to return to homeostasis, to balance of bodily functions.  Dysfunction
threatened the stability of America and its basic unit, the individual, which was both a
person and a nuclear family unit.  
National Efforts
When military officers assessed neuropsychiatric work in World War II, they
often highlighted the future usefulness of war-gained knowledge, or took pains to
explain the problems with extrapolating from war experience to civilian populations. 
This suggests there was a major debate over the ‘lessons’ of war.  The debate, during
and shortly after World War II, presumably focused on the extent to which the military
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190  Bromberg, Role of Conditioned Responses, 26, 30-31.
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102 (January 1946): 433; Flicker makes a similar argument.  The military psychiatrist
“does not have the necessary time to...seek the etiology of the aberration....  It makes no
difference to the patient or the army if the soldier is discharged with the diagnosis of
psychoneuroses, conversions hysteria, or psychoneurosis, anxiety tension state.”   David
J. Flicker, “Army Psychiatric Literature, Factors in Interpretation,” American Journal of
Psychiatry 98 (May 1942): 796. 
neuropsychiatric experience could or should apply to postwar America.  Lieutenant
Commander Norbert Bromberg took umbrage at the very idea that war neuroses were
similar to neuroses seen in civilian life.189 Terms such as “war neurosis” or “combat
fatigue” were as inappropriate as the World War I term “shell shock[,]” he declared. 
Bromberg believed war neuroses differed fundamentally because the symptoms usually
did not persist; true neuroses were long-term, fairly incurable, illnesses.190  In this
assessment he differentiated traditional concepts of neurosis as ongoing internal
conflicts, often due to personality problems, from war neuroses, with an obvious
environmental stressor as cause.  Major John W. Appel warned readers of “Incidence of
Neuropsychiatric Disorders in the United States Army in World War II,” that
exigencies of diagnosis at recruitment stations shaped which classifications examiners
used, probably influencing the high rates of neuroses and personality disorders in his
own statistics.191  Yet, it was hard to ignore that extrapolating from recruitment statistics
suggested at least one of every eight Americans was mentally unsuitable for military
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service.  Kiene argued this high rate “does not indicate that our society is
deteriorating[,]”192 it showed the military had higher standards than in the past.  Based
on hospitalization rates during the war, 2.5 percent of ‘normal’ Americans had little
capacity to adapt, and between 6.7 and 25 percent of apparently healthy Americans
were actually suffering from mental ill health.  Even without including women in the
estimate,193 a pessimist could interpret the war experience as showing more than twenty
percent of American men were sick of mind.  And pessimists did.  Doctor Alan Gregg,
Head of the International Health Board at the Rockefeller Foundation, queried:
[T]he percentage of men between 18 and 35 being disqualified for
military service because of some kind of disorder of personality–14% of
all the men examined?  Does a social structure which, in peacetime,
shows one in seven so definitely deviant not deserve profound reflection
and study?194
Others warned that ignoring knowledge gained during the war could have dire
results.  There was far less debate over the role psychiatry should play in American
society.  The imminent postwar problem was the stress associated with demobilization. 
Helgesson warned of the dire results of unplanned demobilization on neurotic and
preneurotic individuals, which involved millions of soldiers trying to adjust from
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military back to civilian life.  It was necessary to "plan for the solution of psychiatric
problems incident to warfare before they become impossible to solve."195  Helgesson
was not alone in his concern; almost immediately after the war started, the National
Research Council’s Committee on Neuropsychiatry, War Neuroses and Neurosurgery
began planning for eventual demobilization.  As Grinker and Speigel wrote, "Everyone-
-neophytes and psychiatrists have a great deal to learn from the study of war neuroses,
much of which will be applicable to problems in civilian life."196  Neuroses were far
more widespread than the presumably organic psychoses,197 and existing psychiatrists
could not possibly deal with the millions in need of help after the war, especially using
traditional methods.198  
Postwar mental health became a major public, political, and military concern. 
Helgesson prophesied that the potential social cost of "psychiatric mistakes” in World
War II dwarfed the economic cost, “even if it amounts to over a billion dollars[.]"199 
There was a risk of disorganizing American society, the social aspect of the Republic. 
Victims of "psychiatric mistakes” and those unable to adjust to stressful conditions,
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such as the shift from military back to civilian life, threatened to form a large
population drawing away from American society by living lives of "utter uselessness[.]" 
Military neuropsychiatric casualties, and potential casualties, he warned, might be
"relatively content[,] but it is the contentment of asocial beings who contribute nothing
to the community."200  They would never again be normal individuals, remaining
isolated from the group.  Saving American society required application of the
psychiatric ‘lessons of war.’
Increased focus on psychosomatics was another important outcome of the war. 
Leon Saul, explaining the need for “Preventative Psychiatry” in 1949, termed
psychosomatic medicine “a whole new field devoted to exploring the role of emotions
in physical disorders.”201  Psychosomatics, a medical approach focusing on interaction
between mind and body, suggested mental health issues were physical issues. 
The late 1940s also saw a burst of concern for those in mental hospitals.  Mary
Jane Ward’s The Snake Pit moved from page to silver screen.  Albert Deutsch’s The
Shame of the States went on book stands.  Copious newspaper articles decried the
horrific state of life in America’s state mental institutions.  In general, the media
brought conditions within psychiatric institutions into the limelight, and the picture was
ghastly.  Although termed hospitals, many of these institutions served only as
warehouses and appeared akin to overstuffed prisons.  Treatment was slight to
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nonexistent in these overcrowded, underfunded, and understaffed State mental
hospitals.202
Increasingly, a tacit consensus developed that Americans needed education for
mental health.  The people must be prepared, their psychological defenses shored up
“[i]f we are to build a nation prepared to meet atomic warfare[,]” wrote Snyder.203  For
the sake of Americans and America, it was necessary to promote mental health and
prevent mental illness.  The purview of psychiatry broadened and its status increased.204
National Defense- Federal Programs
Between 1945 and 1964, the Federal government passed a series of measures
amply illustrating how Americans’ views on mental health differed from times before
World War II.  Americans increasingly questioned existing assumptions that treatment
for severe mental illness should take place within institutions.  Focus on environmental
factors increased.  Their presumed role in both producing and curing illness grew. 
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After 1945, the Federal government established a National Institute of Mental Health
(NIMH), funded programs for research, established Federal commissions, and
eventually passed the Community Mental Health Act.  For a country previously
delegating care of the mentally ill to the states, these were major changes.  The United
States even proclaimed a ‘Mental Health Week.’205
As discussed in the previous chapter, the shape of mental illness and mental
health altered by the end of World War II.  Emphasis on neuroses increased, alongside
an assumption that neurotic reactions, and personalities prone to neurotic responses,
created the greatest proportion of people not having good mental health.  Focus shifted
from mental illness to an area between the poles of complete mental health and severe
mental illness.
National Institutes of Mental Health
Government actions reflected the new emphasis on mental health as one of the
“problems which affect society as a whole.”206  In 1946, the Federal government passed
the National Mental Health Act.  This legislation provided funds to train mental health
researchers, provide additional training for clinical practitioners, and to fund research
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into the causes and potential cures of mental illness.  It also created a system of grants
to the states, intended to promote creation of new treatment programs.207  Out of the Act
grew two new institutions, the National Mental Health Advisory Council and National
Institute of Mental Health (NIMH).  The Act focused federal action, for the first time,
on promoting mental health more than decreasing the number of institutionalized
mentally ill.208  At the State level, response to the Act was immediate; by 1947, every
State had in place some form of agency to interact with NIMH and organize spending
of Federal and State funds along the Act’s parameters.  Unfortunately most states began
relying on Federal monies for training and professional education and dropped total
spending from $840,000 in 1948 to $360,000 in 1955.209  The initial head of NIMH,
Robert H. Felix, convinced the Surgeon General that the new institution belonged
among medical research institutions, rather than the Bureau of State Services.  NIMH
became part of the National Institutes of Health,210 although its approach differed from
its cohort.  For example, NIMH developed pilot community-based mental health
programs, as well as fulfilling a research and education mandate.
72
211  In his article “Research and Its Support Under the National Mental Health
Act,” American Journal of Psychiatry 106, no.6 (1949): 407-12, Lawrence Kolb,
Director of Research Projects at NIMH argued plans leading to the NMHA developed
from the 1938 Surgeon General of the United States Public Health Service report,
which stated mental disorders were the most pressing public health issue.  Thomas
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public health problem in his addresses published in Public Health Reports.  In his report
to Congress his recommendations for the area of mental hygiene were as follows:
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It is unlikely this drowsy call to action was a turning point hearkening a crusade for
massive changes in mental health institutions, research, or training.  In contrast, Gerald
Grob refers to efforts by Lawrence Kolb, Head of the Division of Mental Hygiene of
Technically this was not the first foray Congress made into promoting mental
health, but earlier efforts were unintentional (from the Federal Congress’ viewpoint).  In
1930, the Public Health Service added a Division of Mental Hygiene, tasked mainly
with fighting and treating addiction.  Heading the Division after 1944, Robert H. Felix
tried realigning this division’s focus toward developing knowledge of the extent and
course of mental problems, broadly construed.  He also began incorporating social
science research into what his predecessor interpreted more exclusively as a medical
problem.
Felix’s work in the Department of Public Health informed the text of the 1946
Mental Health Act.211  Surgeon General Thomas Parran asked Robert Felix to write a
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the Public Health Service, to establish a version of the National Cancer Institute,
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formal proposal outlining what the Division of Mental Hygiene should do.  A modified
form of the plan, introduced to Congress in 1945 and signed into law early in July 1946,
promoted both research and the more radical approach of focusing less on institutional
care and more on community care and services.212  Hospital-based treatments for the
severely mentally ill continued and, through the Hill-Burton Act, expanded.  The
Veterans Administration and the United States Bureau of Prisons had their own
extensive facilities for psychiatric patients, or prisoners with serious psychiatric
problems.  The Hill-Burton Act provided funding to expand the number of beds
available for institutionalized mentally ill, in both mental and general hospitals. 
Overall, the Act focused on increased hospital construction and as a consequence, by
1965, added more than ten thousand beds in general hospitals, and nineteen thousand
beds in mental hospitals, for institutional care of the mentally ill.213  By reducing the
number of beds in each existing and newly built hospital and ward, therefore having
fewer patients per ward, the Hill-Burton Act promoted institutional mental health care
as a therapeutic, rather than a custodial, affair.
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The National Institute of Mental Health (NIMH), headquartered in Bethesda,
Maryland, among other elements of the National Institutes of Health, served mainly as a
center of research on prevention and treatment, if not complete elimination, of mental
illness.  The NIMH remained a bureau within the Public Health Service, in turn
overseen by the Department of Health, Education, and Welfare.  Beginning with a
budget of four and a half million dollars, its programs and financing swelled quickly
until, in fiscal year 1966, NIMH employed over twelve-hundred staff members and had
a total budget greater than two hundred thirty million dollar per annum.214  This
allocation of funds to NIMH reflects Congress considering mental health an extremely
important issue.215  There were separate Associate Directors for activities within the
institution and those outside.  Within the Bethesda laboratories, staff came from a wide
variety of disciplines, all with an interest in mental health and illness.216  They applied a
wide variety of techniques to better understand and treat mental illness.  Encompassed
topics included “community mental health problems, clinical techniques, and the
pharmacological, neurophysiological, biochemical, psychological, and socioeconomic
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aspects of drug addiction.”217  The typically optimistic expectations of science held by
the American public during the late 1940s and 1950s promoted “fundamental inquiry”
on the nature of mental illness, on the assumption that because research “accelerates
understanding of basic disease processes”218 it would lead to treatments, if not cures.
From the first year of funding in 1948, through to 1966, finances associated with
improving training and increasing the number of trained and available mental health
professionals, accounted for a substantial portion of the NIMH budget.  At first, the
Institute used training grants to increase the number of clinical practitioners with
specialties related to the medical aspects of mental health: psychiatry, psychiatric social
work, psychiatric nursing, and psychology.  Grants to the established eighty-four
medical schools recognized by NIMH served “to improve or expand psychiatric
instruction to the medical students.”219  By 1956, annual funding subsidized and
promoted increased psychiatric education for ninety-three percent of all medical
students in the United States.220  Fellowships granted to individual researchers promoted
increased knowledge for the field in general, helped shape the research paths of
individuals, and increased experience for their future investigations.  After passage of a
1956 amendment to the Public Health Service Act, the NIMH expanded grants to
76
221  Connery et al, Politics of Mental Health, 23.
222  Connery et al, Politics of Mental Health, 23.
223  Connery et al, Politics of Mental Health, 23.
224  Connery et al, Politics of Mental Health,  23.
225  Vestermark, Training and Its Support, 417.
States, nonprofit institutions, and metropolitan governments to promote a more
geographically dispersed program of research, focused on improved diagnosis and
treatment. 
In 1959, NIMH initiated the “General Practitioner Program”221 to grant
physicians “awards to specialize in psychiatry”222 or fund short courses in psychiatry for
general practitioners, with the expectation they would return to general practice more
aware of techniques for treatment and prevention of mental ills.  Within six years, the
short course program increased the number of physicians with at least basic psychiatric
training by approximately 14,400.223  Gradual expansion of these programs increased
the number of mental health professionals in auxiliary fields: epidemiology and public
health, psychological and physiological studies of human behavior, and areas of the
biological sciences related to study of mental illness.224  In 1949, thirty percent of
training grant funds gave stipends to undergraduates to support “4 years training in
psychiatry and psychology and 3 years training in psychiatric nursing and psychiatric
social work.”225  Yet demand for mental health services continued to grow at rates far
outstripping all efforts to increase the number of providers.
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Studies of the nature and treatment of mental health, alongside efforts to
increase access to mental health services, helped reshape the role of physicians in
treatment of mental illness.  NIMH set up outposts in cities such as Hagerstown,
Maryland “to determine the relationship between physical and mental health, and social
factors associated with mental disturbances.”226
The Joint Commission on Mental Illness and Health (JCMIH)
During a conference on mental health sponsored jointly by the American
Medical Association (AMA) and the American Psychiatric Association (APA), Dr.
Kenneth E. Appel, 1953 APA president, promoted creating a committee to report on
current methods of caring for the mentally ill.  He hoped the resulting report,
highlighting serious deficiencies, would catalyze mental health professionals in the way
Abraham Flexner’s famous Medical Education in the United States led to dramatic
changes in the content and practice of medical education.227  Appel pointed out the lack
of existing nationwide surveys dealing with the problem of mental illness in general. 
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Pulling together members of the APA and the Council on Mental Health, a group within
the AMA, Appel championed efforts to begin nationwide studies.  He promoted an
inquiry, or study, to State Governors during one of their conferences, held at the Mental
Hospital Institute.
Existing studies, the best known of which were the 1936 Baltimore Eastern
Health District Survey, and the 1938 Williamson County Survey (Tennessee), gave
snapshots of the incidence of mental illness.  They were not in agreement and studied
disparate populations.  The Baltimore survey covered a residential area in the eastern
part of the city, where the average income was lower than the citywide figure.  One-
quarter of the population were African-Americans, with the remainder including many
Czech and Jewish peoples.  Researchers identified cases of mental illness through
written evidence in public institutions, including public schools and, where necessary,
gave a provisional diagnosis based on this secondhand evidence.  They divided forms of
mental disorder into groups reflecting a schema of organic psychoses, neuroses and
personality disorders, and problems in children.  Typical of the pre-World War II
period, most cases fell within the psychoses group.  In a population of 55,000 they
identified 3,337 cases of mental illness (6.05 percent of the population).  A partial
breakdown of their findings is listed below.
79
C
lassification 
Sub-classification
N
um
ber of cases
Percentage of
population
Psychoses 367 .67
Schizophrenia 158 .29
Manic-depressive 41 .07
Senile and
arteriosclerotic
38 .07
Alcoholic 15 .03
Syphilitic 29 .05
with Mental
Deficiency
28 .05
Other and
undiagnosed
58 1.1
Psychoneuroses 171 .31
Psychopathic personality 30 .05
Personality disorder in adults 218 .4
Behavior disorder in
children
449 .81
Minor and possible disorder 651 .118
Epilepsy 75 .14
Table 1. 1938 Baltimore Study
The second major study took place in Williamson County, Tennessee.  Unlike
Baltimore the population was rural, with most families involved in agriculture.  Again
one-quarter of the population consisted of African-Americans, but the remainder was
more homogenous, mainly people of British ancestry.  In this survey, the researchers
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developed relationships within the community over a longer period of time, living
within the community beginning in 1935.  Identified cases came from referrals “by
physicians, nurses, teachers, clergymen, judges, and others who were in contact with
large numbers of residents.”228  The researchers also conducted a house-to-house survey
of three districts within the area, during which they found incidence of mental illness
double the proportion reported by referral.  Although convinced the actual incidence
rates were twice as high, their results reflected similar proportions of mentally ill found
among the general population in the Baltimore study.  Overall rates of mental illness
were approximately 6.9 percent, although intensive case finding suggested the actual
rate might be closer to 14 percent.  Within the psychoses, the reported findings were
remarkably similar for both studies; for the neuroses they varied more (0.31 percent in
Baltimore, 0.4 in Williamson County).  Construing neuroses more broadly, under post-
World War II definitions, the results varied from 0.4 percent to 4.17 percent incidence
depending on the study used and groups included.  The estimate of 4.17 percent comes
from the Williamson County Study, in which the authors concluded actual rates were
probably twice those reported, which would place the actual rate of neuroses at 8.34
percent of the population.229  Although studies with more defined approaches, intended
to identify all cases, were in the works in 1952, there were no completed studies.
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C
lassification
Sub-classification
N
um
ber of cases
(N
ote population of
survey area is
approxim
ately ½
 that in
Percentage of population
Psychoses 156 .63
Schizophrenia 43 .17
Affective (would include
manic-depressive and
depressive)
41 .17
Senile 23 .09
Other 51 .2
Psychoneuroses 99 .4
Psychopathic traits 186 .75
Conduct and behavior
disorders
414 1.67
Organic and miscellaneous 328 1.32
Table 2. 1938 Williamson County Study
The important shift from recognizing need for a national study, to the actual
studying itself, began in 1954 when the Field Foundation donated five thousand dollars
to help set up a commission.230  In Congress, Senator Lester Hill introduced a resolution
for the study of mental illness in February 1955; Congressman J. Percy Priest
introduced a similar legislative proposal to the House of Representatives.  The medical
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director of the APA, Dr. Daniel Blain, helped draft the resolutions, which eventually
congealed to form the Mental Health Study Act of 1955.  This Act passed “without a
dissenting vote[.]”231
The Act gave Federal funding to the Surgeon General of the United States
Public Health Service, who would distribute funds to one of more nongovernmental
organizations to conduct the study.  The existing Joint Commission on Mental Illness
and Health (JCMIH) applied for and received the funds.232  An organizational meeting
for the Commission, in April 1955, involved representatives of thirty-six national
organizations.233  Smith, Kline & French provided funds to continue planning before
Federal monies began to flow, suggesting major pharmaceutical manufacturers saw no
threat in a Commission expected to illustrate need for increased mental health services. 
The Joint Commission was in a potentially awkward position as a nongovernmental
entity endorsed, and partially funded, by the Federal government.234  Those in mental
health related fields generally viewed the arrangement optimistically; the Commission’s
effectiveness would be greater, all parties agreed, if led by professional organizations
such as the American Psychiatric Association, the American Medical Association, the
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Veterans Administration, and the American Hospital Association.235  Between funding
authorized by the Mental Health Study Act in 1955 and later Federal funds, the
Commission’s reports represented more than a 1.4 million dollar investment into
investigating existing mental health and mental illness provision, and developing
proposals for improvement.  Obviously, at this time, there was broad support within
Congress, which also suggests public support, for improved and possibly expanded
efforts to understand barriers and promote mental health.
Based on the mandate set out in 1955, (Public Law 1982, also known as the
Mental Health Study Act) the JCMIH studies looked at mental illness with a very broad
lens.236  The Act’s preamble set out general principles for conducting the research. 
Among the axioms was that new treatment techniques made it possible for a greater
portion of the mentally ill to live their lives outside hospitals where care focused on
custody, and which had inadequate facilities, funding, and personnel.  Research should
focus on cost of existing mental health facilities, as well as effects on families.  The Act
associated mental illness with broader social problems, and implicitly with nonorganic
(functional) neuroses, neurotic reactions, and personality disorders, as well as
situational problems affecting the large proportion of Americans falling between the
poles of mental health and mental illness.  The preamble placed drug addiction, crime,
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and divorce or family breakdown within the boundaries of mental illness for study.
The Joint Commission on Mental Illness and Health planned a series of ten
monographs.  Each studied one aspect of the overall problem and suggested possible
solutions, intended for providing information feeding into a final report of the
Commission as a whole.  The monographs leading to the final report by the Joint
Commission on Mental Health and Illness illustrate the broad concerns associated with
mental illness and health in the 1950s and early 1960s.  In Current Concepts of Positive
Mental Health Dr. Marie Jahoda, a Professor of Social Psychology and Director of the
Research Center for Human Relations at New York University, surveyed various
interpretations of the ideas ‘mental illness’ and ‘mental health.’  “There is hardly a term
in current psychological thought as vague, elusive, and ambiguous as the term ‘mental
health,’ she began.237  Throughout the monograph Doctor Jahoda teased out the
interactions between definitions of mental health and philosophies or value sets
associated with them.  Typical of the post-World War II period, the majority of her
work focused on the area between mental health and mental illness.  “Knowledge about
deviations, illness, and malfunctioning far exceeds knowledge of healthy
functioning[,]” she noted.238  Consequently, she endorsed increased emphasis on the
causes and nature of mental health.
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Jahoda’s survey took place within the existing and popular concepts of
homeostasis and General-Adaptation-Syndrome.  Homeostasis, a concept usually
associated with the works of Walter Cannon, essentially argued there was an
equilibrium within the human body, and stresses interfere with that equilibrium.239  In
mental health terms, the rapid reestablishment of equilibrium, whether the previously
existing one or (preferably) something new, was healthy behavior.  Ability to adapt to
changing situations signified mental health.  Cannon’s theory translated easily within
the precepts of Freudian psychology; mental stresses created a tension between the Id,
Ego, and Superego, which needed resolution to restore homeostasis.  Psychoanalysis
freed individuals from constraints of the past, which allowed personal growth,
interaction with the environment, and redevelopment of homeostasis in an ongoing,
dynamic, manner.  The General-Adaptation-Syndrome (G-A-S) concept was associated
with the works of Hans Selye.240  His physiologic research convinced him there were
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certain commonalities in illness response, existing regardless of the disease, stressor, or
illness.  Stress on the body, no matter whether primarily psychological or somatic,
caused a series of responses designed to mitigate stress.  Quick response to stress
reduced, but did not prevent, somatic damage.
These theories of homeostasis and the G-A-S played important roles later in
justifying widespread prescription of Valium, because they suggested poor response to
stress played an important role in neuroses, psychosomatic disorders, and even somatic
illnesses.  Valium, as a tranquilizer, effectively short-circuited an adrenaline feedback
loop which occurred under prolonged stress, especially in those with neurotic
personalities.  Faced with stressful conditions, the body’s fight-or-flight reflex kicked
in.  Bursts of adrenaline helped an individual remain on alert, but could also result in
reaction to lesser stimuli.  In those predisposed by genetics or experience, or apparently
‘normal’ people facing long-term stresses, a feedback loop could result; stress produced
adrenal response which heightened awareness of stressful stimuli, which produced more
adrenalin and so on, ad infinitum.  
Jahoda’s wrote with implicit assumption of a link between physiology and
psychology, and her findings therefore fit the broader definitions of mental illness and
health typical of the 1950s and 1960s.   In an introduction to the book, physician Jack
87
241  Jahoda, Current Concepts,  xii.
242  Jahoda, Current Concepts,  xii.
243  Jahoda, Current Concepts, 8.
244  Jahoda, Current Concepts, 8.
R. Ewalt, Director of JCMIH, explained that laboratory research “showed us long ago
that severe emotional stress can profoundly alter the physiology of the body.”  Up-to-
date research, he emphasized, only further confirms that “chemical-physiologic
disturbances can affect behavior and perception.”241  Jahoda worked within this
understanding; she placed alcoholism within the boundaries of mental illness, in part
because it was an inappropriate mental reaction to stress, and because it resulted in
“deterioration of the brain” because of alcohol’s toxic properties.242 
Jahoda’s book focused on positive mental health, maintaining mental health for
prevention and treatment of mild mental illness before it progressed toward chronic
mental and physiologic conditions.  Insightfully, she noted two major ways of defining
mental health, either in terms of current behavior, “a momentary function of personality
and situation[,]”243 or as a more continuing dysfunction of personality, what she
described as “differences in behavior and feelings dependent on the stresses and strains
of the situations in which a person finds himself[.]”244 
Dr. Jahoda emphasized that initial assumptions informed ways to examine an
individual’s mental health.  In the first case, mental health studies focused on current
behavior patterns, which could be more healthy or less.  The second approach lead to
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focus on “individuals as more or less healthy[.]”245  Either approach could underlie
acceptable or unacceptable definitions of mental health.  The popularity of both
perspectives led to lack of consensus on definitions and proper approaches to achieve
positive mental health.    
The widespread exclusionary definition of mental health as “the opposite of
mental disease”246 is unworkable, Jahoda argued.  Physiologic identification of mental
disease was impossible, and therefore identification must be based on behavior linked
to organic problems.  But, she pointed out, people widely accepted as mentally ill did
not always show these extremes of behavior.  “[S]imilarities and symptoms[,]” she
wrote, “must not be mistaken for identical disturbances of functions.”247   A wide
variety of symptoms could result from similar functional problems.  Jahoda concluded
that the tendency within psychiatry, to base diagnoses on types of personalities or
patterns of interaction with the external world, was untenable if there was no one-to-one
link between symptoms and functional categories of illness.  
Defining socially unacceptable behaviors as indicators of mental illness is
equally unacceptable, Jahoda continues, this approach usually fails to take into account
cultural differences between acceptable and unacceptable behavior.  Contemporary
work of anthropologists and sociologists illustrated normality, whether based on
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statistical frequency or ideals, remained rooted in culture.248  An underlying theme of
work in these fields was “the plasticity of human nature and... the vast range of what
can be regarded as normal.”249  This means the JCMIH recognized deviations from
behavioral norms in a culture was not an acceptable basis for defining mental illness.  It
did not fit with contemporary ways of defining positive mental health.  Daniel Katz, in
the 1951 edition of Annual Reviews of Psychology, neatly summarized the changes in
psychological theory; “social norms are not statistical averages or modes but
consciously shared beliefs and values[,]” he explained.250  Normal people were ideals,
not commonly found people.
Cutting a broad swath through publications in sociology, psychology,
anthropology, and psychiatry from the mid-1930s to the late 1950s, Jahoda boiled down
the multifarious, nuanced, and implied definitions of mental health into six categories,
two defined by the individual involved, two by socially acceptable behavior, one
identifiable by mental-health practitioners, and the final one identifiable by anyone
possessing mental-health and familiar with the individual involved.251  Personally
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defined measures of mental health included “attitudes of an individual towards his own
self[,]”252 and the extent of “growth, development, or self-actualization[.]”253  
Definitions based on deviation from social norms relied on mid-twentieth century ideals
of American middle-class society; environmental mastery, and autonomy served
effectively as measures of individuality and independence.  Another definition of
mental health, degree of psychological integration – presumably referring to a
successful functional balance between portions of the psyche – informed identification
by a trained psychotherapist.  The remaining approach Jahoda identified is “that mental
health is manifested in the adequacy of an individual’s perception of reality.”254 
Application of this idea required another person to assess mental health or mental
illness, although it suggested trained psychiatrists, neuropsychiatrists, psychotherapists,
or political psychologists held no monopoly on diagnosis and treatment.  Anyone could
tell if a person was facing up to reality, they might be wrong, but in theory any healthy
individual could identify people who could not accurately perceive reality.
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The breadth of approaches accepted by members of the Joint Committee on
Mental Illness and Health influenced how they proposed to solve staffing problems in
the face of increased public demand for mental health services.  The monograph on
Epidemiology and Mental Illness amply illustrates how hard it was to estimate the
proportion of Americans who, although not institutionalized, were mentally ill; it
depended on methodology and definitions.  Physicians Richard Plunket and John
Gordon suggested existing estimates range from five percent to twenty-three percent of
the entire population did not possess mental health.  This and other JCMIH monographs
implicitly accepted that need for services far outstripped availability; in Community
Resources in Mental Health and Mental Health and Manpower Trends, Commission
members argued strongly that current numbers of mental health professionals were
insufficient.  The greatest difference between need and supply existed in state-run
institutional care facilities, but the authors’ concerns focused on a perceived overall
shortage of mental health professionals.   As they stood, institutes of higher education
appeared unable to create a large enough pool to meet staffing demands in the near
future.  The Commission members’ observation that more physicians and allied mental-
health professionals preferred working in clinics or private practice, and therefore with
the less mentally ill, fit the post-World War II trend of interest in neuroses rather than
psychoses.
Focus on poor mental health, rather than treating those defined in earlier times
as mentally ill, also influenced estimates of the economic need for action.  In
92
255  George W. Albee, Mental Health Manpower Trends (New York, NY: Basic
Books, 1959); Rashi Fein, Economics of Mental Illness (New York, NY: Basic Books,
1958); Gerald Gurin, Joseph Veroff, and Sheila Feld, Americans View Their Mental
Health (New York, NY: Basic Books, 1960); Marie Jahoda, Current Concepts of
Positive Mental Health (New York, NY: Basic Books, 1958); Richard J. Plunkett and
John E. Gordon, Epidemiology and Mental Illness (New York, NY: Basic Books,
1960); Reginald Robinson, David F. DeMarche and Mildred K. Wagle, Community
Resources in Mental Health (New York, NY: Basic Books, 1960).
256  Elaine Cumming, “Review: A Review Article– The Reports of the Joint
Commission of Mental Illness and Health,” Social Problems 9, no.4 (1962): 394; Fein,
Economics of Mental Illness, passim.
Economics of Mental Illness Rashi Fein, Professor at Harvard’s School of Medicine,
discussed psychosomatic illness as well as the neuroses and psychoses.255  Although the
cost of mental illness to individuals, states, and the Federal government was staggering,
including potentially psychosomatic disorders (circulation, digestion, gastric, or
respiratory problems) in estimates resulted in mind-boggling drains on the country’s
purse.256
Using a national survey, the authors of Americans View Their Mental Health,
established widespread need for personnel and facilities, if Americans were to achieve
positive mental health.  As well as assessing help-seeking behavior and current sources
of assistance, their survey used an extremely broad concept of what prevented
Americans from achieving mental health.  They looked at achievement and personal
satisfaction with life, but also attempted to understand extent of adjustment problems,
family dysfunction, and other hindrances to happiness.
Personnel, an important factor in supply of mental health services, was a widely
accepted existing problem.  It was axiomatic at the time that promoting mental health
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and preventing or treating mental illness was a pressing national need.257  Apart from
aiding those already sick, early identification and treatment of incipient mental illness
required more professionals,258 “[i]f we are ever to prevent the inexorable flood of
mental illness from rising year in and year out[.]”259  Some, especially politicians and
those whose concern with the problem was primarily fiscal, associated early
identification and treatment with preventing degeneration from neuroses into psychoses,
and therefore reducing the number of institutionalized mentally ill people.  A massive
prevention program focused on identification and early treatment, they believed, could
reduce the overall cost of institutional care.  The pent up demand for goods, often
described as an important reason the economy boomed after demobilization, also
applied to demand for mental health care.  
In general, Americans cared about maintaining the mental health of those closest
to them, and reducing the financial burden for long-term institutional care of others. 
The demand for mental-health professionals was, and continued through to the 1960s,
to be greater than the supply of available providers, especially physicians with
substantial mental health training.  In 1957 Robert Felix who, as head of the NIMH,
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established programs in 1947 to increase dramatically the number of mental health
workers, still bemoaned existing strains on the workforce.  “There are limits to how far
workers can be stretched to cope with mental health needs[,]” he warned.260  This is
surprising when the number of physicians with mental health training was rising.  Most
of these physicians were general practitioners who, by the time Valium entered the
market (December 1963), saw the vast majority of outpatients with mental health
issues.261
Mental Health Professionals
As relative peace allowed massive demobilization of military personnel, the
demographics of psychiatric practice in the United States shifted.  Thousands of newly
trained neuropsychiatrists returned in search of employment.  General practitioners,
previously “unacquainted or resistant to psychiatric concepts were confronted in their
combat experience with undeniable evidence of the influence of emotional disturbance
upon bodily function.”262  They reclaimed their practices with an increased sense that
mental health was not only an important issue, but something they could identify and
potentially treat.  To practice psychiatry, they required a state medical license.  Other
qualifications included membership in professional organizations or certification by the
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American Board of Psychiatry and Neurology, but only the state medical license was
technically required.263
In 1954, for the first time in history, the number of psychiatrists in private
practice exceeded the number associated with institutions, hospitals, and agencies.264 
Approximately one-quarter of those in private practice were effectively psychoanalysts,
seeing a small number of patients for one hour, three or more times a week. 
Considering the small number of patients seen in a week (physicians, unlike lawyers,
have only 12 maximum billable hours per day and saw on average one patient per fifty-
minute hour), it is unsurprising psychiatry ranked among the lowest paid medical
specialities.265  The average fee was between ten and fifteen dollars per hour266 which, at
three to five sessions of psychotherapy a week, placed the cost of treatment above the
income of an average American family (average family income was approximately
seventy dollars per week).  The other seventy-five percent of private practice
psychiatrists were more somatically and behaviorally oriented.  They saw up to
eighteen patients per day, compared with a usual maximum of nine for an analyst. 
General practitioners treated a wider variety of patients, from a broader economic
spectrum, and tended to attend each patient for an even shorter period of time.  On
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average, they saw thirty-one patients per day.  The number of patients seen by
psychiatrists in private practice in the United States annually was approximately equal
to the number of patients in public mental institutions, roughly eight hundred
thousand.267  
At least some psychiatrists in the mid-1950s were consciously aware that
somatic treatments, such as electroconvulsive therapy or pharmaceuticals, could
improve their own economic and social situation.  Henry Davidson, in a paper
presented at the 1955 American Psychiatric Association meeting and later published in
the association’s journal, suggested a somatic orientation could increase the number of
clients seen, allow lower fees, and by allying their practice to other areas of medicine
(physical) offer the prospect of medical insurance covering mental health services.268 
Joseph Eaton, a sociologist/anthropologist, explained to readers of the American
Journal of Psychiatry that Americans wanted certainty from professionals, and
highlighted ties between the psychiatrists’ position and public “confidence in the
remarkable curative powers of drugs[.]”269
One of the most pressing problems identified by the Joint Commission on
Mental Illness and Health was the personnel shortage, a consequence of changing
expectations.  The problems psychiatry could assist with were broader than previously
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thought, including “the enormous mental hospital load, alcoholism, crime,
‘psychosomatic’ disease, and plain unhappiness[,]” all of which were becoming part of
psychiatry’s “operational field[.]”270  Over the course of the late 1940s and 1950s,
medical students increased the amount of time spent taking “in the psychological
aspects of medicine.”271  This produced increasing numbers of non-psychiatrists with
interest in, or at least knowledge of mental health issues and treatments.  General
practitioners increasingly called on psychiatrists for consultations.272  Physicians with
the most extensive training in psychiatry or psychotherapy preferred not to work with
inpatients; they went into private practice, increasing demand for institutional
psychiatrists as well.273  
The allied mental health fields – psychiatric nursing, social work, psychology –
began filling the manpower gap during World War II, and the trend increased postwar
as government efforts established community mental health programs.  These programs,
in intent at least, promoted positive mental health by framing barriers to mental health
in extremely broad terms, then trying to surmount these barriers.  The number of trained
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clinical psychologists went up sixty-six percent between 1952 and 1962; during the
same period the number of psychiatrists and nurses both increased by approximately
thirty-eight percent.274  Social workers and clinical psychologists played an important
role in these new government programs.275
Final Report of JCMIH and Creation of Community Mental Health
Facilities
 The Joint Commission on Mental Illness and Health combined with the
Community Mental Health Centers Act, altered the face of mental health treatment. 
Allied professions increasingly took over short-term psychotherapies.  Counselors
helped families cope with social problems, such as alcoholism and marital dysfunction. 
Medical doctors’ roles within the mental health professions increasingly focused on
somatic treatments, particularly use of pharmaceuticals.  In this way, physicians treating
incipient or mild mental illness became increasingly associated with prescribing drugs. 
Valium and the minor tranquilizers were ideal for the physicians’ new roles in mental
health care; they were safer than previous tranquilizers and sedatives, had a wide
spectrum of uses, and were only available from medical doctors because their
‘specialized knowledge’ was necessary in use of such ‘powerful’ treatments.
In 1961 the Joint Commission on Mental Illness and Health (JCMIH) published
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its final report, titled  Action for Mental Health.  To improve the mental health of the
nation, the group concluded, three major problems needed resolution: insufficient
personnel, inadequate facilities, and ridiculously low funding levels given America’s
psychic woes.276  They suggested increased funding for long-term fundamental, rather
than applied, research on cures for mental illness.  Treatment oriented to restoring
mental health was desirable.  They advised attempting to increase numbers of scientists
and researchers, and funding a greater number of physical facilities for research.  
The report defined mental health and mental illness in a manner privileging
focus on obtaining a positive state of mental health, and treatment of less severe mental
health problems.  Elaine Cumming of the New York State Department of Mental
Hygiene wrote of her shock that although the report “explicitly states that the treatment
of the seriously ill is our most important task,” the Committee’s recommendations
mentioned cost and high numbers, but otherwise did not “relate directly to the seriously
ill[.]”277  The primary approach involved preventing mental illness, or heading off
problems before they became more severe.
Persons who are emotionally disturbed – that is to say, under
psychological stress that they cannot tolerate – should have skilled
attention and helpful counseling available to them in their community if
the development of more serious mental breakdowns is to be prevented. 
This is known as secondary prevention, and is concerned with the
detection of beginning signs and symptoms of mental illness and their
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relief; in other words, the earliest possible treatment.  In the absence of
fully trained psychiatrists, clinical psychologists, psychiatric social
workers, and psychiatric nurses, such counseling should be done by
persons with some psychological orientation and mental health training
and access to expert consultation as needed.278
Framing the issue in these terms resulted in the committee suggesting
“psychiatry and the allied mental health professions should adopt and practice a broad,
liberal philosophy of what constitutes and who can do treatment[.]”279  This idea, as
embodied within the 1963 Community Mental Health Centers Act, reshaped the roles of
mental health practitioners in a manner promoting greater use of
psychopharmaceuticals, such as Valium.  The most effective use of physicians’ time
was to practice approaches the allied professions could not handle.  Only physicians
could prescribe drugs, and therefore short or long-term treatment with pharmaceuticals
became associated with treatment by medical doctors. 
The report also minimized differences between physical and presumably mental
illnesses.  Within the summary of recommendations, the Committee declaimed,
“Mental illness is different from physical illness in the one fundamental aspect that it
tends to disturb and repel others rather than evoke their sympathy and desire to
help.”280  This concept of essential similarity between mental and physical illness was
not novel; Robert Robinson, the APA’s Public Information Officer, referred to it as a
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“common platitude”281 of the time.  The JCMIH report, however, took pains to show
how treating mental illness as different from physical illness helped create the apathetic
state of mental hospitals in 1920s; without prospect of medical treatment, physical
treatment, many superintendents saw their job as “to take custody of any and all persons
committed to their institutions by the courts and thenceforth guard the public and
patients against the latter’s irrational act, if any.”282  The resulting pre-war approach
focused on custodial care rather than medical treatment, “keeping the mentally ill
alive,”283 with little expectation or effort to mitigate the illness.  Although the
Commission did not explicitly promote physical treatment through pharmaceuticals or
surgery, they promoted the idea that caretakers and the public were likely to ignore
therapeutic possibilities as long as they considered mental illness as fundamentally
different from physical illness.
In Action for Mental Health, the Committee put physicians in a privileged,
though limited, position.  The report asserted that “certain kinds of medical, psychiatric,
and neurological examinations or treatments must be carried out by or under the
immediate direction of psychiatrists, neurologists, or other physicians specially trained
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for these procedures.”284  They did not discuss the role of physicians in expansive terms. 
In fact, the committee effectively recommended “nonmedical mental health workers”285
take charge of short-term psychotherapies, including direct interaction with patients
using “objective, permissive, nondirective techniques of listening to their troubles and
helping them resolve these troubles in individually insightful and socially useful
way[s].”286  The Committee even placed longer-term psychotherapeutic techniques
within the purview of psychoanalysts or psychotherapists without a medical degree. 
Unlike short-term therapy, “psychoanalysis and allied forms of deeply searching and
probing”287 held the risk of harming patients, the Committee argued, therefore
practitioners required special training.  Action For Mental Health did not suggest
psychoanalysts and psychotherapists trained initially as physicians, should not practice
these techniques; it did, however, explicitly suggest allowing “psychologists or other
professional persons who lack a medical education but have an aptitude for, training in,
and demonstrable competence in such techniques of psychotherapy”288 into this realm
of mental health practice.  With wary optimism, the Committee suggested that
recruitment drives, scholarship programs, increased educational facilities, expansion of
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medical schools, and “short courses and on-the-job training in some professions and
upgrading for partially trained persons”289 together might make it possible to overcome
the manpower shortage.  In other words, to meet demand for psychiatric services, the
country needed to use a broader array of mental health professionals and semi-
professionals, with public needs served by those with the least training necessary for the
task.
Strangely, the JCMIH in Action for Mental Health did not promote using
psychopharmaceuticals.290  Although most psychiatrists recognized major tranquilizers
had changed the face of institutional psychiatry, making it possible to focus on
treatment and offering the realistic possibility of releasing patients who earlier would
have died within the institution’s confines, this did not necessarily translate into belief
in psychopharmaceuticals as appropriate treatments for mental illness.291  Ideally, major
tranquilizers altered behavior significantly enough for group, behavioral, or short-term
psychotherapy to act therapeutically.  Drugs were an adjunct to treatment, not the
treatment itself.  The JCMIH monograph failed to challenge the dominant
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understanding that minor tranquilizers or barbiturates treated symptoms, not an
underlying problem.  If pharmaceuticals remedied the situation it was due to the body’s
own restitution of health.  It is likely the Commission did not discuss treatment with
pharmaceuticals because they did not consider use of pharmaceuticals a treatment; like
Aspirin, psychopharmaceuticals affected experience of headache, but did not actually
make the underlying problem disappear.
Improving the number of facilities and personnel, and access to them, was
achievable using a two-pronged approach.  There appeared no way to ignore need to
upgrade existing psychiatric care institutions, but the committee also promoted the
principle that government should fund creation of smaller and more dispersed facilities
oriented toward treatment of neuroses, personality disorders, alcoholism, juvenile
delinquency, problems within the family, and other emotional stressors.  The other
means for effectively increasing facilities was, once again, recruiting a wider variety of
professions under the umbrella of ‘allied mental health professionals.’  The national
survey reported in Americans View Their Mental Health identified a wide variety of
professions to which Americans went in the hope they could assist with emotionally
disturbing conditions.  This group, already involved in informal processes of promoting
mental health, included  “clergymen, family physicians, teachers, probation officers,
public health nurses, sheriffs, judges, public welfare workers, scoutmasters, county
farm agents, and others[.]”292 Trained through short courses, they could more formally
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become mental health professionals.
Although there are open questions about the extent of links between the Joint
Committee on Mental Illness and Health’s final report in 1961, President Kennedy’s
Special Message to Congress on Mental Illness and Mental Retardation on 5 February
1963, and passage of the Community Mental Health Centers Act later in 1963,293 the
means and ability to fund such a drastic enlargement of the government’s role in mental
health care remained central to all.  Parties involved in drafting and passing the
legislation accepted the need to “seek out the causes of mental illness” in part to
forestall need for expensive chronic care.  “[P]revention is far more desirable for all
concerned[,]”294 President Kennedy explained in his message to Congress.  Action for
Mental Health, Kennedy’s “Special Message,” and text of the Community Mental
Health Centers Act, each recognized that extensive new federal government funding
would be required, and proffered suggestions how to reduce the fiscal burden on the
government’s purse.
Kennedy glossed over any need to establish what point on the spectrum from
mental health to illness triggered need for assistance.  The president did not address the
problem presumably because he viewed the program as an effort to nip major mental
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illness in the bud, to spot “incipient symptoms of illness.”295  Although deserving full
kudos for optimism and intent, the wording and approach of the Community Mental
Health Centers Act of 1964 contained built in problems that would lead to its own
downfall.  “All of us have an occasional touch of mental illness,” noted social scientist
Joseph Eaton, “[i]n reality, mental health merges imperceptibly and gradually, like the
colors of the spectrum, into mental illness.”296  With both prevention of mental illness
and promotion of mental health as goals, there was no point when the work of
community mental health centers could be considered complete.  
Considering mental ill-health in somatic terms and promoting treatment with
pharmaceuticals were essential steps toward making mental health care more affordable
and accessible.  President Kennedy’s proposal, as he saw it, involved a novel emphasis
relying “primarily upon the new knowledge and new drugs... which make it possible for
most of the mentally ill to be successfully and quickly treated in their own communities
and returned to a useful place in society.”297  This was one way to reduce costs.  The
other was to treat mental health care like other forms of health care; psychiatric
pharmaceuticals were part and parcel of putting mental health care within the realm of
mainstream medicine.298  “[T]he services provided by these centers should be financed
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in the same way as other medical and hospital costs[,]” the President reassured
Congress.  With new technologies, “tranquilizers and new therapeutic methods[,]”
mental illness did not require “long and often permanent courses of treatment.”299 
Development of psychopharmaceuticals, even though usually considered treatments of
symptoms rather than cures, placed treatment or prevention of mental ill-health within
the boundaries of mainstream medicine, with its traditional emphasis on physical illness
and physical treatment.  Health insurance usually applied to physical treatment of
physical illness.  By somaticizing the problem, it was possible to defray costs by
“individual fees for services, individual and group insurance, other third-party
payments, voluntary and private contributions, and State and local aid[.]”300  Kennedy
promoted passage of The Community Mental Health Centers Act by explaining it as a
temporary measure.  “Long-range Federal subsidies for operating costs are neither
necessary nor desirable[,]”301 he assured legislators.  He admitted some private sources
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of funding needed adjustment, particularly health insurance, but mental health for all
was within America’s grasp.
Health Insurance and Access to Physicians
Americans in the post-World War II world expected a personally useful health
care system.  Greater numbers of citizens had access to in- and out-of-hospital services,
partially due to increased affluence in general, and partly resulting from increasing
numbers covered by health insurance.  Effectively, voluntary health insurance in the
United States was a recent development; it began in the 1920s.  Melissa Thomasson, an
economic historian whose research has focused on development of the United States
health insurance system, argues there was neither demand nor mechanisms of supply
before that decade.  She points out that medical expenditures before the 1920s were
relatively minimal and therefore Americans’ financial concerns related to ill health
focused almost exclusively on loss of wages.  Those few policies available were largely
sickness insurance, plans that maintained income in the face of short-term disability.302 
Major innovations in health insurance occurred in the 1930s with creation of
Blue Cross and Blue Shield plans.  Blue Cross developed first, with the earliest plan
formed in 1929 by teachers in Dallas who contracted as a group with Baylor University
Hospital.  In return for a fixed annual payment of six dollars each, the hospital agreed to
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provide up to twenty-one days of hospitalization per member.  Blue Cross plans
typically followed this model of contracts between small groups and hospitals; they
provided protection against illness for individuals and were beneficial to hospitals
which, in the 1930s, faced severe financial constraints.303  The American Hospital
Association organized the umbrella Blue Cross group as an attempt to prevent their
member hospitals from undercutting one another.  Blue Shield developed as a prepaid
voluntary health insurance plan, but arranged with physicians rather than hospitals. 
Thomasson argues physicians took the initiative in forming Blue Shield plans, even
though they were traditionally opponents of health insurance on the grounds that it
interfered with physician autonomy and restricted income.  But Blue Cross quickly
proved popular.  There was fear Social Security legislation might include national
health care, and hospitals might begin including physician services as well as hospital
services in Blue Cross plans.  The American Medical Association promulgated a set of
ten cardinal rules for voluntary insurance involving physicians.  In large part, the focus
was on insuring physicians would supervise and control the system, retaining the ability
to set their personal fees.  Blue Shield subscribers were responsible for paying the
physicians, and reimbursed by Blue Shield for a fixed amount per procedure.304 
World War II was a turning point in development of health insurance, with
establishment of more plans covering a wider variety of medical expenses, which
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applied to a greater number of Americans.  In an effort to stem skyrocketing domestic
inflation and costs during the war, the Federal government attempted to control both
workers’ wages and prices of goods.  The 1942 Stabilization Act helped prevent
employers from competing among themselves for scarce labor by increasing wages, but
allowed and inadvertently promoted, companies using benefits to maintain or increase
their own workforce.  Health insurance was one of the most important benefits offered,
especially as employers did not pay payroll taxes on contributions to their employees’
health insurance plans.  As a result, increasing numbers of working Americans gained
some form of health insurance through their employers during World War II.305 
Yet, having more Americans with health insurance did not imply either that a
high proportion of Americans had insurance or that there was great breadth of coverage
for each member.  In 1940 “less than 10 per cent”306 had insurance covering in-hospital
medicine (only 40% of this group was thought to have insurance that covered surgery). 
Typical benefits for hospital treatment covered five dollars per day for room and board
and up to thirty days of care.307  The percentage of Americans with insurance covering
out-of-hospital, “non-surgical” care308 was a mere two percent.  What changed over the
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1940s and 1950s was that more Americans became aware of, and used, the health care
system.  Voluntary health insurance became more common, with more group policies
and increased coverage of out-of-hospital care.  Returning soldiers had experience with
health care, including mental health, paid for entirely by their employer, the military. 
The head of NIMH estimated eighty percent of Americans had some form of coverage,
however slight, by 1962.  Yet insurance still paid only one-quarter of what individuals
were billed for mental health treatments.309  Experience and access to the heath care
system undoubtedly played an important role in the widespread use of prescription
pharmaceuticals from the 1950s to the 1970s.  
Specialization of medicine was an important alteration to the mid-twentieth
century professional landscape.  Herman M. Somers, Professor of Political Science, and
Anne R. Somers, Research Associate specializing in industrial relations and “social
welfare[,]”310 estimated the percentage of medical specialists compared to generalists
rose from eleven percent in 1923 to thirty-nine percent in 1955.  They documented an
even greater shift among physicians in private practice (fifty-two percent by 1949, and
fifty-eight percent in 1955).311  But it is important to recognize most white middle-class
Americans dealt almost exclusively with family doctors and group practices when
dealing with mental health issues.  Some patients saw psychiatrists or psychologists, but
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increasingly few entered hospitals or institutions.  And when patients interacted with
physicians for mental health issues, the treatment they received was generally short-
term, and somatic or behavioral.  Psychotherapy might be fashionable, but it was
expensive and time consuming.312  
Mental Health and Health Insurance
Mental health had, and still has, a troubled relationship with health insurance. 
“There is no such thing today as psychiatric insurance[,]”313 wrote the Assistant director
of the AMA’s Department of Economics in 1966.  General health insurance policies
either covered some or did not cover at all, mental health treatment.  Psychiatrists were
unique among physicians in having their most common treatments generally excluded
from insurance coverage.  
In general, Blue plans (Blue Cross and Blue Shield) paid approximately
seventy-five percent of hospital bills and forty-five percent of physicians’ bills; they
were therefore only partial payment plans and of use mainly to the growing middle
class.314  Blue plans were not uniform, but overall they either explicitly or implicitly
excluded mental illnesses.  Some plans paid if physicians found the condition organic in
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cause, or if the patient treatment took place in a general hospital (which rarely had the
capacity for specialized psychiatric treatment).  Other plans excluded “disorders due to
alcohol or drugs[,]”315 probably on the grounds that even if addiction was a medical
condition it was self-inflicted.  The Health Insurance Plan of New York included a
psychiatric consultation service, but no psychiatric treatment.316  A report by the Joint
Information Service of the American Psychiatric Association and the National
Association for Mental Health concluded plans were covering in-hospital care of mental
illness more than previously, but rarely covered out of hospital treatment.  When mental
problems were covered, insurance was “characterized usually by multiple
limitations.”317  Commenting on the situation, Henry Davidson hypothesized that
“[b]ehind these conscious reasons lies...the feeling that psychoneurosis is a voluntary,
self-induced, basically unreal disability which reflects weakness of character.”318 
Davidson’s analysis focused on how psychiatrists could adapt to the existing situation. 
Psychiatry needed to become associated more closely with other branches of medicine,
he concluded; “Perhaps we could analogize a psychiatric disorder to a surgical one.”319
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The increasing importance of health insurance, albeit mainly to middle-class
Americans and veterans, created a strange tension within the post-World War II
understanding of mental health and mental illness as a continuum, and neuroses as
common conditions.320  Accepted topics within the purview of mental health
professionals now included such broadly dispersed categories as “[m]arriage
counseling, vocational guidance, trouble in reading, juvenile delinquency[,]”321 as well
as neurotic reactions, personality and mood disorders, alcoholism, and the psychoses. 
Yet medical insurance plans limited mental health treatment based on insurance
principles which required a condition to be voluntary, uncommon, and occurring in a
measurable way in terms of rate, costs, and proper treatment.322  Functional disorders
such as neuroses, delinquency, marital problems, drug addiction and alcoholism did not
fit their models unless they related to physical conditions, unless medicine and
insurance considered the mind, brain, and body a single unit.  A Joint Information
System Report concluded that shorter hospital treatments and greater experience should
provide the actuarial information required to show mental health coverage for inpatients
would not increase premiums substantially.  They foresaw a day in the near future when
it would be “possible to have the same coverage for inpatient care on the same basis as
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physical illness.”323  Coverage of ambulatory treatment, however, would require
“additional actuarial experience.”324
What appears the turning point promoting at least moderate coverage of mental
ill-health was somaticizing the problem.  By 1960, the benefits of psychoanalysis were
increasingly questioned; psychiatrists no longer widely accepted it as the gold standard
of treatment.  It was “appealing and useful only to certain fairly restricted segments of
the population.”325  The utility of psychoanalysis also came under attack, with Charles
Hall jr., the Assistant Director of the AMA’s Department of Economics, referring to it
as “not only ineffective for treating many forms of psychiatric illness but also
forbidding and frightening to large masses of the working population.”326  The picture
of mental health coverage shifted in the late 1950s; while only fifty percent of Blue
Cross plans covered even hospital care for mental conditions in 1955, by 1963 eighty-
two percent of these policies included coverage without a separate rider.  Twenty-one
percent of Blue Cross plans nationwide “provided the same benefits as for other types
of illness,” although this could require hospitalization, just like somatic illnesses.327 
Benefits under Blue Shield plans changed similarly.  Insurance companies recognized
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use of drugs such as Valium contained costs, compared with psychological treatments. 
Treatment with psychopharmaceuticals meant the treatment was physical; drugs
acted on body and brain.  Physical treatment of neuroses also promoted of short-term
treatment on an outpatient basis.  President Kennedy, proselytizing for the Community
Mental Health Centers explained the necessity and realistic expectation that private
business could provide the primary source of funding.
The success of this pattern of local and private financing will depend in
large part upon the development of appropriate arrangements for health
insurance, particularly in the private sector of our economy.  Recent
studies have indicated that mental health care – particularly the cost of
diagnosis and short-term therapy, which would be major components of
service in the new centers – is insurable at a moderate cost.328
The President was not alone in his optimism.  By increasing use of short-term,
low-cost, outpatient treatments and also highlighting the somatic aspects of neuroses,
modern medicine appeared to create affordable mental health care for the masses.  As
the American Medical Association’s Assistant Director of Economics phrased it, “One
of the real problems facing insurance today is to keep their policies up to date with
developing modes of treatment.”329
Conclusion
Overall, the period from 1945 to 1963 was characterized by tensions between
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increasing demand for services to promote positive mental health and battle mental ill-
health, and limits placed by available personnel, facilities, and costs.  The resolution
developing by 1963 created a situation wherein Valium and other
psychopharmaceuticals played a greater role.  The focus by 1960 was on obtaining
mental health and treating mild, rather than severe, mental illness.  Stress and the
tensions of everyday life in America were barriers to positive mental health.  Physicians
differed from other mental health professionals in large part because they could
prescribe pharmaceuticals.  Valium was suitable for treating neuroses, minor mental
ailments, and preventing stress and ongoing everyday tensions from tipping the balance
from mental health towards mental illness.  Tranquilizers were a short-term treatment,
available only from physicians.  Because general practitioners wrote most prescriptions
for psychotropics, use of drug treatments nicely avoided the problem of health
insurance plans which placed limits on the number of visits to psychiatrists.330
Overarching theoretical structures increased interest in the treatment of tension
and anxiety.  Hans Selye popularized his theory of the General Adaptation Syndrome in
the popular press.  Ego and dynamic psychiatry promoted the concept of health
involving some form of dynamic tension, a balancing, between intrapersonal forces. 
Psychosomatic medicine tried promoting a more holistic understanding of illness, with
mind and body both involved in ongoing disease.  In each case the theories identified
tension, stress, and anxiety (including an ongoing feedback loop of anxiety), as an
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important problem.  In 1963, Roche introduced Valium as a treatment useful for the
wide variety of cases these three theories–Selye’s G-A-S, dynamic psychiatry, and
psychosomatics–identified as rooted in anxiety, tension, and stress.
Prescribing tranquilizers was justifiable on multiple levels, it could help father
deal with job stress, and mother with the grinding madness of motherhood in the
suburbs.  It could keep families intact, which many Americans apparently associated
with a strong and well regulated democratic society.  Minor tranquilizers, those less
sedating than ones suited to use within the confines of long-term psychiatric care
institutions, served what the American populace and its leaders saw as pressing national
needs.  Whether used in the short term to treat the psychological aspects of
psychosomatic illness, or in the longer term to deal with immature personalities
adapting poorly to social roles, few interested Americans questioned tranquilizers’
potential medical benefits.  The drugs’ use fit with what was ‘known’ about the
workings of mind and body.  The teachings of contemporary medicine tacitly justified
widespread use of minor tranquilizers to treat a wide variety of physical and
psychological problems.
The combination of mental health services delivered by the Community Mental
Health Centers Act of 1963, focus on neuroses, promotion of positive mental health and
rapid diagnosis and treatment of mild mental illness, characterization of more mental
illnesses as physical or part of psychosomatic conditions, and widespread use of minor
tranquilizers prescribed by general physicians for the stresses and tension that could
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lead to neurotic reactions, helped solve the impasse between under supply of mental
health services and increased public demand.  To promote mental health and stave off
mental illness required national mobilization of resources.  In the 1950s and 1960s
America appeared willing to try eradicating neuroses wholesale, to test Brigadier
Menninger’s claim that if we “had the manpower and the effort and the time...devoted
to preventive aspects of psychiatry...we too could have perhaps demonstrated
spectacular achievements comparable to vaccination or DDT.”331
Based on this optimistic belief that medical science could meet the widespread
need for mental prophylactics, pharmaceutical companies drew on existing knowledge
of mental health and illness and contemporary understandings of the nature of neuroses
in order to develop valuable treatments.  One outcome of their programs was Valium. 
Whether its usefulness was more akin to vaccination or DDT remained to be seen.
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CHAPTER 4.  DEVELOPING NEUROSES:
MENTAL HEALTH THEORY BEFORE VALIUM
Mental health theory provides the context behind Valium’s discovery, testing,
and marketing.  Psyche and somatic-based theories of the mind and brain developed and
intertwined from 1900 to 1960.  Concepts explaining the nature of neuroses altered;
neuroses became things scientists could induce and – at least their correlates – measure
in laboratory animals.  This opened the possibility of discovering and treating neuroses
with drugs such as Valium.  The theoretical backdrop helps explain the ways
pharmaceutical manufacturers, physicians, and pharmacologists in the 1950s and 60s
understood neuroses and anxiety.  A combination of theories, including those discussed
in this chapter, justified Hoffmann-La Roche putting money into the search for new
tranquilizers and development of pharmacologic testing methods used to test
Sternbach’s compound.  Psyche and neural-based theories were not mutually exclusive. 
They intertwined and complemented each other, possibly because the physicians and
scientists involved saw less of a mind/body divide than the average philosopher. 
During the 1950s pharmaceutical manufacturers introduced a series of drugs
into the psychiatric armamentarium which changed the face of institutional psychiatry. 
Dominant types of somatic (bodily) treatments altered, with techniques such as
psychosurgery and insulin coma nearing extinction.  The first pharmacologic
antidepressants, including amphetamines, appeared around this time.  But of broader
121
332  The concept of functional mental illness developed from early twentieth
century efforts to identify physical lesions or deformities related to dementias,
schizophrenia, and psychotic behaviors.  By the 1950s functional mental illness could
best be defined as those conditions not thought organic-based.  Mental retardation,
senile dementias, schizophrenia, paresis, mania, and possibly alcoholism were believed
to have somatic, bodily, basis.  Functional mental illness, in theory, included
maladaptations of behavior, affect, or learning, all of which were related to functions of
the mind, rather than diseases of the brain.
social importance was the discovery of tranquilizers.  Chlorpromazine and reserpine,
later classified as antipsychotics or major tranquilizers, were the earliest heralds of the
flood.  Their rapidly proven utility in calming psychotic and manic patients eased life
for both institutional patients and doctors.  Companies reevaluated substances already
on the market, especially antihistamines, which were endowed with sedative, and
therefore potentially calming, properties.  And toward the end of the 1950s came a new
type of tranquilizer...one believed nonaddictive, mild, not dulling the mind, and with
little risk of overdose; chlordiazepoxide (Librium) was the first of these
benzodiazepines, followed quickly by the drug this dissertation focuses on, diazepam,
known by its trade name, Valium.
To understand the peculiarity of Valium’s identification and marketing, it is
essential to place its discovery in the context of 1950s mental health, as well as
developments in behavioral and pharmaceutical research.  How mental health
professionals understood functional mental illnesses, broadly conceptualized as
neuroses, shaped study of potential treatments and guided testing potentially useful
compounds.332  The discovery of major tranquilizers – chlorpromazine and reserpine –
affected expectations surrounding potentially useful compounds.  Discussions of
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previously used drugs, including barbiturates and bromides, suggest many physicians
and pharmacists thought they affected the body and not the mind.  Pharmaceutical
companies began looking for compounds that seemingly altered the mind as well as
body.  The focus on mental health, neurotic reactions, and stress, all melded with one
another in ways that created Valium as a social entity, a drug useful for widespread
conditions.  It was a good solution to a perceived problem.  This chapter focuses on
changes in conceptualization of neuroses, neurotic reactions, anxiety, and stress from
the 1940s through to 1960, in order to help explain development and plans to market
Valium (and Librium).
Development of Mental Health Theories
Although an over-generalization, it is useful to divide pre-1940 mental health
theory into two broad categories, neural- and psyche-based.  Neural theories, often
termed behavioral, focused on overt and observable behavior as a window into the
mind.  Comparatively, mental or psyche-based theories tended to focus on interaction of
the unconscious mind with conscious thought and behavior.  To illustrate general
characteristics of these theories, how they shaped perceptions of mental illness, and
mutated into forms influencing discovery of Valium, Pavlovian behavioral conditioning
techniques and Freudian psychoanalytic theory will act as exemplars for the two broad
categories of theory.  It is important to recognize that these theoretical positions are
only exemplars.  Most of the articles read for this dissertation suggest
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many leading physicians and scientists had an eclectic approach, either showing little of
their theoretical foundations, or freely using a combination of psyche and neural
theories.  Discussing the exemplars – at least in the period before 1940 – does, however,
provide more clarity.  Pavlov’s work informed techniques used to identify physiological
correlates of neuroses.  Freud’s theories helped explain links between neuroses and
stereotyped behavior.
Ivan Pavlov, 1849-1936: Neural/Behavioral Theories
Ivan Petrovich Pavlov was born in Ryazan, Russia, to an impecunious priest and
his wife.  After basic educational training in a theological seminary, he studied at the
University of St. Petersburg, graduating in general science and moving on to a program
in medicine at the Military Medical Academy.  He gained a license to practice medicine
after completing the program in 1879, but only obtained his M.D. in 1883 after working
with a well-known clinician.  It was during this period he began working extensively
with experimental research animals.  From this point a combination of hard work, skill,
and connections resulted in a rapid rise from privat-docent in physiology in 1884 to
Director of the Physiology Department at the Institute of Experimental Medicine in St.
Petersburg in 1890.
Now established head of a research program, Pavlov spent the remainder of his
life working, directing research, and garnering increasing renown.  Research on
physiology of digestion, using dogs as research animals, resulted in a 1904 Nobel Prize
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in physiology.  Yet by 1902 he and his numerous doctoral students were adapting
earlier techniques to “the problem of the higher nervous processes of the brain.”333 
Around 1923, when his son read one of his lectures before the International
Physiological Congress in Edinburgh, Ivan Pavlov’s research gained broader
international notice.  From that time to his death in 1936 he garnered international
awards and memberships, funds and a pension from the Soviet government and,
probably most importantly, iconic status sufficient for him to remain professionally
successful in Russia while openly anti-Bolshevik.334  
Pavlov’s interest in mental phenomena developed from an interest in
physiology, so it is not surprising that he viewed action of the mind as rooted in the
brain.  Innovative in his focus on long-term studies of conditioning as well as external
events,335 he was the first well-known scientist to recognize neuroses created in animals
under laboratory conditions.  In 1901, during experiments on animal digestion, he noted
his dogs secreted digestive juices before they saw, smelled, or tasted food.  Tinkering
with environmental conditions suggested these animals had learned to associate a sound
before food arrived with the process of eating to the extent their stomachs prepared for
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digestion before ingestion.336  To isolate the brain area causing this effect, Pavlov tried
producing the same learning conditions in decorticated dogs (he excised the brain’s
cortex) and found the animals unable to associate the bell stimulus with the act of
eating.  Without the “cerebral hemispheres[,]” the dog became “a helpless invalid, and
cannot long survive unless it be carefully tended.”337  He concluded that these animals
learned through association, conditioned to recognize events outside the body with
those inside the body; furthermore the association formed within the brain’s cortex.
Pavlov focused on the influence of environmental alteration and changes in
behavior because he considered observation of the physical actions of the brain
impossible.  Ongoing interaction between the environment and the individual produced
“a state of perpetual flux,”338 of mental activity “changing so rapidly that it becomes
practically impossible to observe any aspect of it in an entirely pure and
uncontaminated form[.]”339  Behavior was observable, providing “very definite but
purely external signs,” useful for deducing how animals learned.
The core of Pavlovian method involved relating unconditioned reflexes (UR)
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and unconditioned stimuli (US), in order to produce conditioned responses (CR). 
Unconditioned reflexes were the natural reactions of the body, innate behaviors such as
respiration, digestion, physical sexual response, blinking, fight or flight reflexes. 
Certain conditions triggered these innate behaviors, in the presence of unconditioned
stimuli such as the body’s need for air, eating food, pheromone sensing, avoiding rapid
motion toward the eyes, or perceived danger.  Conditioned responses developed when
unconditioned stimuli and neutral stimuli occurred together or in close time sequence. 
This occurred in natural learning, so Pavlov assumed he could reproduce it under
controlled laboratory conditions.  The result of this pairing preexisting conditions
producing a reflex with new stimuli, was association within the brain of the two stimuli,
thereby creating a conditioned stimulus.  The brain would now react to the stimulus
with the conditioned reflex action.
Pavlov explained creation of conditioned stimulus and response by postulating
some sort of temporary physical link between a point in the cortex involved in
analytical thought and a point in an area of the subcortex responsible for unconditioned
reflex.  As he explained, “The fundamental mechanism of development of a conditioned
reflex depends upon excitation of some definite point in the cortex coincidently with a
more intense excitation of some other point, probably also of the cortex[.]”340  Creation
of this link between two points in the brain was the physical essence of conditioning.
He conceptualized the link in terms of excitation, activation, of specific areas of
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342  He did however study with clinicians, and worked “as the director of a
laboratory in the clinic of the renowned Botkin for several years.”  L. A. Andreyev,
“The Great Teacher and Master of Science,” The Scientific Monthly 45, no.2 (1937):
163.  The laboratory Pavlov directed in the clinic, however, appears to have been that
involved in experimental animal work.
the physical brain.  This connection was an action, perhaps most easily analogized as a
wave or tension.  Like waves in a pond, the initial activation created a prolonged pattern
that gradually weakened; “if such a coincident stimulation of these points is not
repeated for a long time the path becomes obliterated and the connection disrupted.  But
once such a path had been firmly established it remains intact without further practice,
for months and years.”341  Like a wave, repetition of the same pairing of unconditioned
stimulus with neutral stimulus strengthened the connection.  By our analogy, repetition
of the activation increased the amplitude of the wave.
Pavlov himself was not a clinical practitioner of psychiatry,342 yet his theories
informed later treatment approaches.  In general, behavioral or environmental
approaches find their roots in Pavlovian theory.  Essentially the focus is on changing
patterns of learning through alteration of stimuli or response to stimuli.
Pavlov considered unconditioned stimulus and reflexes, what he termed ‘natural
responses,’ more persistent links than conditioned stimulus-response (S-R) chains.  But
they were of the same basic type.  Repeated use of conditioned stimulus without
reinforcement decreased, even possibly extinguished the connection.  For example, a
dog who learned his owner says “walkies” before taking her out for a walk may learn to
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pick up a leash and head for the front door.  But if the owner uses the term walkies
capriciously, the dog is less likely to expect an outdoor expedition is imminent. 
Although Pavlov’s own position on extinction of CS-CR behaviors is unclear, he
understood weakening of the association as a process of inhibition (as opposed to
excitation).  He apparently believed the initial connection persisted, as the inhibition
reversed (disinhibition) more quickly than an initial learning pattern created and fixed.
  Behaviorism, throughout the early and mid-twentieth century, was about
learning.  Pavlov associated learning with conditioning of the organism through
reaction to the environment; “It is obvious that the different kinds of habits based on
training, education and discipline of any sort are nothing but a long chain of
conditioned reflexes[,]” he pontificated.  “We all know how associations, once
established and acquired between definite stimuli and our responses, are persistently
and, so to speak, automatically reproduced, sometimes even although we fight against
them.”343  But he realized the brain was not a simple machine, because the excitation
between points was not a simple and self-contained connection.  Excitation of a point
within the cortex was akin to setting up a wave, affecting peripheral areas, albeit to a
lesser extent the farther away they were.  This explained why similar stimuli could
evoke the same conditioned responses.  Organisms learned through direct conditioning
as well as generalizing and differentiating between stimuli.  The concept of learning in
terms of waves, or links with greater or lesser strength, provided a way to explain
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tranquilizers as central nervous system depressants.  Tranquilizers treated psychoses
and neuroses by altering the strength and rate at which CS-CR pattern were established,
extinguished, repressed, or altered.
  What Pavlov himself learned about the United States was not entirely positive. 
Already a Nobel Laureate and “one of the most distinguished physiologists in the
world,” Pavlov and his son visited the United States for three weeks in 1923.  “He was
robbed of $2,000 in a train in the Grand Central Terminal, was forced to become the
guest of the Rockefeller Institute because of his predicament and then was refused a
British visé to his passport because he was a Russian.”  It is hard to imagine being a
guest of the Rockefeller Institute was one of the Professor’s negative experiences.344
Pavlovian conditioning was not strictly deterministic.  Although some of
Pavlov’s statements suggest a stark view in which the individual is a near automaton,
simply responding to the environment, his understanding was far more nuanced. 
Environmental conditions were internal as well as external; Pavlov refers to the
“minutest changes in the environment or inside the organism itself” having “a profound
effect upon the cortical activities.”345  Yet the constitution of the organism also played
an important role, preparing the groundwork upon which conditioning developed. 
Certain individuals learned more quickly from one form of stimulus than another.  In
more recent terminology, individuals had learning curves and learned better from
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certain types of information.  Some constitutions tended to produce overgeneralized
responses, applying conditioned responses to diverse related conditions.  Others had a
remarkably high or low threshold for stimulus in general.  Those who persisted in
applying a conditioned response, either by overgeneralizing or by delaying the
extinction of a response after removal of reinforcement, were the constitutions, in mid-
twentieth century terms the personalities, who tended toward neurotic reactions.
Adding to the complexity were the first and second ‘signalizing systems.’  Apart
from that portion of the brain responsible for unconditioned reflexes, Pavlov argued
there was a first signalizing system which involved the conditioned responses.  Initial
conditioning was development of connections between these two portions of the brain. 
What added further complexity was the second signalizing system, widely distributed
throughout the brain.  This second signalizing system resulted from interplay of primary
conditioned responses through interaction and generalization.  It was through this
signalizing system that human beings gained the capacity for language and abstract
thought.
The behavioral model of stimulus-response provided a framework for
understanding mental illness that placed few boundaries between organic and functional
problems.  “Contemporary medicine distinguishes “nervous” and “psychic”
disturbances–neuroses and psychoses,” Pavlov complained, “but this distinction is, of
course, only arbitrary.”  Because he understood mental activity as rooted in the physical
interworkings of the brain, it was impossible to understand mental illness as a disease of
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the mind that did not involve the brain; “physiology and medicine are inseparable[,]” he
told listeners of his 1906 Harvey Lecture.346  By understanding learning in terms of
association with innate reflexes, he further blurred any putative boundary between the
nervous system and brain.  In his own words, “The distinction between “nervous” and
“psychic” affections is a distinction made on grounds of greater or smaller complexity
and subtlety in the disturbance of the nervous activity.”347  Mental illness was both
psychological and physiological.
The extent to which the details of Pavlov’s theories carried over to the operant
conditioning theories of the 1950s is a point of debate.  As discussed later in the
chapter, one of the best known figures in midcentury behaviorism, B. F. Skinner,
believed it was only possible to understand behavior, not thought.  Whether he was
correct is a side issue for the rationale for seeking and using tranquilizers; the more
important question is whether Skinner, and others of his theoretical ilk, considered
behavior rooted in the physical brain.  If neuroses were at least in part physical, they
might be directly, physically, treated.  Did they understand mental illness as both
physiological and behavioral?
Sigmund Freud, 1856-1939: Psyche-Based Theories
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The relation between pre- and post-1940s psyche-based theories is more easily
described, and how practitioners of these theories understood action of drugs appears
more consistent.  Depending on the interpretation, Sigmund Freud was either the father
of psyche-based theory, or the straw man for alternative interpretations.  In the late
1950s and early 1960s, the time of Valium’s development and introduction to the
American market, talk therapies such as psychoanalysis were the traditional gold
standard of treatment.  Freud provided the theoretical underpinnings of a system which,
with prolonged and intensive treatment, could modify personality enough to protect
individuals from developing maladaptive neuroses.
Sigmund Freud’s theories and techniques of psychoanalysis were highly
influential, especially in the 1940s and 1950s after his death.  Freud’s writings vary
dramatically from his earliest efforts to heal the mind through talk therapy, association,
or hypnosis and suggestion.  Nevertheless, until the time of his death his own work
defined orthodox psychoanalysis.  As he wrote in 1914 “...I feel myself justified in
assuming that none can know better than myself what psychoanalysis is, wherein it
differs from other methods of investigating the psychic life, what its name should cover,
or what might better be designated as something else.”348  By the 1940s the
psychoanalytic school of thought formalized the essential theories considered core to
their discipline.  Psychodynamics, ego psychiatry, and other post-1940 psyche-based
theories were outside the bounds of orthodox Freudian theory.
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Freudian psychoanalysis is a general methodology based on a certain
understanding of human development and the mind.  The mind, or psyche, is tripartite,
formed of the id, ego, and superego.  Although the actual terms refer to more specific
and nuanced ideas, it is a useful shorthand to associate the id, ego, and superego with
instinct, self, and conscience respectively.  The id or instincts were present at birth, the
ego developed during infancy, and superego through resolution of the Oedipus conflict
(in the traditional Freudian interpretation) or more generally through internalization of
social mores and parental teaching.
Freud’s understanding ties intimately to physiological thinking.  Instinctive
drives are similar to energies which are neither created nor destroyed, only temporarily
repressed, transferred, or sublimated into other forms.  Normal behavior involved
development of mechanisms to deal with this energy in ways allowing instinctive drives
and expression of the self to meet their desired ends within the bounds of socially
acceptable action.  When this energy, usually discussed in the early twentieth century as
a creative or constructive urge termed either Eros or the libido, was pent up, the
individual became neurotic, anxious.  Typically, Freudian theory described these
conflicts as taking place between the superego and ego over resolution of the id’s
desires.  If neuroses formed because of conflicts within an individual, pharmacologic
treatments could not touch the underlying disorder.  Psychotherapy was necessary to
understand the cause of neuroses and adjust personality, fix current, and prevent future,
problems.
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Freudian psychoanalytic theory focused on learning; the individual developed
according to interplay between inner drives and environmental or social conditions as it
attempted to reconcile desires with the limits of social reality.  This was a process of
negotiation within the individual as well as learning the constraints of society. 
Transference, projection, sublimation, and repression were efforts to channel drives in
order to achieve personal goals within the constraints of the social environment.  These
efforts to channel energies and conflict between drives to be normal and healthy
behaviors...mostly.  When the original problem remained unresolved, neuroses might
result.349  Psychoanalysis was an attempt to uncover details of the compromise, making
the conscious mind aware, and by showing what was “repressed within the id”350 to
promote development of responses to the conflict that “correspond better to a
psychically mature condition[.]”351
Traditionally, writers describe behavioral and psychoanalytic theories as
separate philosophies, different ways of understanding.  Yet there are remarkable
similarities in the underlying assumptions and implications of these pre-1940 theories. 
Both Pavlov and Freud’s interest focused on individual development and the interaction
between internal and external events.  In Pavlov’s case, an individual had a constitution
which influenced the process of learning and interaction with the environment.  In
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Freud’s case the inner drives attempted to reconcile instinct with the social
environment.  Both theories were about learning.  Pavlov’s individual learned, through
association and generalization, to develop complex conditioned stimulus response
chains.  Freud’s individual learned techniques of accomplishing goals in a realistic
fashion, dealing with the requirements of society in ways that channeled internal
energies.
Mid-Century Modifications
By the 1950s, purported behaviorists and psychoanalysts worked with
significantly modified versions of the initial theories; variants which placed greater
emphasis on the roles of stress and anxiety in mental illness, thereby preparing the way
for tension reducing drugs.  Although many writings of professed behaviorists or
psychoanalysts show an eclectic use of both neural and psyche theories, there remained
a recognized split between “the two practice groups in psychiatry...the analytic-
psychological...and the directive-organic[.]”352  In both cases emphasis increasingly
focused on the role of will or self, an assumption that human beings preferred stability,
and an association of mental health with adaptation to a changing environment.  In
theories of both groups, physical and mental life interacted, mainly in one direction;
mental processes affected physical.  The operant conditioning theories of B.F. Skinner,
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as well as Jules Masserman and W. Horsley Gantt’s work on conditioning and neuroses,
illustrate these changes.  Psyche-based theories will be discussed more generally
because they were significantly more differentiated, albeit with characteristic
similarities. 
B. F. Skinner, 1904-1990
Undoubtedly the most famous modification of Pavlov’s stimulus-response (S-R)
framework was B. F. Skinner’s operant conditioning model.  Skinner worked at the
Biological Laboratories of Harvard University.  During his studies on habit formation,
he concluded Pavlov’s methods and understanding of the conditioning process had
limited value.  The Russian recognized only two main types of conditioning, Skinner
complained, internal only and those impelled by an external stimulus.  In one case, the
linking of unconditioned reflex and unconditioned stimulus strengthened into a
conditioned S-R relationship due to temporal sequence, but the correlation was already
in place.  In the second form of conditioning, the original stimulus was paired with an
external event, a stimulus which “prepares the organism by obtaining the elicitation of
a response before the original stimulus has begun to act, and it does this by letting any
stimulus that has incidentally accompanied or anticipated the original stimulus act in its
stead.”353  Skinner promoted the idea of a third type of conditioning in which there is no
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obvious and immediate stimulus.  This ‘operant’ conditioning placed greater emphasis
on learning through trial and error, or thought, rather than mechanical conditioning
through reaction to outside forces.
It is important to note Pavlovian conditioning theory did encompass the
conditions Skinner defined as his new idea.  Pavlov presumably would have interpreted
this form of apparent learning as occurring through the secondary signalizing system
and the extinction of certain conditioned responses and development of new ones.  The
organism’s environment reinforced suitable new responses and strengthened the
connection between those events and the reflexes.354  Skinner himself was interested in
the role of social situations as “techniques of control[,]”355 in other words events
reinforcing certain culturally approved behaviors.  Pavlov’s presumed interpretation
differed substantially from Skinner’s because the former considered the reaction in
more deterministic terms, as chains of discrete events, and therefore rooted in different
ideas of learning.
As well as a change in understanding the learning process, the operant
conditioning model suggested significantly different ways to study learning.  If the
organism was adaptive rather than acted upon by the environment, whether adaptation
was positively or negatively reinforced was important.  As Skinner explained in his
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scathing response to J. Konorski and S. Miller’s “On Two Types of Conditioned
Reflex,”356 psychologists needed to recognize responses as learning experiences,
promoted or hindered because of reinforcement.  It was far more important to measure
the “rate of occurrence of the response” than the strength of relationship between
conditioned S-R.357  Change in rate of occurrence was measurable; alteration in the
strength of the S-R connection was poorly quantifiable.
In terms of the experimental conditions used to identify tranquilizers, B. F.
Skinner is far more important for promoting study of observable events without
interpreting mental events from them.  In 1950 he outlined his basic concerns in “Are
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Theories of Learning Necessary?”358  If “learning is a process in the behavior of the
individual[,]”359 he argued, it is inappropriate to use average behavior of a group. 
Instead, Skinner argued, you needed to study the “probability of response” in one
creature.360  This was a measurable phenomenon that varied over time, and therefore
held the possibility of expressing the change involved in learning.  His methods,
however, were hijacked by scientists seeking physically observable correlates of mental
events.  Others recognized that rate of response in laboratory animals provided an
experimental shorthand for identifying whether a drug altered the central nervous
system, if it was active at the higher levels of integrating perception and learning from
the environment.
Use of probability of response as a measure of learning has various implications. 
The organism learns to adapt to changing conditions.  Therefore learning occurs with
introduction of stressors, alterations to the usual environment.  Because probability of
response is a measure of learning over time, it emphasizes speed of adaptation. 
Skinner’s methodology is part and parcel of a conceptual shift toward focus on quick
adaptation to stress as a measure of mental health.
Contemporaneously with Skinner, other behaviorists tried to understand the
nature of neuroses.  In the 1940s and 50s, Jules Masserman, of the University of
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362  In Jules H. Masserman and Curtis Pechtel, “Neurophysiologic and
Pharmacologic Influences on Experimental Neuroses,” American Journal of Psychiatry,
113 (December 1956): 510-14.  Adaptation was important enough to be included in 3 of
the 8 variables studied.  
Chicago (1936-46) and Northwestern University (beginning in 1946)  worked within
the operant conditioning model as he conducted animal studies, attempting to
understand development of neuroses and their relation to frustration, fear, and 
aggression.361   W. Horsley Gantt, who set up and worked at the Pavlovian Laboratory
in Johns Hopkins University, tried to relate development of neuroses to the frustration
of uncertain or conflicting learning conditions.  Both of these influential behavioral
scientists helped shape an understanding of neuroses as physical and emotional
reactions based on the internal conflicts induced by changes in external events. 
Capacity to adapt to environmental changes was an essential part of mental health,362
and lack of viable options prolonged mental illness.
Jules Masserman, 1905-1994
Jules Masserman refined laboratory methods of inducing neuroses in animals, in
order to study behavioral changes resulting from modification of the creature’s
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environment.363  He identified signs of neuroses which were physical and measurable. 
These observable features later served as indicators of how well Valium mitigated
symptoms associated with neuroses and anxiety.
His neurosis experiments were grounded in his interpretation of Pavlov. “In the
Pavlovian system[,]” he wrote, “neurotic behavior was thought to arise when ‘external’
stimuli produced simultaneous but incompatible reactions of excitation and
inhibition[.]”  He took from this the idea that neuroses resulted from “conflictual
incentives and the consequences of their frustration...when he [the animal] could no
longer react with more directly adaptive behavior[.]”364  
Using laboratory animals such as monkeys, Masserman tested the idea that
“conflictive ‘psychological’ traumata”365 could produce neuroses; he provided creatures
with a frustrating situation, where expected conditions of cause and positive effect
suddenly conflicted with new and often irrational conditions.  First, animals learned and
therefore expected certain feeding conditions.  In one experiment, “[e]ach animal was
taught, in from four to six months, to press an electrical switch exactly four times for
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food, to alternate between two switches, and to choose the correct one of the two as
differentially indicated by a bell or light signal.”366  These animals now had a low stress,
predictable environment.  The investigators then introduced various mobile or vocal
representations – new stressors interfering with the monkeys’ predictable environment –
outside the cage, and observed the creatures’ reactions to the stressors.  The most
pronounced effects occurred with presentation of a “toy rubber snake[.]”367  The
animals responded with various degrees of “horripilation, alarmed vocalization, rapid
breathing, diffuse movements, ejectile defecation, and disturbances of discriminatory
patterns in signal-response and switch manipulation that persisted for from 15 to 30
minutes.”368  Stripped of scientific language, the scientists tormented monkeys with a
rubber snake, scared the s**t out of them, watched them signal for help, and recorded
the entire situation in apparently clinical terminology.  These well respected and funded
researchers tested a variety of other stimuli such as “a toy rubber lizard, a rubber spider,
or a coiled steel spring undulating along its length[.]”369  The results were less dramatic
and of shorter duration, and by the time the scientists presented them with “a walking
Donald Duck”370 the caged monkeys showed no fear.
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The fact that these experiments appear bizarre and cruel to later readers suggests
either that the Masserman laboratory at Northwestern University was staffed by
psychopaths, or this experiment and its results were understood by the scientists as
explaining important aspects of behavior, applicable to humans.  Given that the
Masserman lab was continually funded, and that he was not driven out of the state when
the results were presented to the New York Academy of Sciences, the latter explanation
appears more likely.  World War II had established that mental health and mental
illness were a continuum, with most citizens either neurotic or potentially so. 
Therefore, understanding neuroses with animal models held broad social importance;
they could “shed light on many problems of human behavior.”371  Masserman
established laboratory experiments in which he could reproduce neuroses at will, and
study conditions that prolonged, repeated, moderated, or removed them.  For example,
he established an association between the anxiety of initial frustration (trauma) and
sensitization producing prolonged anxiety.  As he explained sensitization, “all animals
began showing lowered thresholds of startle to sudden or unusual stimuli in any
modality, and marked evidence of anxiety[.]”372 Masserman’s experiments established
that similar conditions could produce a wide variety of reactions, physical and
psychological, all resulting from a similar underlying condition.  Although this
experiment did not test the efficacy of tranquilizers in mitigating initial trauma, or
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375 Masserman, of course, considered it worthwhile to investigate this potentially
troublesome variable.  His analysis showed “high ratings on pre-neurotic combativeness
correlate significantly with relative resistance to neurotigenic traumata;” but this
tendency of non-neurotic cats to resist becoming neurotic was a matter of level of
neurotiganic stimuli required.  All cats could become neurotic, but not all started that
way.  Jules H. Masserman and K. S. Yum, “An Analysis of the Influence of Alcohol on
Experimental Neuroses in Cats,” American Journal of Psychiatry 48 (January 1946): 
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ongoing anxiety, it tested two modified versions of psychotherapy.  Individual
psychotherapy, which worked on all species of monkey except the Rhesus, took the
form of petting and reassurance for one female Spider monkey, and requiring a male
Vervet to explore the cage in order to acquire food.  Rhesus monkeys required group
therapy.  The female, who would not approach the cage alone, tested the apparatus and
then “seemed to encourage similar behavior in her companions.”373
The relation between neuroses and social behavior, seen in the Rhesus monkeys,
was an important thread of Masserman’s research.  In an attempt to understand changes
in social behavior, dominance and aggression, he trained sixteen cats each to open a box
containing a food pellet when a “bell-light”374 signaled the box was unlocked.  He
paired single cats in various combinations to identify a dominance hierarchy, based on
which of a pair of cats ate first (dominant) and which did not try to eat until the
dominant cat finished (submissive).  Although it might be argued that all cats are
neurotic to begin with,375 Masserman induced neurotic behavior in dominant cats by
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380  Similar results were found in his earlier work on alcohol and cats.  Mildly
neurotic cats returned to normal behavior when given small doses of alcohol.  Strongly
neurotic cats, he thought, became addicted to booze for psychologic rather than
physiologic reasons.  It was “a learned adaptation contingent upon inter-current neurotic
stresses and reversible when these stresses were removed.”  In other words, neurosis
could lead to drink.  Masserman and Yum, Influence of Alcohol, 51.
“exposing them to adaptational conflicts between learned patterns for securing food...as
opposed to fear of repetition of a threatening experience.”376  This experiment is typical
of his approach and understanding of the conditions producing neuroses; motivation
conflicts create neurotic behavior if conditions within the organism and environment
were suitable.377  Behavior became “abnormally indecisive, substitutive, diffusely
symbolic, and biologically inefficient[.]”378
The effects of drugs played a role in Masserman’s research.  Using 142 cats and
43 monkeys, he examined the effects of alcohol, opiates, barbiturates, mephenesin,
chlorpromazine (Thorazine), meprobamate (Miltown) and other drugs on animals who
were either normal or suffered from experimentally produced neuroses.  In monkeys, he
found none of the drugs “with the possible exception of alcohol”379 protected against
either initial or continuing stress of neuroses.380  In cats, the drugs most similar to
Valium (barbiturates, some ataraxic drugs, and alcohol) were those which lessened
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neurotic symptoms once they formed.381
This research highlights parallels between alcohol and tranquilizers which
would underlie later debates in the broader social sphere.  Masserman identified alcohol
(because it depressed the cortex) as a substance reducing action in the portion of the
brain thought most important for integrating and synthesizing experience, the cortex. 
Later explanations of Valium’s action sometimes applied this logic.  He assumed
expectation of anxiety, lack of security, and ability to regress and focus on personal
needs were important effects of a “cortical depressant[.]”382  In his own words: 
precisely these “pharmacologically decorticant effects might be sought
by a neurotic animal to whom its environment had become
prevasively[sic] and poignantly threatening, since under such
circumstances transient but welcome relief would be afforded by any
drug that blurred and disorganized apperceptions provocative of anxiety,
diminished inhibition and facilitated a regression to relatively
elementary but need-fulfilling behavior.383
Alcoholism, however, was also partially psychological.  Masserman argued “alcoholism
is no more a disease than gambling or biting your nails.”  He followed the statement up
by pointing out it was a habit, similar to both gambling and nail biting.384  The
physiological and psychological mixed, so although not a true disease alcoholism was a
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legitimate “social behavior problem[.]”385  
Jules H. Masserman provides an excellent example of how behavioral and
psyche-based theories intertwined to create an intellectual foundation for the discovery
of Valium.  Masserman characterized his theoretical foundation as “Dynamic Psycho-
Biologic”386 because it applied modified traditional Pavlovian behavioral techniques of
inducing neuroses and more contemporary psychodynamic ideas of adaptation and
frustration of drives, using both obviously and symbolically related methods of dealing
with stresses.  Masserman chose muscle tension as one of the three most important
items (out of sixty used) for studying neuroses and drugs in cats.387  Roche labs would
use small animal tests involving muscle tension to identify potentially marketable
tranquilizers.
Masserman’s drunken cat experiments gained popular notice.  Dr. Joyce
Brothers used the experimenter’s work to reassure one reader there was precedent for
their problem beer-drinking cat.388  The Salt Lake tribune ran a report of the research on
its front page, focusing on how “cool cats...can come down with anxieties, tensions,
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phobias and....[l]ike man, they experience relief of their neuroticism by taking to drink.” 
The story’s hook, however, was that Masserman, “The Chicago Psychoanalyst[,]”
illustrated development of neuroses “in animals that do not have a background of
unresolved sex conflicts.”389  Public perception of mental health research assumed both
behavioral and psyche-based theories played important roles.
W. Horsley Gantt, 1892-1980 
W. Horsley Gantt, working at Johns Hopkins’ Pavlovian Laboratory, focused his
animal neuroses studies around behavioral methods, but with a more explicitly
mentalist interpretation than Masserman.  Gantt’s work tied together observable signs
of neurosis with theory of underlying mental behavior.  Bringing a broader group of
theories into alignment made questioning any of them less likely.  Therefore his
influence on development of Valium was on both establishing neuroses as externally
observable, and therefore testable, conditions and establishing utility of stress
mitigating pharmaceuticals, an antineurotics.  Gantt’s interests included the relationship
between conflict and neuroses in terms of their physiological correlates.  But he
interpreted frustration and conflict in terms of conflicting drives internal to the animal
and inability of adapt to new stressors.  Similar to psychologist Gordon W. Allport’s
idea of functional autonomy of drives, discussed later in this chapter, Gantt identified
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the roots of neuroses in frustration and conflict, but developing into continuing
problems due to associations in the mind and/or brain of the animals.
Gantt saw his behaviorist roots tied to the methods and theories of Pavlov.  He
focused on both the primary and secondary signalizing systems of Pavlov, and used
terminology of excitation and inhibition.390  Perceiving himself as the Russian’s
intellectual offspring, when he focused on the role of constitution – individual factors –
he assigned primacy of this discovery to Pavlov.  Yet ultimately he focused more than
Pavlov on the internal events of an animal’s mental life.
Although Pavlov and his followers aimed for objective measurement, they were
not as focused on finding statistical norms as would be late twentieth-century scientists. 
Earlier twentieth-century behaviorists considered temperamental differences between
animals important, especially in their research on creation of experimental neuroses. 
Gantt recognized this element of Pavlovian research; some individuals were prone to
develop neuroses more quickly, strongly and persistently than others.391  Discussing
why initial stresses only developed into neuroses in some of his lab animals, he wrote
“The two chief factors seem to be (1) the constitution of the individual, and (2) the
severity of the conflict.”392  Pavlov had tied this in to the stability of the animal, its
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capacity to learn quickly.393
The need to adapt quickly was important when faced with a stressor, which in
Gantt’s lab was conflict between “the signal for the positive activity (excitation) and the
negative (inhibition).”394  As well as conditions producing stresses through instincts –
such as fear, fighting, shock – Gantt’s methods involved stressful learning conditions,
ones producing both excitation and inhibition.  One technique used association of one
pitch of a sound with availability of food, another without.   Experimenters could adjust
tones associated with food and not-food until they were too similar to differentiate
accurately.  This created frustration and anxiety in animals attempting to learn.395  A
popular science writer described Gantt’s interpretation of the resulting “typical anxiety
attack” as the outcome of “conflict when the animal could no longer discriminate[.]”396 
In this experiment Gantt feigned no hypotheses (in other words, ‘pulled a Newton’),
writing “I shall omit discussion of the theoretical considerations[,]”397 but then turned to
only two possible interpretations “a physical one of overlapping of cortical processes of
excitation and inhibition, or whether the conflict is based on a more highly organized
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psychobiological level, such as is indicated by ‘frustration.’”398  Implicitly, Gantt
favored the second interpretation.  
Articles by Hoffman and Gantt, as well as Whitehorn, reported that in animals
previously introduced to conflicting stimuli, heart rate sped up before muscle action; the
animal was hyper alert, keenly expecting something to happen.  This suggested to them
the nervous system must be excited (in some specific portion), leading to the physical
action.  When learning new conditioned responses, the cardiac response appeared
earlier in training and persisted longer when there was no reinforcement of response. 
Gantt viewed this as an important clue to the nature of “nervous dysfunction on the
higher level of behavior[.]”399  Physical stress reactions developed from frustration.
Neuroses were extensions of the conflict frustration over a long period. 
Neurosis was maladaptation, dysfunctional behavior, continuing after removal of
external stressors.  Neurosis was not a good adaptation, but it was an adaptation
according to Gantt.  Organisms preserved an equilibrium with their environment
through conditioned reflex actions.
Counterproductive reactions were learned behaviors showing poor adaptation to
the stress, dysfunctional behaviors.  They tended to produce new strains on the nervous
system because they retained “visceral reactions, based on earlier maladaptive
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behaviors.”400  These maladaptations to initial stress formed a condition Gantt termed
schizokinesis.  This was more common in man than animals because of more changes
in the modern human environment, and internal factors which often produced a
compromise rather than continuous adaptation.401  As science writer Patricia McBroom
explained Gantt’s theory: 
A single episode –shock or traumatic emotional experience– may
produce permanent heart changes that linger in the central nervous
system as a source or a trace of pathology.  This source then becomes
capable of disturbing the body physically and mentally, long after its
original usefulness is past.402
Laboratory study of developing neuroses was essential to identifying observable
factors useful for predicting who would “break under a certain psychic load.”403  Useful
signs included: muscular activity and metabolism, gastrointestinal symptoms,
respiratory, cardiac, urinary, and sexual symptoms, certain social behaviors, and
generalization of neurotic behavior to multiple physiologic systems.404
Studying physiological reactions to initial stress offered the possibility of
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identifying “the spread of the nervous imbalance...before it is overtly expressed.”405
This was essential.  Human mental health required identifying and treating the incipient
neurotic before the maladaptation had progressed too far, becoming a generalized
condition.  This was an essential step in maintaining mental health because “[o]nce the
disturbance is thoroughly established, therapy is difficult.”406  
To understand why Valium was so widely prescribed, it is important to note the
wide variety of physiological problems associated with neurotic personalities.  These
conditions were warning signs of mental illness.  The strains of, and causing, mental
illness needed mitigating before a neurosis became fixed, thoroughly established. 
Muscular tension, gastrointestinal ills, asthma, heart palpitations, high blood pressure,
frequent urination, impotence or nymphomania, and antisocial behavior could be
observable warning signs of an underlying neurosis.  They needed treatment for the
core disorder before the problems spread, became fixed, and caused further health
problems.  Ignoring early signs risked ongoing bodily dysfunctions and damage, but
more importantly allowed the neuroses to become fixed and relatively untreatable.  In
contrast to other tranquilizers, Roche’s marketing of Valium would highlight treatment
of the physiological symptoms Gantt identified.
W. Horsley Gantt’s understanding of neuroses – linking physiological
symptoms to mental ones, development in some personalities from distress in one
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physiological system to others, and as forms of maladaptation that had taken on a life of
their own – are all neatly packaged in the case of Nick, the neurotic dog.  Coincident
with other research, Gantt and his colleagues discovered two animal cases providing in-
depth and continuous evidence of neurotic personalities.  Nick, studied for thirteen
years, retained Gantt’s fascination, driving him to seek professional help and treatment
for the creature.  The other dog, studied for six years, had the simple moniker V3.407
Personality types of the two were opposite.  When introduced to the lab at one
year of age, Nick seemed a normal dog whereas V3, who had been in the laboratory
since birth, showed a frightened and unfriendly personality from the start.  Nick began
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showing signs of neuroses after a month of experimentation, “running violently in and
out of the experimental room, barking, panting, refusing to eat, negativism.”408 
Admittedly the experimental conditions were suited to producing troublesome behavior
since Gantt designed the stimulus or reward and punishment system to conflict with
itself.  
What Gantt considered evidence that Nick was a neurotic dog was that
symptoms seen during the conflict experiments were minor compared with those
developed more than one year after the experiments ended.  According to the behavioral
scientist, the cause was earlier events; “Overwhelming evidence of the relation of these
late symptoms to the original conflict were brought out by appropriate experiments[,]”
he claimed.409  V3, on the other hand, received no conflict experience from experiments. 
Gantt referred to V3 as an “extremely pathological animal, persistently neurotic[.]”410 
V3 was already neurotic, formed maladaptive associations easily, and retained them
strongly.  
V3 took part in experiments relating sexual excitement to alcohol consumption,
and showed a ridiculously strong reaction, apparently learning to associate use of the
camera, alcohol and sexual stimulation.  When cut off by the end of the experiment he
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returned to behaving strangely and in an increasingly “stereotyped”411 manner,
“showing many interesting features reminding one of compulsions, echopraxia, panic,
and catatonic behavior with catalepsy.”412  Left alone, V3 behaved normally.  Opening
his paddock made him run in circles, dash to the back corner with tail tucked, dash past
the scientist (“frightened hypermanic flight”413), head into the experiment room and
wait standing on three legs.  He waited, oblivious to noise or strong stimuli (but
affected by mild ones).  Unless the scientist stayed in the closed experiment room for a
minute with V3, the canine refused to return to the paddock.  Although a near caricature
of neurotic behavior, V3 showed the same diffuse symptoms, in roughly the same
physiological systems that Gantt identified in other lab work.
Nick, in contrast had a good personality to begin with, and Gantt had no
intuitive explanation why an apparently normal dog developed neurotic behavior well
after the initial experiments.  Pavlov had suggested the possibility of conflict-creation
through stimulation of contradictory responses, and believed there were different
temperaments to begin with, but Nick’s temperament showed no initial signs suggesting
a neurotic personality.  Existing knowledge did not adequately explain the results.
As Gantt’s explanation of human neurotic development continued, he gained
insight into Nick’s condition.  Based on experimental neurosis work, Gantt concluded
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humans subject to nervous breakdown were responding to internal, rather than external,
events.  These neurotic individuals did not harmoniously intertwine their internal and
external reactions; “It involves a basic discrepancy between the more external
expressive movements (which, being in our consciousness, appear to us usually as
voluntary and purposeful) and the generally hidden visceral responses, which are
ordinarily out of consciousness[,]” Gantt explained.414   In humans, symbolic behavior
helped hide the tensions; the basic bodily reactions, such as a startle reaction, appeared
well before observable effects in main physiological systems.  In Gantt’s words: 
The very function of symbolization responsible for our marvelous ability
to adapt is also the function at the basis of disturbed behavior.  Due to
the characteristics of excess reaction to symbols, and the property of split
function, there is a greater retention of the visceral components than of
the more external motor and secretory ones.  That the organism may be
superficially at rest but violently disturbed internally has a physiological
basis as well as a Freudian one.415
Gantt focused on the possibility of ties between Nick’s neuroses and the initial
experiments.  Therefore understanding the link could lead to treatment.  Perhaps the
symbolic associations continued, appearing in externally noticeable behaviors a year
after the experiments concluded.  Indicative of the links between behaviorist and
psychoanalytical approaches, the behaviorist Gantt turned to a group of psychoanalysts
for their interpretations of links between the experiments and Nick’s neuroses.    
The psychoanalysts’ answers were similar, gliding easily between behavioral
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and psychoanalytic terminology.  Their letters were characteristic of the Freudian
tradition, discussing the role of internal conflicts between drives as an individual seeks
to fulfill his needs in ways acceptable to society.  They were also characteristic of
midcentury psychiatry in focus on the individual as a social animal.416  Talk therapy
might not work with a dog, but the four psychoanalysts appeared comfortable
interpreting the problem leading to Nick’s neuroticism.
One correspondent, Dr. French, pointed out direct links between behaviorism
and psychoanalysis, tying a positive conditioned response to “an affective association”
and suggesting inhibition of learned behavior was “parallel to Freudian repression.” 
Both internal and external factors played a role; the experiment created fear and the dog
faced “failure of gratification” when he could not resolve his conflicting responses.417
Dr. Leon Saul was also able to put the behavior into psychoanalytic terms.  Nick
faced a conflict between desire to flee the experiment area, an instinctive drive, and a
social desire to please his master.  The dog faced a troubling conflict.  Dr. Saul pointed
out how Nick’s situation was remarkably similar to a problem commonly seen in
clinical psychiatry:
in the second generation son, conditioned by his father to ideals of
success, independence, self-made man, etc., but by his mother to being
soft, dependent, indulged, spoiled by her.  It has always seemed to me
that this type of conflict is quite analogous to that seen in animals
conditioned to salivate to one stimulus and not to salivate to a closely
similar one.  However, the level at which this conflict takes place is not
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clear.  It is probably at a rather low level, far from consciousness
although higher levels could be secondarily involved.418
In Nick’s case, Saul diagnosed, the initial conflict became internal.  The
experimental situation was “very disturbing”419 when Nick desired the security of a
stable world.  Nick wanted to find a solution, to adapt, to please, but he was in an
untenable situation and conflict between drives appeared unresolvable.  The dog’s
strong attachment to Dr. Gantt was “of the normal canine variety.”420  Faced with
another stress-inducing experiment his instinct was to flee, but when Dr. Gantt, his
master who he loved, depended on, and obeyed, took him into the laboratory the
instinct to flee conflicted with his feelings towards Dr. Gantt.  “Because the dog must
remain well behaved his excitation cannot be adequately discharged in direct and
primitive action.  It is pent up and seeks discharge in other directions.  This is apparent
in the diffused excitement of the animal[.]”421  Nick developed an unpleasant
association with the man he loved, resenting both the laboratory and Dr. Gantt, “his
master who is the experimenter who treats him this way.”422
Before consulting the psychoanalysts, Gantt and his colleagues tried various
treatments based on their understanding of the problem.  In behavioral terms, the dog
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faced “two antagonistic nervous waves[,]”423 conditioned responses in conflict within
the brain.  They probably were in the secondary signalizing system because of the semi-
symbolic nature of the conflict, then radiating from the initial conflict to other areas,
resulting in a “conditioned-reflex connection by indirect signalization[.]”424  In 1934,
Gantt tried cortin on the dog.  It was a drug known to diminish motor hyperactivity in
sheep.  Ineffective.  In 1935, he tried moving the experiment area to a different part of
the room, but Nick remained frightened and hyperaware of the original location.425 
Periods of rest in another environment produced more pronounced symptoms.  In the
summers of 1938 and 1939, on the advice of Doctor Alan Gregg, they gave Nick
alcohol, a drug known to relieve tensions temporarily.426  Although the alcohol did
relieve some symptoms, it “removed the inhibitory effect of the camera on sexual
reflexes” which he had learned earlier, when Nick got off the booze his sexual problems
were even worse.427
Made aware of the social conflict (“reciprocal relations were definitely found to
be operative[,]”428) Gantt tried to reduce Nick’s anxiety by having people spend time
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with him.  As a science writer for The Science News-Letter explained Gantt’s new
approach, “Social factors, such as the presence of a human in the room or of a friendly
dog, reassures the nervous animal so that he does not have an attack.”429  Nick did not
respond well to this therapeutic approach, in fact he “developed a negativistic attitude
with marked respiratory and cardiac changes toward these persons.”430  By 1939, the
experimenters had only found one method of temporarily alleviating his symptoms,
“putting the dog in the same paddock with a female in estrus[.]”
After consulting psychoanalysts, Gantt changed his approach.  He moved Nick
to his farm for a year and a half, giving the dog “an opportunity to develop new
relationships toward me.”431  Nick strengthened his friendship with the experimenter
and at first appeared healthy when returned to the lab.  But the neurotic behavior
quickly recurred.  Gantt took him back to the farm and within two days his heart rate
had fallen from 200 to 110 beats per minute.432  In the summer of 1940 Nick returned to
the farm and more intensive therapy (quality time) with Dr. Gantt.  Gradually the
symptoms lessened, and although reminders of the experiment continued to act as
stressors, strengthening and reassuring him of his social role effected a cure.  “[H]e
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became a most devoted companion, following me everywhere,”433 Dr. Gantt reported. 
The experience with Nick solidified his conviction that once full-blown neuroses
developed it took extensive measures, social and environmental, to alleviate the
symptoms.  Cure remained a problem, therefore identification and prevention of
developing neuroses was crucial.
Links Between Neural and Psyche Theories
Developments within the psyche framework in the late 1940s and 1950s
paralleled those in the neural.  They promoted the idea that humanity desired stability as
well as an outlet for creative and destructive energies.  Adaptation of the individual was
key; rapid and realistic adaptation to environmental change reduced stresses and
restored stability.  As Peter Madison of Swarthmore College explained, “Repression
and defense are the heart of the contemporary conception of mental illness.  Together
with their sister concept of anxiety, they have become the core of modern psychiatric
theories, even when these disclaim a Freudian orientation in a narrower sense.”434 
Science writer Patricia McBroom pointed out the links between behavioral research and
Freudian-type analysis, in an article outlining Horsley Gantt’s work.  His work, she
wrote, “has taken Pavlovian concepts far beyond their original mechanistic rigidity.” 
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The course of his research brought him “closer to Freud than to Pavlov.”435  The idea
that a single traumatic episode earlier in life could create neurosis, part of the popular
interpretation of Freud, appeared similar to Gantt’s focus on the “latent excitation”
which was “capable of acting independently of additional external influences.”436
Walter Cannon’s influential idea of homeostasis illustrates the common
assumption that physiological concepts included psychological aspects.  Cannon studied
medicine at Harvard then proceeded to a distinguished career including thirty-six years
as the George Higginson Professor of Physiology at Harvard, and President of the
American Academy for the Advancement of Science.  During undergraduate studies on
digestion he noted the dramatic influence of emotion.  He began investigating
interactions between emotion and bodily systems, which led him to the concept of
homeostasis.  The sympathetic nervous system and adrenal medulla played an important
role in regulating widespread bodily systems in order to restore balance, he noted.437 
Homeostasis referred to the body’s tendency to adjust to internal and external stresses
in order to preserve stability of physical functions.  Cannon himself associated
emotional reaction to external events with change in the body; they triggered the
nervous system’s efforts to adjust.  “[E]motional upsets,” he remarked, “in the nervous
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pathways, have concrete and obvious effects[.]”438  Scientists needed to recognize this
interaction and find ways to identify the early physiologic signs of stress, if they wanted
to prevent overwhelming of homeostatic action and development of dysfunctions, in
turn creating chronic disorders.  “It is stupid[,]” Cannon declared, “to belittle or neglect
such complaints.  The powerful influence which emotional states can exert on bodily
functions needs no argument.”439
Nigel Walker explicitly attempted to apply Cannon’s idea of homeostasis to
Freud’s theories, seeking the sources of important contemporary physical/mental
concepts as well as errors, compared to knowledge in the 1950s.  Shoe-horning
homeostasis into psychoanalytic theory, he argued Freud’s statement that “the nervous
system is an apparatus having the function of abolishing stimuli”440 anticipated
cybernetic focus on feedback mechanisms and physico-psychological concepts of
homeostasis.  The defense mechanisms used by the ego to mediate demands of the id
with reality and requirements of society, Freud understood as attempts by the central
nervous system (CNS) to reduce internal stimuli, according to Walker.  Freud’s error
was his focus only on the ego’s attempts to lessen stimuli.  This led the originator of
psychoanalysis to identify a death instinct – what Freud termed Thanatos – as the effort
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to reduce stimuli to nothingness.  Walker held homeostasis as true and tried to either
find signs of it in Freud, or find Freud in error.  He found parallels between
development of neuroses into psychoses, through swamping the ego’s defenses by
overwhelming demands of the id, and homeostatic mechanisms restoring norms until
they “reach a point at which the mechanism of homeostasis ceases to operate in such a
way as to restore the end-state.”  This was the “point of breakdown[.]”441   Human
beings craved stability, dealing with stress and restoring psychologic and physiologic
balance, as well as a stimulating environment, allowing id and ego to act in moderate
and healthy ways.  Problems arose with overstimulation.
The idea of equilibrium as an underlying state needs to be understood in the
context of Allport’s concept of functional autonomy, and the more general field of
dynamic psychology.  Gordon W. Allport was an early proponent of dynamic
psychology, which he saw as a more useful replacement for Freudian psychoanalysis. 
What made this approach dynamic was recognizing the historical context and its
influences on a man’s life, but focusing on the current situation, focusing on change.
The problem with psychoanalysis, according to Allport, was its ridiculous belief
that “a very few basic motives suffice for explaining the endless varieties of human
interests.”442  Eros and Thanatos, the constructive and destructive drives, had to apply in
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such a myriad of forms to explain actual cases as to make them useless.  Even with
addition of one or two more drives, the psychoanalytic approach could only describe
events, not explain why they occurred.  It was an “over-simplified theory[,]” Allport
concluded.443
A dynamic approach included historical dimensions, but placed more emphasis
on the contemporary situation.  The man grew from the child, there was no doubt about
it.  But this was no simple unfolding in which you could trace the roots of current
problems back to infancy.  Allport promoted the concept of ‘functional autonomy’ of
the individual.  As a sense of self-developed, will supplanted the mechanistic drives,
and the individual became autonomous, separate from the initial drives.  Mental health
professionals needed to understand the mature adult in terms of motives, “infinitely
varied, and self-sustaining[.]”444  Functionally, man was separate from any core drives
that might, or might not, still exist.  The dynamic aspect of functional autonomy placed
the frame of reference in the present, and therefore actions existed with reference to a
steady state rather than a historical process.
Dynamic psychiatry still accepted that the individual tried to negotiate with the
environment to fulfill needs, it simply did not accept ties between those needs and
historic, basic, drives.  As Allport explained: 
The pursuit of literature, the development of good taste in clothes, the
use of cosmetics, the acquiring of an automobile, strolls in the public
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park, or a winter in Miami -- all may first serve, let us say, the interests
of sex. But every one of these instrumental activities may become an
interest in itself, held for a life time, long after the erotic motive has been
laid away in lavender. People often find that they have lost allegiance to
their original aims because of their deliberate preference for the many
ways of  achieving them.445
The drives were diverse, and their manifestations took on a life of their own.  Current
behavior was not understandable as a simple manifestation of drives.
The individual discussed in midcentury psyche theories was not the mechanistic
individual of Freud, he was an individual who lived in society and was a social animal. 
Social psychology gained prestige during the 1950s.  Kurt Lewin, who came to the
United States from Berlin shortly after Hitler formalized his autocracy, played an
important role in development of social psychology.  He introduced the concept of ‘life
space,’ the totality of dynamic forces within and surrounding an individual.  Internal
forces, drives in the earlier Freudian parlance, were now motivations and purposes as
well as needs.  These internal forces interacted, through the self, with the external
environment.  The individual acted through society and tried to maintain a sort of
equilibrium between internal and external requirements. He construed environment
broadly, with greater focus on society and its expectations, roles, and norms.
At a time when psychology implicitly defined individualism through the
individual’s relationship with society,446 it is unsurprising that another major therapy
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gaining ground in the 40s and 50s was ‘client-centered’ therapy, associated with the
work of Carl Rogers.447  In a nutshell, the approach was to focused on feeling than
content in a clinical setting, and assumed patients had a natural motivation to develop
insight.  “If the therapist accepts, recognizes, and clarifies the feelings expressed by the
client,” Rogers’ theory suggested, “there will be movement from negative feelings to
positive ones, followed by insight and positive actions which are initiated by the
client.”448  The approach focused on the role of social interaction, acceptance of the
client by the therapist, and focusing on promoting interaction.  Carl Rogers was
particularly in favor of counseling to help an individual promote realistic and mature
recognition of problems.449
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Conclusion
In the 1940s and 1950s, when events shaping development of Valium solidified
–  psychology and the theory of mental health, whether behaviorist, psychodynamic,
client-centered  or otherwise defined – had several commonalities.  Individuals were
social creatures with motivations and desires.  Individuals were the core units of
society, but they were not apart from it.  Stability or equilibrium was the basic state of
man.  And adaptation, whether to new stimuli and stressful conditions, or negotiating
the needs of ‘self’ within the environment, was a key aspect of mental health.
Merging and interaction of behavioral and mental theories provided background
assumptions guiding development of tranquilizers.  Both theories similarly explained
how psychoactive drugs worked, the nature of neuroses, and the developing feedback
relationship of body and mind tying initial stress into more incurable maladaptions,
detrimentally affecting a wider variety of bodily systems.  Stress, therefore, led to a
wide variety of physical problems.  Some individuals adapted poorly to stress,
psychologically and physiologically; in Masserman’s terms, “alleviation of anxiety is
an integral part of all psychiatric therapy.”450  Neurotic reactions, as well as response to
overwhelming stressors in more ‘normal’ personalities, were identifiable through
physiologic measurements.  Objective measurements of dysfunctional behavior in
animals included maladaptive fight or flight responses, including continued rapid heart
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rate, high blood pressure or muscle tension, as well as poor adaptation to changing
conditions, seen in learning, righting reflexes, aggression, or climbing behaviors.
Just as the pre-1940 behavioral and psyche-based theories had underlying
similarities, post-1940 modifications in both realms were similar.  Both theoretical
perspectives began to focus more on drives, which were now more broadly construed,
adaptation (reactive attuning) to the physical and social surroundings, and a broad
variety of behaviors which were manifestations of developing or full-blown neuroses.  
Mental health professionals understood action of drugs on the central nervous
system in similar ways, whether they advocated behavioral or psyche-based treatments. 
Either drugs modified development, generalization, and extinction of conditioned
responses, or they released inhibitions and previously repressed material.  In both cases
the physical mechanism of the action was unknown.  But, researchers including Pavlov,
Masserman, and Gantt, had elaborated measurable physiologic correlates of
maladaptive responses to stress, of incipient or full-blown neuroses.  This
understanding could be applied to identification and testing of new chemical
compounds, such as Valium. 
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CHAPTER 5.  FINDING TRANQUILITY, DEVELOPING REASON:
COMPETITOR COMPOUNDS 
AND STERNBACH’S SYNTHESIS OF DIAZEPAM
Valium was a drug well suited to its time.  Although a trite statement, following
necessarily from the fact of a drug being successful in the marketplace, the conditions
surrounding Valium’s identification, development, and marketing were particular to its
time.  These conditions shaped what Valium was.451 Pharmacologists would have vetted
the same chemical compound identified twenty years earlier with different tests.  Roche
might have ignored it as not useful, or marketed it for a different purpose, perhaps as a
sedative or muscle relaxant.  But ataractics, pharmaceuticals giving a feeling of active
tranquillity, fit the spirit of the age.  Physician H. Angus Bowes declared, “The
‘emotional aspirin’ is likely to become just as much a part of our way of life as the
epileptic’s anticonvulsant, the alcoholic’s amphetamine, the executive’s antacid, the
salesman’s hip flask, and the socialite’s sedative.”452
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Naming Pharmaceuticals
Richard Ruge, a Harvard-trained lawyer writing on “Regulation of Prescription
Drug Advertising,” explained the tripartite naming system used for naming drugs in a
manner that parallels development of Valium.  “A discrete drug substance may be
known by three types of names[,]” he explains.  “Its chemical name simply lists every
part of a drug’s molecular structure.”  Leo Sternbach synthesized, or discovered, the
chemical compound.  Ruge continues, “Its generic name abbreviates the components
but still informs a doctor of the drug’s chemical composition, from which he can
determine its general effect on the body.  Ordinarily a drug will have only one generic
or nonproprietary name.”  Lowell Randall and his team of pharmacologists identified
the general effects of this compound.  Clinical trials illustrated its potential uses in
humans.  This effectively turned it into the benzodiazepine diazepam, a tranquilizer. 
“Finally,” Ruge explained, “a drug is sold under a trade or brand name which identifies
the drug with a particular manufacturer but conveys little information about its nature or
composition.”  This process of market positioning and marketing created Valium, a
tranquilizer associated with images, uses, and experiences different from other
tranquilizers.  Roche marketed Valium for specific conditions, and identified it with
particular benefits and problems.453  This chapter focuses on Valium’s development up
to Sternbach’s synthesis, his discovery of a chemical compound, in an effort to explain
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why anyone would care to look or be prepared to find the molecule later called Valium.
The intellectual background surrounding identification and development of
Valium shaped it, helped define its meaning, and suggested it was worth testing. 
Because in hindsight we view it mainly as a psychotropic drug, and because
contemporary understandings of psychosomatic disorders informed their treatment with
psychopharmaceuticals, it is necessary to examine the identification, testing, and
shaping of Valium as a drug acting on mind and body via the central nervous system
(CNS), a drug acting in the locus, the trope, of the mind/brain/psyche as well as the
autonomic and sympathetic nervous systems.
Existing medicinally used psychotropic and psychosomatic drugs provided a
comparative framework for Valium’s development, testing, and marketing.  Valium’s
synthesis occurred within a specific context which included availability of other
tranquilizers, each with perceived uses, modes of action, and problems.  The conditions
of Valium’s birth helps explain why and for what purposes it was marketed.  Public
concern about mental health encompassed a broader group of people and conditions
than ever before.  Medical knowledge informed appropriate use of tranquilizers. 
Anxiety, tension, and adrenal feedback were privileged causes of widespread illness,
physical and mental.  Existing sedatives and tranquilizers suggested promising areas of
research, especially where existing compounds either failed to work, or had undesirable
effects.  Valium’s identification occurred within the confines of expectation and
knowledge of the times.  That Valium was a drug well suited to its time is trite, but true.
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Previous tranquilizers, sedatives, and hypnotics
Humanity in most times and places has proven ingenious at ferreting out
psychotropic substances.  Acquiring drugs from physician or pharmacist, as well as
self-medication, for mental effects was not new in the 1950s.  Opiates played an
important role in treating insomnia or anxiety, and coping with the stresses of life in the
nineteenth century.454  By mid-twentieth century America, the drugs of choice for
dealing with stresses of life, neuroses, and functional rather than organic disorders,
included bromides, barbiturates, and alcohol.455  Bromides, first used in treatment of
epilepsy, were used as hypnotics in the mid-1860s.456  By the 1950s they were in
declining use,457 and appear to bear little relationship to development and marketing of
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Valium.  Barbiturates, however, were both widely used in the 1950s and prescribed in a
manner overlapping that of Valium in the 1960s.458  Phenobarbital was one of the “most
commonly used medications” for anxiety neuroses, and barbiturates in general had
“been employed for many years to control the emotional surmenages found in neurotic
and so-called ‘nervous’ patients.”459  Although the rates of use for these sedatives are
surprisingly high, they pale by comparison to the main drug serving to insulate
Americans from tension and stress – alcohol.460  
Barbiturates
By 1950, barbiturates, especially phenobarbital, held a long established place
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among pharmaceuticals in the United States.  Their wide use as sedatives and hypnotics 
–  treatments for tension, anxiety, and insomnia – made them competition for any
tranquilizers Roche planned to market.  The barbiturate class of drugs, all derived from
barbituric acid, were of longstanding use by midcentury.  Barbituric acid’s initial
synthesis was by von Baeyer in 1883461 or Concord and Gut-zeit in 1882,462 depending
on the source of information.  Scientists developed specific medicinal compounds based
on barbituric acid early in the twentieth century; barbital in 1904, phenobarbital in
1912.463  Used mainly for disorders associated with ‘nerves,’ situations related to the
central nervous system (CNS) –  inability to sleep, anxiety, tension – their use boomed
after World War I.  By 1948, annual production of barbiturates within the United States
was around 336 tons, “...or about 24 therapeutic doses per each man, woman, and child
in the country!”464  Consumption continued to grow.
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Despite booming interest in newer tranquilizers among mental health and
pharmacology professionals after 1953,465 barbiturates remained the most widely used
psychopharmaceuticals from the 1940s through to 1970.  In 1963, approximately one
decade after the first major tranquilizer, chlorpromazine (Thorazine), began its meteoric
institutional career, phenobarbital remained both the most widely sold generic drug and
the most commonly used of the barbiturate class.466  Of the approximately 374 million
new prescriptions issued in that year, barbiturates accounted for 14.59 million new
prescriptions, each of which could be enough for a month or more.  Refills accounted
for another 30.18 million scrips.467  
Legislation passed in the early 1950s, specifically the Durham-Humphrey
Act,468 restricted writing prescriptions for barbiturates to licensed medical practitioners,
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section 503 required habit-forming drugs–narcotics and hypnotics–be prescribed by a
physician and refills authorized by that physician either in writing or verbal
authorization to a pharmacist.  New York Academy of Medicine, Report on
Barbiturates, 1155-56.
470  H. Isbell, “Addiction to Barbiturates and Barbiturate Abstinence Syndrome,”
Annals of Internal Medicine 33 (1950): 108-09.
471  Isbell, Addiction to Barbiturates, 109; G. P. Grabfield, “Hypnotics” JAMA,
96, no.1865 (1931).
472  Fort, Problem of Barbiturates, III; Grabfield, Hypnotics; Sollmann, Manual
of Pharmacology, 776-77; one gram contained 15.4324 grains.  Charles Caspari, jr.  A
Treatise on Pharmacy for Students and Pharmacists, 6th ed., revised by E. F. Kelly. 
(Lea & Febiger: Philadelphia, 1920), 35; The quantity reported by Fort is within the
boundaries of the National Prescription Audit.
and required written or oral permission for renewal of prescriptions.469  Rates of
benzodiazepine use continued to climb.  Periodically, there were swells of public
concern that long-term repeated use of original prescriptions, and sale without
prescription, contributed to addiction.470  But barbiturates were most commonly
obtained by physicians’ prescriptions, and this continued.471  By 1960, a conservative
estimate suggested 852 tonnes of barbiturates, in a variety of forms, were sold in the
United States each year, sufficient to give every man, woman, and child 33 one-grain
(66.7 milligrams) doses.472   G. P. Grabfield, in 1931, placed the dose of barbital
required to guarantee a full night sleep in any hospital patient at 160 milligrams, amytal
at 94 milligrams, pentobarbital at 46 milligrams, and phenobarbital at 72 milligrams.  A
one-grain dose, 66.7 milligrams, is therefore close to that required to knock out a
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barbiturates in Canada.  England faced similar increases; prescriptions in 1951
accounted for 90,000 pounds of barbiturates, in 1959 162,000 pounds.  The quantity
also reflects how widely this class of drugs was used compared to other
pharmaceuticals; in 1959 barbiturates accounted for seven percent of all prescriptions
written in England.  S. J. Holmes, “Barbiturates –Friend or Foe?” Addictions 9 (1963):
25.
hospitalized adult with phenobarbital.  Sedation, rather than sleep, required a fraction of
this dose.  Assuming most children consumed less than average, and poorer members of
society could not afford this tax deductible martini, the quantity in circulation appears
sufficient to ensure a good night’s sleep, or at least perpetual mellowness, among a
substantial portion of America’s citizenry.473 Barbiturates were so widely prescribed for
ailments major and minor, that J. Phillips Frohman, Chairman of the General Practice
Section of Washington D.C.’s Medical Society, quipped, “If Macbeth were
representative of modern man, his serious mental illness and symptomatic insomnia
would warrant a prescription for phenobarbital, at least – if not one for Seconal, or even
Amytal.”474
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476  Isbell, Addiction to Barbiturates, 109; The groundbreaking reports were: H.
S. Dunning, “Convulsions Following Withdrawal  of Sedative Medication,”
International Clinics 3 (1940): 254; Kalinowsky, Lothar. B., Convulsions in Non-
Epileptic Patients on Withdrawal of Barbiturates, Alcohol and Other Drugs, Archives of
Neurology and Psychiatry, 47 (1942): 946; Brownstein,   S.  R.,  and  Pacella,  B.  L.,
“Convulsions  Following Abrupt Withdrawal  of Barbiturate: Clinical and
Electroencephalographic Studies, Psychiatric Quarterly, 2 (1943): 112; Osgood, C. W.,
Long acting phenobarbital
barbital
Midrange amobarbital/Amytal
butabarbital/Butisol
Short acting hexobarbital/Evipal
pentobarbital/Nembutal
secobarbital/Seconal
Figure 3. Types of Barbiturates and Duration of Action475
Medical and nonmedical writers alike widely considered barbiturates mentally
but not physically addictive, even after English language reports published in the 1940s
identified a consistent pattern of physical withdrawal symptoms.  Because physicians
often assumed physical addictiveness of drugs was specific to opium and its derivatives,
and characterized by a single pattern of withdrawal symptoms, only with identification
of a regular withdrawal profile did the medical community begin associating
barbiturates with physical as well as mental addiction.  In “recent years this mistaken
concept [that barbiturates are not physically addictive] has been shaken by the
appearance of reports of convulsive seizures following withdrawal of barbiturates[,]”
wrote Harry Isbell, one time Director of the National Institute of Mental Health’s
Addiction Research Center.476  In an act emblematic of the complexities of how the
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479  For example, see Marie Nyswander, “Drug Addictions,” in American
Handbook of Psychiatry, volume 1, ed. Silvano Arieti (New York: Basic Books, 1959),
614-22.
educated medical community at large understood addiction even after publication of
these reports, Isbell continued to consider barbiturate addiction substantially mental; he
believed similar types of “personality defect” largely explained who “succumbed to
morphine and barbiturate addiction.”477
Most discussions of drug addiction continued to separate narcotic and barbiturate
addiction, in part because they separated tolerance, habituation, and physical
dependence.  Tolerance involved requiring increased doses over time, to achieve similar
effects.  Habituation referred to psychological addiction, while the term physical
dependence described the body developing a requirement for the drug to such an extent a
predictable syndrome of withdrawal symptoms occurred upon stopping consumption.478
Physicians and popular press authors regularly compared barbiturates’ effects
with those of alcohol.479  Symbolic of this link is how they described cumulative effects
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480  For example, see Karl M. Bowman, “Some Problems of Addiction,” in
Problems of Addiction and Habituation, eds. Paul H. Hoch and Joseph Zubin. (Grune &
Stratton: New York, 1958) 161-176; the term intoxication was also used in reference to
the effects of opiate use.
481  Jules H. Masserman, “Experimental Psychopharmacology and Behavioral
Relativity,” in Problems of Addiction and Habituation, eds. Paul H. Hoch and Joseph
Zubin. (New York: Grune & Stratton, 1958),  110-48, 130.
482  New York Academy of Medicine, Report on Barbiturates, 1147.
483  Ebbe Curtis Hoff, “Current Advances in the Ambulatory Medical Treatment
of Alcoholics,” Academy of Medicine of New Jersey Bulletin 9, no.3 (1963): 146.
of barbiturates, as intoxication.480  Jules Masserman’s research on changes in behavior
under the influence of various psychoactive substances showed similar effects with
alcohol and barbiturates; they were all drugs providing “relief of neurotic tension.”481  In
their “Report on Barbiturates,” a committee of the New York Academy of Medicine
referred to concerns that people used barbiturates as a substitute for alcohol, writing, 
“Addiction is probably limited to persons who, if barbiturates were not available, would
take excessive quantities of alcohol or other drugs.”482  Underlying these comparisons is
description of both barbiturates and alcohol as tranquilizers, substances used to relieve
tension.  Alcoholism could also be interpreted as an outcome of alcohol’s imperfect
tranquilizer activity.  Ebbe Curtis Hoff, explains how alcoholism can result if the
alcoholic does not “effectively learn from his drinking experience and alcohol is
therefore not a good tranquilizer.”483  In this way barbiturates and alcohol were both
similar to, and competitors for, the formally marketed tranquilizers such as Valium.
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Other Treatments in Psychiatry,” in The New Chemotherapy in Mental Illness: The
History, Pharmacology and Clinical Experiences with Rauwolfia, Phenothiazine,
Azacyclonol, Mephenesin, Hydroxyzine and Benactyzine Preparations,  ed. Hirsch L.
Gordon (New York: Philosophical Library, 1958), 343-50, 347.
485  Fazekas et al., Ataratics in Medical Practice, 42.
486  Fort, Problem of Barbiturates, II.
487  Fort, Problem of Barbiturates, II; Publication of reports arguing barbiturates
had detrimental autonomic depressant effects, that in large enough doses they depressed
respiratory reflexes, did not translate into immediate recognition of a problem.  Even
pharmacologists well versed in the subject did not necessarily take the reports of
barbiturate dangers as a proven fact.  In a 1961 publication, Lowell Randall classified
phenobarbital as a drug without autonomic blocking effects, along with Miltown and
Librium.  Chlorpromazine was listed as an autonomic blocker.  It appears from this
publication, that Librium in 1961 could not have been marketed as less dangerous than
precursors on these grounds. L. O. Randall, “Pharmacology of Chlordiazepoxide
(Librium),” Diseases of the Nervous System 22, section 2, suppl. 7 (1961): 7-15.
Valium as a better barbiturate
Barbiturates had unwanted side effects, leaving them prone to displacement on
the market by drugs with similar benefits, but fewer detrimental side effects.  Apart from
the issue of addiction, intoxication and lethality remained important barbiturate side
effects.  In sufficient doses, long acting barbiturates such as phenobarbital produced
intoxication; they “cloud the patient’s sensorium.”484  The problems associated with
bromides were similar but greater than those in barbiturates; “in effective doses they
commonly produced such a deep state of sedation that the patient was rendered useless
and helpless in his environment.”485  Repeated doses of long-acting barbiturates
compounded the effect.486  Because they were respiratory depressants they could cause
death, whether the taker intended suicide or not.487  Almost one-quarter of all patients
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489  The New York Academy of Medicine reached this conclusion in its Report
on the Barbiturates, 1144-58.
490  Fazekas et al., Ataratics in Medical Practice, 46.
491  Joseph F. Fazekas was in the Department of Physiology and Pharmacology.
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admitted to hospitals for poisoning in the early 1960s had taken barbiturates.488  
Overall, American physicians and the public underestimated both the risks and
benefits barbiturates offered; for every noted addict or suicide there were hundreds,
probably thousands, for whom the drug appeared unconditionally beneficial.489  “There is
hardly an organic disturbance in which the administration of a tranquilizing agent would
not be beneficial,”490 enthused Joseph Fazekas of Albany Medical College.491  Writing
for the United Nations Office of Drug Control Bulletin, in 1964, Joel Fort explained that
“many physicians in the United States appear to think and act as though barbiturates are
completely harmless drugs that can be prescribed in unlimited quantities.”492
The concept of legitimate medical use remained nebulous, a harbinger of the
widespread ailments considered suitable for treatment with Valium in the 1960s and
1970s.  They were drugs for nerve-related problems, and the central nervous system
interacted extensively and intimately throughout the body.  Within institutions, wrote
Harold Himwich, physician in Albany Medical College’s Department of Physiology and
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493  Harold E. Himwich, “Prospects in Psychopharmacology,” in The New
Chemotherapy in Mental Illness: The History, Pharmacology and Clinical Experiences
with Rauwolfia, Phenothiazine, Azacyclonol, Mephenesin, Hydroxyzine and
Benactyzine Preparations, ed. Hirsch L. Gordon (New York: Philosophical Library,
1958), 23-35, 23.
494  Fazekas et al. Ataractics in Medical Practice, 42.
495  New York Academy of Medicine, Report on the Barbiturates, 1145.
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Pharmacology, “Barbiturates bring surcease to the patient and to the physician who
attends him, but the results are usually ephemeral.”493  In ambulatory patients, those with
neuroses or ‘nerve’-related conditions, effects were mixed.  Barbiturates masked rather
than cured psychological ills, thus reducing the likelihood of patients ever seeking more
thorough treatment.494  Yet barbiturates met a widespread perceived need in American
society.  They reduced anxiety and tension, as well as fighting insomnia.  The New York
Academy of Medicine concluded “The wide prevalence of psychiatric complaints among
the population must add up to a large volume of legitimate therapeutic need.”495 
Physicians prescribed barbiturates because they were the best available option, the
Academy recognized; to reduce barbiturate use it would be necessary to either prevent
“the prevalent unrest and anxiety”496 or find better treatments.  Given the high rate of
barbiturate prescribing, a large number of Americans saw pharmacologic treatment more
viable than the possibility of preventing widespread unrest and anxiety.
The search for better drugs, effective in treating tension, anxiety, sleeplessness,
alcoholism or addiction, and epilepsy, was a major impetus for pharmaceutical
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497  Nyswander, Drug Addictions, passim.
498  Hirsch L. Gordon, “Introduction,” in The New Chemotherapy in Mental
Illness: The History, Pharmacology and Clinical Experiences with Rauwolfia,
Phenothiazine, Azacyclonol, Mephenesin, Hydroxyzine and Benactyzine Preparations,
ed. Hirsch L. Gordon (New York: Philosophical Library, 1958), xi-xviii, xiv.
499  Fazekas et al. Ataractics in Medical Practice, 47.
manufacturers to develop and market drugs treating neuroses; these were all symptoms
or conditions associated with neurotic reactions or neuroses.  Barbiturates were widely
sold and associated with detrimental side effects.  A mild sedative or hypnotic which did
not depress respiration would be safer, more salable.
Focus on reducing the physical effects of withdrawal also promoted efforts to
identify new drugs useful for treating drug and alcohol addiction, as well as introduction
of substitute pharmaceuticals with less addiction potential, into the medical arsenal. 
Marie Nyswander, the Senior Supervising Psychotherapist at New York’s Postgraduate
Center for Psychotherapy, as well as consultant to the New York City Department of
Health wrote, in 1959, “of prime importance in the treatment of this addiction is the use
of the same drug for withdrawal.  There is no substitute drug for withdrawal.”497 
Pharmacologic and clinical trials tested most tranquilizers for capacity to aid in drug or
alcohol addiction,498 either as a substitute or alternate treatment form.  It was an expected
part of the tranquilizer profile.  Physicians regularly faced the “combative and assaultive
acutely inebriated individual.”499  Treatment with major tranquilizers, what physicians in
the late-twentieth century termed antipsychotics, were “most suitable for management of
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such patients[,]” in part because “of their immediate onset of action,”500 and sedation
while leaving patients able to care for themselves.501  
In theory, major tranquilizers also ameliorated longer term side effects of alcohol
or barbiturate addicts shifting to teetotaler status.  “The majority of patients suffering
from the after-effects of continued overindulgence in alcohol require treatment for
insomnia, anxiety and tremors. Here again the immediate control of the disorder is best
accomplished by one of the phenothiazine derivatives. Sleep will be induced within 30 to
45 minutes[.]”502
Part of this benefit arose from the tension reducing nature of tranquilizers; “In
chronic alcoholics [they reduce] the tension that finds release in inebriety.”503 
Tranquilizers could function through supplanting an addictive and less specific tension-
reducing agent, alcohol, for one less addictive and more specific in action.  Some
physicians claimed meprobamate (Miltown), aided alcohol withdrawal, as well as
“menstrual stress, neurodermatitis and the reaction to pain.”504  Premarketing trials
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507  Phenytoin was known as a substance altering response to EEG patterns, in
the 1930s.  By 1950, it “became the drug of choice for tonic-clonic seizures, since it
produced less intellectual impairment and little sedation relative of phenobarbital.”
Perrine, Chemistry of Mind-Altering Drugs, 152.  Cleft lip or palate could be produced
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suggested Valium was useful for its ability to aid withdrawal from addiction to alcohol
and other drugs.505  Ebbe Curtis Hoff, Chairman of the Division of Psychiatric Research
at the Medical College of Virginia, argued his clinical tests proved Valium useful in the
battle against addiction.
Barbiturates were a medical marvel in treatment of epilepsy.  There was hope
that minor tranquilizers would mirror barbiturates in suppressing seizures. 
Phenobarbital, a long acting barbiturate, allowed countless epileptics to lead fairly
normal lives.  “In this they were the first miracle drugs of their day,” writes academic
chemist Daniel Perrine, “it was more than 50 years before antiseizure medications other
than phenobarbital became available”506 and the side effects of the first alternative
antiseizure medications could be life threatening, especially to offspring.507 
Pharmacologists tested for antiseizure properties in the first generations of major
tranquilizers.  For example, Leonore Koploff and his colleagues at the New York State
Psychiatric Institute and Hospital tested chlorpromazine’s effect on epileptic monkeys
and found rapid administration during a seizure caused “flaccidity, diminished
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508  Leonore M. Kopeloff, Joseph G. Chusid, and Nicholas Kopeloff, “Effect of
Chlorpromazine Upon Epileptic and Normal Monkeys,” Proceedings of the Society for
Experimental Biology and Medicine 90 (1955): 283.
509  Frohman, The Barbiturates, 432; Essig, Addiction to Barbiturate, 188.
responsiveness, reduced aggressiveness, lethargy and somnolence[.]”508  As a
preventative it could not compete with phenobarbital; unfortunately chlorpromazine
tended to sedate or reduce responsiveness in epileptics not currently suffering seizures. 
Tranquilizing drugs had existing associations with both physical muscle relaxation and
relief from mental tension, each of which related to epileptic seizures.  Therefore,
continued testing of new tranquilizers for these properties was reasonable.  If Valium
could provide a safe alternative, there was a ready market among epileptics concerned by
the side effects of barbiturates.
Any nonaddictive antineurotic, tranquilizer, or sedative would be a highly
marketable alternative to barbiturates.  Although majority opinion in the medical
community continued to be that barbiturate addiction was not true addiction, as it did not
result in classical symptoms associated with opiates,509 it continued to accept
psychological addiction to barbiturates as fact.   Barbiturate users were unfortunates, like
alcoholics in having a definite moral failing, and possibly a physical one.  As I. Phillips
Frohman characterized the situation, barbiturate addicts were “psychically impoverished
individuals” who tried “to escape from the responsibilities and challenges of ordinary
living, and they resort to their use to create a state of insulation against reality whenever
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511 Harold Himwich describes tri-fold benefits: increasing the number of patients
who can be discharged, making ambulatory treatment of psychoses and neuroses
possible, and allowing the mentally ill to continue a normal life “with less effort.”
Himwich, Prospects in Psychopharmacology, 24.
512  Himwich, Prospects in Psychopharmacology, 34.
they can.”510  Addicts did not engage properly with society, which automatically
identified their behavior as unhealthy within 1950s and early 1960s terms.  Similarly,
underlying later debates on the nature and physical reality of Valium addiction are
questions of whether smooth interaction within a social environment shows mental
health, and under what conditions long-term drug taking is itself a medical condition.
Widespread use and risks associated with barbiturates created a climate of
opportunity for any pharmaceutical company developing an alternative compound with
more specifically beneficial effects and fewer risks.  The early major tranquilizers,
chlorpromazine and reserpine, were of seminal importance within psychiatric
institutions511 but took little away from the main markets for barbiturates, those seeking
relief from insomnia, situational or ongoing stress, tension, and epilepsy. Harold
Himwich accurately prophesied: 
These drugs are effective not only for disturbed patients with
psychomotor overactivity but also for emotionally tense ones with acute
anxiety. The value of these drugs is being tested for various clinical
categories, and in general one might predict that in many conditions for
which bromides were formerly used and now barbiturates are prescribed,
the new drugs will receive preference.512
Major sedatives had strong sedating effects.  Barbiturates were widely used in outpatient
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populations, those people seeing general physicians, psychiatrists, or psychoanalysts. 
The new tranquilizers, whether minor tranquilizers or low doses of major tranquilizers,
could substitute for barbiturates.  As Dr. Lothar Kalinowski enthused, “The neurotic
patient falls ever more into the domain of the general practitioner and non-psychiatric
specialist.  For this group you will prescribe the new drugs in the same way as you
prescribed Phenobarbital or other barbiturates in former times.”513  Ideally, a barbiturate
substitute would treat anxiety, tension, related psychosomatic complaints, control
seizures, and help alleviate insomnia.
Although critics later condemned Roche’s Valium marketing for widening the
boundaries of mental illness and the limits of acceptable anxiety, barbiturates were
applied with a similarly wide brush.  Use of pharmaceuticals for ‘nerve’ related
conditions, construed broadly, was an acceptable clinical practice well before Valium’s
introduction.  Most Americans taking barbiturates presumably did not consider
themselves sick, only needing a little something to deal with a minor issue, such as
sleeplessness or the stresses of work or home life.  Concern about individuals refilling
prescriptions repeatedly over long periods of time, which led to legislation increasing
control over barbiturates, including limits on the number of refills allowed, also
illustrates a popular understanding of appropriate barbiturate use.  Many barbiturate
users did not consider it necessary to see a physician regularly, they believed it
appropriate to continue refilling the same prescriptions.  Boundaries between healthy
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identifies daily drinking in moderation, but for “relief from inner tension”(Hoff, 13) as
pre-alcoholic behavior.  Alcoholism is associated with needing a drink in the morning
just to face the day ahead, drinking alone, hiding drinking from others and rationalizing
it to oneself.  Ebbe Curtis Hoff, Aspects of Alcoholism (Philadelphia: J. B. Lippincott
company, 1963), 13.
use, inappropriate use, and addiction were debatable, but the vast number of barbiturates
consumed each year in the United States suggests use of these drugs for widely existing
conditions, or at least to alleviate concerns shared by a substantial portion of the adult
population.
Relationship Between Valium and Alcohol
Less obviously an alternative to barbiturates, sedatives, hypnotics, and
tranquilizers, was the far more widely used drug, alcohol.  In the mid-twentieth century
United States, most adult men and women drank.  As with barbiturates, medical
professionals only considered a fraction of those imbibing as drug abusers.  In Aspects of
Alcoholism514 Ebbe Hoff, Chair of the Medical College of Virginia’s Division of
Psychiatric Research, estimated the number of alcoholics in the early 1960s at roughly
five million citizens.  Considering that moderate social drinking, or a tipple after work
most days, was generally not considered symptomatic of alcoholism, the popular
assumption that most adult males drank a few times a week seems reasonable.515  Early
twenty-first century definitions of alcoholism are broader, including regular social
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518  Robert W. Rasor, “Narcotic Addicts: Personality Characteristics and
Hospital Treatment,” chapter 1 in Problems of Addiction and Habituation (Grune &
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drinking as a sign of alcoholism.
Medical professionals mainly diagnosed alcoholism in men, with 5.8 diagnosed
for every woman.  Most were working age and living within a family, although Hoff
only goes so far as to say “[m]ore than half” were living with their wives.516  He tries to
show the social life of alcoholics are not those of social misfits; these were mainly men
with a stable life, ongoing jobs, no recent moves, living within a household.   Unstable
social conditions, he implicitly argues, are not major causes of alcoholism.  Alcoholics
might not be statistically normal Americans, but their profile fit with widely held social
ideals regarding normalcy.517
During the 1950s and 60s, medical opinion was making a slow and wide turn
toward considering alcoholism, as well as drug addiction, as medical issues.518  There
remained a strong tendency within the medical community, like the public at large, to
identify alcoholism as a personal failing.  But the way of defining a person – in terms of
personality, typical behavior patterns, or ways of interacting with society – placed
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alcoholism into the broad category of mental illnesses, a medical categorization.  In
psychiatric classification it usually fell into the character disorders,519 or was specifically
categorized as alcoholism or addiction based on the need for specialized treatment.
Valium has an interesting relationship with alcohol; clinical trials and to an
extent medical practice suggested its usefulness as a treatment for alcoholism, and both
Valium and alcohol served as tension reducers.  Each drug potentiated effects of the
other.  Valium was effectively and explicitly conceptualized by some medical
professionals as an improved alternative to alcohol; a more scientific and specifically
acting compound with similar beneficial effects alongside fewer detrimental side effects.
In the late 1950s and 1960s, early clinical trials for any tranquilizer included
testing usefulness as treatment for acute alcoholism.  Major tranquilizers, those used in
institutional psychiatry and their derivatives, provided a more effective means to get
alcoholics through the first stages of withdrawal, when behavior was similar to
psychoses.  Unfortunately, these phenothiazine derivatives and rauwolfia compounds not
only caused severe blood pressure drop in some patients, they occasionally caused
extrapyrimidal side effects in alcoholics, just as they did in other patients given them.520
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Some alcoholism researchers and clinicians saw benzodiazepines as a boon to
treating alcoholism.  Although they acted on different parts of the brain, clinicians tested
minor tranquilizers as alternatives; they fit the public’s expectation of a medical cure for
alcoholism.  Ebbe Hoff complained of the widespread belief among alcoholics that
physicians will give them something to get them through withdrawal quickly, and the
patient’s erroneous belief that continued abstinence will be easy afterwards.521  Some
physicians chose to treat alcohol addiction by substituting another substance, transferring
the addiction “from alcohol to sedative, tranquilizers, or other addictive modalities.”522 
Hoff argued alcohol’s addictive nature derived, in part, because it was “not a good
tranquilizer[;]”523 it could only reduce tension moderately, and in alcoholics the tension
turned to fear and guilt.  Alcohol did not remove tension when used as more than “a
social beverage” because it only suppressed tension, possibly by depressing the “alerting
mechanisms to the cortex[.]”524  Pharmacologic trials of diazepam suggested it helped
relieve tension, but differed from sedatives and major tranquilizers by not stunning the
mind’s ability to react; it did not depress alerting mechanisms.  Laboratory tests and
clinical trials with Valium suggested it was not physically addictive, and it was less
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525   Hirsch Gordon, for example, classified drugs by presumed area of action
within the body.  He differentiated “central nervous system depressants and
stimulants[,]” into four groups, “The autonomic drugs: sympathomimetic (adrenergic),
sympatholytic (adrenergic blocking), parasympathomimetic (cholinergic) and
parasympatholytic (cholinergic blocking)[.]” Gordon, Introduction, xi. 
likely to cause psychological addiction than euforiant or quick acting substances such as
alcohol.
Although alcohol was socially acceptable, at least in moderation, members of the
American media, and the medical community, recognized how its use paralleled that of
compounds such as barbiturates and minor tranquilizers, substances viewed as
medicinal.  A tipple after work relieved the tension of the day, but ongoing tensions
created risk of over-consumption and addiction.  Tranquilizers marketed by
pharmaceutical firms were more effective at targeting tension; they were a safer, and tax-
deductible, martini.  Whether Valium was physiologically addictive became a contested
issue around 1970.  Previously, most physicians appear to have associated it with active
tranquillity, reduction of tension without removing alerting mechanisms.  In this, Valium
was an improved version of alcohol.
Drug Classification
Classification of psychoactive drugs in the 1950s was basic and fluid.  Psychiatry
and psychotherapy used four main types, defined by their action and effects: shock
producing, sedative-hypnotic, analeptic, and tranquilizing.  No standard typology for
psychopharmaceuticals existed before the 1960s.525  Shock producing agents, which fell
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526  Reserpine played a lesser role in the late 1950s than chlorpromazine, and
will only be mentioned in passing through the remainder of this dissertation.  Reserpine
represents a purified version of a “resin fraction[.]” Gordon, Introduction, xi. from roots
of the plant Rauwolfia Serpentine, a plant “known for centuries in India for a variety of
healing powers for the body and the mind[.]” Gordon, Introduction, xi.  Efforts to
isolate sub-portions of the plant, to isolate specific effects, occurred at least as early as
1931 when “Drs. Salimuzza-man Siddiqui and Rafat Hussain Siddiqui isolated from its
roots five alkaloids used with disappointing results (1931).”  Reports from “Drs.
Cananath Sen and Kartick Chanra Bose,” boosted interest in developing
pharmaceuticals from the plant when they “claimed that it reduced high blood pressure
and controlled ‘insane mania.’”  Gordon, Introduction, xi.  Once the ‘Gupta Group’
identified a resin in the plant’s root as conveying most pharmacological activity,
European pharmaceutical manufacturers and physician-scientists took more note.  “Ciba
started its Rauwolfia research in 1947 and a year later it sent one hundred grams of
Ajmaline (prepared by the Siddiquis) to Sir Robert Robinson in Oxford for further
study.” Gordon, Introduction, xi.  From 1949 to 1953 testing focused on hypertensive
largely out of use for mild neuroses in the 1950s, created convulsions.  These drugs
(most commonly insulin and metrazol) had proven efficacy, but there was no consensus
on how or why they worked.  Although used for schizophrenia and manic-depression,
shock treatment was most useful in cases of depression.  Sedatives-hypnotics were
sometimes simply called sedatives, with the implicit understanding that induction of
sleep was always a property of sedatives.  Sedative drugs, widely used at midcentury,
included barbiturates, alcohol, and morphine.  The dominant interpretation in medical
and pharmacologic literature assumed these drugs had a general depressant effect on the
central nervous system (CNS).  Analeptic drugs – caffeine, amphetamines,
methamphetamines, and autonomic agents such as epinephrine (adrenalin) – appear
associated with CNS stimulants.  Three drugs dominated the tranquilizer market before
Sternbach discovered the benzodiazepines: chlorpromazine (marketed as Thorazine in
the United States and Largactil in the United Kingdom), reserpine,526 and meprobamate
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properties, but links to tension were quickly made.  “H. J. Bein of Ciba experimenting
on rabbits found that reserpine has an anti-hypertensive and sedative action, but the
animals could easily be aroused.” Gordon, Introduction, xi-xii.  After Robert W.
Wilkins, in 1953, reported on reserpine in hypertension and in 1954 at a symposium
held in the New York Academy of Medicine he reported that it relieves psychoneurotic
symptoms.” Gordon, Introduction, xii, half a dozen pharmaceutical manufacturers
quickly placed fractions, isolates, and modifications of reserpine (the CIBA isolate) on
the market under names including “Serpasil (Ciba), Serfin (Parke-Davis), Reserpoid
(Upjohn), Rau-Sed (Squibb), Rauwiloid (Riker), Moderil (Pfizer), and Raudixin
(Squibb)[.]” Gordon, Introduction, xii.
527  The best known of these antihistamines was marketed as Atarax which had
both a sedating and antihistaminergic effect.  The generic name is hydroxyzine and it is
currently mainly prescribed for allergic reactions in which psychosomatic factors may
be a component.  Marketed by J. B. Roerig & Company, its generic name was
hydroxyzine hydrochloride.  “Its sedative properties are greater in intensity than the
common side effect of antihistaminic drugs. It modifies psychosomatic manifestations
when they were caused by an increase in emotional tension. In states of excitation,
anxiety neurosis and arteriovisceral conditions the therapeutic results are particularly
effective.” Gordon, Introduction, xvi.
(marketed by separate companies as Miltown and Equanil).  Other drugs in this category
were derivatives of the major three, or forms of antihistamines.527
Although medical writers could explain tranquilizers’ effects in a plethora of
ways, most framed explanations in the context of over- or under-activity of electric,
metabolic, or chemical components of the central, sympathetic, or parasympathetic
nervous systems.  As John Ferguson, a doctor from Michigan’s Traverse City State
Hospital, explained to an audience of physicians interested in the new
psychopharmacology, “Behavior is like a teeter-totter.”  Healthy people went through
periods when they were more or less active, but there was a general balance.  The
healthy could voluntarily rein themselves in when overactive, and stimulate themselves
into action as appropriate.  “It is when one factor - overactivity or underactivity is
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528  John T. Ferguson, “What’s New and Usable in the Chemical Treatment of
Abnormal Behavior,” in The New Chemotherapy in Mental Illness: The History,
Pharmacology and Clinical Experiences with Rauwolfia, Phenothiazine, Azacyclonol,
Mephenesin, Hydroxyzine and Benactyzine Preparations, ed. Hirsch L. Gordon (New
York, NY: Philosophical Library, 1958), 50-59, 56.
529  Pollack comments on Bowes in Bowes, Ataratic Drugs, 20; presumably
Pollack is Seymour L. Pollack a physician at Illinois’ Galesburg State Research
Hospital.
530  Fazekas et al., Ataratics in Medical Practice, 42.
531  Both these drugs continued to be used in hospitals through the 1960s.
clinically manifested - that we have abnormal behavior[,]“528 Ferguson argued.  This is
not to say behavioral change was mental illness, it was a visible sign.  Scientifically
minded physicians usually held to a combination of biological, social, and psychological
factors as the ‘causes’ of mental illness.  Literature in psychopharmacology tended to
focus on stimulation or inhibition in brain or nerves, possibly mediated by neural
humors, what in hindsight we identify as neurotransmitters.  For example, Pollack
claimed “[i]t is quite obvious that mental illness is the product of multifactorial changes
which seem to be related to an interference with the major enzyme systems.”529  
Drugs useful in promoting mental health helped restore balance between over
and under activity.  Stimulants, such as amphetamines, coffee, or methylphenidate
(Ritalin), increased activity.  Before 1950, drugs prescribed “for the management of
hyperexcitable states[,]”530 CNS depressants, included chloral hydrate and paraldehyde
as well as the more commonly used barbiturates.531  Pharmaceutical companies
introduced dozens of mental depressants to the United States market in the 1950s;
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532  Morris Fishbein, “The Tranquilizing Drugs,” in  The New Chemotherapy in
Mental Illness: The History, Pharmacology and Clinical Experiences with Rauwolfia,
Phenothiazine, Azacyclonol, Mephenesin, Hydroxyzine and Benactyzine Preparations,
ed. Hirsch L. Gordon (New York, NY: Philosophical Library, 1958), 3-5, 3.
533  Phenothiazine compounds (chlorpromazine and related substances), in
general, were “assumed to exercise a depressant action at the myoneural junction and
directly on the muscle, an inhibiting action on the diencephalic centers and a dampening
effect on the arousal mechanism in the reticular substance.” Gordon, Introduction, xiii. 
The effect was widespread throughout the brain and central nervous system “acting
primarily at the subcortical level in cerebrum, diencephalon, medula and, to a lesser
extent, on the peripheral autonomic system.” Gordon, Introduction, xiii.
chlorpromazine (Thorazine), reserpine, and meprobamate (Miltown, Equanil) are among
the best known, in part because they were the first of their types and remained the
archetype for each category.  Each of these drugs depressed, inhibited, tranquilized, or
otherwise reduced over-activity in portions of the brain.  Pharmacologic research
suggested “reserpine and chlorpromazine depress the hypothalamic mechanisms,
particularly that part concerned with the patterns for emergency, for fight and flight.” 
The more general and apparently stronger effects of chlorpromazine (Thorazine) arose
from it depressing “not only these mechanisms but also the sympathetic and
parasympathetic nervous systems.”532  This schema of stimulation, and depression or
inhibition of the central nervous system offered an explanation for the benefits and
problems of a broad spectrum of sedating drugs, including alcohol, opiates, and the
prescribed major and minor tranquilizers.
The bumper crop of new CNS depressants identified in the 1950s and 1960s
forced changes in drug classification, mainly dividing existing categories by focusing on
physical location and extent of de-excitation, inhibition, or tranquilization produced.533 
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534  Fishbein, The Tranquilizing Drugs, 4.
535  Abraham Winkler, The Relation of Psychiatry to Pharmacology (Baltimore,
MD: American Society for Pharmacology and Experimental Therapeutics, 1957) 
Section 2.
536  Edward Shorter, A History of Psychiatry: From the Era of the Asylum to the
Age of Prozac (Toronto: John Wiley & Sons, Inc., 1997), 26.
“The discovery of new drugs of this type invariably sets off a chain reaction[,]” doctor
Morris Fishbein, editor of JAMA, declaimed “in which new fields are investigated and
various combinations of new and old drugs are tested for specific effects.”534 
Tranquilizers, the developing typology implied, were similar to sedatives but with effects
on more specific parts of the CNS.  As a result, most physicians or mental health
professionals who did contemplate the relative merits of pharmaceuticals, identified
tranquilizers with drugs calming agitation of the body, or the nerves, while not clouding
consciousness nor interfering with intentional action.  They were milder versions of
sedatives.
Depending on your theoretical bent, these drugs either disrupted/modified
learned connections in the brain/mind, or altered the balance between id, ego, and
superego, thereby forcing the ego to relearn and adapt.535  Written descriptions of
psychotherapeutics in medical journals flow smoothly between behaviorist and mentalist
descriptions; it appears mid-twentieth century physicians, pharmacologists, and
behavioral scientists saw less of a divide between behavioral theory and analytic
descriptions than some late twentieth-century books suggest.536
One possible explanation for assumptions of links between externally visible
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537  Winkler, Relation of Psychiatry to Pharmacology, 5.
538  Sakel, who introduced insulin shock as a therapy, discussed the rationale in
M. Sakel, “The Classical Sakel Shock Treatment: A Reappraisal,” Journal of Clinical
Psychopathology 15 (1954): 255-316.
539  Gellhorn and his research group conclude the effect of insulin shock is
removing inhibitory processes.  E. Gellhorn and H. Minatoya, “The Effect of Insulin
Hypoglycemia on Conditioned Reflexes,” Journal of Neurophysiology 6 (1943): 161-
71; E. Gellhorn, “Is Restoration of Inhibited Conditioned Responses Specific for
Pavlovian Inhibitions?” Archives of Neurology and Psychiatry (Chicago) 56 (1946):
216-21; M. Kessler and E. Gellhorn, “The Effect of Electrically and Chemically
behavioral patterns and patterns physically or psychically existing in the brain, is
interpretation of learning and thought as patterns of electric activity.  The link between
psyche and somatic theories can be understood in terms of electrical patterns or tensions,
which could be modulated, take different forms when an individual was awake or asleep,
and develop or lose paths between areas of activity.  This possible interpretation also ties
understanding of human physiology and psychology to medical technologies rising to
greater use and precision, such as the electroencephalogram (EEG).
Doctors prescribed a wide array of drugs for psychological and somatic
problems.  Insulin, for example, was prescribed to treat narcotic addiction,537 but more
commonly used to produce convulsions and coma or hibernation.  During World War II,
doses too low to produce coma or convulsions found application in treating ‘combat
fatigue,’ and other conditions associated at the time with psychoneuroses.  Although
earlier physicians thought the therapeutic mechanism rooted in rest and allowing time for
the body to adapt,538 by the 1950s explanations turned to disruption of learned
maladaptive behavior patterns,539 or destroying the fragile equilibrium within the psyche
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Induced Convulsions on Conditioned Reflexes,” American Journal of Psychiatry 99
(March 1943): 687-91.  Winkler explains the traditional Pavlovian explanation would
be allowing development of protective processes if insulin was used to produce coma. 
Winkler, Relation of Psychiatry to Pharmacology, 228.
540  Winkler, Relation of Psychiatry to Pharmacology, 7.
541  It is important to notice that the declining use of electroconvulsive therapies
did not lead to their disuse.  How they work remained a point of debate throughout the
twentieth century, that they were highly effective in certain cases, particularly
depression without history of mania, was not questioned.
542  L. S. Kubie and S. Margolin, “The Therapeutic Role of Drugs in the Process
of Regression, Dissociation and Synthesis,” Psychosomatic Medicine 17 (1945): 147-
51.
and forcing the ego to adjust in more practical ways.  There were no consistent results, or
overwhelming proof, that coma or chemical convulsant treatments improved a patient’s
condition by the time pharmaceutical manufacturers introduced tranquilizers.540  Drug-
based convulsive therapies fell from favor with introduction of safer alternatives.541 
Sedatives and analeptics found use in psychoexploration, narcoanalysis, narcosynthesis,
and elevation of mood.  Psychoexploration typically involved combining psychoanalysis
with drugs to reshape the relationship between patient and analyst, either by altering
consciousness or reducing repression, and as a result allowing the patient consciously to
explore events and emotions previously repressed.542  Analeptics produced bursts of
speech, useful in therapy, and improved energy level as part of treating depression. 
Barbiturates, widely used by the American public in the mid-twentieth century as all-
purpose tranquilizers/sedatives/hypnotics, served similar purposes; in theory, they
removed inhibitions, allowing instinctive or subconscious thoughts and behavior to
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543  Narcosynthesis, narcoanalysis, drug induced abreaction, and similar methods
gained notice during World War II.  At the time there was a focus on high rates of war
neuroses and the need to get soldiers back to duty as quickly as possible.  For examples
see: R. R. Grinker, “Brief Psychotherapy in War Neuroses,” in Proceedings of the 2nd
Brief Psychotherapy Council, volume 1, 6-19. (Chicago: Institute for Psychoanalysis,
1944); S. J. Horsley, Narcoanalysis (Oxford University Press: London, 1943); H. L.
MacKinnon, “Narcoanalysis and Allied Procedures,” American Journal of Psychiatry
105 (September 1948): 224-25; J. S. New and A. R. Kelley, jr.  “Narcosynthesis in
Civilian Practice,” Southern Medical Journal 40 (1947): 349-55; D. W. Orr,
“Psychiatric uses of Sodium Pentothal.  Experiences in a Forward Area,” Naval
Medical Bulletin (Washington, D. C.) 49 (1949): 508-16; and J. F. Wilde, “Narco-
Analysis in the Treatment of War Neuroses,” British Medical Journal 2 (1947): 4-7.
544  S. Dworkin, W. Bourne, and B. B. Raginsky, “Changes in Conditioned
Responses Brought About by Anesthetics and Sedatives,” Canadian Medical
Association Journal 37 (1937): 136-39.
545  E. A. Wentink, “The Effects of Certain Drugs and Hormones Upon
Conditioning,” Journal of Experimental Psychology 22 (1938): 150-63.
surface, and prevented patients from guarding their speech.  Narcosynthesis, whether
with sedatives or analeptics such as methamphetamine, served either to force a cathartic
experience, relive trauma, or otherwise shake up the balance between id, ego, and
superego in order to produce a resynthesis of the individual’s psyche.543  In terms of
learned behavior, Simon Dworkin of McGill University’s Laboratories of Physiology
characterized the effects of sedatives as impairing ability to recognize if conditioned
responses were positive or negative.  As a result, creatures felt free to try different
responses and could therefore more easily learn and adapt.544  E. Wentink noted
phenobarbital’s ability to extinguish conditioned responses in rats, if used at high enough
doses.545  Dworkin tried applying essentially the same technique to humans.  
Explanations of analeptics, such as amphetamines and methamphetamines often
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546  Winkler, The Relation of Psychiatry to Pharmacology, 176-77.
547  B. F. Skinner and W. T. Heron, “Effects of Caffeine and Benzedrine Upon
Conditioning and Extinction,” Psychological Record 1 (1937): 340-46.
use atypical interpretations.  These drugs improved mood in depressed patients, but
laboratory measures suggested they sometimes functioned as sedatives.  On EEG tests,
the results were similarly cloudy, in fatigue states they restored normal patterns, in large
doses they often desynchronized expected alpha and beta wave patterns.546  B. F.
Skinner, with his usual diplomacy, declared amphetamines and caffeine simply outside
understanding, “We may just as well say that the effect...is to cause the organism to
release energy at a higher than normal rate whether it is in a state of inhibition or not. 
The surplus energy is used by the animal in doing what it is accustomed to doing[.]”547 
Tranquilizers were fairly new at the time Sternbach began modifying them. 
Derived from antihistamines, muscle relaxants, and traditional hypotensive medicines,
the earliest psychopharmaceuticals, given the moniker ‘modern tranquilizers’ – because
they acted specifically on the CNS and functional behaviors – were chlorpromazine, and
reserpine.
Doctors mainly used chlorpromazine, the first major tranquilizer introduced, in
mental institutions because of side effects identified during its intended use; originally
developed to prevent shock during surgery, it also appeared to calm conscious patients. 
Physicians charged with running institutions, who often were administrators more than
clinical practitioners, immediately identified the practical and possibly therapeutic benefits
of chlorpromazine; their patients were less violent, more calm, and approachable both
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548  Robert B. Bross, “The Modern Mood-Changing Drugs,” The American
Journal of Nursing 57, no. 9 (1957): 1142-43 & 1146, 1142.
549  Winkler, Relation of Psychiatry to Pharmacology, 177.
550  Winkler, Relation of Psychiatry to Pharmacology, 188.
physically and psychologically.  The drug appeared to act on both the CNS and autonomic
nervous systems, and as a result “strikingly reduces the patient’s sensitivity to his own
emotions and to his environment.”548  In theory, this offered improved possibility of
treatment through traditional psychoanalytic methods, or the more recent group therapy, and
the learning of life skills and socially acceptable behaviors necessary to leave the institution. 
Chlorpromazine’s effectiveness in other areas was at least equally important to some
administrators; with fewer violent patients, employee turnover decreased and costs reduced,
coincident with cleaner, less destructive, more self-maintaining patients. 
The neural action of chlorpromazine involved “synchronization of spontaneous
cortical electrical activity”549 on electroencephalograph (EEG) tests.  In some ways the drug
behaved similarly to stimulants, in others akin to central nervous system depressants. 
Neurologically, chlorpromazine acted mainly on the reticular system, but to an extent on
more brain areas than traditional sedatives.550
Pharmaceutical firms quickly developed drugs with similar behavioral and EEG
profiles, but fewer side effects.  Existing theoretical links between psychoses and neuroses
suggested doctors could prescribe the same drugs at lower doses, or milder tranquilizers, to
outpatients with less severe mental illnesses.  Outpatients formed a far larger market.
In the mid- and late-1950s there were few studies, especially animal and behavioral,
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551  Winkler, Relation of Psychiatry to Pharmacology, 114-15.
552  David Herzberg, Happy Pills in America: From Miltown to Prozac
(Baltimore: The Johns Hopkins University Press, 2009), 24.
on the newer tranquilizers, the best known of these being reserpine and meprobamate
(Miltown and Equanil).551  Yet even the scanty published trials suggested newer tranquilizers
better suited treatment of the widespread neuroses; they had relatively clean side effect
profiles and apparently lesser sedative effects.
The concept of major and minor tranquilizers fit with the popular and professional
interpretation that neuroses were similar to, but more mild than, psychoses.  Sometimes
physicians assumed psychoses were organic in cause, while neuroses were maladaptive
functional behaviors; therefore psychopharmacologic treatments for neuroses did not require
strong physically sedative effects.  Because actions of meprobamate and benzodiazepines
were more specific and mild, they appeared suitable for treating neurotic responses to stress
in ambulatory patients, while the stronger tranquilizers, such as chlorpromazine (CPZ)
appeared the best choice for treating psychoses within institutions.  
One tradition of historical discussions of psychopharmaceutical development places
meprobamate on the border between major (CPZ and reserpine) and minor (benzodiazepines,
hydroxyzine) tranquilizers.  David Herzberg, in Happy Pills in America: From Miltown to
Prozac, explains how officials at Wallace Laboratories intentionally positioned Miltown “by
calling it a tranquilizer rather than a sedative, while also distinguishing it as a minor rather
than major tranquilizer[.]552 This marketing effort, to link meprobamates with the
psychopharmaceutical revolution heralded by chlorpromazine (Thorazine), downplays the
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553  Seymour Rosenblatt and Reynolds Dodson, Beyond Valium: The Brave New
World of Psychochemistry (New York: G. P. Putnam’s Sons, 1981), 39.
554  A second anomaly is not discussed in this dissertation, for reasons of brevity;
antihistamines, which tended to have a sedative or hypnotic side effect profile, were
identified, modified, and/or marketed for their sedative properties.  Reviewing recent
developments in psychopharmacology, J. D. French divides tranquilizers into four
groups, based on chemical type: (1) reserpine, (2) chlorpromazine and related
phenothiazines, (3) meprobamate and other propanediols, and (4) azacyclonol and
related diphenylamines.  Reserpine comes into western psychiatry through recognition
of a naturally occurring compound (Rauwolfia) with a long history of use outside Euro-
America.  Azacyclonol was the isomer of an existing stimulant, and its broader history
is not significant to this dissertation.  Chlorpromazine/phenothiazines are derived from
antihistaminergic compounds.  J. D. French, “Drug Actions Upon the Brain:
‘Psychopharmacology’,” Annual Reviews of Medicine 9 (1958): 333-46.
logic of Miltown’s development.  It fits well with Doctor Seymour Rosenblatt and Reynolds
Dodson’s reference to Miltown’s creation as a scientific accident.553  This explanation is
insufficient.  One important anomaly is mephenesin, a drug appearing on the market before
the beginning of the psychopharmaceutical revolution (1953) and leading more directly than
the major tranquilizers to development of minor tranquilizers such as meprobamate
(Miltown), chlordiazepoxide (Librium), and diazepam (Valium).554
Mephenesin and Meprobamate
The history of mephenesin, marketed as Myanesin or Toserol, begins before CPZ
heralds onset of the psychopharmaceutical revolution.  Discovered in 1946 by Berger and
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555  F. M. Berger and W. Bradley, “The Pharmacological Properties of αβ-
dihydroxy-(2-methylphenoxy)-propane (myanesin),” British Journal of Pharmacology
1 (1946): 265-72.
556  John Hay, “Observations on the Use of Myanesin in Psychiatric Cases,”
Canadian Medical Association Journal 60 (March 1949): 224.
557  E. H. Hare, “The Effects of Mephenesin in Neurotic Anxiety,” Journal of
Mental Science 101, no. 422 (1955): 172-74.
558  John Hay uses the comparison of mephenesin and curare in “Observations
on the Use of Myanesin in Psychiatric Cases,” Canadian Medical Association Journal
60 (March 1949): 224-27.
559  Hay, Observations on the Use of Myanesin, 224.
Bradley555 while systematically working through the “α substituted ethers of glycerol,”556
screening showed mephenesin had the widest dosage range of anti-curare effects between
that causing paralysis and that resulting in death of the tested compounds.  Obviously from
this test battery, these chemists did not uncover mephenesin in a search for tranquilizers;
Berger and Bradley cared about muscle control properties of chemical compounds.  Yet
within a year, readers of the Journal of the Canadian Medical Association learned that
humans given mephenesin intravenously gained a feeling of “euphoria and relaxation.”557 
Either chemists, pharmacologists, and medical professionals already assumed links between
muscle and mental relaxation preexisted or they rapidly made this connection.  
Although mainly prescribed to ameliorate effects of curare, muscle paralysis, tension,
or spasm,558 that small doses of mephenesin caused “a generalized muscular relaxation
without, however, impairing voluntary muscular control”559 led researchers to test usefulness
in psychiatric institutions where damage from physical spasms associated with ECT
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560  Birger R. Kaada used knowledge derived from a variety of the drug’s
specific actions to conclude it effected the central nervous system in general and had a
selective depressant or inhibition action.  Birger R. Kaada, “Site of Action of Myanesin
(Mephenesin, Tolserol) in the Central Nervous System,” Journal of Neurophysiology
13, no. 1 (1950): 89-109; a similar study in 1954 appears to link questions about the
CNS localization of muscle and mental relaxation with reflex experiments similar to
those used by Lowell Randall in showing diazepam was a potentially useful
tranquilizer.  Ellen Eva King and Klaus R. Unna, “The Action of Mephenesin and Other
Interneuron Depressants on the Brain Stem,” Journal of Pharmacology and
Experimental Toxicology 111, no. 3 (1954): 293-301.
561  Hay, Observations on the Use of Myanesin, 226.
562  Louis Paul, “Mephenesin in Anxiety-Tension States,” Psychosomatic
Medicine 14, no. 5 (1952): 381.
563  Bross, Modern Mood-Changing Drugs, 1143.
remained a problem.  It reduced or removed symptoms associated with Parkinson syndrome,
such as tremors and muscle rigidity.  The results were best explained by positing some
effects occurred within the cerebral cortex;560 psychiatric patients in general experienced
“psychic phenomena, chief of which appears to be a feeling of relaxed well-being[,]”561
wrote John Hay.  In 1952, while physicians first read of chlorpromazine (Largactil) in
Archives Internationales de Pharmacodynamie, Veterans Administration physicians
published comments on mephenesin’s use for psychiatric conditions.  They studied neurotic
individuals with symptoms including anxiety and tension; in twenty-six of thirty patients, the
drug produced “a feeling of reduced muscle and psychic tension, often with a sense of well-
being[.]”562  Mephenesin produced results similar to the widely used barbiturates, including
reduction of stress and anxiety, as well as improved sleep, but was less toxic and, because it
reduced tension in “voluntary muscles without affecting the muscles of the diaphragm[,]”563
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564  Note that the comparison is mine, but the facts of its action are matters of
record.  For example the effects of Mephenesin on the diaphram is noted in Bross,
Modern Mood-Changing Drugs, 1143.
565  For examples of physicians’ desires to find an effective antianxiety
medication becoming bogged down in complexities of proof, see Paul, Mephenesin in
Anxiety-Tension States, 378-82; John A. Ewing, “Clinical Evaluation of the Effects of
Mephenesin on Anxiety,” Journal of Mental Science 99, no. 416 (1953): 464-72; Hare,
Effects of Mephenesin in Neurotic Anxiety, 172-74; and P. A. L. Scott, “A Controlled
Study of the Effects of Mephenesin on Psychiatric Out-Patients,” Journal of Mental
Science 101, no. 422 (1955): 163-71.
566  French, Drug Actions Upon the Brain, 333-46.
567  M. Engler, “Mephenesin (Tolserol) and Mephenesin Carbamate in Spastic
Conditions,” Journal of Mental Science 101, no. 423 (1955): 391-98.
568  F. M. Berger, C. D. Hendley, B. J. Ludwig, and T. E. Lines, “Central
Depressant and Anticonvulsant Activity of Compounds Isomeric with 2-Methyl-2-η-
Propyl-1,3-Propanediol Dicarbamate (Miltown),” Journal of Pharmacology and
– muscles associated with breathing – it should have proved less of an overdose risk.564 
Mephenesin had a short shelf life as a chemical treatment for anxiety and tension,565
compared to longer term use as a muscle relaxant.  In 1958, the inaugural report on
psychopharmacology in Annual Reviews of Medicine identified mephenesin only as a muscle
relaxant,566 but noted its benefits and defects played a major role in development of
meprobamate (Miltown) and the benzodiazepines.  Existing medical and scientific theories
suggested muscle tension was a measure of stress, that the body responded to stress in both
physical and psychological ways, and therefore reduction of muscle and psychic tension
should relate to overall well-being.  E. B. Squibb and Sons developed mephenesin carbamate
in an effort to create a more potent version with longer duration of effect.567  Of more lasting
importance, scientists at Carter Laboratories developed a “somewhat related”568 compound,
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(DEP) and some of its Homologues and Esters,” Journal of Pharmacology and
Experimental Therapeutics 100, no. 1 (1950): 27-39.
571  Berger, Pharmacological Properties of 2-methyl-2-n-propyl-1,3-propanediol
dicarbamate (Miltown), 414.
572  F. M. Berger, “The Anticonvulsant Activity of Carbamate Esters of Certain
2,2-disubstituted-1,3-propanediols,” Journal of Pharmacology and Experimental
Therapeutics 104, no. 2 (1952): 229-33.
573  Charles R. Boddington Joyce, ed., Psychopharmacology: Dimensions and
meprobamate, with a better activity profile as an antianxiety, anti-tension agent.
Carter Laboratories developed meprobamate as part of efforts to improve on
mephenesin as a muscle relaxant and antianxiety agent.  They theorized that mephenesin was
active in the body for only a short period because the primary hydroyl group oxidized
rapidly, thus changing the compound.569  Efforts to prevent oxidation resulted in a series of
new compounds570 of which one discovered in 1950, meprobamate,571 possessed a longer
duration of action, a wider spectrum of activity, and more consistent pharmacologic
properties.572
Meprobamate proved an effective muscle relaxant and fit with the profile of existing
tranquilizers; it appeared to prevent convulsions and have a calming effect on behavior.573 
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Perspectives (Philadelphia: Lippincott, 1968), 120.
574  Abraham Gardiner, “Meprobamate–A Clinical Study,” American Journal of
Psychiatry 114 (December 1957): 524.
575  Clinical trials focused on treatment of psychoses suggested meprobamate
could be used as an adjunct to other pharmacotherapies.  Veronica M. Pennington, “Use
of Miltown (Meprobamate) with Psychotic Patients,” American Journal of Psychiatry
114 (December 1957): 257-60; Other clinical studies focused on relief of tension
associated with alcohol or drug withdrawal, or anxiety in general.  Gardiner,
Meprobamate, 524-26; Arnold H. Zucker, Stanley D. Machlin, and Winfield Scott, “An
Evaluation of Meprobamate in Opiate Withdrawal,” American Journal of Psychiatry
115 (September 1958): 254-55; John H. Medenhall and John A. Ewing, “Further
Psychometric Evaluation of the Effect of Mephenesin on Anxiety,” Journal of Mental
Science 100, no. 418 (1954): 262-66.
576  Frank J. Ayd, “Meprobamate: A Decade of Experience,” Psychosomatics, 5
(March-April 1964): 82.
577  As a result grants from Wallace funded research establishing relative
efficacy of meprobamate and phenobarbital, the most commonly used barbiturate.  E.
H. Uhlenhuth, Arthur Canter, John O. Neustadt, and Henry E. Payson, “The
Symptomatic Relief of Anxiety with Meprobamate, Phenobarbital and Placebo,”
American Journal of Psychiatry 115 (April 1959): 905-10.
Wallace Pharmaceuticals began marketing the new drug in 1955, as the tranquilizer
Miltown.  Also under license from Carter, Wyeth marketed it as Equanil. Marketing focused
on a larger population than institutionalized patients; as a compound “producing a profound
tranquilizing effect without impairment of alertness,”574 physicians could prescribe it to
outpatients without fear it would interfere with their regular activities.575  This opened an
enormous potential market to Wallace and Wyeth, the majority of Americans whose mental
health was not absolute yet did not require institutional care.  This “vast number of neurotics
and mild psychotics”576 were those interacting primarily with general physicians. 
Barbiturates were the main preexisting alternative and their limitations were well-known.577 
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578  Ayd, Meprobamate: A Decade of Experience, 82-87.
579  Berger, Pharmacological Properties of 2-methyl-2-n-propyl-1,3-propanediol
dicarbamate (Miltown), 413-23.
580  Berger, Pharmacological Properties of 2-Methyl-2-n-Propyl-1,3-Propanediol
Dicarbamate (Miltown), 414.
581  Clinical research regarding addictiveness of meprobamate was published in
the late 1950s.  Considering later debates over addictive potential in benzodiazepines,
such as Valium, it should be noted that physicians John Ewing and Thomas Haizlip
identified withdrawal symptoms similar in barbiturates and meprobamate.  Rather than
warning against use, they suggested the drug be started and stopped slowly.  The
authors note their gratitude for Wyeth’s support, therefore they did have ties to
companies marketing meprobamates.  John A. Ewing and Thomas M. Haizlip, “A
Controlled Study of the Habit Forming Propensities of Meprobamate,” American
Journal of Psychiatry 114 (March 1958): 835.
The meprobamates quickly became the most commonly prescribed psychopharmaceuticals,
continuing in this position until at least 1964.578  
Published research identified three characteristic behaviors of meprobamate in mice
and rats: sedation at low levels, loss of righting reflex at medium doses, and paralysis at high
doses.579  Compared with the barbiturates, the drug produced sedation and aided sleep
without an initial period of restlessness.580  Its action was stable, predictable, and fit the
concept of tranquilizers as CNS depressants.  Obviously another improvement for future
drugs would be a wider range of doses between that producing ataraxia, active tranquillity,
and mental or physical sedation.581
Therefore, when Sternbach set out on the trail of new tranquilizers, doctors
recognized these drugs as useful adjuncts to psychiatry and general medicine, but medical
scientists knew few details about how they functioned.  Contemporary knowledge of
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582  For an overview of the company’s history see Hans Conrad Peyer, Roche: A
Company History, 1896-1996 (Basel, Switzerland: Editiones Roche, 1996).
583  Narconumal was a sedative-hypnotic form of narcotic, while Persedon was a
more mild hypnotic.  Peyer, Roche: A Company History, 128.
psychopharmaceuticals suggested to psychoanalysts that they should act on repression, and
in behaviorist translation that they should modify conditioned responses and reduce
excessive or ongoing physical responses to stress.  Both approaches were consistent with
interpreting events in terms of stimulation and depression or repression of the physical brain. 
Existing tranquilizers suggested observable signs and behaviors to look for in identifying
new versions, EEG patterns, muscle tension, righting reflex, changes to learning and learned
responses, and reduction in signs of anxiety or tension.
Research and Development at Roche
By the late 1930s, Hoffmann-La Roche was a major pharmaceutical company with a
substantial research and development commitment.  Headquarters and facilities in
Switzerland complemented those at Nutley, New Jersey.  Pharmaceutical development
encompassed a wide variety of fields, including the two main areas in which Sternbach
worked, vitamins and tranquilizers.582  The work of Otto Schneider had already produced
Narconumal in 1939 and Persedon in 1943.583  Initially, Roche hired Dr. Leo Sternbach to
work on vitamin research.
Sternbach, upon completing a doctorate in Chemistry at the University of Cracow in
1931, continued to serve as a teaching assistant for six years.  In reminiscences, Sternbach
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584  Lloyd Shearer, “The Man Who Invented Valium,” Oakland Tribune June 27,
1976.
regularly tied his later interest in benzodiazepine-like substances to his early research. 
Attempts to develop heterocyclic dyestuff compounds failed, but he remembered his love of
these compounds’ basic properties, synthesis in large quantities was rather simple and the
compounds crystallized “beautifully.”584  
Postdoctoral work in Zurich not only improved his career, it allowed him to leave
Poland in 1937, slightly ahead of the Nazi advance.  Both research and life at his
boardinghouse were instrumental factors moving him from academe to corporate work.  At
the Eidgenössische Technische Hochschule he worked with Leopold Ruzicka, soon to be a
Noble Laureate for his work on sex hormones.  At his boardinghouse the fascination was
with Herta Kreuzer, daughter of the landlord.  Realizing a postdoc did not provide sufficient
funds to support a family, he moved on to Roche in Basel, with his new wife Herta.  With
World War II looming, even near Switzerland, the company moved its more vulnerable
employees to Nutley, New Jersey, effectively Roche’s wartime headquarters.  Sternbach, a
Polish Jew, was at serious risk should the Nazis take Switzerland.  In New Jersey, Roche set
the young chemist to work synthesizing vitamins. By 1954, members of the board at
Roche faced declining income from vitamin sales.  The two-pronged approach taken
explains Sternbach’s work history at the firm.  First, Roche leaders wanted to lessen costs of
producing vitamins.  At the time, vitamins were fairly new synthetic pharmaceutical
compounds, and therefore highly profitable if produced in large amounts through
inexpensive processes.  Quick development of an economical process creating biotin and
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585  Peyer, Roche: A Company History, 170.
586  Peyer, Roche: A Company History, 172.
587  Even in 1957 there were only a few tranquilizers on the market and
meprobamates were the sole alternative to chlorpromazine and reserpines.  Bross,
Modern Mood-Changing Drugs, 1146.
588  These qualifications for financially remunerative drug development are
outlined in O. L. Burns, “Some Statistical Considerations in the Selection of Research
intermediate compounds for riboflavin improved Sternbach’s status within the company. 
Second, Roche leadership put greater resources into the search for new and marketable
pharmaceuticals.585  Around 1955 Sternbach gained a new task, although exactly what that
task was, and the parameters given him is debatable.  Perhaps supervisors told him to
develop a tranquilizer, although the methods used to test it suggest the company either
wanted a muscle relaxant, anticonvulsant, or improved mild sedative along the lines of
barbiturates or meprobamates.586
Profiles of existing tranquilizers included these properties; tranquilizers were
pharmaceuticals reducing forms or manifestations of stress and tension, including muscle
tension.  If they calmed but did not substantially dull the mind you could call them
tranquilizers.  These compounds, minor tranquilizers or ataractics, first entered the market in
the early 1950s.  By 1955, it was apparent that Miltown was a financial success, and there
were few improved compounds successfully competing with it.587  Gaining a strong market
share depended on developing and marketing a useful substance before competitors, and
entering with a drug whose properties were at least slightly better than those already on
sale.588  In some versions of written recollections, Sternbach’s task was similar to that driving
218
Projects in the Pharmaceutical Industry,” Applied Statistics 11, no. 3 (1962): 170-83.
589  Tonya Koeppel, Leo H. Sternbach, transcript of interview 12 March 1986,
unpublished (Philadelphia: The Beckman Center for the History of Chemistry,
Chemical Heritage Foundation, 1986), 25.
590  For example, Sternbach patented a spasmolytic in 1953.  Leo Henryk
Sternbach, assignor to Hoffmann-La Roche, Inc. 1953. Esters of 1-Azabicycloalkanols.
development of Miltown, start with the short acting muscle relaxant Mephenesin and find a
stronger and longer acting version.  In other branches of hindsight, Sternbach wrote of efforts
to create tranquilizers based around a new core molecule.589
Roche’s interest in tranquilizers or sedatives is understandable.  Institutional
psychiatrists in the United States and abroad were fascinated with chlorpromazine, but side
effects made it impractical for outpatient use.  Based on the common assumptions – that
psychoses were either organic or functional; that neuroses were milder versions of functional
psychoses; that there was a spectrum from mental health to mental illness with most
Americans falling between the two poles; and that muscle relaxation as well as
antihistaminergic activity were associated with sedative tranquilizers – there was an
obviously large market for less dangerous and milder versions of tranquilizers; especially
because in the broader public market they were a safer substitute for barbiturates. 
Pharmaceutical manufacturers knew from past experience that slight modifications to
existing compounds could produce similar beneficial activities and better side effect profiles. 
Wyeth’s development of meprobamate illustrated the size of the market.  If Roche could get
a slightly better compound to market quickly, profits might be enormous.
Exactly what task Roche gave Sternbach remains debatable.590  The main point of
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U.S. Patent 2,648,667, filed April 18, 1951, and issued August 11, 1953; Washington
Post Staff Writer B. D. Colen, after interviewing Sternbach, wrote that the chemist was
told to create a tranquilizer similar to meprobamate, and start with the same basic
molecule.  B. D. Colen, “Adventurous Chemist and His Pill; Valium: The Most Popular
Most Abused Prescription Pill,” The Washington Post January 20, 1980.
591  Excellent diagrams for the structures of chlorpromazine, meprobamate,
phenobarbital, chlordiazepoxide (the first of Sternbach’s benzodiazepine series) can be
seen in Randall, Pharmacology of Chlordiazepoxide (Librium), 7-15.
592  In an interview, Sternbach speaks of the research and chemical synthesis
leading to the benzodiazepines in terms suggesting his work was driven more by
personal interests than a planned program of research.  His supervisor, Dr. Goldberg,
appears resentful of Sternbach’s inability to accept direction.  Koeppel, Leo H.
Sternbach, 26-27.
593  Sternbach recalled working on these compounds after the project officially
ended.  Koeppel, Leo H. Sternbach, 26.
confusion lies in just why the chemist was playing with heterocyclic compounds; these were
quite different from existing tranquilizers, muscle relaxants, sedatives, or hypnotics.591 
Sternbach did know a great deal about the compounds he chose.  He spent many of his
postdoc years studying them, but as potential dyestuffs.  Established methods were to modify
known marketable compounds.  This was less risky and faster than beginning with a random
molecule that appeared, but was not yet proven, useful.  However, a new core molecule was
more likely patentable.  Some of Sternbach’s writings suggest his supervisors were unhappy
with the track his research was taking.592  Five years of research produced nothing; he spent
years developing new molecules before hitting on one with desirable properties.
Sternbach’s work appeared a dead end, so Roche directed his efforts elsewhere. 
Perhaps he ate the memo, or simply ignored it.593  Luckily for Roche, when faced with
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594  The compounds leading to Librium were synthesized in 1955 and submitted
for testing in 1957.  Leo H. Sternbach, The Benzodiazepine Story (Basel, Switzerland:
Editiones Roche, 1980).  p. 11.
595  Koeppel, Leo H. Sternbach, 28.
596  According to Sternbach he only submitted one of the two remaining
compounds for testing.  The molecule tested formed the basis of Librium.  Valium
derived from the same compound, but formed from the precipitate’s decomposition.  It
therefore was synthesized as part of a more complex substance in 1955, and as a
separate substance in 1959.  Koeppel, Leo H. Sternbach,28-31.
tidying up lab space to set up new projects, Sternbach sent two compounds, synthesized
years earlier, to Lowell Randall in the Pharmacology Lab.594  Why he did not submit them
earlier remains an open question.  Roche might be cutting their losses at the lab, but at least
testing might produce a publishable paper or two.  Sternbach’s colleague Earl Reeder asked
“Shouldn’t we test these compounds?”595  They sent the substances off for testing and within
a few days received a note from Lowell Randall, calling the compound “interesting[.]”596
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597  Possibly the focus on synthesis as discovery relates to requirements of the
patent system.  Compounds could be patented, proof of utility could not.  Date of
synthesis, being earlier than date at which efficacy was established, helped establish
priority.
598  Based on published articles in Journal of Pharmacology and Experimental
Therapeutics, Randall moved up the ranks in the Experimental Research Laboratories
of Burroughs Wellcome & Company in the United States; between 1940 and 1942
publications listed him as third or fourth author, by 1943 he ranked position as either
the first or second author.  He tested compounds linked to later concepts of
tranquilizers, such as modification of epinephrine and amine oxidase inhibition. Axel
M. Hjort, Edwin J. DeBeer, and Lowell O. Randall, “Experiences with the Biological
Assay of Several Sympathicotonic Substances Including Epinephrine,” Journal of
Pharmacology and Experimental Therapeutics 71 (1941): 105-13;  Axel M. Hjort,
Edwin J. DeBeer, Johannes S. Buck, and Lowell Randall, “Relative Pharmacological
Effects of 2,2-dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochlorides,” Journal of
Pharmacology and Experimental Therapeutics 76 (1942): 71-74; Axel M. Hjort, Edwin
J. DeBeer, Johannes S. Buck, and Lowell O. Randall, “Relative Pharmacological
Effects of 2-alkyl-1,2,3,4-tetrahydroisoquinoline hydrochlorides,” Journal of
CHAPTER 6. THE MOUSE THAT ROLLED.
FROM DIAZEPAM TO VALIUM™:
TESTING THEORIES AND FINDING USES
Most existing histories of the ‘discovery’ of Valium focus on Leo Sternbach’s role.597 
However, there is an essential connection between synthesis of the compound and
identifying diazepam as potentially useful, and useful in novel ways.  The connection
resulted from the battery of screening tests used by Lowell O. Randall in the Roche
pharmacology labs, followed by clinical testing by outside physicians.  Randall earned a
Ph.D. in biochemistry at the University of Rochester.  After four years working for the state
of Massachusetts, he moved on to Burroughs-Wellcome,598 then five years later to
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Pharmacology and Experimental Therapeutics 76 (1942): 64-72; Axel M. Hjort, Edwin
J. DeBeer and Lowell O. Randall, “Relative Pharmacological Effects of 3-methyl-3,4-
dihydro- and 3-methyl-1,2,3,4-tetahydroisoquinoline Derivatives,” Journal of
Pharmacology and Experimental Therapeutics 76 (1942): 258-262; Lowell O. Randall
and George H. Hitchings, “Effect of Tyrosinase on Phenethylamine Derivatives,”
Journal of Pharmacology and Experimental Therapeutics 81 (1944): 77-83; Lowell O.
Randall, “Oxidation of Phenethylamine Derivatives by Amine Oxidase,” Journal of
Pharmacology and Experimental Therapeutics 88 (1946): 216-20; Axel M. Hjort,
Lowell O. Randall, and Edwin J. DeBeer, “The Pharmacology of Compounds Related
to β-2,5-dimethoxy phenethyl amine: I. The Ethyl, Isopropyl and Propyl Derivatives,”
Journal of Pharmacology and Experimental Therapeutics 92 (1948) 283-90.
599 Mary Ellen Bowden, Amy Beth Crow, and Tracy Sullivan, Pharmaceutical
Achievers: The Human Face of Pharmaceutical Research (Philadelphia, PA: Chemical
Heritage Press, 2003), 122-24.
600  Hans Conrad Peyer, Roche: A Company History, 1896-1996 (Basel,
Switzerland: Editiones Roche, 1996), 172.
Hoffmann-La Roche.  Both major pharmaceutical firms put him to use in pharmacological
testing.  By 1957, he headed the pharmacology lab that tested compounds developed by
Sternbach’s team.599  Randall’s position involved overseeing administration of
pharmacological tests for various psychotropic development projects.  He worked with Dr.
Alfred Pletscher in the 1950s development of mono amine oxidase inhibitors (MAOI), an
enzyme modifying group of antidepressants.600  
In 1951, Lowell Randall and his colleagues at Hoffman- La Roche were already
looking at compounds which, a few years later, they might have considered tranquilizers.  In
an article titled “The Adrenergic Blocking Action of Some Dibenzepine Derivatives[,]” they
reported results of studies on one of a series of eighteen dibenzepine derivatives.  The
pharmacologists identified drug Ro-2-3248 the most promising member of the series because
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601  Lowell O. Randall and T. H. Smith, “The Adrenergic Blocking Action of
Some Dibenzepine Derivatives,” Journal of Pharmacology and Experimental
Therapeutics 103, no.1 (1951): 10.
602  Randall’s earliest articles based on research at Roche focused on the
sympathetic nervous system, modified antibiotics (paralleling the research program
leading to mephenesin), ganglionic blocking agents (meprobamates fell into this
category), modified narcotics, adrenalin blockers, antispasmotics, and curare or anti-
curare agents (muscle tension related).  G. Lehmann and Lowell O. Randall,
“Pharmacological Properties of Sympathomimetic Diamines,” Journal of
Pharmacology and Experimental Therapeutics 93 (1948): 114-25; Lowell O. Randall
and G. Lehmann, “Pharmacological Studies in Analgesic Piperidine Derivatives,”
Journal of Pharmacology and Experimental Therapeutics 93 (1948): 314-28; E.
Grunberg, Lowell O. Randall and R. J. Schnitzer, “The Chemotherapeutic and
Pharmacological Properties of the L-Ephedrine Salt of Penicillin G (Tersavin),” Journal
of Pharmacology and Experimental Therapeutics 95 (1949): 336-48; Lowell O.
Randall, William G. Peterson, and G. Lehmann, “The Ganglionic Blocking Action of
Thiphanium Derivatives,” Journal of Pharmacology and Experimental Therapeutics 97
(1949) 48-57; Lowell O. Randall and G. Lehmann, “Pharmacological Properties of
Some Neostigmine Analogs,” Journal of Pharmacology and Experimental Therapeutics
99 (1950): 16-32; Lowell O. Randall and G. Lehmann, “Analgesic Action of 3-
hydroxy-n-methyl morphinan hydrobromide (Dromoran),” Journal of Pharmacology
and Experimental Therapeutics 99 (1950): 163-70; Lowell O. Randall, “Anticurare
Action of Phenolic Quaternary Ammonium Salts,” Journal of Pharmacology and
Experimental Therapeutics 100 (1950): 1-5, 83-93; Lowell O. Randall and Thomas H.
Smith, “The Adrenergic Blocking Action of Some Dibenzepine Derivatives,” Journal
of Pharmacology and Experimental Therapeutics 103(1951): 10-23; Lowell O. Randall,
Wilbur M. Benson, and Paul L. Stefko, “Spasmolytic Action of Bicyclic Basic Alcohol
Esters,” Journal of Pharmacology and Experimental Therapeutics 104 (1952): 284-90;
Lowell O. Randall, “The Conversion of Decamethonium-Like Agents to Tensilon-
Reversible Agents by Aromatic Substituents,” Journal of Pharmacology and
Experimental Therapeutics 105 (1952): 16-26; Lowell O. Randall, “Synthetic Curare-
like Agents Which are Reversible by Tensilon,” Journal of Pharmacology and
Experimental Therapeutics 105 (1952) 7-15. 
of its “maximal adrenergic blocking action[;]”601 it appears Roche was already looking at
drugs which effectively served as tranquilizers by blocking adrenal feedback mechanisms
associated with Hans Selye’s General-Adaptation-Syndrome.  Yet Randall and his
colleagues did not refer to these compounds as tranquilizers.602
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603  For a list of characteristics considered common to tranquilizers see p. 499 of
J. Delay and P. Denneker, “Caractéristiques Psycho-Physiologiques Des Médicaments
Neuroleptiques,” in Psychotropic Drugs, eds. S. Garattini and V. Ghetti (New York:
Elsevier Publishing Company, 1957), 485-501.  Note these characteristics are those
associated with compounds later termed major tranquilizers, such as chlorpromazine,
rather than minor tranquilizers, such as Valium.
The term tranquilizer became associated in the early 1950s with compounds such as
chlorpromazine and reserpine, which had a deeply sedating action, causing tranquillization
of highly agitated patients.  It referred to substances which were central nervous system
depressants, but those with a broad spectrum of action, usually including sedation at high
doses.  These substances gained notice within the American psychiatric profession,
especially among hospital administrators in the mid-1950s, after publication of Randall’s
article on Dibenzepine derivatives.  Because the popular press brought use of major
tranquilizers in institutional psychiatry to the public’s attention, pharmaceutical
manufacturers chose to market products such as diazepam (Valium) as minor tranquilizers,
drugs treating milder mental illnesses by tranquilizing without sedating.  Advertising and
professional medical literature often treated minor tranquilizers as milder versions of
compounds like chlorpromazine.603  
Use of the term ‘blocking action’ by Randall and colleague T. H. Smith, to describe
their debenzapine derivatives, is significant because of similarity to descriptions of
meprobamate’s mechanism of action.  G. Mengoli and G. Maccagnani, who tested
meprobamate in an Italian provincial psychiatric hospital, considered it settled knowledge
that the drug acted “on the central nervous system by blocking the interneuronic synapses
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604  G. Mengoli and G. Maccagnani, “Laboratory and Clinical Observations on a
Group of Psychiatric and Neurological Patients Treated with Meprobamate,” in
Psychotropic Drugs, eds. S. Garattini and V. Ghetti (New York: Elsevier Publishing
Company, 1957), 561-562, 561. 
605  Frederick F. Yonkman, “Sympathetic Blocking Agents,” Annual Reviews of
Medicine 7 (1956): 195.
606  Randall and Smith, Adrenergic Blocking Action, 10-23; In 1960 he
published a study similar to his work on diazepam, but looking at meprobamate’s
effects on aggression, activity, and conditioned avoidance behavior.  Lowell O. Randall,
William Schallek, George A. Heise, Eaden F. Keith, and Robert E. Bagdon, “The
Psychosedative Properties of Methaminodiazepoxide,” Journal of Pharmacology and
Experimental Therapeutics 129 (1960): 163-71; Randall and Smith, Adrenergic
Blocking Action of Some Dibenzapine Derivatives, 10-23.
selectively, particularly on a level with the thalamus and the caudate nucleus.”604  Blocking
agents that acted on the sympathetic nervous system were usually termed adrenergic
blocking agents.  In hindsight, the link between these substances and other
psychopharmaceuticals appears obvious.  Adrenergic blocking agents included those
affecting two major neurotransmitter types, “epinephrine [adrenalin] and norepinephrine in
particular[,]” as well as any substance blocking their action or distribution.605  They
interfered with the anxiety feedback loop.
Already immersed in development of methods to screen new muscle relaxant and
adrenal blocking compounds, and compare them to existing ones,606 Randall knew how to
assess the potence of tranquilizers, muscle relaxants, sedatives, and hypnotics.  At least as
important, he knew some procedures tested the usefulness of potential drugs, others tested
theories.  Screening tests identified potentially useful compounds, theory testing provided
leads in development of new and more accurate measurements.
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607  Neal E. Miller, “Objective Techniques for Studying Motivational Effects of
Drugs on Animals,” in Psychotropic Drugs, eds. S. Garattini and V. Ghetti (New York:
Elsevier Publishing Company, 1957), 83-103, 91.
For use at Roche, screening methods needed to be efficient financially and
temporally, provide a yes or no answer whether the compound should continue down the
testing pipeline, and do so by testing properties easily observable and associated with the
drug’s intended purpose.  Long-term studies of animals with induced neuroses were not
feasible because hundreds, if not thousands, of compounds needed screening each year. 
However, induced neurosis experiments informed simpler, faster, tests because they
identified easily observable factors, which in turn appeared to identify neurotic reactions and
states.  For pharmacologic tests to be viable they had to use small animals.
Pharmacologists could not directly test tranquilizing effects; these were experiences
or sensations whose observable features included well-known side effects of other effective
tranquilizers.607  Randall began with a simple mouse-based test for muscle relaxation and
speed of response, a test for avoidance of conditioned stimuli, and a simple test for reflex
responses.  Each test was quick.  They identified properties already associated with
tranquilizers and early identification of neuroses, and were quantifiable.
Pharmacological Testing of Diazepam
The first published pharmacology reports for diazepam (Valium) and
chlordiazepoxide (Librium) show use of a similar battery of tests used to compare toxicity
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608  L. O. Randall, “Pharmacology of Methaminodiazepoxide,” Diseases of the
Nervous System 21, section 2, suppl. 3 (1960): 7-10; L. O .Randall, G. A. Heise, W.
Shallek, R. E. Bagdon, R. Banziger, A. Boris, R. A. Moe and W. B. Abrams,
“Pharmacological and Clinical Studies on Valium™ a New Psychotherapeutic Agent of
the Benzodiazepine Class,” Current Therapeutic Research 3 (September 1961): 405-25.
609  Results of the initial pharmacological tests were published as a ‘Therapeutic
Monograph’ in the journal Clinical Therapeutic Research.  Randall et al,
Pharmacological and Clinical Studies on Valium, 405-25.
610  George A. Ulett, Anton Heusler and Joseph Callahan, “Objective Measures
in Psychopharmacology (Methodology),” in Neuro-Psychopharmacology: Proceedings
of the Second Meeting of the Collegium Internationale Neuro-Psychopharmacologicum
(Basle, July 1960), ed. E. Rothlin (New York: Elsevier, 1961), 401-09.
611  Miller, Objective Techniques, 91; Use of a battery of tests for tranquilizers,
with muscle relaxant and taming effects.608  In both cases, the pharmacologists observed
effects of these drugs on mice trying to keep their footing on an inclined screen (the mouse
roll test) and when placed in conditions designed to make them fight.  The scientists tested
how well the drugs blocked induced seizures.  They studied muscle relaxation and EEG
patterns in cats, while rats provided a biological tool to identify changes in overall activity
level, and capacity to mitigate physically caused aggressive behavior.  The battery of tests
provided information on the expected effects of a tranquilizer: reduction of tension, activity,
or aggression, whether it caused problems of coordination, affected convulsion threshold,
caused changes in conditioned avoidance behavior, and if it had an effect on the physical
brain as well as behavior.609  The tests established differences from existing tranquilizers,
including barbiturates, information useful to decide if the drug had strong marketing
prospects.610  Employing a battery of tests, the scientists could “cross-check” results by using
“a variety of diverse techniques.”611
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“to establish each new drug’s range of action compared to other similar agents[,]” was
normal in the late 1950s.  Ulett, Heusler and Callahan, Objective Measures in
Psychopharmacology, 401; For a contemporary explanation of the need for test batteries
in dealing with tranquilizers, see R. Wein, “Experimental Methods of Examining
Tranquilising Agents,” in Psychotropic Drugs eds. S. Garattini and V. Ghetti (New
York: Elsevier Publishing Company, 1957), 369-70.
612  The assumption being that risk of death was linear or exponential with
increased dose.
613  Randall et al., Pharmacological and Clinical Studies on Valium, 405-25.
Published results on diazepam (Valium) focused on distinguishing how this drug
differed from the already marketed Roche benzodiazepine, chlordiazepoxide (Librium). 
Proof of basic efficacy was not the issue, diazepam was a derivative of chlordiazepoxide
(Librium), therefore assumed also useful.  Overall, Randall’s research approach was to
compare the dose at which the drug produced an effect in fifty percent of cases.  
The ratio of effective dose50 for a task (ED50) to lethal dose50 (LD50) was a quick
measure of risk that effects would occur at a dosage similar to that causing life-threatening
danger.612  The results were numerical; ratios of the ED50 for diazepam compared to that of
Librium allowed the Roche pharmacologists to assert Valium was “5 times as potent as
Librium as a tranquilizer and muscle relaxant in animals and 10 times as strong as an
anticonvulsant.”613  That the point of comparison for the effective and lethal dose was that at
which there was a fifty percent response, suggests a typically mid-twentieth century
assumption that psychotropic drugs were rarely effective in the vast majority of cases; there
might not be an ED90 to find.
The use of an LD50 also fits with an assumption that lethality of tranquilizers came
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from suppression of central nervous system responses, including respiration, and that risk of
death rose suddenly and sharply with increased dosage.  Contemporary research justified
pharmacologists seeing a spectrum of behavior associated with depression of the central
nervous system as they increased dosage of tranquilizers, from effects on more complex
reasoning, to more dramatic effects on the brain including sedation, followed by induction of
sleep, coma, and with high enough doses, death.  Tranquilization was a stage on a continuum
of action.  The LD50 identified the dosage at which half the study group died, while those
remaining presumably suffered a lesser rate of central nervous system suppression or
depression, probably resulting in sleep, sedation, or some form of tranquilization.  By
comparing the ED50 with the LD50, Roche’s pharmacology team showed two points on this
spectrum of action.  Wider difference in dosage between the two measures suggested a safe
dosage range at which the drug had desirable properties.
Randall and his colleagues studied most of diazepam’s effects at six or fewer dosage
levels, signaling the experimenters’ assumptions of great individual variation, and that the
drug interacted with the body as a whole.  Tight gradation between dosages made sense if the
experimental population’s responses were fairly uniform; using a small number of dosage
levels suggests the experimenters had preexisting expectations of the effective dosage level
and they expected individual variation too great for a tighter gradation of dosages to show
‘real’ results.  The pharmacologists measured dosage based on the animal’s weight rather
than a per animal dosage, suggesting they thought results showed a drug’s interaction with
the body as a whole.  Whether the important effects resulted from interaction between drug
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614  Marcel Monnier, “Topic Action of Psychotropic Drugs on the Electrical
Activity of Cortex, Rhinencephalon and Mesodiencephalon : (Excitement,
Tranquilization, Sedation and Sleep), “ in Psychotropic Drugs, eds. S. Garattini and V.
Ghetti (New York: Elsevier Publishing Company, 1957), 217-34
and body, or drug and brain with the body, is not clear.  In either case, fixing dosage by total
weight heightened the difference between amounts given to individuals in the study group;
dosage based on extrapolated brain weight or size subjected the results to greater error and
resulted in lesser differences between doses given.  The choice to use a small number of
dosage levels, each based on body mass, tied to underlying assumptions that individuals
varied widely in mental and behavioral responses to drugs having a physical interaction with
the body and/or brain.
The battery of tests Randall used to show the compound promising enough to begin
clinical trials illustrates how he expected tranquilizers to act.  He assumed a relationship
existed between muscle relaxation, rate of response, the capacity to learn or unlearn
avoidance behaviors, and anticonvulsant properties; phenobarbital affected each.  Both EEG
patterns and nocturnal activity levels of mice gave insight into effects of a drug on alertness;
chlorpromazine (Thorazine) altered both.  EEG (electroencephalograph)  patterns differed
between individuals on major versus minor tranquilizers.614  Medical professionals already
knew barbiturates and alcohol caused a mixture of agitation and sedation; they referred to
these results as paradoxical.  Technicians could incite aggression in more than one way, for
example by creating physical lesions in the brain, or putting mice into environments
designed to induce conflict; meprobamates altered aggression.  Tests focused on more than
one area of the brain; psychopharmacologists believed minor tranquilizers affected fewer and
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615  Randall, Pharmacological and Clinical Studies on Valium, passim.
616  Randall, Pharmacological and Clinical Studies on Valium, 407.
617  Miller, Objective Techniques, 92.
more specific areas of the brain and nervous system than did major tranquilizers and
barbiturates.615
The tests chosen did not identify all testable effects of tranquilizers; Randall chose
procedures to identify responses he considered indicative.  Large doses of tranquilizers
usually put patients to sleep.  Physicians often prescribed them for conditions barbiturates
had earlier treated, for example as sleep aids.  Yet Randall and his colleagues did not directly
test the hypnotic properties of benzodiazepines; the most relevant test involved the nocturnal
activity of rats.  They tested activity during a period when the animals were most alert,
therefore testing reduction of alert behavior rather than induction of sleep.616  Roche
pharmacologists chose and adapted tests thought appropriate for their needs.
Randall and his colleagues sought to identify potential tranquilizers, then distinguish
them from similar drugs.  The wide range of phenomena studied, in establishing the basic
pharmacological properties of diazepam through animal tests, suggests the broad scope of
ideas such as psychosomatic disorders and the hypnotic-sedative-tranquilizer spectrum. 
They could test for variety of observable actions.  Tranquilizers presumably affected a group
of symptoms; as Yale Psychologist Neal E. Miller phrased it, “Fear, anxiety, guilt, tension,
and worry seem to form a related cluster and probably involve certain physiological
mechanisms in common.”617  Potentiation or blocking the effects of barbiturates or
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618  Randall, Pharmacological and Clinical Studies on Valium, 415; this method
of identifying similarities between tranquilizers, based on EEG patterns can also be
seen in P. B. Bradley, “Effects of Drugs on the Electrical Activity of the Brain and
Behavior,” in Psychotropic Drugs, eds. S. Garattini and V. Ghetti (New York: Elsevier
Publishing Company, 1957), 291-92.
619  Randall, Pharmacological and Clinical Studies on Valium, 406-07, 413.
convulsants served as means to show the individuality of diazepam, how its profile varied
from that of potential competitors.  By establishing how a cat’s EEG pattern differed from
normal, experimenters illustrated diazepam’s place within the spectrum of tranquilizers; cats
on diazepam produced patterns similar to those produced by chlordiazepoxide (Librium).618 
Results of earlier experiments suggested a relation between EEG frequency patterns in the
cortex, hippocampus, amygdala, and septum and sedation.  Higher doses of sedative-
tranquilizers produced greater change in the brain’s electrical patterns, coincident with
inducing sleep.619  Muscle relaxation, sedation, reduction of anxiety, tension, and need to
move, all inhibition of action, resulted from depressing parts of the central nervous system. 
With increased knowledge of the differential effects of drugs in specific areas of the brain,
the results of these tests suggested a slightly different mode of action in diazepam and
chlordiazepoxide (Librium) compared with existing tranquilizers.  Reduction in avoidance
response, and changes in creation or extinction of learned patterns of behavior, went hand in
hand with studies of aggression.  All studied different forms of altering the link between
stimulus and response.  No matter whether you studied the effects in complex behaviors or
near mechanistic responses, they were part and parcel of studying a drug used in treating
psychosomatic disorders.
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620  Erik Jacobsen, “The Effect of Psychotropic Drugs Under Psychic Stress,” in
Psychotropic Drugs, eds. S. Garattini and V. Ghetti (New York: Elsevier Publishing
Company, 1957), 119-24, 120.
621  Jacobsen, Effect of Psychotropic Drugs Under Psychic Stress, 122.
622  Jacobsen, Effect of Psychotropic Drugs Under Psychic Stress, 121.
623  For example see Harold E. Himwich, “Psychopharmacologic Drugs,”
Science n.s. 127, no. 3289 (1958): 59-72.
624  J. D. French, “Psychopharmacology,” Annual Reviews of Medicine 9 (1958):
Randall’s battery of tests did not evaluate simple CNS depressant properties;
contemporary theories suggested existing tranquilizers depressed different parts of the CNS,
possibly through localized effects, selective repression, or action in areas of the brain
associated with more or less complex mental processes.  Dominant medical theory suggested
chlorpromazine (Thorazine) and reserpine had a wide scope of physical actions in the brain,
as a result “simply an increasing stupor[.]” 620  Alcohol affected a constellation of behaviors,
disinhibing some (reducing repression), inhibiting conditioned behaviors, and usually
decreasing tension.621  Meprobamate appeared to normalize behavior; it did not alter feeding
behavior, yet reduced anxiety caused by conflict situations or environmental alteration, but
without producing sluggishness or stupor.622  
In the late 1950s, focus on the central brain stem was a hot new topic.623  Researchers
previously thought it only had effects on basic bodily processes.  However, researchers such
as S. Margolin now “identified [it] as the seat of the principal integrating system of the brain,
which by virtue of its manifold functions and widely dispersed ramifications, has come to be
known as the ‘unspecific’ Reticular Activating System (RAS).”624  The concept of an
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625  E. J. Fellows and L. Cook refer to the “complex mechanisms” involved in
tests of motor coordination, such as climbing a pole.  E. J. Fellows and L. Cook,  “The
comparative Pharmacology of a Number of Phenothiazine Derivatives,” in
Psychotropic Drugs, eds. S. Garattini and V. Ghetti (New York: Elsevier Publishing
Company, 1957), 397-404, 398; G. L. Gatti and M. Frank, “The Technique of the ‘Pole
Climbing Response’.  Effect of Various Types of Drugs on the Latency-Period and
Flight Reaction of the Rat,” in Neuro-Psychopharmacology: Proceedings of the Second
Meeting of the Collegium Internationale Neuro-Psychopharmacologicum (Basle,
Switzerland, July 1960), ed. E. Rothlin (New York: Elsevier, 1961), 147-50; Leonard
Cook and Roger T. Kelleher, “The Interaction of Drugs and Behavior,” Neuro-
Psychopharmacology: Proceedings of the Second Meeting of the Collegium
Internationale Neuro-Psychopharmacologicum (Basle, Switzerland, July 1960), ed. E.
Rothlin (New York: Elsevier, 1961), 77-92.
ascending level of integration from perception of stimuli to understanding, knowledge, or
thinking, helped explain the range of behavioral effects found in tranquilizers.  Published
articles associated chlorpromazine use with a constellation of side effects, usually termed
extrapyramidal, explicable by assuming the drug acted on the brain stem, and therefore
affected more systems than the more physically and behaviorally targeted minor
tranquilizers.  Association of the RAS with arousal, (sleep to fully awake), sorting of sensory
stimuli (possibility of overstimulation, stress responses) and emotional regulation (anxiety),
proved a mechanism for explaining the hypnotic/sedative/tranquilizer spectrum of action.
The mouse roll test was similar to established methods for assessing effects on
complex and interacting systems of mental and muscle coordination by testing reaction
speed and coordination in escape from painful stimuli.625  Randall and his associates took
three groups of rats and gave each a different dose of diazepam.  Roche labs had previously
used this test in studies of chlorpromazine, meprobamate (Miltown), and other existing
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626  L. O. Randall, “Pharmacology of Methaminodiazepoxide,” Diseases of the
Nervous System 21, section 2, suppl. 3(1960): 7-10; Research at other laboratories,
using nearly identical methods allowed comparison with mephenesin.  Thomas B.
O’Dell, Loretta R. Wilson, Martha D. Napoli, Harold D. White and Joseph H. Mirsky,
“Pharmacology of a Series of New 2-substituted Pyridine Derivatives With Emphasis
on Their Analgesic and Interneuronal Blocking Properties,” Journal of Pharmacology
and Experimental Therapeutics 128, no. 1 (1960): 65-74. 
tranquilizers; preexisting information paved the way for comparison of results.626  The
pharmacologists lowered dosed mice onto a thirty degree inclined screen.  Whether a mouse
rolled off or kept his footing produced the discrete data necessary to identify one of three
doses as the ED50.  When the mouse rolled, it suggested the pharmaceutical dose interfered
with rapid adjustment of muscle response.
The ED50, identified by the mouse roll test, was a combination of ingenious methods
and quantitative reduction forced by exigencies of experimental conditions.  In a simple
laboratory test, Randall and his colleagues produced a quick and dirty assessment of
potential tranquilizers.  Ideally, a drug showed an effective dose substantially below the
lethal dose; if the effective dose was significantly smaller than the lethal, the drug was worth
further assessment because it could produce muscle relaxation or incoordination without risk
of death.  The LD50 of diazepam was over 700 mg/kg, but it took only 25 mg/kg to make half
the mice roll.  It took 100 mg/kg of Librium to produce the same results (ED50).  Yet,
because they examined only three dosages of diazepam, the investigators could only show an
effective dose within a broad range.  With sample groups of six mice, individual variation
could easily change the result; one mouse more or less shifted a dosage from the ED50 to the
ED34.  One mouse-sized toenail, stuck in a screen, would significantly change the results. 
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first and more telling procedures.
628  Leonard Cook and Edwin Weidley, “Behavioral Effects of Some
Psychopharmacological Agents,” Annals of the New York Academy of Sciences 66, no.
3 (1957): 740-52, 746.
629  Early research on chlordiazepoxide (Librium) also referred to the compound
as methaminodiazepoxide or Ro 5-0690.
630  Randall, Pharmacology of Methaminodiazepoxide, 7-10; at the time the
‘rotorod’ provided a more common test of incoordination in mice.  Quantification
occurred by counting the number of mice falling off a rod rotating along a horizontal
axis at a regulated speed.
Reporting the results in quantitative form, without suggesting a range, gave an air of
certainty far beyond the actual results. 
Sternbach’s recollections suggest results of the mouse roll was the most important
test in showing his compounds were promising.627  The reason is simple.  Excluding the
barbiturates, meprobamates (Miltown, Equanil) were the main existing competition.  The
mouse roll test illustrated a major difference between Sternbach’s compounds and Miltown. 
Mice on meprobamate, wanting to escape an electrified floor by climbing a rod, did not have
sufficient muscle control.  Changed response to punishment appeared to occur at the same or
a higher dose as that causing lack of muscle control.628  Pharmacologic testing for
diazepam’s sister, chlordiazepoxide (Librium),629 showed it reduced muscle tension enough
to cause a mouse to roll, while allowing the rodent enough dignity to walk away from the
embarrassing situation, at least when prodded.630  Chlordiazepoxide (Librium) and
diazepam’s actions were more selective.
For a more direct link showing diazepam’s muscle relaxant properties, Randall and
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631  Randall, Pharmacological and Clinical Studies on Valium, 406; similar tests,
with inconclusive results, were performed at other labs in order to establish muscle
relaxant properties of mephenesin and other muscle relaxants.  Adolph P. Roszkowski,
“A Pharmacological Comparison of Therapeutically Useful Centrally Acting Muscle
Relaxants,” Journal of Pharmacology and Experimental Therapy 129 (1960): 75-81.
his laboratory colleagues turned to more controlled studies in cats; they tested reduction of
decerebrated cats’ muscle rigidity up to four hours after ingesting diazepam.  Knowing
removal of a cat’s cerebral cortex resulted in rigidity of limbs, spine, and tail, the
pharmacologists could more directly study the relationship between drug and body; they
isolated a portion of the brain, and removed the intervening variables of personality, social
and environmental interactions.  The researchers scored cats on a scale from zero to three for
each joint of the limbs, spine, and tail, with 0 identifying “complete relaxation[.]”631 
Tellingly, these pharmacologists recorded the range within the study group, again suggesting
they expected individual variation even with an animal’s learned responses surgically
excised.  Yet, ultimately, it was the maximum change they sought to identify.  They graphed
maximum reduction in rigidity at various dosages, and interpolated to identify a dose
reducing rigidity by half.  That was the identified ED50.  Even more than with the mouse roll
test, quantitative result covered assumptions with a veneer of statistical objectivity.  
A similar set of experiments studied aggression with or without the possibility of
behavior forming an intervening variable.  In general, these tests used numerical scores to
quantify observations of qualitatively different behavior.  Naturally aggressive animals
became tame, violently competitive mice learned to live together in semi-harmony, and
surgically induced nastiness was mitigated.  
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632  Randall, Pharmacological and Clinical Studies on Valium, 410.
633  Randall, Pharmacological and Clinical Studies on Valium, 410.
634  Randall, Pharmacological and Clinical Studies on Valium, 410.
635 Randall, Pharmacological and Clinical Studies on Valium, 410; The second
edition Van Nostrand’s Scientific Encyclopedia defines ataxia as “Lack of muscular
coordination due to disease of the brain, particularly the cerebellum, or spinal cord.”
Leo A. Aroian, Howard C. Colton, Charles W. Cunningham, Richard M. Field, Warren
Using “[c]onsistently vicious”632 Macaque monkeys, members of the laboratory
created a measurement called the “Depressant M.E.D.” or median effective dose, which they
considered a measure of the drug’s potency as a CNS depressant.633  Randall’s statement that
“A blind procedure was not used” in this portion of the testing, is an understatement
considering that, as well as observing activity through a one-way mirror, members of the
laboratory team assessed aggression in terms of “behaviors specifically directed at the
experimenter, such as forward lunge, baring teeth, attacking handler’s glove.”634  They
sought to find the minimum dose reducing activity and aggression to seventy-five percent of
the baseline score.  Comparing dose necessary to reduce aggression by seventy-five percent,
to that producing a similarly large decrease in activity, provided a quick and tidy numerical
measurement of dosage range between effectiveness as a tranquilizer and as a sedative.  
Determining an appropriate level of aggression mitigation for tranquilizers was
subjective but relatively obvious for experimenters at risk of primate-created punctures. 
When the aggression to activity ratio was roughly 1:2 these primates behaved like tame
creatures, they “failed to retaliate when handled or poked,” but at the same time were “not
appreciably sluggish or ataxic.”635  Diazepam proved an improvement over chlordiazepoxide
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Lindsey, D. E. Mack, Bernard S. Meyer, Frederick T. Morse, R. Sterling Mueller, C. B.
Neblette, L. R. Quarles, Lloyd L. Smail, Edward S. C. Smith, Ralph K. Strong, Silas M.
Thronson, LeRoy D. Weld and R. M. Whelden, contributing editors, Van Nostrand’s
Scientific Encyclopedia, second edition (New York: D. Van Nostrand Company, Inc.,
1947), 122.
636 Randall, Pharmacology of Methaminodiazepoxide, 8; Randall used a less
quantified test of taming in cats.  Librium, he discovered “causes muscular relaxation
and quieting.  At a dose of 10 mg/kg orally, the cat hangs limply and without struggling
when held by the scruff of the neck.... (mean cats became amenable to handling and
became contented, sociable and playful.” Ibid, 9.
637  Stata Norton, “Behavioral Patterns as a Technique for Studying Psychotropic
Drugs,” in Psychotropic Drugs, eds. S. Garattini and V. Ghetti (New York: Elsevier
Publishing Company, 1957), 81-82, 81.
638  The isolation induced fighting method was associated with P. Janssen, the
(Librium) in this situation, which in turn worked more effectively than meprobamate,
chlorpromazine, or phenobarbital; “Monkeys...did not fight back when teased; under the
other drugs they continued to retaliate until motor depression rendered them incapable[.]”636
To study aggressive social behavior, the researchers required more than one situation
and species; extant publications illustrated differences in behavioral responses to drugs.  On
methamphetamine, cats became both aggressively and defensively hostile; hamsters were
only defensively hostile.  In contrast, hamsters on LSD tended towards contentment, whereas
cats definitely did not.637  To test diazepam, Randall and his team used well established
methods.  They placed pairs of mice in conditions designed to make them fight, then
attempted to find the dose of a drug which ‘tamed’ half of the pairs.  Traditionally, scientists
induced aggression through previous conditions of isolation (lack of social stimulus) or
electrical shock (adverse environment).638  The goal was identification of a drug dose that
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Male Mice,” Journal of Pharmacology and Experimental Therapeutics 129 (1960):
471-75; R. E. Tedeschi, D. U. Tedeschi, A. Mucha, I. Cook, P. A. Maltis and E. J.
Fellows, “Effects of Various Centrally Acting Drugs on Fighting Behavior of Mice,”
Journal of Pharmacology and Experimental Therapeutics 125 (1959): 28-34; Other
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Scriabine and M. Blake, “Evaluation of Centrally Acting Drugs in mice with Fighting
Behavior Induced by Isolation,” Psychopharmacologia 3 (1962): 224-26.
639  Randall, Pharmacological and Clinical Studies on Valium, 406.
640  Norton, Behavioral Patterns, 73.
produced lack of fighting, a more appropriate social behavior.639  Again, this was an effort to
identify doses of diazepam and other drugs improving capacity to interact with others.  By
studying patterns of social or antisocial behavior, Randall and his colleagues could quantify
behavior in ‘natural’ settings because, as Stata Norton of Wellcome’s Research Laboratories
explained “It is axiomatic that behavior occurs in patterns[.]”640 By examining changes in
overall behavior, they could identify ‘tame’ or positive social behaviors.
To test physically caused aggression, arguably more definitively separate from
personality, Randall’s team surgically created lesions in the septal region of rats’ brains,
modifying the physical brain to create rodents prone to violence with little prodding.  As
with the cat-rigidity experiment, they created behavior through localized destruction of the
physical brain.  The test examined the extent to which tranquilizers, including diazepam,
brought the animal closer to normal patterns of environmental interaction.  Surgically created
vicious rodents responded aggressively to pesky interactions with the fascinated scientists. 
Using a scale that rated response from zero to four, with higher numbers denoting more
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violent reaction, laboratory technicians examined response under a fixed series of situations
including, “blowing air on back...touching whiskers with stick...prodding back with
stick...picking up tail with forceps and lifting rat off the floor.”641  Drug evaluation involved
comparing baseline measures with those at three to five other dosage levels.  Once the team
established baseline responses, the reactive rodents were dosed and retested half an hour, one
hour, and two hours later.  They tallied the numerical scores rating each rat’s response at
these periods, and used the mean for all rats used to compare dosage levels to response when
dosed with saline (rat placebo).  Connecting the dots, the five points represented a decrease
in aggression at ascending dosages of diazepam; Randall and his colleagues extrapolated to
find an ED50, “the dose reducing the score to half the value following saline injection.”642
Using these two experiments, the fighting mouse test and aggression in septal rats,
the team at Roche’s pharmacological laboratory produced numerical evidence of diazepam’s
capacity to reduce violent antisocial behavior.  They could compare results for multiple
drugs, establishing how diazepam was different from, and hopefully an improvement on,
previously marketed compounds.  They could compare results in numerical format, which to
positivist scientists appeared more objective and trustworthy than descriptive evidence.
Having tested effects on muscle tension and aggression, Randall and co-workers
moved on to study anxiety and learning.  Physicians interested in somatic treatments
generally accepted tranquilizers’ usefulness for treating abnormalities of behavior
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Psychotropic Drugs, eds. S. Garattini and V. Ghetti (New York: Elsevier Publishing
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644  For discussion illustrating how self-professed Pavlovians saw conditioned-
response drug experiments see W. Horsley Gantt, “Discussion Second Symposium, (a)
Discussions by Invitation, W. Horsley Gantt,” in Neuro-Psychopharmacology:
Proceedings of the Second Meeting of the Collegium Internationale Neuro-
Psychopharmacologicum (Basle, Switzerland, July 1960), ed. E. Rothlin (New York:
Elsevier, 1961), 124-25; see also Andrzej Jus, “Discussion Second Symposium, (a)
Discussions by Invitation, Andrzej Jus,” in Neuro-Psychopharmacology: Proceedings
of the Second Meeting of the Collegium Internationale Neuro-Psychopharmacologicum
(Basle, Switzerland, July 1960), ed. E. Rothlin (New York: Elsevier, 1961), 125-31.
(sometimes manifest through somatic problems), possibly because the drugs influenced
mediation of the mind’s response to internal stressors or the organism’s environment. 
Therefore part of the test battery focused on fear or anticipation of, and response to, noxious
stimuli.  Avoidance experiments looked at how an individual, in this case of the rodent
variety, behaved when faced with events which were stress producing because they were
unpleasant or unpredictable (noxious stimuli).  In other words, they tested the conditions
under which rats avoided electric shocks.  This provided a means to create ‘psychic stress.’643 
They carried out avoidance experiments on small numbers of rodents, studied individually. 
Randall chose a sequence of three experiments, each in turn expected to identify more
targeted characteristics of CNS depressant drugs, in order to find improvements or
differences between diazepam and similar compounds.
The avoidance experiments’ form relates to behaviorist techniques of the Pavlovian
school as well as later operant conditioning techniques.644  Classical conditioning – capacity
to learn stimulus-response pairs – played an important role in Randall’s screening battery. 
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645  Miller, Objective Techniques, 87.
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647  The test used punishment as a penalty for inaction, making it a form of
avoidance conditioning or a variant of variable-interval tests using reward.  Miller,
Objective Techniques, 87, 94.
The more recent operant conditioning paradigm appears in implicit assumptions of variables
– the animal’s thoughts, expectations, internal mental life – existing between stimulus and
response.  Use of Skinner-type boxes allowed establishment of regular conditions as well as
numerical scoring of responses.645
The first test was one of “non-discriminated” avoidance,646 in which researchers
shocked the feet of rats without any warning.  This tested learning behavior because the
shock came every 40 seconds, if the rat failed to press the correct lever during the
intervening period.  Rats needed to learn preemptive action based on previous experience. 
Then, with rats under influence of tranquilizers, the scientists reexamined changes in learned
behaviors.
Published research already associated certain result patterns with tranquilizers; if rats
responded less frequently, it theoretically indicated lesser preoccupation with impending
pain.647  Tranquilizers typically mitigated or extinguished conditioned avoidance behavior
before affecting the unconditioned response to pain.  A good tranquilizer, therefore, altered
responses such that they were to pain rather than to warnings.  Theoretically, this was a test
of motivational change, “that the drug affects responses motivated by fear more than it does
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example of a similar type of test used to compare effects of multiple
psychopharmaceuticals see William J. Kinnard, Mario D. G. Aceto, and Joseph P.
Buckley, “The Effects of Certain Psychotropic Agents on the Conditioned Emotional
Response Behavior Patterns of the Albino Rat,” Psychopharmacologia 3 (1962): 227-
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650  Randall, Pharmacological and Clinical Studies on Valium, 409.
651  Randall, Pharmacological and Clinical Studies on Valium, 409.
those motivated by pain.”648
The second classical avoidance test, in which the rat heard a distinctive sound
immediately preceding the shock, showed “more specific characterization of the distinctive
actions of different types of depressant drugs[.]”649 Again, basic procedures were well
established and therefore likely to be accepted by the community of pharmacologists as
proof.  In this second procedure, pairing a five-second warning sound with immediately
subsequent shock, the researchers created predictive anxiety in rats.  Rats avoided pain by
associating the warning sound with need to press the lever quickly.  An “avoidance
response”650 referred to success.  When rats failed in avoidance they received shock for up to
five seconds, which they could terminate early by pressing the lever.  If they failed to press
the lever during this five seconds of shock it was a “response failure[.]”651  Establishment of
learned behavior, a baseline, involved establishing avoidance response in ninety percent of
occurrences for each rat.  One reason these tests produced predictive anxiety in the rats was
because the warning noise or shock did not occur at regular, predictable, intervals.  Ideally,
245
652  Randall, Pharmacological and Clinical Studies on Valium, 409.
with a well-functioning tranquilizer, rats would react not during the interval between
warning and shock, but only during the shock period.
To test the active drug, Randall and his colleagues put the trained rodents through
their paces for one hour, after which the creatures received the drug and continued in the test
conditions for one hour, approximately one-hundred and fifty potential jolts.  Randall and his
colleagues attempted to show that although diazepam increased failure to avoid shock,
failure to respond quickly once shock had begun required a substantially higher dose.  In
theory, this illustrated the drugged rats were not anxious but remembered and responded
quickly to terminate pain.
The experimenters tested a handful of doses and extrapolated results through graphs
to find the dose creating avoidance failure in one quarter of trials, and a higher dose
producing failure to respond quickly to shock (response failure) ten percent of the time.  The
pharmacologists assumed median results for all rats (for twenty-five percent avoidance
failure) produced a relevant measure of drug potence in alleviating anxiety about future
events; the ratio of median dose producing ten percent failure to respond with ten percent
failure to avoid measured “the amount of escape responding”652 to noxious external stimuli.
This test of ability to pair stimulus and response, with or without a drug in the
system, provided means of showing difference between tranquilizing and hypnotic dosages
and the drug’s effect on learned behavior, especially learned response to current danger or
pain – ‘noxious stimuli’ – without preoccupation regarding potential dangers.  The
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experimenters found the ratio of response failure to avoidance failure was high in
tranquilizers but lower in barbiturates and other hypnotics.  This suggested tranquilizers were
more suitable in treating nervous disorders because they allowed an organism to still respond
to the external environment (including dangerous situations) while not remaining anxious, in
a heightened state of apprehension.  Those taking the drug could safely interact with their
environment, and did not need the controlled conditions of a hospital or psychiatric
institution.  Learning remained unhindered, predictive stress reduced.  
Similar experiments were performed at other laboratories.  Irving Geller and his
colleagues at Wyeth laboratories, which marketed meprobamate (Miltown), looked at the
effect of tranquilizers, including chlordiazepoxide (Librium), on willingness to accept
punishment in return for food.653  They interpreted the results, that Librium “attenuates the
punishment discrimination”654 while chlorpromazine caused rats to give up food in order to
avoid shocks, as showing clinically important differences between minor (Librium) and
major (chlorpromazine) tranquilizers.   Essentially, the tests at Roche and Wyeth looked at
extinction of learned or conditioned responses to impending, but not currently existing
noxious stimuli.
Testing diazepam, Randall showed the drug produced a response not in anticipation
of pain, but only after experience of pain.  The rats were not as anxious, yet still responded to
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pain; they retained beneficial but not stress-causing learned reactions.  These tests helped
place diazepam within the spectrum of available tranquilizers; effects were similar, but not
the same as other compounds.
Once pharmacologists at Roche studied the drug’s effects on a rat’s capacity to
predict and prevent problems, and ability for heightened alertness to produce fast reactions,
they moved on to assess ability to associate a conditioned stimulus (initial five seconds
warning sound) with shock following an intermediate delay.  This was once again a test of
learning in the Pavlovian sense; it looked at extinction and creation of new patterns, pairing
and re-pairing conditioned stimulus to conditioned response.  Yet, it also fit with newer
operant conditioning theories, because the longer temporal period between stimulus and
response implied reaction might not be automatic, it reflected learning.  As in previous tests
the initial training involved learning, proven by a high rate of association, in this case
ensuring that a rat responded to the initial sound by pressing a lever to avoid shock in ninety
percent of trials.  Rats needed to respond during the initial warning noise, rather than the
silent gap; this was a test of both predicting results (acting ahead of time to avoid pain) and
effects of five seconds of apprehension as rats waited for the shock.
Results refined the scientist’s knowledge of diazepam’s behavioral relation to major
tranquilizers.  The pharmacologists extrapolated from a small number of dosages to find that
producing failure to respond during the stimulus (warning noise) in, on average, a quarter of
situations; the failure of proactive response.  They also identified the dose at which one-
quarter of all rodents, on average, failed to respond during the gap between noise and shock;
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the failure to respond predictively.  A ratio of the two measurements above, one-quarter
failure to avoid shock over one quarter failure to respond to the noise, differentiated minor
tranquilizers and related drugs, in this case chlorpromazine and other phenothiazines.
Although based on established methods, Randall and his team modified existing
techniques to further focus studies on identifying desirable properties which could establish
diazepam as an improvement over existing compounds.  They modified tests of learning to
examine the anxiety component of learning and behavior rather than willingness to accept an
adverse environment.  At Smith, Kline & French, Leonard Cook and Edwin Weidley
developed a technique “to evaluate the CNS active pharmaceutical agents for specific effects
on a conditioned response developed in rats.”655  Yet because “the buzz and the shock [were]
delivered simultaneously” they had no means of differentiating between ongoing
apprehension and temporary anxiety.656  Randall’s use of experiments where the conditioned
stimulus preceded pain, allowed his team to differentiate between changes in failure to
respond to the stimulus (sound) and failure to respond to the adverse event itself (electric
shock).  As a result, the laboratory tests provided ammunition for marketing; diazepam
affected tension and anxiety at low doses, but required a much higher dose to cause sedation
and lack of response to dangerous stimuli.  In comparison to the competition, there was a
much safer dose range, or at least a wider one.  Comparing doses required to achieve an ED50
illustrated quantitative differences from Librium.
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If diazepam was to be marketed it needed to be either more effective, differently
effective, or as effective as existing compounds.  As long as tests could be cited to compare
only specific drugs for specific effects, diazepam appeared ideal.  Across-the-board
comparisons, however, were not so clear-cut.  Diazepam’s competition included
chlorpromazine, meprobamate (Miltown and Equanil), barbiturates, and Roche’s own
chlordiazepoxide (Librium).  The pharmocologic profile Randall and his associates
published, based almost exclusively on laboratory research in animals, showed diazepam
superior to each of these alternatives in at least one aspect.  Gram for gram, diazepam was
more potent than chlordiazepoxide (Librium) in muscle relaxant, calming, and
anticonvulsant properties.  This could be a marketing feature, but the overall human dosage
forms simply needed more or less inert filler; in either case the quantity of active drug
required remained small.  Diazepam had greater capacity to reduce physiological muscle
rigidity in decerebrated cats than any of its potential competitors, however the extent to
which a decerebrated cat needs to relax is questionable.  It kept rats more active than those
on chlordiazepoxide (Librium) or chlorpromazine (Thorazine), although sedated them as
much as pentobarbital and more than meprobamate.  A broad range of dosages could be used
without toxic effects; barbiturate dosage needed closer monitoring to prevent intoxication or
potentially lethal effects on breathing.  Taming actions, seen in behavior of violent
Macaques, fighting mice, and septal rats, were better overall with diazepam, although results
showed significant variation.  The naturally violent Macaques were most pleasant to
associate with when on diazepam or chlordiazepoxide (Librium); none of the other drugs
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tested made them even moderately amiable companions.  Other tests showed interspecies
differences with chlorpromazine (Thorazine); monkeys became less hostile on the drug,
while cats became more so.657  Randall and associates reported diazepam (Valium) “4 times
as active as a calming agent in the fighting mouse test[,]”658 but did not publish comparisons
with other drugs; in septal rats, diazepam was less effective than chlordiazepoxide (Librium)
or chlorpromazine (Thorazine), on the same level as pentobarbital, and only showed more
effectiveness than meprobamate (Miltown, Equanil).
Interpreting results of the learned avoidance experiments posed problems.  In
nondiscriminated avoidance, Valium showed a wide range of doses between that reducing
avoidance and that producing failure to escape.  Compared to meprobamate (Miltown,
Equanil) and pentobarbital, the results were wonderful; compared to chlordiazepoxide
(Librium) and chlorpromazine (Thorazine) the results were only good.  Efficacy was similar
for all the drugs in experiments involving warning noise immediately followed by shock, all
worked poorly.  In the final avoidance test, which Randall explained “provided more
sensitive and specific measures[,]”659 differences were more pronounced.  Chlordiazepoxide
(Librium) and diazepam had a wide effective dose compared to the others.
Overall, the results established that diazepam fit the profile of existing minor
tranquilizers and was similar to chlordiazepoxide (Librium), but did not establish benefits
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above and beyond all competitors.  Across-the-board improvements were neither expected
nor necessary to justify moving to more extensive and expansive tests in humans.  Existing
psychotropics used as tranquilizers, sedatives, or hypnotics (those treating “hyperactive
states”660) had known problems, they produced initial excitation, sleepiness, addiction
(potentially), and a wide variety of unwanted effects.  Randall concluded diazepam deserved
further research and Roche needed more information before they could position diazepam as
a marketable compound, as Valium.  It appeared to be an effective tranquilizer and muscle
relaxant which reduced anxiety while keeping an individual alert enough to respond
appropriately to its environment.
In hindsight, barbiturates appear to provide little competition for benzodiazepines
such as diazepam (Valium).  Barbiturates carried risk of addiction, intoxication, or death.  It
is easy to categorize barbiturates as sedatives or hypnotics (sleeping pills) and diazepam
(Valium) as a milder antianxiety agent.  But looking at the battery of tests Randall’s
laboratory used to decide if diazepam was worth further study, whether it might be profitable
to market, shows that researchers focused many tests on diazepam’s performance in
comparison to the risks and benefits of the barbiturates.
Given existing knowledge, and the limits imposed by use of small animals, reporting
methods, and the ill-defined mechanisms of tranquilizers, Randall and his colleagues
developed a solid and workable battery of tests.  The underlying action of tranquilizers was
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unknown.  Existing theories were controversial and possibly contradictory.  The Roche
pharmacologists took a practical approach, identifying properties commonly seen in existing
tranquilizers and studying how diazepam compared to its competitors.  They sought to
identify a drug of potential clinical utility, to suggest what further tests might be profitable
and useful.  Small laboratory animals were expensive enough when studying drugs whose
use was only potential.
The scientific subcommunity of pharmacology had a pool of existing tests; the fact
pharmacologists used these tests did not necessarily establish they tested the properties
purported, but it vetted them for reliability and variability.  Moreover, it provided a means
for members of one laboratory to talk to others, to publish results in a common language.  By
1961 that language was increasingly physiological, behavioral, and quantitative.  By using a
battery of tests, Lowell Randall and his colleagues attacked the problem from a variety of
angles.661  Muscle relaxation and sedation existed in all existing tranquilizers, so it made
sense to identify compounds with this property.  Changes in development and extinction of
conditioned responses were also established measures.  Mitigating aggression was seen in
existing tranquilizers; it was a characteristic of major tranquilizers that helped convince staff
at psychiatric institutions to use chlorpromazine in the 1950s.  Anticonvulsant properties
were associated with certain barbiturates, drugs used as tranquilizers.  Changes in EEG
suggested relationships to other CNS depressants, so they were also studied.  Valium was a
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tranquilizer.  It worked on animals.  It was time to find out how this tranquilizer was useful
in humans.  
Clinical Trials
Pharmacological tests suggested the effects of Valium in humans, but whether studies
using animal models translated into useful results in humans required clinical testing.  That
Librium, a closely related compound, was already on the market probably influenced
Valium’s testing.  Writing in the journal Science, Walter Modell of Cornell University
Medical College noted that although laboratory trials provided important information, the
effects in animals “may differ qualitatively as well as quantitatively from that of man.”662 
Medical professionals only learned the complete risks and benefits of a drug once the public
used it for a few years.  Similar molecular structures suggested Valium was simply a variant
of Librium; major risks should already be apparent.  With Librium already on the market for
two years, the post-marketing test pool, namely everyone who took it, was testimony to the
pharmaceutical’s safety and, by proxy, the safety of Valium.
Early clinical trials helped define what actual illnesses or symptoms Valium
mitigated; in general the focus was affecting one or more target symptoms associated with an
illness.  Many of these trials sought to identify the psychiatric categories for which Valium
appeared effective.  Others compared it with potential competitors.  But a significant group,
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based on contemporary medical theory, studied either psychosomatic or somatic illnesses,
conditions entirely outside the boundaries of psychiatry before World War II.
It is important to consider that the scientists involved might not have understood
Valium as a substance acting directly on symptoms.  Neal Miller, a psychologist at Yale,
argued symptoms were external manifestations of something more central, motivations. 
Drugs such as Valium might effect changes in motivation, and “if the underlying motivation
is relieved, a whole constellation of symptoms may permanently disappear.”663  Tests on
conditioned avoidance behavior suggested the drug selectively altered motivations.  Perhaps
Valium treated the root of a constellation of mental and physical symptoms, treated
psychosomatic illnesses, did something greater than simply mitigating specific symptoms.
Publication of clinical trials occurred alongside planning for the Roche marketing
campaign.  By the time of Valium’s introduction into the American market in late 1963,
journal articles suggested it was safe and useful as a muscle relaxant or anticonvulsant, for
neurotic anxiety and other illnesses with an anxiety, tension, or agitation component.  A
flood of articles in 1963 and 1964 argued Valium was useful in diverse areas of
psychosomatic and somatic illness.
Only one early clinical trial directly applied Randall’s pharmacologic research under
similar conditions.  S. Elamrousi and M. K. Soliman applied taming of animals to larger
beasts.  In “Some Haematological and Biochemical Studies Following Administration of the
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Tranquilizer RO-5-2807 in Egyptian Buffaloes.”664 the scientists utilized diazepam to tame
the normally ornery Egyptian Buffalo, an important farm animal.  Most studies, however,
concerned use by the more economically important group, homo sapiens. 
Testing Valium: The Thalidomide Crisis and Reform of Drug Laws
Initial clinical tests on human beings took place in 1961 and 1962.  At the time,
Americans were aware of the need and dangers of clinical testing to an extent not seen since
the 1930s.  The 1938 Federal Food, Drug, and Cosmetic Act passed into law in the wake of
the ‘Elixir Sulfanilamide’ disaster.  In September 1937, Massengill Company placed a liquid
form of sulfanilamide, an early sulfa drug, on the market.  Unfortunately the company
examined the liquid base, diethylene glycol, for “appearance and taste[,]”665 but not for
toxicity.  More than one-hundred deaths later, the company and the FDA were far more
aware how tough it proved to remove a drug from the market.  The company could only be
prosecuted by the FDA for mislabeling.  The 1938 reform of FDA powers introduced
premarketing safety approval requirements from the FDA.666
In 1960, a small group of physicians began identifying the common factor underlying
a rash of children born with deformed limbs; mothers of these children took the sleeping pill
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thalidomide early in pregnancy.  Thalidomide was a popular drug in Germany and England,
where it was first offered to the public in 1958 as a cure for insomnia.  Unlike other sleeping
potions, such as barbiturates, thalidomide was effective at inducing sleep but did not leave
users drowsy in the morning.  While useful for the purpose intended, when pregnant women
took the drug some of their children came into the world deformed.
Thalidomide was a teratogen with a very specific effect.  When taken between the
thirty-first and forty-forth days of pregnancy it caused phocomelia.667  This deformity of the
limbs did occur naturally, but only rarely.  After introduction of thalidomide, the number of
afflicted children increased dramatically.  One West German clinic saw only seven cases
between 1948 and 1958, before thalidomide entered the market.  By 1960 the same clinic
saw twenty-seven cases, and one year later the number had climbed to sixty-five.668  Doctor
Helen Taussig, who toured hospitals in England and Germany during March and April of
1962, reported the result was “the most ghastly thing you have ever seen.”  Phocomelia
created deformed limbs; the name derived from the Greek for seal (phoke) and limbs
(melos).669  Arm and leg bones failed to grow, sometimes leaving hands and feet growing
from the shoulders and hips, and sometimes creating lack of arms or legs altogether.  Mental
capacities were most often unaffected, creating children with “great abilities as well
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as...severe disabilities.”670  
Frighteningly, pharmacologists had tested thalidomide in the laboratory, and there
had been no signs of teratogenicity in offspring.  Apparently, serious side effects might not
show until a drug was on the market.  Animal tests could not definitively prove a drug’s
safety.  The fact Valium’s pharmacologic safety profile appeared excellent did not obviate
the need for clinical trials, trials with human beings.  
In the early 1960s, physicians did not require Federal government approval before
beginning human subject tests with investigational drugs.  All a pharmaceutical company
need do was keep records of shipments, and label the drug packages with the statement
“caution, new drug limited by Federal law to investigational use.”671  Officially the FDA did
not deal with clinical or animal testing until they received a New Drug Application.  It was
therefore possible for companies to proceed with human trials before completing animal
trials.672  Doctors receiving investigational drugs had to sign a form attesting to their
qualifications.  After that point the physician could give the drug to patients.  He need not
tell them the drug was investigational.673  If he wished, the doctor could even charge the
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human guinea pig.  As an FDA official explained, doctors rightfully decided whether to
inform the patient, because the information could influence experimental outcome and
therefore the validity of the results.674  Doctor Helen Taussig, in a Scientific American article
entitled “The Thalidomide Syndrome,” explained that the FDA “exercises no control until
the drug is ready for sale.”675  Doctor Kelsey, the FDA inspector who prevented thalidomide
from reaching the U.S. market, pointed out the need to test experimental drugs on human
subjects was a necessary step in proving them safe for sale to the public.  “Animals don’t
answer all the questions,” she explained. 
In 1961 and 1962, politicians of all flavors and ideologies tried channeling public
concern into legislation.  Estes Kefauver continued his prolonged hearings on drug prices,
safety, monopolistic behavior, and other alleged abuses by the pharmaceutical manufacturing
industry.676  President Kennedy continued his calls for passage of a law providing consumer
drug protection.  In mid-March he set out his program to increase consumer protection from
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high prices, low quality, and fraud.  The consumer had certain rights, the president asserted. 
The public had a “right to safety,” “The right to be informed,” “The right to choose,” and
“The right to be heard.”677  
The problem, as Kennedy framed it, was that the wonder drugs introduced in the past
twenty years were more powerful than anything in the past.  They therefore held both
promise and danger on a level never before seen.  In his message to Congress the President
spoke of “The successful development of more than 9,000 new drugs in the last twenty five
years[.]”678  These novelties had the capacity to save lives but were “placed on the market
with no requirement that there will be either advance proof that they will be effective in
treating the diseases and conditions for which they are recommended or the prompt reporting
of adverse reactions;”679 if Congress was concerned about the public well-being it should
pass a law to protect Americans.  After all, Congress already offered this level of protection
to medication for animals; “It is time to give American men, women and children the same
protection we have been giving hogs, sheep and cattle since 1913 under an act forbidding the
marketing of worthless serums and other drugs for the treatment of these animals[,]”680
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Kennedy explained.
To accomplish his goals, Kennedy suggested changing the existing Food and Drug
Act to make drugs “better, safer and less expensive.”  Specifically, he argued the updated
law should require that companies offer proof new drugs were both safe and effective “for
their intended use” before marketing.  Kennedy called for listing generic names on labels, to
promote competition between older brand-name pharmaceuticals and generic versions of the
drugs.  He called for all drug manufacturing facilities to follow industry-standard Good
Manufacturing Practices (GMP), to ensure quality and reliability in their products.  To
guarantee they were up to snuff, the FDA should inspect factories regularly.  The
government should require that companies report to the FDA any incoming evidence
pointing to problems in already marketed drugs.  When the FDA doubted safety of a drug, it
should be able to withdraw it from the market immediately.  In general, Kennedy’s consumer
protection program was compatible with Kefauver’s bill.  It was silent, however, on the issue
of patient notification.681  
By the second week in April 1962, when the thalidomide scare broke, the Drug
Reform Bill was struggling for life.  Rather than appearing on the Senate calendar to be
debated, it had been referred to the Committee on Patents.  In all likelihood that committee
would not disgorge it during the 87th Congress.  The thalidomide scare resuscitated the
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Kefauver drug reform bill.  Public demand pushed Congress to pass the bill, or a bill, into
law.
A New York Times editorial titled “The Control of Pharmaceuticals,” indicates how
people reacted to the news of thalidomide’s effects.  The editor, horrified by the events in
Europe, wrote about the moral of the situation, “even more stringent tests of drug safety are
needed[,]” he warned.  The editor associated this need with passage of the Kefauver drug
reform plan, which he considered important “regulatory legislation.”  The FDA discovered
formidable difficulties in recalling thalidomide and identifying all doctors given the drug. 
Therefore, to prevent a similar occurrence in the U.S.A., regulation should allow the
government “immediately to ban the drug in question and submit it to further tests rather
than wait to see if enough reports of damage to human beings come in to prove the lack of
safety.”682  Unfortunately, the bill ultimately passed into law was shaped by political,
administrative, legislative, legal, and corporate concerns.
The Kefauver-Harris bills proceeded quickly through Congress.  The Senate
Judiciary Committee released the bill on 20 August 1962, with two final amendments
requiring ‘substantial’ proof of efficacy and authorizing government inspection of factories. 
Senate bill 1552 did not include provisions demanding informed consent by human subjects
of experiments or a mandatory arsenal of animal tests before human trials.  The bill moved to
discussion on the Senate floor within the week and by mid-October went over the final
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hurdles into law.683  The Kefauver-Harris bill proceeded to the White House where President
Kennedy signed it on 10 October 1962, in the presence of Senator Kefauver, Representative
Harris, FDA Commissioner Larrick, and Dr. Frances Kelsey.684
Before passage of the 1962 Act, government agencies could remove unsafe or
ineffective drugs from the market, but existing regulations were little help.  Ineffectual
pharmaceuticals could go on the market as long as proven safe.  After they were in the hands
of the public, the FDA could gather its own information on how well they worked.  They had
control over labeling, which provided an indirect means for requiring that manufacturers sell
drugs with a medical purpose.  Lack of efficacy was not enough to justify removing a drug
from the market.  In order to recall a drug, the FDA had to prove that the manufacturer was
engaging in false advertising to doctors.  If companies advertised and sold directly to the
public, the Federal Trade Commission regulated advertising.  Therefore, when the makers of
Rybutol told the public their drug would treat “tiredness, loss of a sense of well-being, loss
of happiness and appearing and feeling older than one should,” the FDA believed they
deceived the public, but it was the FTC that charged the makers, Lanolin Plus, with false
advertising.  The FDA governed pharmaceutical companies’ literature sent to doctors; on a
single day the FDA seized two types of antibiotics because the literature sent with them to
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doctors stated usefulness in treating “tonsillitis, bronchitis, lobar pneumonia, influenza and a
number of other conditions.”  The safety clearance granted for those drugs was only for use
in treating the common cold and preventing secondary infections.685
One of the strangest aspects of the assumption that thalidomide caused passage of the
Kefauver bill was that the bill dealt with drug control in general, but did little to assure
teratogens never again reached the public.  Proponents referred to Kefauver’s reform plan
using terms such as “tighter control over drugs,” but apart from allowing the FDA to
withdraw a drug from the market before holding hearings, few of Kefauver’s provisions
could be formulated as thalidomide preventatives.  The same editor who referred to the
Kefauver bill’s “tighter control over drugs” also made a point of explaining the need for
additional legislation to prevent a recurrence of the thalidomide scare in the future.  “[I]t is
clear that other action is needed too if the full implications of this epidemic of deformed
babies are to be dealt with[,]” he wrote, “[c]ertainly the regulations governing experimental
distribution of drugs need to be tightened up.”686  Another editorial referred to the reform
plan as “an important step toward preventing such tragedies as followed the use of
thalidomide,” yet noted that even provisions for testing drugs on animals could not have
shown the dangers of thalidomide; “Tests on animals had found thalidomide to be safe when
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given to normal adults.”687
The issue of informed consent amply illustrates the oversimplification inherent in
considering the thalidomide scare as cause for passage of the Drug Reform Act.  That
thousands of Americans acted unknowingly as human guinea pigs to test thalidomide
terrified them.  Yet both the new FDA regulations on use of investigational drugs and the
1962 Drug Reform Act were silent on this issue.  Dr. Frances Kelsey, who prevented market
approval of thalidomide in the United States, believed doctors should retain the right to
decide whether to inform patients that they were taking an experimental drug, or to remain
silent.  “There may well be times in which it would not be desirable for the patient to know,”
she told a television interviewer.688
The concept of volunteer test subjects proved illusory.  In May, Doctors Mary and Ira
Gabrielson, commenting on the need for better premarket testing, complained that pregnant
women were involuntarily turned into test subjects every time they filled a prescription. 
True human volunteers, those involved in premarket testing of experimental drugs, “incur
risks willingly,” they wrote in the New York Times, “and know that their hazard is of known
dimension.”689
Scientists, doctors, and pharmaceutical companies were less than thrilled by the
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changes.  Pharmaceutical companies discovered many doctors were wary of participating in
clinical trials, “afraid lest another ‘thalidomide’ crop up as unexpectedly as the real one
did.”690  The prospect of new regulations did not assuage their fears, possibly because the
Kefauver-Harris amendments did not include any provisions that would have stopped
thalidomide reaching the public.  Its manufacturer performed animal tests on rats before
giving thalidomide to humans.  As scientists were discovering, the teratogenic effects of this
drug were hard to reproduce in animals, so even using larger mammals probably would not
have revealed the drug’s dangers.  The prospect of required animal tests for all drugs
offended manufacturers and physicians for other reasons; although most ‘reputable’
manufacturers did animal tests before conducting human trials (experiments consumed an
estimated nine million animals in 1961), some researchers feared the regulations, created for
the entire industry, would be too strict.  They warned that rigid requirements could “have a
paralyzing effect on such programs as the national multi-clinic cooperative screening effort
aimed at developing cures for cancer.”691  Other authors explained the changes damaged
physicians on a more personal level because they “eliminate the use of professional
judgement, which is the basis for true investigations.”  Doctors were used to using their own
judgement in prescribing investigational drugs.  Some, like Howard A. Rusk, considered the
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692  Howard A. Rusk, “Drug-Test Regulations: U.S. Proposals Innocuous on
Surface, But Lowering of Standards is Feared,” New York Times September 16, 1962.
693  Anon, “Drug-Test Rules Will Be Flexible: F.D.A. Assures Physicians of
Modification in Revisions of Draft Regulations,” New York Times October 25, 1962.
694  Randall et al, Pharmacological and Clinical Studies on Valium, 417, 421.
multiplication of regulations demeaning, reducing the physician to a technician “limited to
confirming or denying a hypothesis.”692  After receiving over three hundred letters from
concerned physicians and  researchers, FDA officials made a point of reassuring them the
final regulations would be “flexible enough to encourage research.”693
Hoffmann-La Roche performed clinical tests on Valium before and during this
turbulent time.  Laboratory tests showed no obvious changes in fetal development,694 but the
thalidomide crisis illustrated how pharmacological testing on animals was only the first step. 
Human trials were necessary before a pharmaceutical manufacturer could market a drug
legally, ethically, and practically.  The nature and expected uses of Valium raised further
quandaries.  What qualities were they testing for?  Studying effects of a drug combating
diseases with a specific pathogen was easy.  Drugs worked if the pathogen became harmless
and symptoms subsided.  Psychopharmaceuticals were far more problematic.  Neuroses
tended to be self-limiting; left untreated, some patients would get better anyhow. 
Quantifying symptoms was not easy.  And no one could definitively state what symptoms
best illustrated Valium’s actions.
From Diazepam to Valium™: Testing Theories and Finding Uses
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695  It was well-established by this point that meprobamate was marketable as an
antianxiety agent.  H. Bauer, “Meprobamate in Neurological Disturbances,” in
Psychotropic Drugs, eds. S. Garattini and V. Ghetti (New York: Elsevier Publishing
Company, 1957), 560.
696  Paul H. Hoch, “Problems Arising from the Generalized Use of Psychotropic
The nature of clinical studies on Valium are a remarkable melange of techniques or
choices probably influenced in part by the thalidomide crisis, and other aspects which
suggest clinicians involved took entirely different lessons, if any, from the crisis.  Clinical
trials of Valium, mainly performed by physicians with few or no official links to Roche,
occurred once extensive experiments with multiple species suggested toxicity risks were
low.  Randall and his associates conducted teratogenicity studies in the laboratory, but in
light of the thalidomide crisis it is fascinating to note that women were not excluded from
early trials.  Researchers commonly noted what portion of their subject pool was female, but
rarely separated out results by gender.  The investigators excluded women from clinical trials
only with studies carried out in all-male hospital wards.
Pharmacologic testing suggested Valium had an activity profile similar to
meprobamates, phenobarbital, and chlorpromazine, as well as the expected similarities to its
sister compound, Librium.  Physicians mainly prescribed these drugs as tranquilizers.  They
reduced tension and dampened reaction to stress, they sedated mildly, and could battle
insomnia through stress reduction, or more direct action on the physical brain.  It made
sense, therefore, to test Valium in clinical settings where meprobamate, phenobarbital,
chlorpromazine, and Librium were in use.695  Physicians already prescribed existing
tranquilizers for “practically every psychiatric condition with varying success.”696
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Drugs,” in Neuro-Psychopharmacology: Proceedings of the Second Meeting of the
Collegium Internationale Neuro-Psychopharmacologicum (Basle, Switzerland, July
1960), ed. E. Rothlin (New York: Elsevier Publishing Company, 1961), 9-16, 9.
697  The pre-1963 articles are: J. Collard and J. Kerf, “Le Traitment De
L’Anxiéte Néurotique par le Valium,” Encéphale 51 (November-December 1962): 571-
73; R. J. Kerry and F. A. Jenner, “A Double Blind Crossover Comparison of Diazepam
(Valium, Ro 5-2807) with Chlordiazepoxide (Librium) in the Treatment of Neurotic
Anxiety,” Psychopharmacologia 3 (1962): 302-06; J. Whitney Kelley, “Management of
Psychiatric Disorders with Diazepam,” Clinical Medicine 69, no.8 (1962): 1789-1802;
Ruth M. Crossfield and Manuel E. Soria, “Parenteral Use of Diazepam,” Diseases of
the Nervous System 23 (November 1962): 647-48; Eugene J. Chesrow, Sherman E.
Kaplitz, John T. Breme, Joseph Musci and Raoul Sabatini, “Use of a New
Benzodiazepine Derivative (Valium) in Chronically Ill and Disturbed Patients,” Journal
of the American Geriatrics Society 10, no.8 (1962): 667-70; M. L. Towler, B. D. Beall
and J. B. King, “Drug Effects on the Electroencephalographic Pattern, with Specific
Consideration of Diazepam,” Southern Medical Journal 55 (August 1962): 832-38;
Carl Ludvig Laane, “Erfaringer Fra Poliklinsk Behandling Med Librium og
Libriumanalog, Valium, Spesielt Ved Svære Angst- og Tvangsneuroser,” Tiddskrift For
Den Norske Lægeforening; Tidsskrift For Praktisk Medicinm Ny Række 82 (1 August
1962): 960-62; J. Collard, “Clinical Experience with Diazepam in Neuroses,” Journal
of Neuropsychiatry 3, suppl.1 (August 1962): S157-S158; M. I. Vilkin and J. B. Lomas,
“Clinical Experience with Diazepam in General Psychiatric Practice,” Journal of
Neuropsychiatry 3, suppl.1(August 1962): S139-S144; M. L Towler, “The Clinical Use
of Diazepam in Anxiety States and Depressions,” Journal of Neuropsychiatry 3, suppl.
1 (August 1962): S68-S72; P. E. Feldman, “An Analysis of the Efficacy of Diazepam,”
Journal of Neuropsychiatry 3, suppl 1 (August 1962): S62-S67; S. Merlis, W. J .Turner,
and W. Krumholz, “A Double-Blind Comparison of Diazepam, Chlordiazepoxide and
Chlorpromazine in Psychotic Patients,” Journal of Neuropsychiatry 3, suppl. 1 (August
1962): S133-S138; Lowell O. Randall, G. A. Heise, W. Shallek, R. E. Bagdon, R.
Banziger, A. Boris, R. A. Moe and W. B. Abrams, “Pharmacological and Clinical
Studies on Valium™ a New Psychotherapeutic Agent of the Benzodiazepine Class,”
Current Therapeutic Research 3 (September 1961): 405-25.
Although there are only thirteen clinical trials published before 1963 relating to
Valium (also identified at the time as diazepam or Ro 5-2807), they illustrate remarkable
similarities of approach and expectations.697  The authors treat Valium as both a muscle
relaxant and a compound reducing psychic tension.  Physicians Ruth Crossfield and Manuel
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698  Crossfield and Soria, Parenteral Use of Diazepam, 647-48.
699  Kelley, Management of Psychiatric Disorders, 1789.
700  Collard and Kerf, Traitment De L’Anxiéte Néurotique, passim; Walter
Pöldinger, “Klinische Erfahrungen mit dem Librium-Analogon Ro 5-2807 (Valium) bei
Psychotischen Zustandsbildern,” Zweite Wissenschaftliche Sitzung (May 19-20, 1962):
510-14; Chesrow et al., Use of a New Benzodiazepine Derivative, 667-70.
701  Max Pollack, Eric Karp, George Krauthamer, Donald F. Klein and Max
Fink, “Neuropsychologic Response Patterns of Some Psychotropic Drugs,” in Neuro-
Psychopharmacology: Proceedings of the Second Meeting of the Collegium
Soria explained how the apparent complexity of mental illnesses provided opportunity for
treating a specific symptom, which in turn could affect a wide variety of syndromes. 
Textbook explanations for symptoms of mental illness varied widely, these physicians
argued, although “Their dynamics,... are well known –  namely, that a vicious cycle of
anxiety-guilt-depression (sometimes with aggression) is usually to be found.”698  J. Whitney
Kelley, a physician publishing in the journal Clinical Medicine, prefaced discussion of his
research with a brief description of psychopharmaceuticals recently introduced.  “Although
not curative,” he explained, “these drugs have been instrumental in reducing the symptoms
of psychotic and psychoneurotic disorders[.]”699  Many of the authors had previous
experience using chlordiazepoxide (Librium), and expected diazepam to behave similarly.700 
Symptoms occupying their interest were reduction of anxiety and tension, nervous agitation,
and sedation.
One possible theoretical framework for these trials is what Max Pollack and his
colleagues in the Department of Experimental Psychiatry at Long Island’s Hillside Hospital
termed the “neurophysiologic-adaptive hypothesis.”701  This approach examined behavioral
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Internationale Neuro-Psychopharmacologicum (Basle, Switzerland, July 1960), ed. E.
Rothlin (New York: Elsevier, 1961), 381-84.
702  For example of the international span consider the place of publication of the
following: Norway, Carl Ludvig Laane, Erfaringer Fra Poliklinsk Behandling, 960-62;
Argentina, Alfredo Buzzi, Jose Cibera, and Emma Apolinario, “Valoracion Clinica E.
Instrumental de un Nuevo Relajante Muscular: El Ro 5-2807,” La Prensa M’edica
Argentina 49 (March 16, 1962): 625-29; France, Collard and Kerf, Traitment De
L’Anxiéte Néurotique, 571-73; Mexico, J. R. Monroy, “Resultados Con el Uso Clinico
Del Ro 5-2807,” Archivos Del Instituto de Cardiologia De Mexico 32 (September-
October 1962): 553-58; Germany, Pöldinger, Klinische Erfahrungen mit dem Librium-
Analogon Ro 5-2807 (Valium), 510-14; Italy, L. Molinego, “Modifcazioni Provocate da
Alcuni Depressori del SNC nel Ratto Valutate per Mezzo Dell’Inhibizione Operativa,”
Archivo Italiano di Scienze Farmacologiche 13 (July 1963): 224-27; Canada, Lucien
LaRue and Jean-Yves Gosselin, “L’Apport du Diazepam (Valium) à la Psychiatrie
Moderne,” Laval Médical 34 (December 1963): 1208-20; and Belgium, J. Van Herck,
“Essai D’Évaluation Clinique D’Un Nouvel Anxiolytique du Groupe Des
Benzodiazepines,” Bruxelles-Médical: Revue Belge Des Sciences Médico-Chirurgicales
change resulting from both interaction of chemicals with the brain and an aspect of mind,
personality.  In clinical trials of Valium, the test subjects were not ‘normal’ people,
investigators selected them based on existing medical problems.  Perhaps this approach
helped remove some personality variables from the trials; those in test and control groups
already had personalities rendering them prone to mental or physical illness.  Another
explanation is simply that the drug was developed for treating ill individuals, and clinicians
therefore saw no rationale for testing Valium’s effects on a ‘normal’ population.
The sweep of articles published in 1962 and 1963 show a breadth of interest within
the academically-oriented medical community in use of pharmaceuticals for treatment of
minor psychiatric illnesses.  Although small in number, these research publications brought
this prospective new drug to the attention of physicians in the United States, Belgium,
Norway, Argentina, Mexico, England, and Germany.702  Passing reference to other studies
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43, no.37 (September 15, 1963): 933-46.
703  Crossfield and Soria, Parenteral Use of Diazepam, 648.
704  An exception are the two articles continuing laboratory pharmacological
work.  Towler, Beall and King, Drug Effects on the Electroencephalographic Pattern,
832-38; William J. Kinnard, Mario D. G. Aceto, and Joseph P. Buckley, “The Effects of
Certain Agents on the Conditioned Emotional Response Behavior Pattern of the Albino
Rat,” Psychopharmacologia 3 (1962): 227-30.  
705  Kelley, Management of Psychiatric Disorders, 1791; Walter Poldinger’s
study also included patients with a wide variety of diagnoses.  Pöldinger, Klinische
Erfahrungen mit dem Librium-Analogon Ro 5-2807 (Valium), 510-14.
706  Pöldinger was interested in classification of psychiatric drugs.  Part of the
reason for his interest in the behavior of Librium and Valium was because the third
World Congress of Psychiatry, held in Montréal in 1961, included debates whether the
major tranquilizers should be reclassified as neuroleptics, with meprobamate
representing tranquilizers, and the role of Librium, at that time the only marketed
benzodiazepine, positioned either between the two, or even more differentiated from
suggest a large number of small investigations and evaluations, before or during 1962,
remained unpublished; Crossfield and Soria mention “preliminary investigations and pilot
clinical evaluations” involving “183 investigators” and “almost 3000 patients with different
psychiatric disorders.”703 
These early articles generally focused on neuropsychiatry and show atheoretical
approaches to psychiatry.704  The test populations were rarely uniform, more often consisting
of those with “both psychiatric and neuropsychiatric disorders[.]”705  Even when an aspect of
theory testing appeared, as with Walter Pöldinger’s report on effects in psychotic patients, it
focused more on differentiating between types of tranquilizers rather than attempting to
understand how any of these compounds interacted with the brain or caused specific effects
in the body.706
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neuroleptics.  Pöldinger, Klinische Erfahrungen mit dem Librium-Analogon Ro 5-2807
(Valium), 510-14.
707  K. W. Schultze and V. Patt, “Zur Behandlung des Abortus Imminens mit
Valium, Einem Benzodiazepinpräparate,” Geburtshlife und Frauenheilkunde 23
(November 1963): 1003-09.
708  Joseph T. Brock and Mark Dyken, “The Anticonvulsant Activity of
Chlordiazepoxide and Ro 5-2807,” Neurology 13, no.1 (1963): 59-65; Ayerbe, Ensayo
Terepéutico Con El Ro 5-2807, 899-900.
709  Don L. Winfield, “The Use of Diazepam in Clinical
Electroencephalography,” Diseases of the Nervous System 24 (September 1963): 542-
47; use in psychotherapy was assessed in Harry H. Farb, “Intravenous Diazepam as a
Pre-Interview Medication (A Clinical Note),” Diseases of the Nervous System, 24
(April 1963): 233-36.
Most early work attempted to establish appropriate diagnostic categories for
prescribing Valium.  The 1962 studies focused on neuropsychiatry, both inside and outside
institutions.  Articles encompassed a broad spectrum from psychoses including
schizophrenia, to neuroses, personality disorders, and neuropsychiatric disorders associated
with senility.  As a group, the investigators concluded Valium effectively treated anxiety and
tension, reduced agitation, and had relatively mild side effects.
Research publications based on clinical studies of Valium, published soon after
Roche obtained a New Drug Application in December 1963, illustrate how Valium’s utility
expanded out from a starting point as treatment for neurotic anxiety and towards popular
promotion as a substance useful in a broader variety of psychosomatic conditions. 
Researchers tested the potential application of Valium’s antispasmodic properties to
preventing miscarriage or premature labor707 and as an anticonvulsant.708   They examined its
utility as an adjunct for nonpharmaceutical treatments.709  Researchers also noted the
273
710  Henry A. Cromwell, “Controlled Evaluation of Psychotherapeutic Drug in
Internal Medicine,” Clinical Medicine (December 1963): 2239-44; Robert Rathbone,
“The Role of a Therapeutic Drug in Internal Medicine,” Medical Times 91 (December
1963): 1186-91.
relevance of this new drug to nonpsychiatrists, the class of physicians who would later write
the vast majority of Valium prescriptions.710
The clinical trials reported in the early 1960s typify some of the most problematic
aspects of testing psychiatric drugs.  Practitioners planning clinical trials chose between two
types of test populations, inpatient or outpatient.  Each group had advantages and
disadvantages.  In the larger picture, multiple trials (some involving inpatients, others
outpatients) provided greater knowledge of Valium’s potential use in psychiatry.  
Inpatients resided day and night in either a psychiatric ward, an institution entirely
devoted to psychiatric patients, or a general hospital.  One benefit of tests involving
inpatients was the capacity to control outside issues; physicians could accurately study and
take into account concomitant drug use.  Patients were more likely to remain in the study
group, whether because they had few viable alternatives or by virtue of a climate
conditioning patients to obey staff rules and regulations.  Another benefit to using inpatient
populations was that most suffered from long-term illnesses.  The paths of their illnesses
were predictable, and remission unlikely.  Because many of the ill-defined psychiatric
conditions were often self-limiting, investigators faced problems in separating improved
condition due to drug effects from improvements resulting from the natural course of illness.  
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711  Armo Hormia, “The Patient’s Subjective Need of Treatment as a Cause of
Success or Failure in the Ambulatory Treatment With Psychotropic Drugs,” in Neuro-
Psychopharmacology: Proceedings of the Second Meeting of the Collegium
Internationale Neuro-Psychopharmacologicum (Basle, Switzerland, July 1960), ed. E.
Rothlin (New York: Elsevier, 1961), 251-54, 252.
712  Hormia, The Patient’s Subjective Need of Treatment, 251.
713  Hormia, The Patient’s Subjective Need of Treatment, 252.
By 1957, ambulatory treatment of neuroses was the norm.711  Most potential Valium
users, including those with mental health or psychosomatic problems, saw general
practitioners in their offices.  Doctors treating these outpatients (ambulatory patients) were
Roche’s target market.  But a trial population in this setting was less controllable as the
patient “decides how long the therapy is continued.”712  The likelihood these patients
considered themselves in need of treatment by tranquilizers differed greatly depending on
diagnosis; those who interpreted their symptoms as somatic problems were unlikely to
“accept the idea of a psychogenic origin of their disease,”713 and therefore likely resistant to
treatment with Valium.
The disadvantages of using an inpatient population for clinical trials were twofold:
the spectrum of diagnoses seen was less similar to that of Valium’s expected target market,
and this spectrum generally involved more severe mental illnesses.  The major
pharmacologic breakthrough in treatment of severe mental illness, mostly seen in psychiatric
institutions whose role had degenerated largely into custodial care, was discovery,
development, and use of the major tranquilizers.  The already known profile of Valium
suggested its usefulness in less severe cases, because among its benefits was a relatively mild
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side effect profile which allowed use in clients who did not see physicians on a day-to-day
basis.
The second major disadvantage to studying outpatient populations was that the
illnesses seen were less severe than those seen within psychiatric care institutions. 
Outpatients had the symptoms Roche was most interested in, but it was tougher for
researchers to show change in moderate symptoms.  One consequence of the post-World
War II conceptualization of mental health and mental illness as a spectrum, was an implicit
assumption that drugs mitigating symptoms in the severely mentally ill provided proof of
efficacy in less severe mental illnesses.  If there was a spectrum of mental illness, with
untreated neuroses potentially becoming more chronic psychoses, any pharmaceutical
capable of mitigating severe conditions would also have benefit for milder cases.  Valium’s
efficacy, in theory, would be less noticeable in outpatient populations; although the eventual
users would be outpatients, proving Valium’s usefulness was easier using severely mentally
ill patients.
Choosing use of an outpatient population in clinical trials reflected similarly
weighing advantages and disadvantages.  Among the advantages, outpatients were more
likely similar to Valium’s ultimate users.  Patients seen in private practice might have long-
term illnesses, but doctors saw them intermittently; prescription drugs needed a moderate
and mild side effect profile.  Whether general physicians, neuropsychiatrists, or those with a
greater deal of specialization in psychiatry – somatic or psyche based – the clientele was
more likely to include a large variety of patients suffering from reactive neuroses, neurotic
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714  The small group of these trials include Merlis, Turner, and Krumholz,
Double-Blind Comparison of Diazepam, Chlordiazepoxide and Chlorpromazine, S133-
S138, and Kerry and Jenner, Double Blind Crossover Comparison, 302-06.
personalities, situational stresses, insomnia, agitation or obsessional behavior.  Underlying
these diagnoses, which physicians usually based on assumptions of causal factors, were
certain common symptoms thought highly suitable for treatment with Valium: physical or
mental tension, psychic stresses causing insomnia or agitation, and general anxiety.
The disadvantages of using an outpatient population, included having less control
over drug taking behavior.  Published reports of clinical trials among outpatients suggest that
when Valium did not have an expected effect, physicians began investigating concomitant
drug use.  Outpatients could easily hide alcoholism, or concurrent use of other drugs without
the physicians’ knowledge.  Assessing Valium’s side effect profile was more problematic
when using a population who, when experiencing disturbing side effects, could easily drop
out of the pool of test subjects, perhaps seeing little personal advantage in the substance, and
possibly even switching to another physician.
Today, double-blind placebo trials are an accepted ideal.  In the early 1960s,
however, the medical profession was divided on the benefits of this trial design type.  Use of
double-blind placebo trials for psychopharmaceuticals was rare.714  Investigators used this
research design for investigations into which of two or more drugs performed better.  In the
1950s and early 1960s medical professionals did not consider double-blind placebo trials the
gold standard for objective proof of the drug’s efficacy; many physicians considered them
especially unsuitable for psychiatric, and psychosomatic illness-affecting drugs.  In these
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715  Gerald L. Klerman, “Discussion Fourth Symposium,” in Neuro-
Psychopharmacology: Proceedings of the Second Meeting of the Collegium
Internationale Neuro-Psychopharmacologicum (Basle, Switzerland, July 1960), ed. E.
Rothlin (New York: Elsevier, 1961), 319-22, 320; placebos were used sporadically in
early clinical trials of Valium.  For an example see Henry P. Hare, “Comparison of
Diazepam, Chlorpromazine and A Placebo in Psychiatric Practice,” Journal of New
Drugs 41(July-August 1963): 233-40.
cases many of the conditions were self-limiting; therefore, patients taking placebos were
likely to respond beneficially in large numbers simply because of the nature of their
illnesses.  Recent research suggested some people, possibly with characteristic personality
types, were prone to respond to any substance, including placebos.715  The role of doctor-
patient interaction, highlighted by well-established techniques such as psychoanalysis,
psychotherapy, and group therapy, suggested expectations of medical personnel who knew
or guessed which drug was active, or patients discussing experiences among themselves,
biased and altered placebo based trials.  An additional problem was that many patients in
studies had experience with a broad variety of psychopharmaceuticals.  This experience, or
knowledge gleaned from others, meant patients often knew the side effect profiles of existing
tranquilizers, and therefore could distinguish inactive placebos.  Patients anticipated certain
side effects and they likely expected any substance which did not cause problems such as
mental sedation, inability to sleep, nausea, changes in blood pressure, or other common side
effects, to be a placebo.  Matching the shape, color, smell, taste, or size of pills was far easier
to accomplish than finding a placebo with a similar side effect profile.  Because of these
concerns, investigators mainly used double-blind placebo trials only for studies comparing
the effects of more than one active substance as well as the placebo.
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716  H. E. Lehmann and D. A. Knight, “Measurement of Changes in Human
Behaviour Under the Effects of Psychotropic Drugs,” in Neuro-Psychopharmacology:
Proceedings of the Second Meeting of the Collegium Internationale Neuro-
Psychopharmacologicum (Basle, Switzerland, July 1960), ed. E. Rothlin (New York:
Elsevier, 1961), 291-303, 292.
Reporting trial results was far more complex for Valium than in cases where a
specific drug attacked an identifiable specific pathogen, as with antibiotics.  The illness
typologies used in psychiatry were becoming standardized by the 1960s, but continued
including categories based on unobservable presumed causes, overlapping groups of
symptoms, and no absolute method of consistently defining the extent to which a drug
affected specific symptoms.  Overall, cleanly comparative data was impossible, given the
“lack of a solidly established methodology of test procedures for the observation and
measurement of action of psychotropic drugs on the human organism.”716  There was no
expectation that tranquilizers cured mental illness; they mitigated symptoms which in turn
might promote cure.  Later, physicians interested in psychosomatics might interpret Valium
as a cure, but the way psychiatrists defined mild to moderate mental illnesses, produced
conditions in which it was hard to consider any patient permanently cured; positive mental
health was a goal, something constantly at risk.
In general, the clinical trials on Valium reported results separately for each diagnosis,
and assessed efficacy on how completely it reduced or removed symptoms.  The boundaries
between categories such as mild or moderate improvement were essentially subjective, even
when based on a combination of observation by one or more trained medical professionals,
use of self-assessments by patients or their relatives, and use of standardized inventories
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717  Lehmann and Knight, Measurement of Changes, 292.
718  Examples of this focus is evident in the following reports: LaRue and
Gosselin, L’Apport du Diazepam (Valium) à la Psychiatrie Moderne, ” 1208-20;
Molinego, Modifcazioni Provocate da Alcuni Depressori, 224-27; V. E. Gscherlacht,
“Ambulante Behandlung Psychisch Kranker Mit Dem Neuen Psychopharmakon
Valium (Roche),” Schweizer Archiv für Neurologie, Neurochiurgie und Psychiatrie 92
(1963): 193-203; William B. Cline, Jr., “Treatment of Emotional Disorders with
Amobarbital, Diazepam, and Psychotherapy,” Texas State Journal of Medicine 59 (June
1963): 512-17; Armand DiFranchesco, “Diazepam, A New Tranquilizer,” American
Journal of Psychiatry (April 1963): 989-90; George A. Constant and Frank A. Gruver,
Jr., “Preliminary Evaluation of Diazepam in Psychiatric Disorders,” Psychosomatics 4
(March-April 1963): 80-84; Antonio M. Ayerbe, “Ensayo Terapéutico Con el Ro 5-
2807 en Clínica Psiquiàtrica: Nota Preliminar,” La Semana Me’Dica 122 (9 May 1963):
899-900; Einar Geert-Jørgensen, “Treatment of Anxiety Neuroses and Psychosomatic
Syndromes by a New Librium-Metabolite: Valium,” Acta Psychiatrica Scandinavica
39, suppl. 169 (1963): 218-22; Georges Boittelle, Claudine Boittelle-Lentulo, Jeanine
Cophignon, Gérard Blotnikas and Jacques Thomas, “Indications du Ro. 5-2807 Dans
les États D’Excitation et D’Anxiété,” Annales Me’dico Psychologiques 2 (June 1963):
83-86; W. Meusert, “Erfahrungen mit einem neuen Psychotropen Präparat Aus Der
Librium-Reihe (Ro 5-2807- Valium),” Medizinische Welt 34 (24 August 1963): 1680-
83; Harry F. Darling, “A Comparative Study of Diazepam and Chlordiazepoxide in
Psychoneurotic Patients,” Diseases of the Nervous System 24 (August 1963): 501-03;
Benjamin Blackman, “The Adjunctive Role of Diazepam in the Treatment of
Depression,” Clinical Medicine (August 1963): 1495-1500; Irving Hirshleifer and
William Kroger, “Benzodiazepines in the Differentiation and Treatment of Anxieties,”
Clinical Medicine (September 1963): 1673-78; Leo E. Hollister, J. L. Bennett, Isham
Kimbell, Charles Savage and John E. Overall, “Diazepam in Newly Admitted
such as the MMPI (the Minnesota Multiphasic Personality Inventory).  Journal articles
suggest many researchers believed structured psychological tests offered the most reliable
results possible.717
In 1963 and 1964 the majority of published reports of clinical trials with Valium
continued to focus on mental health and illness, but construed psychiatric illnesses more
broadly.  They began including study of psychoneurotic personalities prone to somaticize
anxiety, and psychosomatic disorders.718  By reducing tension, patients stopped obsessing
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Schizophrenics,” Diseases of the Nervous System 24 (December 1963): 746-50; Van
Herck, Essai D’Évaluation Clinique D’Un Nouvel Anxiolytique, 933-46; J. Collard and
J. Kerf, “Un Nouvel Anxiolytique: Le Ro 5-2807 ou Diazepam,” Acta Neurologica
Belgica 63 (December 1963): 1004-10; Cromwell, Controlled Evaluation of
Psychotherapeutic Drug, 2239-44; Hare, Comparison of Diazepam, Chlorpromazine
and A Placebo, 233-40; and Julian Love, “Diazepam in Treatment of Emotional
Disorders,” Diseases of the Nervous System 24 (November 1963): 674-77.
719  F. J. Ayd, Jr. “A Critique of Tranquilizing Drugs,” in Psychotropic Drugs,
eds. S. Garattini and V. Ghetti (New York: Elsevier Publishing Company, 1957), 548-
55, 549.
about their symptoms.719  In theory, Valium reduced adrenal feedback interfering with,
prolonging, or producing  psychosomatic illnesses.  Increasingly, these publications began to
show interest in use of Valium to treat, or as an adjunctive treatment, for psychosomatic
illness.  Actions earlier identified as side effects interested more and more researchers, who
looked at how Roche’s Valium might be more widely useful.  By late 1963, the core activity
profile of Valium was settled; it reduced mental and physical agitation, had mild if any
sedation effects, and reduced both mental and muscle tension.  Yet clinical research
continued expanding the sweep of conditions Valium was suitable to treat.
Conclusion
The breadth of laboratory tests and clinical trials published or started before Roche
placed Valium on the U.S. market is remarkable, not only as a sign of the interrelated
complexity of symptoms and conditions for which doctors prescribed the drug, but also as a
touch point for examining later changes in drug testing.  In the 1950s and early 1960s it was
possible to bring drugs onto the American market for symptomatic treatment of nebulous
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conditions, such as neuroses, and to market compounds variously termed tranquilizers, minor
tranquilizers, antineurotics, or ataractics.  They could treat motivations, symptoms, clusters
of reactions.  By 1980, the therapeutic landscape differed dramatically; pharmaceutical firms
needed to prove a drug efficacious for a specific condition, and strong formal and informal
guidelines shaped the types of tests and scale of populations used.
Following the thalidomide scare, legislators in Congress were able to push through
the Kefauver-Harris amendments, legislation that would eventually dramatically alter the
role of the FDA in drug testing, approval, and monitoring.  Although thalidomide never
made it past the experimental stage in the United States – theoretically, doctors only
prescribed it in the United States as an investigational drug – changes went far beyond
improving controls over the use of investigational drugs.  Manufacturers needed to perform
premarket testing to prove the usefulness of pharmaceuticals, a caveat of the legislation
which effectively required drugs be proven useful for symptoms and conditions with more
narrow and measurable definitions.  Once a pharmaceutical manufacturer submitted a New
Drug Application (NDA) and test results, the FDA had to act to permit marketing. 
Previously, unless the FDA denied the application, in 180 days the compound had been
automatically approved for sale.  The FDA could pull drugs from the market more readily,
although threat of litigation promoted hesitance to use this option.  Increasingly wary
researchers shied away from using ‘possibly pregnant’ women in their clinical investigation
of new drugs, especially after 1974, when the Supreme Court declared the distinction
282
720  Geduldig v. Aiello, 417 U.S. 484 (1974).
721  In this year the F.D.A. published Guidelines for the Clinical Evaluation of
Antianxiety Drugs (Washington, D.C.: U.S. Government Printing Office, 1977).  Based
on the now typical series of clinical trials grouped in three stages, the guidelines stated
it unethical to include “women of childbearing potential” (3) in Stage 1 trials, which
were those establishing effects of the pharmaceutical in humans and thereby the
potential uses of the substance.
722  129 women and 54 men were in the study group reported in Constant and
Gruver, Preliminary Evaluation of Diazepam, 80-84; 74 women and 32 men were
included in Hirshleifer and Kroger, Benzodiazepines in the Differentiation and
Treatment of Anxieties, 1673-78; 21 women and 11 men in Collard and Kerf, Un
Nouvel Anxiolytique, 1004-10; 32 women and 17 men in Hare, comparison of
Diazepam, Chlorpromazine and A Placebo, 233-40; 46 women and 26 men in Love,
Diazepam in Treatment of Emotional Disorders, 674-77; overall a relatively steady
proportion of two women per man is apparent in studies of psychiatric disorders when
schizophrenia is not a dominant diagnosis, and neuroses are the major disorder group
between pregnant and nonpregnant persons nondiscriminatory.720  
The thalidomide crisis highlighted awareness of the potential effects of
pharmaceuticals on embryonic development.  Reminders of the physical differences between
men and women brought unintended consequences; for the remainder of the twentieth-
century drug testers excluded women from most drug trials.  They argued women’s
hormonal cycles brought too many variables into play, as well as that women were
essentially the same as men, and therefore they were represented sufficiently, when their
gender was not represented at all.  The category of ‘possibly pregnant’ effectively excluded
all women between the ages of 14 and 60 from clinical testing of pharmaceuticals.  The pre-
Kefauver-Harris days, when investigators tested Valium for antineurotic potential, would be
hard to replicate after 1977;721 most outpatients treated by psychiatrists for neuroses were
women, who were over-represented in clinical trials of Valium.722  
283
under study.
Valium was studied, tested, and introduced during a nexus of change.  Drug
regulations were in flux.  The first generation of psychopharmaceuticals – major
tranquilizers, antihistaminergic anxiolytics, and MAOI antidepressants – were replaced by a
second generation which targeted more narrow groups of symptoms and attempted to retain
therapeutic efficacy with fewer side effects.  Concepts of mental health were also in flux,
moving from a focus on mitigating internal response to the external environment, towards
selective modification of central nervous system activity through enzymes, and increasingly
based on sites of transmission and reception of chemical compounds within the brain. 
Pharmaceutical regulation was shifting from an era of trust in the personal observation of
physicians, to formalized rules limiting what companies could market and how.   
Valium slipped into the market during this period of flux.  Roche tested and marketed
it as a minor tranquilizer, a drug with more selective action and fewer side effects than
earlier compounds.  Doctors studied and used it to mitigate the body’s reaction to anxiety,
overstimulation, and perception of pain.  They used it to treat psychosomatic conditions and
the feedback loop of anxiety and adrenalin.  Physicians also prescribed Valium as a general
CNS depressant, a minor tranquilizer with more selective effects on the brain and therefore
fewer side effects.  Hoffmann-La Roche started marketing Valium just after passage of the
Kefauver-Harris amendments.  At the time, the FDA did not have new regulations in place; it
was trying to cope with the backlog of drugs already on the market, figuring out ways to
assess thousands of existing drugs for their efficacy.  Roche could present Valium as a
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compound closely related to Librium, and therefore effectively an existing drug.  It was an
in-between drug, not existing on the market before 1962, nor being a truly new drug
undergoing the rigors of a new FDA.
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Philadelphia, PA.
724  Before the 1962 amendments came into effect, the Federal Trade
Commission controlled advertising of drugs and the FDA controlled labeling. 
Information available solely to physicians fell into a grey area based on the doctors
forming an educated audience, presumably less susceptible to marketers’ trickery. 
Pharmaceutical companies trod a thin line when they presented educational and semi-
educational information to doctors.  They could run afoul of rules for labeling or
advertising.  In practice, the legal system made it nearly impossible to efficiently
CHAPTER 7.  THE SOMATIC MASK: MARKETING VALIUM™
In December 1963, Hoffman-La Roche applied to the Food and Drug Administration
for acceptance of their New Drug Application (NDA).723 Soon after, Roche placed Valium
on the market.  So by early 1964 Americans, and more so their doctors, became aware of a
new tranquilizer, called Valium.  The NDA occurred before the Kefauver-Harris
Amendments, passed earlier in 1962, came into effect.  Therefore, technically, all Roche had
to prove was the new compound was safe.  Realistically, more extensive tests showing
usefulness were still necessary.  By 1963, clinical testing in North America and Europe
prepared Valium for the market.  Tests suggested use for psychiatric disorders, especially
neuroses, as well as muscle related and psychosomatic conditions.  Roche developed more
extensive evidence of Valium’s utility through clinical trials in humans.  This was essential
to prove it nontoxic.  As long as the evidence Roche gathered explained Valium’s use within
the general profile of a tranquilizer, they could use this new information to promote the drug
without triggering FDA efforts to prevent wrongful labeling in doctor-oriented marketing.724  
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prosecute companies.
Valium  rapidly rose in use, becoming the most widely prescribed brand-name
pharmaceutical in history.  Its success in the market grew from a combination of its benefits
over other drugs and skillful marketing.  Roche promoted Valium use for psychosomatic
conditions, psychological components introducing problems with treatment of chiefly
somatic disorders, as well as conditions already associated with other tranquilizers.  The
Roche campaign also skillfully played on doctors’ concerns about the quality of evidence
provided by pharmaceutical companies, and whether widespread prescription of tranquilizers
fit with their beliefs of what it meant to be a doctor.
It is important to consider that few of Valium’s major competitors were falling out of
use because of existing and recognized problems.  Valium did not step into an empty market;
doctors prescribed similar drugs in large numbers, and known profiles of action suggested
how these drugs would be used and what side effects to expect.  Presumably the Roche
marketing department focused its concerns on the obvious competition: chlorpromazine and
its derivatives, meprobamates, barbiturates, and chlordiazepoxide (Librium).
Tranquilizer Advertising  
Whether doctors should prescribe major tranquilizers – chlorpromazine (Thorazine),
and to a smaller extent reserpine derivatives – for treating mild and moderate neuroses was
already debated in medical literature.  Smith, Kline & French laboratories (SKF) marketed
Thorazine in the 1950s and 1960s, as a substance suited for hospitalized patients once
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725  Smith, Kline & French, “The Discharged Mental Patient...and Thorazine,”
Journal of the American Medical Association 187, no. 1 (January 1964): 18.
726  Smith, Kline & French, The Discharged Mental Patient...and Thorazine, 18.
727  Smith, Kline & French, The Discharged Mental Patient...and Thorazine 18.
returned to society.  A 1964 advertisement, in the Journal of the American Medical
Association shows the back of a man fishing, the epitome of calmness of action and
environment.  Presumably SKF intended to illustrate the state of tranquility experienced by
patients on Thorazine.  The text focuses on marketing to family physicians who “must often
assume responsibility for the discharged mental patient.”725  The benefits of Thorazine, its
makers explain, are experienced by the patient, the physician, and his family.  Turning the
sedating properties into a benefit, Smith, Kline & French argue the drug “helps prevent
relapses by insulating him [the patient] from the impact of stressful experiences.”726 
Physicians concerned about continuing the high dosages of Thorazine used in mental
institutions could be tempted, the advertisement warns, to reduce dosages.  Reassuring
readers that high dosages for long periods of time were justified and appropriate treatment,
the advertisement suggests side effects are less of a concern to the general physician than
practitioners coping with psychotic inpatients.  The makers do not argue Thorazine has a
mild side effect profile.  Instead, the advertisement focuses attention on the idea that hospital
doctors would notice serious side effects early in a patient’s treatment.  Therefore, family
physicians treating outpatients could use high dosages in long-term therapy with little risk. 
“Continuing therapy is almost always well tolerated, and it is central to most patients
continued well-being[,]” assures the text.727
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Although the Thorazine advertisement suggests it is a safe and needed tranquilizer,
the approach accepts that doctors are unlikely to prescribe it for the run-of-the-mill neurotic
without prodding.  Doctors were well aware of side effects and the association of Thorazine
with institutional treatment, hence the ad needed to reassure physicians that dangerous side
effects would already have been experienced during hospitalization.  The major tranquilizers
were mentally sedating and tended to induce sleep, acting as hypnotics.  They insulated
individuals from stressful experiences.  The side effects, life threatening in a small number
of patients, frequently often involved drops in blood pressure; they required supervision by a
physician for at least the early weeks during which a patient began taking the drug, and
necessitated frequent returns to the doctor by any outpatient.  This led to many physicians
assuming major tranquilizers were inappropriate for treating the vast majority of American
neurotics, when an important goal of treatment was to prevent hospitalization.  Furthermore,
because medical literature often described neuroses as less severe versions of the psychoses,
it was hard to sell the idea that an individual needed a powerful, and potentially dangerous,
medicine.  Smith, Kline & French still tried positioning chlorpromazine (Thorazine) for this
use.  
After World War II introduced broader concepts of mental health, a spectrum
between absolute mental health and complete mental illness, the major tranquilizers were
suited to those falling close to the extreme of mental illness.  The majority of Americans now
thought to need assistance in promoting mental health, preventing mental ill-health, or
treating neuroses and neurotic personalities, were theoretically better served by a mild form
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of tranquilizer, less sedating to the mind, not inducing sleep inappropriately, and safe for
everyday use in outpatients because it had an excellent safety profile.  The new interpretation
of mental health and mental illness expanded the market for tranquilizers, but required
greater effort on part of pharmaceutical manufacturers in establishing an apt, and expansive,
niche for their product.  Major tranquilizers suited inpatient use and continuing treatment for
schizophrenia and major thinking disorders.  Conceptually, small doses of a major
tranquilizer appeared rational treatment for mild mental illnesses, but pharmaceutical
manufacturers faced growing competition from the new, ‘minor’ tranquilizers.
The more recently introduced meprobamates met some concerns about using major
tranquilizers in the outpatient population and treatment of neuroses.  They had a broader
spectrum of action, fewer side effects, were better tolerated and safer than major
tranquilizers.  How Roche positioned and marketed Valium was in part their attempt to
differentiate the benzodiazepines and meprobamates; to take part of the market share from
the most successful antineurotic (minor tranquilizer) of the early 1960s, meprobamate.  In
the popular press, meprobamate marketed under the trade name, Miltown, was better known
than the same molecule marketed as Equanil.  By the mid-1960s, generic meprobamate and
combination drugs also competed in the psychopharmaceutical marketplace.
Pharmaceutical manufacturers marketed meprobamate compounds for treatment of
anxiety, emotional components of somatic illness, and psychosomatic illnesses; Roche
promoted Valium for a similar spectrum of medical conditions.  In the 1965 issues of GP:
General Practitioner, Lederle Laboratories touted Pathibamate (combination tridihexyl
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729  Wallace Laboratories, “For Treatment of Emotional Factors in
Cardiovascular Disease,” GP; General Practitioner 31, no. 1 (1965): 214-15.
730  Wallace Laboratories, “For Treatment of Emotional Factors in
Cardiovascular Disease,” GP; General Practitioner 31, no. 1 (1965): 214-15.
chloride and meprobamate) for treatment of “organic and functional disorders of the
gastrointestinal tract, including ulcer – real or potential – especially when accompanied by
anxiety, neurosis or tension.”728  Wallace Laboratories pushed Miltown “[f]or treatment of
emotional factors in cardiovascular disease[.]”729  They referred to meprobamate as “The one
tranquilizer that belongs in every practice[.]”730 
Because of its name brand recognition as Miltown or Equanil, and widespread use by
1963, the meprobamates were important competitors to Valium.  Having been on the market
for years, doctors already prescribed these pills, they knew the benefits and dangers more
thoroughly, simply because large numbers of people had used the compounds for years. 
Some writers questioned the addictiveness of meprobamates, but they were less addictive
than the earlier alternative, barbiturates.  Meprobamates produced drowsiness, but less
dramatically than the major tranquilizers.  Like Valium they improved regular sleep but had
little impact on patients maintaining an active day.
Librium, although also sold by Hoffmann-La Roche, was competition to Valium.  In
published clinical trials, doctors regularly referred to Librium either as a parent compound to
Valium, a sister compound, both closely related benzodiazepines, or as Valium as a
derivative of Librium.  This link to a molecule already on the market benefitted Roche;
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existing tests and extensive market use suggested to the FDA, physicians, and the patient
population that Valium was also safe and useful.  But similarities between Valium and
Librium also necessitated Roche creating a marketing campaign differentiating the two
compounds.  
Roche’s overall campaign focused on Valium having a broader spectrum of action
than Librium and being more potent.  They used less openly emotional advertising than for
Librium.  Roche played up the fact smaller quantities of Valium produced similar effects, but
the quantities in question were small and it is likely patients interpreted Valium as a stronger
drug than Librium because of differences in their delivery systems.  Librium tablets were
coated, Valium not.  As a result patients experienced the effects of Valium more quickly,
giving the impression of a stronger drug.
Unfortunately a common property among addictive drugs is also the ability to gain a
sense of euphoria or relief quickly enough for an individual to make a strong association
between consuming the drug and pleasure or relief.  No matter how similar these
compounds, Valium and Librium, were at a molecular level, Valium’s delivery system
endowed it with greater potential for psychological addiction. Yet, in 1963 when Roche
introduced Valium to the market, its elder sister was at a stage of maturity when widespread
use resulted in published reports of less common, but potentially dangerous, side effects.
By 1960, reports were already surfacing about side effects of Librium.  In a letter to
the editor, I. M. Ingham and Gerald C. Tilbury, of the Southern General Hospital in
Glasgow, reported side effects in over half of their patients treated with Librium.  Most were
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drowsy, dizzy, listless, or otherwise bothered by side effects to the extent some patients
stopped work.  They note Librium was already commercially available and “widely
advertised in terms of taming effect on wild animals and ... value in controlling phobic and
obsessional symptoms in psychoneuroses although the published evidence for this is
slight.”731  The authors advised doctors be wary prescribing Librium and remain skeptical of
its usefulness “until the results of controlled trials are available.”732
As Roche planned its marketing campaign for Valium, they tried to deal with the
types of concerns doctors such as Ingham and Tilbury expressed.  Roche marketed Valium
based on images of good science, rational clinical medicine, controlled trials, objective
evidence, and proven efficacy.  The resulting advertisements may look insulting in how they
portray patients, but Roche did not intend these advertisements for general public
consumption.  They placed them in medical magazines for physicians, who were usually
male, affluent, and socially conservative.  Roche tried to sell Valium as part of good science-
based medicine.  The written and visual aspects of these ads are part of an interaction
between the pharmaceutical marketing company and a physician, without the patient as a
central part of the equation.
One outstanding question is why Roche marketed Valium alongside Librium.  The
company sunk substantial monies into introducing and marketing Librium; why not build on
success?  If Valium offered a longer monopoly, why not drop Librium and focus on the
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newer drug?  Why did Roche promote both substances?  They chose to market both and it
turned out well.  By 1972, Valium was the most commonly prescribed brand-name drug, and
Librium was the third or fourth.  Obviously both pharmaceuticals could compete
successfully for essentially the same market.
Advertising strategy differentiated the substances.  In the 1960s and early 1970s,
Librium marketing focused more strongly on treatment of psychiatric disorders and
responses to environmental or social stress.  Valium marketing mainly promoted its use in
psychosomatic disorders, or somatic conditions where stress allegedly interfered with
successful treatment.  A major Valium marketing campaign, entitled the ‘Somatic Mask,’
will be discussed later in this chapter.
The barbiturates are less commonly recognized as competitor compounds, but their
popularity declined as Valium’s rose, and they were prescribed for overlapping groups of
symptoms.  By 1963, medical journals treated barbiturate addiction as fact, but often treated
it as an affliction of deficient personalities, affecting mainly those already prone to addiction. 
Assessing public awareness of barbiturates’ dangers is harder; newspaper and magazine
articles made information on addiction and suicide available, but do not appear related to any
major decrease in barbiturate prescription or refill rates.
Barbiturates had a marked effect as mental and physical relaxants.  They relaxed
muscles including the diaphragm, and therefore at least in large doses, created risk of
unplanned death as the body became unaware or unable to breathe.  Perhaps Roche could
have used this problem to promote Valium’s benefits over the barbiturates, but it is not clear
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to what extent the average doctor interpreted widespread barbiturate use as increasing
suicide rates.  As noted previously, people usually obtained barbiturates by doctor’s
prescription.  They required doctor approval before buying refills.  A wide variety of legal
pharmaceuticals included small doses of barbiturates; some of the drug’s risks declined
alongside the quantities consumed in composite pharmaceutical products.  Prescription and
usage rates of barbiturates and barbiturate compounds remained high in the 1960s.
Rates of new and refill prescriptions suggest continuing widespread use of
barbiturates as solitary compounds.  In the mid-1960s, McNeil laboratories ran ads in JAMA
(the Journal of the American Medical Association) for Butisol, a barbiturate compound
which differed from the more widely used phenobarbital because “it does not tend to
produce cumulative toxicity.”  The photograph used in the advertisement is typical of what
we would expect Valium ads to be in the 1960s based on government hearings and
publications of the 1970s and 1980s.  Talking on the phone, hair in curlers, pictures of
famous men attached to her wall, is a teenager obviously ignoring her mother.  The daughter
is not the only problem, the picture suggests, looming over her is a mother, shaking her
finger and obviously telling the young woman how inappropriate is her behavior.  An apron
over her clothes, hair tied back with a scarf, mop in hand, mom is the one whose “nervous
tension augments family problems[.]”  Evidently, even in the mid-1960s, pharmaceutical
corporations promoted barbiturates for treating women suffering from the stresses of
everyday life, running a home, being a wife and mother, or balancing career and family. 
Even these doctors, concerned with the barbiturate intoxication associated with long-acting
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compounds such as phenobarbital – itself the most prescribed generic drug until 1967 – had
well marketed alternative barbiturates at their fingertips.733
That barbiturates sedated the mind or induced sleep when taken in larger quantities
was less of a concern by 1960, because most barbiturate compounds incorporated only small
doses of barbiturates, which made their suppression of autonomic functions less of a
problem.  As an example, Burroughs Wellcome & Company marketed Cardilate-P, a
compound including phenobarbital, for treatment of angina.  They justified inclusion of
phenobarbital by arguing it “allays the anxiety and tension which often trigger anginal
attacks.”734  McNeil Laboratories promoted a similar compound as Butiserpazide, described
as a “combination of the smooth, not cumulative ‘daytime sedative’ Butistol butabarbital
with established ‘background therapy’ of hypertension[.]”  In this case, the graphic shows an
angry looking middle-aged matron staring outward, evidently toward the physician who is
taking her blood pressure.  Her gaze appears both angry and apprehensive.  Alongside the
graphic is a caption “Normalize both her blood pressure and emotional state with
BUTISERPAZIDE.”735
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Times September 9, 1980; Liz Hodgkinson, “Costs of Tranquillity – The ‘Happy Pill’ is
a Horror Story,” The Times (London) February 18, 1988.
The dominant explanations for decline in barbiturate use are: that increased
regulation reduced prescribing and increased awareness of long term use; that physicians and
the public became more aware of these drugs’ dangers, therefore prescribing and using them
less often; or, that introduction of newer drugs displaced barbiturates from the market.736 
Prescription requirements introduced by the Humphrey Act impacted barbiturate use little. 
Whether or not the public was more aware in the 1960s than the late 1950s that barbiturates
were addictive and potentially lethal, usage rates remain high through to the late-1960s. 
Arguably, reduced rate of use relates to introduction of benzodiazepines, but whether this is a
matter of chronological chance or obvious improvements and merits is disturbingly hard to
establish.  
Perhaps how physicians learned to understand barbiturates’ actions undercut the
rationale for prescribing them.  The effects of barbiturates were a combination of agitation
and sedation.  Within developing concepts of tranquilizer action, this created an awkward
situation for explaining proper conditions for prescribing barbiturates as hypnotics,
sedatives, or tranquilizers.  In the 1950s medical literature discussed tranquilizers as central
nervous system depressants.  A tranquilizer should, therefore, be a compound causing
sedation, whether mentally mild, sedating, or in large enough doses, sleep.  Because
barbiturates had a combined action of agitation soon after dosing, followed later by sedation,
they did not fit with contemporary understandings of how tranquilizers acted; they fell
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outside the parameters defining tranquilizers.  Advertisements for Miltown pointed out that
unlike barbiturates, their drug “does not cause paradoxical excitation[,]”737 suggesting
Wallace Laboratories’ marketing staff were conscious that contemporary ways of explaining
drug actions poorly explained barbiturates effects.  
Although barbiturates were virtually the only safe and effective substance reducing
occurrence and severity of epileptic episodes, Valium’s profile as a tranquilizer in general
made it more logically consistent to use for anti-epileptic properties.  Valium fit better within
the boundaries of existing medical knowledge because its presumed mode of action fit
expectations.  An underlying theme in History of Science speaks to this issue; results fitting
expectation are less strongly questioned than those going against the existing models and
accepted knowledge. 
Marketing Valium
Roche’s marketing strategy took the competition into account.  Valium was not
uniformly better than every alternative.  Roche competed for a portion of an existing market. 
Although Valium critics in the 1970s and 80s remembered it expanding boundaries of
tranquilizer use, this largely results from their tendency to use the term ‘Valium’ when
referring to tranquilizers in general.738  The post-World War II understandings of mental
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health and mental illness expanded the boundaries within which doctors could justifiably
prescribe minor tranquilizers well before Valium’s 1963 debut.  In the 1960s, physicians
wrote tranquilizer prescriptions for an assortment of ills it is hard to imagine in early twenty-
first century terms as having any justification.  However, seen within the boundaries of
normal science at the time, it’s questionable whether Valium or any other tranquilizer
expanded boundaries of correct treatment for mental illness or social problems.  Valium
marketing made physicians aware of this specific pharmaceutical, and tried to explain why
they should choose to prescribe it rather than alternatives, through promotion of
psychosomatic concepts and its use in problematic diagnoses.  
Roche’s marketing strategy promoted use of Valium in a wide variety of conditions,
not just as a tranquilizer for anxiety or stress alone.  Mickey Smith gives a broad outline of
the campaign in the eminently readable A Social History of the Minor Tranquilizers: The
Quest for Small Comfort in the Age of Anxiety.  He gives only a single visual example of
Valium advertising.  The picture shows an unhappy housewife sitting in an armchair, the
magazine on her lap remaining unread as she stirs her tea and smokes cigarettes.  The
caption “Psychic support for the ‘always weary’“739 easily gives an impression Roche
approached doctors by promoting Valium as a way to re-create or restore the perfect
housewife, but it is not established as typical of Roche advertising to physicians.  This
visually oriented advertisement does include what the FDA required as minimal information,
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indications and warnings, something administration leaders and FDA critics considered
inadequate and misleading in all psychotropic drug ads.  In all likelihood, it is this minimal
information which resulted in Smith including the unhappy housewife advertisement.  The
large print text reads “When psychic tension is the reason for chronic fatigue, Valium
(diazepam) can help provide the right kind of support.  That’s because, in proper dosage
Valium calms the tense, tired patient while seldom dulling the senses or interfering with
function.”740  In a part of the book where doctor Smith focuses less on treatments of mild
situational anxiety, his analysis of tranquilizer advertising in the journal Medical Economics
fits the advertising profile I found in Clinical Medicine, Journal of the American Medical
Association, Image, and the detailman’s book Aspects of Anxiety.  
The Roche marketing campaign plays into how physicians saw their role as medical
professionals.  Beginning in 1964, Roche promoted the idea that animal and clinical studies
already proved Valium safe and useful. Presumably the fact that a very similar drug,
Librium, was already vetted by the market and its safety extensively tested in this post-
marketing forum, made severe problems with Valium unlikely.  Yet, in marketing a drug just
after the thalidomide crisis, Roche needed to exert extra effort to reassure physicians of drug
safety.  The Valium campaign focused on promoting the drug as a product of extensive
scientific testing and vetting.  Roche’s advertisements reassured physicians using images of
‘objective’ science.  In an issue including a series of four nonadvertising pages discussing a
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recent symposium called “Man Under Stress,”741 an advertisement for Valium lays out
information on the ‘new’ medicine, with no pictures, drawings, or catchy slogans.  A chart
shows results of diazepam use in forty-four psychoneurotic patients with various diagnoses. 
Tight hand column includes, in smaller text, apparently detailed information on appropriate
dosages, warnings, available forms, and the citations for ten different articles in well-known
journals.  The titles on two columns are understated, almost dry; one reads “Excellent
Response in Emotional Tension With Somatic Components,” the other “Valuable for Muscle
Relaxation in Cerebral Palsy and Atheoid Patients.”742  
The major campaign series, called the Somatic Mask, promoted Valium use in
psychosomatic disorders and somatic conditions with psychological complications.  This
campaign ran in the mid- to late-1960s, parallel with Valium’s rise to the most prescribed
brand-name drug in the United States.  In 1965, advertisements focused on use in a specific
psychosomatic condition; the somatic mask in which patients experienced anxiety and
tension, whether mental or physical, as chest pain.  Advertisements inside the cover of
Clinical Medicine show a stoic man looking down, waiting for a verdict from the physician
whose face appears over his shoulder.  These respectable men are anxious about the medical
condition.  
In 1967, Roche added heartburn to its list of conditions which might be somatically
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masked.  These physically experienced conditions, Roche argued, were often rooted in
anxiety and tension.  Doctors could never be sure if the condition was somatic or
psychosomatic, unless they tried prescribing Valium.  The ‘Somatic Mask’ advertisements
suggested physicians needed a way to differentiate causes of chest pain; “heart disease or
psychic tension?” is the question.743  In 1968, advertisements focused on treating somatic
conditions in general, the idea being that anxiety associated with somatic illness complicated
a patient’s path to recovery.  In the early-1970s, Roche continued to market Valium based on
psychosomatic symptoms, and reduction of anxiety associated with conditions such as heart
attacks, of which no physician could deny the reality.  It is only in the mid-1970s that Roche
marketing campaigns begin turning to a general concept of psychic tension in journal
advertisements for physicians.744
Roche’s general marketing approach for Valium differs from marketing and use of
tranquilizers in general.  Valium becomes a symbol of differential diagnosis to women,
marketing campaigns focusing on tranquilizers for psychological tensions, drugs treating
problems of living.  Perhaps the fact Valium competed within a field filled with minor
tranquilizers marketed as antianxiety or antineurotic drugs removed the need for Roche to
market their own drug’s potential in this sphere.  Valium was a minor tranquilizer, so it
followed necessarily that doctors could prescribe it for worried and neurotic patients. 
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Instead, Roche spent its marketing dollars explaining to physicians how they could view
themselves standing at the forefront of medical science, while running a successful practice
with efficient and appropriate diagnosis, unhindered by the psychological problems of their
patients.  
The actual marketing of Valium, before 1967, focused primarily on psychosomatic
conditions and how anxiety or tension components problematised treatment of somatic
conditions.  This focus on interplay between psyche and soma takes a particular shape during
the 1950s and 1960s, one which places emphasis on the role of stress.  Because the dominant
concept of psychosomatic illness at that time focused on the intimate interactions between
body and mind, flowing in both directions, and producing ‘real’ physical illnesses, it differs
from early twenty-first century divisions between physical and mental illnesses.  
It is hard for us simply to accept their broad concept of psychosomatic illness as part
of legitimate medicine.  It fits our own training to assume widespread use of tranquilizers in
the 1960s and 1970s was and should have been viewed as a problem.  The idea that these
drugs were responsible for improperly expanding the boundaries of mental illness, that they
were lifestyle drugs, is an easier concept for us to accept.  Yet numerous articles in medical
journals highlighted the role of stress in creating and perpetuating somatic illness, and as a
complicating factor in cure.
Promoting use of Valium for somatically experienced ills took it out of the realm of
psychiatry and into the general practitioners’ domain.  General practitioners, whether
referred to as family or primary physicians, saw most patients with nervous complaints. 
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Psychiatrists’ clients already identified their ills as mental.  General practitioners faced
clients repeatedly returning with nebulous complaints – conditions where diagnosis was
difficult – as well as middle class and less affluent clients who were more comfortable with
physical diagnosis of psychosomatic ills.  Roche advertising suggested Valium eased general
practitioners’ treatment of problem patients, no matter whether these people created
problems by taking up time, returning repeatedly, or by perversely refusing to have a
constellation of problems fitting a clear diagnosis and cure.
One of the most pervasive trends developing alongside, and probably influencing, the
development of Valium, is blurring philosophical boundaries between mind and body in the
mid-twentieth century.  Post-1940 behaviorists normally considered physiology related to
behavior, whether or not they were willing to extrapolate mental processes from behavioral
evidence.  Jules Masserman and Horsley Gantt created experimental neuroses in animals
through psychological stresses, and assessed changes in behavior and measurable physical
effects.  Pharmacologists, including Lowell Randall, measured physical responses – righting
reflex, heart rate, blood pressure, muscle flexibility – in efforts to identify, distinguish, and
characterize psychoactive drugs suitable for affecting anxiety and stress, conditions
noticeable only through internal experience.  
The existence of compounds understood as psychopharmaceuticals implied many
Americans – scientists and medical professionals as well as everyday people – could accept
(perhaps by ignoring the issue) a physical compound had effect on behaviors associated with
the psyche.  Sedatives were physical calming compounds; accepting their existence did not
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require belief in an interaction of drug and mind.  Tranquilizers, as developed and used, were
compounds changing behavior, feelings, the very pattern of interaction with the world
understood as personality.  Whether aware of the tension or not, accepting that tranquilizers
worked required acknowledging they could modify the very things identified as self:
emotions, patterns of interaction, goals, aspirations, dreams, anger, and an emotion-bound
perception of the world tightly bound to our past experiences.  Whether used to treat
neuroses, personality disorders, psychosomatic conditions, or the emotional and anxiety
complications preventing efficient somatic medical treatment, Valium was effectively a
psychosomatic drug.  Understanding how scientists and the medical profession, and through
them the public, understood psychosomatics helps explain the rationale that made
widespread prescription and use of Valium reasonable.
The roots of North American psychosomatic theory lay largely in ideas of figures
discussed earlier in this dissertation: Walter Cannon’s focus on homeostasis, Hans Selye’s
General-Adaptation-Syndrome, channeling or blocking the flow of energies within Freudian
theory, the work of Flanders Dunbar, Roy Grinker’s neuropsychiatric work during and after
World War II, and S. Margolin’s focus on the ascending reticular activating system as locus
of interaction between psyche and soma.745  Overall, North American psychosomatic theory
characteristically privileged the role of interaction between emotion, stress and glands on
development of higher thinking from sensation.  This focus played an important role in use
of tranquilizers, because it suggested an expanded role for stress by conceptualizing it as
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bodily change derived from interaction with the internal or external environment.  Stress
itself could be a pathogen, underlying a wide variety of illnesses which could manifest long
after the originating events.  Tranquilizers acted on the reticular activating system, offering
the possibility of influencing experience of stress at a level of integration from sensation to
thought, allowing experience of tranquility without preventing the body from restoring itself
to balance.
Consequently, Roche positioned Valium both as a competitor to existing
pharmaceuticals and a more broadly useful drug.  Valium could break the psychosomatic
feedback loop of anxiety – bursts of adrenalin, apprehension, overreaction to stressors
leading to bursts of adrenalin, and so on.  Existing medical theory associated this feedback
circle with psychosomatic disorders as well as short-circuiting physical treatment of diseases
and dysfunctions considered entirely somatic.  Valium treated the underlying condition
according to this interpretation; it was a cure rather than a palliative medicine.
Selling Scientific Medicine
During and after World War II, the United States pharmaceutical industry moved out
of its infancy, becoming a troublesome teen.  Hard on the heels of large-scale production and
sale of antibiotics during the war, came a series of important discoveries.  Within a
generation, sulfa drugs, antihistamines, hormones, analgesics, antispasmodics, antidiabetics,
diuretics, vaccines, antiseptics, dermatologicals, treatments affecting cancer, blood
anticoagulants, and psychotropics brought physicians an armamentarium to fight common
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illnesses.  In 1939, the pharmaceutical industry sold roughly 149 million dollars worth of
prescription drugs; in 1958 the figure was 2 billion.746  
With swelling sales and efficacious drugs came greater public concern about the
ethical implications and dangers of prescription drugs.  Senate hearings raised public
awareness of situations of ethically problematic practices.  Hearings highlighted cases in
which pharmaceutical manufacturers funded trials with friendly physicians, arranged
publication of positive results in respected medical journals, or promoted detailmen bringing
selective, unprofessional, or misapplied research reports to physicians.747  Hearings and
newspaper reports exposed illegal or unethical practices of pharmaceutical industry
members, to physicians as well as the lay public.  Roche’s campaign took into account
existing physician concerns that pharmaceutical manufacturers provided nonobjective
evidence, results from small-scale surveys, tended to selectively report only positive results,
and over all tended to market drugs in a manner insulting to their perceived professional
abilities and status.
Physicians might read medical journals such as JAMA (the Journal of the American
Medical Association), General Practitioner, American Journal of Psychiatry, or the New
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England Journal of Medicine.  However, many probably flipped through or past the
advertisements.  Roche could sponsor research which eventually produced articles in these
journals, bringing their message to doctors reading those specific articles in the specific
journals.  Yet, there was another approach to advertising, one doctors found it harder to
avoid, to escape from, detailmen.  Detailmen were company representatives who visited
doctors in person, telling them about the company’s new drugs, their benefits, and often
giving out perks (such as pens, cups, calendars, golf balls) with the company and drug name
prominently displayed.  These marketing agents also brought news of the latest research,
especially that putting their company’s products in a good light.
An example of the information approach to advertising used by detailmen in
marketing Valium is the book Aspects of Anxiety.  First published in 1965, it was released in
a second, enlarged, edition in 1968.  Although the publisher of record was J. B. Lippincott
Company, there is little doubt it was a Roche publication.  Printed inside the cover are the
words “Presented to ____________ With the Compliments of Roche Laboratories, Division
of Hoffmann-La Roche Inc., Nutley, N. J..”  A copy in the author’s possession was given to
P. E. Lashburn, and a sticker on the same page identifies Powell Douglas as the Roche
representative detailed to Doctor Lashburn.  In format and style it is similar to other Roche
publications such as The Anatomy of Sleep, published in 1966, and Aspects of Alcoholism,
published in 1963.748  Clinching the fact that Roche produced this book for their detailmen to
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pass on to primary physicians is a statement in the preface that the information was “collated
by Roche laboratories into a single volume.” and the book written “for the purpose of
bringing these matters to the attention of the primary physicians[.]”749
Aspects of Anxiety exemplifies the soft sell; soothing physicians’ fears that the
pharmaceutical manufacturers were attempting to hoodwink them.  The framework of
medicine Roche highlights, and ties to anxiety, broadens the realm under which it is rational
to prescribe Valium.  Physicians already associated tranquilizers such as the meprobamates,
hydroxyzine (Atarax), and (chlordiazepoxide) Librium with treatment of neuroses.  As long
as Roche did not distance Valium too far from the broad tranquilizer profile, there was no
need to highlight that it functioned as an antineurotic.  Aspects of Anxiety wastes no pages
showing a use for Valium that doctors would assume suitable.  The way this book enlarges
possible uses for Valium is by tying anxiety into psychosomatic medicine, and its utility as
adjunctive treatment to prevent complications to somatic treatments.
Aspects of Anxiety tries to put forward three main points.  First, the text argues that
issues important in family practice medicine – termed primary medicine – could usually be
treated with Valium.  Second, Roche argues anxiety and neuroses lay at the root of most
cases where it was hard to identify a somatic cause.  Third, the book suggests that even in
cases which had an easily identifiable somatic cause, alleviation of anxiety was a rational
adjunctive treatment, because it reduced complications and augmented and improved
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somatic based treatments.750  
Publishing and gifting doctors hardcover books that linked aspects of accepted
medical knowledge in order to justify prescription of the company’s drugs, was a brilliant
tactic.  It faced and passed through FDA and the American Medical Association concerns
about abusive pharmaceutical advertising.  Because Aspects of Anxiety does not mention any
specific drug, and was direct marketing to physicians, there was almost no way the FDA
could insist on changes to the text.  Arguably the book was educational, not advertising. 
Failing to mention specific pharmaceuticals also helped Roche present an impression of
objectivity.  And because this book is a soft sell, relying on doctors to make the connection
between the way Roche explains mainstream medicine and actually prescribing Valium to
patients, it appears to respect the intelligence and autonomy of physicians.
Conclusion
Explaining development of Valium in the 1950s and widespread use in the 1960s,
without reference to later events, ties to a tangle of related questions.  How was the
relationship between mind and body understood in ways explaining research and marketing
of Valium?  Why did Valium use make sense to physicians and the general public?  There
must be reasons, otherwise widespread use would not have occurred.  Widespread
prescription and use of Valium was reasonable at the time, for reasons outlined in this
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dissertation.
The post-World War II conceptualization of mental health and illness as a spectrum,
with the majority of Americans falling between the poles, and therefore either neurotic or at
risk heightened interest in mechanisms and concepts of mental health.  Increased availability
of health insurance brought more Americans to their physicians.  National programs –
establishment of the National Institutes of Mental Health, passage of the Hill-Burton Act,
and formation of a Joint Commission on Mental Illness and Health through the 1955 Mental
Health Study Act – recognized widespread support for programs to increase the number of
mental health practitioners and facilities focused on neuroses, personality disorders, and
outpatients in general.  Popular theories, including Walter Cannon’s homeostasis and Hans
Selye’s General-Adaptation-Syndrome, promoted the idea that stress, and response to it,
were among the most important aspects of health.  The American public increased its
demands for mental health services.  Interplay between these conditions promoted use of
psychopharmaceuticals.  They were quick to prescribe and therefore allowed doctors to see
more patients each day.  They somaticized mental illness, bringing it within the boundaries
of traditional medical insurance coverage.  They did not cure an illness, they reduced
symptoms and therefore either allowed the body to recover, or in an ongoing fashion
prevented immature personalities from reaction to stresses in a manner leading to more
serious medical problems.
In the 1950s, it became possible to search among chemicals for a tranquilizer.  The
expense of creating and treating experimental neuroses in animals to screen chemical
311
compounds was prohibitive.  Yet these experiments informed pharmacologists; they could
identify antineurotic or tranquilizing drugs through physical manifestations.  With
availability of antibiotics, pharmaceutical industries could keep fairly healthy populations of
mice, rats, cats, and monkeys for testing.  Chlorpromazine’s discovery and introduction into
institutional psychiatry, around 1953, set out the basic features defining a tranquilizer.  By
1958, pharmacologists had the ability and expectations required to inject a mouse with
diazepam, check if it rolled off an inclined screen and, observing the tumbling rodent,
recognize the ingested molecule was a potentially marketable tranquilizer. 
Valium’s development and discovery took place when tranquilizers were new and
held out the promise as mental health prophylactics, mild sedatives, and safe hypnotics. 
Mild mental illness needed rapid, effective, and fairly inexpensive treatment.  Faced with a
patient undergoing severe or ongoing stress, doctors logically turned to anxiety-reducing
drugs in order to prevent psychosomatic mechanisms resulting in any of a dozen physical
illnesses.  Compared with earlier alternatives – barbiturates, alcohol, major tranquilizers –
Valium was safe, nonaddicting, and had few if any dangerous side effects. 
Valium became a drug of abuse in the final years of the 1960s, recognized as such by
inclusion on the Schedule of Controlled Subclassification started in 1955 and fought step-by-
step until 1973, by which time mental health had been substantially reconceptualized.  When
it first entered the market, it was medically justifiable to prescribe Valium widely. 
Prevention of mental illness was a pressing national need.  Stress of everyday life produced
physiological effects.  Prolonged or extreme stress, or even everyday stresses experienced by
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a neurotic personality, strained the body’s resources, led to gastrointestinal, sexual, cardiac,
circulatory, asthmatic or other dysfunctions of nervous system components.   Valium was an
important preventative treatment for nervous system illnesses.  The anxiety associated with
somatic illness interfered with normal treatments and the healing process.  Valium was a
useful adjunct to other treatments, preventing stress reactions interfering with recovery. 
And, like other tranquilizers, Valium could normalize behavior of neurotic personalities.  
Although the statement remains trite, widespread Valium use was a product of its
time.  The ways of understanding mental health, medicine, and the interaction of body and
mind, all play into justifying widespread use of minor tranquilizers, such as Valium.  Why
Valium, rather than alternatives, became the best-selling brand-name pharmaceutical – in
1972 retail pharmacies filled roughly 530 million prescriptions for Valium751 – remains an
unanswered question.  Yet, understanding more about the context of Valium’s development,
up to the point when Roche placed it on the market, prepares the way for well-grounded and
informed further investigation.  Better understanding Valium as a construct, formed by
interplay between a molecule and the assumptions and actions involved in identifying and
defining it as a marketable and useful psychopharmaceutical, creates a touchstone for
understanding how acceptable and unacceptable use of Valium changed over time.
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